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Abstract 
 
 
 
 
Cervical human papillomavirus (HPV) infection is a very common sexually 
transmitted disease which is now considered to be a necessary, but not sufficient, 
cause of cervical cancer. It has been suggested that the association between HPV 
infection and cervical neoplasia can be exploited to improve the efficiency and 
effectiveness of primary- and secondary-prevention programmes for cervical cancer. 
However, whether this aspiration can be realized in practice requires a greater 
understanding of the natural history of early cervical HPV infection and its role in the 
acquisition of epithelial abnormalities of the cervix. In this thesis, a longitudinal study 
of young women who had recently embarked on sexual activity has provided 
sequential observations on the natural history of cervical HPV infection. This thesis 
addresses four aspects of this natural history: the association between HPV infection 
and the proximity of first sexual intercourse to menarche; the association between 
smoking, cervical HPV infection and high-grade cervical disease; the validation of a 
neutralising antibody assay and its use in defining the kinetics of the humoral 
immune response to cervical HPV16 and HPV18 infections; and the analysis of 
measurements of the viral load of HPV16 and HPV18, and their association with 
epithelial abnormalities of the cervix. 
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Foreword 
 
 
 
Cervical human papillomavirus (HPV) infection is a very common sexually 
transmitted disease which is now considered to be a necessary but not sufficient 
cause of cervical cancer. 
 
It has been suggested that the association between cervical HPV infection and 
cervical neoplasia can be exploited to improve the efficiency and effectiveness of 
secondary-prevention programmes, if not to replace them outright with primary-
prevention strategies. However, whether these aspirations can be realized in 
practice requires a greater understanding of the natural history of cervical HPV 
infection and its rôle in the acquisition of cervical abnormalities, than we currently 
possess. Such an understanding can best be derived from longitudinal observations 
on women who are free of both infection and disease at recruitment. 
 
In this thesis a longitudinal study of young women who had recently embarked on 
sexual activity has provided sequential observations on the natural history of cervical 
HPV infection. This thesis addresses four distinct, but interrelated, aspects of the 
natural history of cervical HPV infection and its relationship to the subsequent 
development of epithelial abnormalities of the cervix. I address each of these four 
aspects in stand-alone groups of chapters which consist of background, methods, 
results and discussion. These groups of chapters are preceded by introductory 
chapters which describe: the epidemiology and aetiology of cervical cancer; cervical 
HPV infection; strategies for the prevention of cervical cancer; the design of the 
cohort study which has provided the data for this thesis; and some of the statistical 
and methodological issues which have arisen with this study design.  
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Chapter 1 
 
THE DESCRIPTIVE EPIDEMIOLOGY OF CERVICAL CANCER 
 
 
 
 
 
Orientation 
 
In this chapter I describe the incidence of, mortality and survival, from cervical 
cancer, and how these vary with geographical location, calendar period, and age.  
 
 
 
 
 
1.1 THE INCIDENCE OF CERVICAL CANCER 
 
In 2002, 5,060,657 new cases of cancer, excluding skin cancer, were diagnosed in 
women, worldwide: 493,243 (9.7%) were cancers of the cervix, making cervical 
cancer the second most common cancer among women, after breast cancer and just 
ahead of colon and rectum cancer, and the seventh most common cancer overall. 
The incidence rate in 2002, standardised to the age distribution of the world 
population, was 16.2 per 100,000, and the cumulative risk of cervical cancer prior to 
the age of 64 years was 1.3%, compared with 9.5% for all cancers combined (Parkin 
2005). 
 
1.1.1 Geographical variations in the incidence of cervical cancer 
 
In 2002, 83% of cervical cancers occurred in developing countries, where they 
accounted for 15% of all cancers occurring in females. The highest incidence rates 
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were in sub-Saharan Africa, Melanesia, Latin America, the Caribbean, south-central 
Asia, and southeast Asia. In comparison, incidence rates were low in developed 
countries, where cervical cancer accounted for 3.6% of cancers occurring in 
females, and also in China and Western Asia. This was not the case prior to the 
introduction of (organised) screening programmes from the 1960s onwards, when 
incidence rates in developed countries were comparable to those currently seen in 
developing countries (Parkin 2005). Age-specific incidence varies according to 
country, and typically depends upon the availability of a screening programme in that 
country: in the absence of such a programme, the incidence of cervical cancer tends 
to increase with age, as with the majority of the epithelial tumours. The greatest 
incidence occurs in women over the age of 50 years (Bosch 2003).  
 
In 2005, 144,756 new cases of cancer, excluding non-melanoma skin cancer, were 
diagnosed in women in the UK: 2,803 (1.9%) were cancers of the cervix, making it 
the twelfth most common cancer in women (CRUK website, August 2008). The 
crude incidence rate was 9.1 per 100,000, with the incidence rate in England being 
21% lower than that in Scotland.  
 
In the UK, the incidence of cervical cancer varies with age, with the highest 
incidence rates seen in women aged 30 to 34 years, but with a second increase in 
women aged 85 years or over (figure 1.1.1). This phenomenon, i.e. two “peaks” in 
incidence, one early, and one late, in life, is not confined to the UK alone (Bosch 
2003). 
 
In the UK, the cumulative risk of cervical cancer by the age of 65 years is currently 
estimated to be 0.6%, with only a slight additional increase when calculated over a 
lifetime (CRUK website, August 2008). 
 
Figure 1.1.1. Number of new cases of cervical cancer, and incidence rates of 
cervical cancer, by age group, for the UK in 2005 (CRUK website, August 2008). 
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1.1.2 Temporal trends in the incidence of cervical cancer 
 
Over time, there has been a substantial decline in the incidence of cervical cancer 
worldwide. This decline has not been confined just to those countries with well-
established screening programmes, but has also been seen in some developing 
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countries, in particular in China (Parkin 2005). In Great Britain, the incidence rate of 
cervical cancer has fallen by nearly 50% since the mid-1980s (figure 1.1.2). 
 
 
Figure 1.1.2. Trends in incidence rates of cervical cancer in Great Britain for 
the period 1975-2005, age-standardised to the European population (CRUK 
website, August 2008). 
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1.1.3 Squamous cell carcinoma of the cervix 
 
Squamous cell carcinoma is the most frequently diagnosed histological type of 
cervical cancer, comprising around two-thirds of all cervical cancers diagnosed in 
England and Wales in 1997 (Quinn 2001), although it has also been reported to 
comprise up to 85% of cervical cancers (Vizcaino 1998, Souhami 2005). A study 
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based on cancer registry data, collected between 1962 and 1991 from 25 mostly 
developed countries, with either systematic screening programs, or high-levels of 
opportunistic screening, found a progressive decline over time in the incidence of 
invasive squamous cell carcinoma in a majority of countries, with essentially stable 
rates in the remainder (Vizcaino 2000). The exceptions was the UK, where, despite 
an overall decline, there was an increasing trend in both incidence and mortality 
among women under the age of 50 years in England and Scotland. The assertion 
that this had begun to decline by the early 1990s is not supported by a more recent 
study (Bray 2005a). 
 
1.1.4 Adenocarcinoma of the cervix 
 
Adenocarcinoma is the second most frequently diagnosed histological type of 
cervical cancer, comprising nearly 15% of all cervical cancers diagnosed in England 
and Wales in 1997 (Quinn 2001). The incidence of adenocarcinoma of the cervix is 
rising at the same time as that of squamous cell carcinoma of the cervix is falling 
(Bray 2005b). A study based on cancer registry data, collected between 1962 and 
1991 from 25 mostly developed countries, with either systematic screening programs 
or high-levels of opportunistic screening, found an increase over time in the 
incidence of invasive adenocarcinoma and adenosquamous carcinoma of the cervix 
in 12 of the 25 countries, including the UK; no change in 11 countries; and a decline 
in three (Vizcaino 1998). The authors of the report on this study noted that most of 
the countries with increasing trends in the incidence of adenocarcinoma of the cervix 
were those which were devoting considerable effort toward screening, and that some 
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of the increase may have been due to increased screening efforts during the 1980s. 
This is unlikely to provide the full explanation however. 
 
1.2 MORTALITY FROM CERVICAL CANCER 
 
In 2002, there were 2,927,896 deaths from cancer among women worldwide, of 
which 273,505 (9.3%) were attributed to cancer of the cervix, making cervical cancer 
the third most common cause of cancer-death in women, behind breast and lung 
cancer, and the seventh most common cause of death overall. Mortality rates are 
lower than incidence rates: the mortality rate in 2002, standardised to the age 
distribution of the world population, was 13.2 per 100,000. The cumulative risk of 
death due to cervical cancer prior to the age of 64 years was 0.7%, compared with 
4.9% for all cancers combined (Parkin 2005). 
 
1.2.1 Geographical variation in mortality from cervical cancer 
 
There is substantial variation in mortality rates from cervical cancer according to 
geographical location: in 2002, the age-standardised mortality rate ranged from 34.6 
per 100,000 in Eastern Africa, to around 3 per 100,000 in developed countries; 
mortality rates in China and Western Asia were comparable to those seen in 
developed countries (Parkin 2005). 
 
In 2006, there were 73,621 deaths due to cancer in women in the UK: 949 (0.6%) 
were deaths due to cancer of the cervix, making cervical cancer the sixteenth most 
7 
 
common cause of cancer-death in women in the UK (CRUK website, August 2008): 
the crude mortality rate was 3.1 per 100,000, with slight national variations among 
the “home” nations. Cervical cancer mortality rates increased steadily with increasing 
age. 
 
1.2.2 Temporal trends in mortality from cervical cancer 
 
Over time, there have been substantial declines in mortality from cervical cancer, in 
both developed countries with well-established screening programmes, and also in 
some developing countries without such programmes (Parkin 2005).  
 
In the UK, mortality from cervical cancer has decreased dramatically since 1971 
(CRUK website, August 2008). This decrease has occurred in all age groups, with 
the exception of women aged between 25 and 44 years, for whom incidence is high 
but mortality is low (figure 1.2.2). 
 
Figure 1.2.2. Trends in mortality rates of cervical cancer in the United Kingdom 
for the period 1971-2006, age-standardised to the European population (CRUK 
website, August 2008). 
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1.3 SURVIVAL FROM CERVICAL CANCER 
 
In 2002, the worldwide five-year age-adjusted survival rate for cancer of the cervix, 
estimated as the ratio of mortality to incidence, was 55% (Parkin 2005). 
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1.3.1 Geographical variations in survival from cervical cancer 
 
In 2002, the five-year age-adjusted survival rate for cancer of the cervix was 61% 
(range 51% to 70%) among nations of the developed world, compared with 41% 
(range 21% to 58%) among developing nations, where cases are more likely to 
present at an advanced stage (Parkin 2005).  
 
For cervical cancers diagnosed in 2000-2001 in the UK, one-year survival rates were 
83%, age-standardised to the European population; this fell to 66% after five years, 
but decreased only slightly, to 62%, by ten years (CRUK website, August 2008). 
Five-year relative survival decreased with increasing age, with women diagnosed at 
age 80 years or over having a relative survival rate which was a quarter that of 
women diagnosed before the age of 40 years. 
 
1.3.2 Temporal trends in survival from cervical cancer 
 
In the UK, there has been a modest but steady increase in survival from cervical 
cancer since the 1970s (CRUK website, August 2008). For cancers diagnosed in 
1971-75, the ten-year age-standardised survival rate was 46%, but this had 
improved to 62% by 2000-2001. 
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Summary 
 
Cervical cancer is common throughout the world, but is becoming less so over time, 
with many countries experiencing a dramatic decline in incidence: the incidence rate 
of cervical cancer is highest in women over the age of 50 years in most countries. 
The fall in incidence is not seen in all histological types: the incidence of squamous 
cell cervical carcinoma is falling at the same time as that of adenocarcinoma and 
adenosquamous carcinoma is rising. Worldwide, cervical cancer is still a leading 
cause of cancer-death, although in developed countries with well-established 
screening programmes, such as the UK, this is no longer the case. Survival is poor 
in undeveloped countries, but has improved over time in the UK. 
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Chapter 2 
 
THE AETIOLOGY AND PATHOGENESIS OF CERVICAL NEOPLASIA 
 
 
 
 
 
Orientation 
 
In this chapter I: 
 
• describe the anatomy of the cervix 
 
• describe the natural history of cervical neoplasia 
 
• describe risk factors for the acquisition and progression of epithelial abnormalities 
of the cervic, and how these vary according to type of disease 
 
 
 
 
 
2.1 ANATOMY OF THE CERVIX 
 
The cervix is a continuation of the uterus, the upper two-thirds of which is a distinct 
site in terms of diagnostic, staging and treatment criteria (Souhami 2005). The cervix 
is the lower, narrower third of the uterus (figure 2.1). It is cylindrical, or conical, in 
shape, but size and shape vary widely with age, hormonal state, and parity. Under 
appropriate examination conditions, approximately half of its length is visible, 
typically 3 centimetres long by 2.5 centimetres wide, with the remainder lying above 
the vagina, beyond view (Singer 1989). 
 
The upper limit of the cervix is an anatomically and histologically ill-defined junction; 
it is considered to be the internal os, the opening where the uterus narrows to meet 
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the cervix. At its opposite end, the cervix meets the vagina; the portion protruding 
into the vagina is called the portio vaginalis. The external os is the lowermost 
opening between the cervix and vagina: before childbearing, it is a small, circular 
opening at the center of the cervix. The portion of the cervix exterior to the external 
os is the ectocervix. The passageway between the external os and the endometrial 
cavity, with upper limit the internal os, is referred to as the endocervical canal. 
 
The nature of the epithelial lining of the cervix varies according to location, with both 
columnar and squamous epithelia present at different locations within the cervix. 
Most of the ectocervix consists of stratified squamous epithelium similar to that found 
in the vagina, i.e. layers of flattened cells which protect against the relatively harsh 
environment of the vagina. The parts of the cervix closer to, or contiguous with, the 
uterus are subject to a more mild environment: the epithelia here consists of simple 
columnar epithelium, i.e. a single layer of rectangular column-like cells, which 
secrete mucus. This “glandular” epithelium covers a varying portion of the 
ectocervix, as well as lining the endocervical canal. The epithelium in the 
endocervical canal has folds and invaginations that make up the endocervical glands 
(they are not true glands). These complex topographical features make the 
cytological screening, and the colposcopic examination of endocervical tissues 
technically more difficult, and less reliable, than for the smoother and more 
accessible squamous epithelium of the ectocervix (these folds are not illustrated in 
figure 2.1). 
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2.1.1 The transformation zone 
 
The junction between the squamous epithelium and the glandular epithelium is 
called the “new” squamocolumnar junction (SCJ), which is marked by a line of 
metaplasia. The exact location of the SCJ varies, with age and hormonal status 
being the most important factors which influence its location. It is adjacent to the new 
SCJ that the process of squamous metaplasia occurs throughout the reproductive 
years: this is a normal process, during which columnar epithelium is replaced by 
squamous epithelium. The border between the metaplastic epithelium arising during 
the reproductive years, and the original squamous epithelium, is called the “original 
SCJ.” The transformation zone (TZ) is the area of metaplastic epithelium between 
the original and new SCJs.  
 
It is within the TZ that over 90% of all cervical neoplasia arises. Metaplasia, which is 
particularly active during puberty and during a womans first pregnancy, increases 
the risk of abnormal changes, since there is a rapid turnover of new cells. The 
metaplastic epithelium adjacent to the new SCJ is the newest and the least mature 
squamous epithelium on the cervix. As new metaplastic epithelium arises, the older 
metaplastic epithelium is moved outward toward the original SCJ, leaving the newest 
and least mature metaplasia adjacent to the new SCJ (Singer 1989). 
 
Figure 2.1. Anatomy of the cervixa. 
 
 
aThe dashed-line circumscribes the approximate location of the cervix. 
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2.2 THE NATURAL HISTORY OF CERVICAL CANCER 
 
The natural history of cervical cancer is thought to be characterized by a well-
defined, and what was once believed to be a lengthy, pre-malignant phase. 
Preinvasive lesions are asymptomatic, although other coexisting conditions may 
produce incidental symptoms (Souhami 2005). During the preinvasive phase, the 
normal maturation of epithelial cells within the TZ becomes disrupted, resulting in 
dysplastic lesions (Franco 2002). Dysplasia refers to lesions which have 
morphological changes giving them the characteristics of malignancy (atypia), but 
without involvement of the full thickness of the epithelium by basal-type neoplastic 
cells (Miller 1999). The majority of low-grade dysplastic lesions will regress without 
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intervention, whereas others may become high-grade by expanding to cover the full 
thickness of the cervical epithelium. Thereafter, in a significant proportion of, but 
again not in all, women with high-grade dysplastic lesions, the lesion may progress 
through the microinvasive to the invasive stage by invading the basement membrane 
separating the epithelium from the underlying connective tissue. Once it has become 
invasive cancer, the tumour may subsequently reach blood and lymphatic vessels, 
resulting in metastatic tumours in local pelvic lymph nodes, and eventually in distant 
lymph nodes and other organs (Franco 2002). 
 
2.2.1 Precursors of cervical cancer 
 
The epithelial abnormalities of the cervix are assumed to form a continuous 
spectrum within one disease, an assumption recognised by the adoption of the term 
cervical intraepithelial neoplasia (CIN) to provide a unifying description of pre-
malignant cervical abnormalities. According to this paradigm, cervical disease is a 
disease in which each degree of abnormality merges imperceptibly into the next. 
Differences between the cells and the structure of the epithelium in one part of the 
spectrum compared with another are thus quantitative, rather than qualitative, with 
no well-defined boundary between them (Singer 1989). The finding that cervical 
cancer and its precursors have similar risk factors, with the strength of association 
being lower for precursors than for cancer, lends credibility to this model of the 
natural history (Franco 2002). But clearly, progression along the spectrum is not 
inevitable. 
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The terminology used to describe premalignant lesions of the cervix has changed 
over time (see table 2.2.1). Adoption of terminology based on a rigid subdivision of 
an essentially continuous underlying disease process may appear counterintuitive, 
but is common practice in pathology (Singer 1989). Unfortunately, the manner in 
which the terminology has changed over time does not necessarily reflect an 
improvement in the understanding of the natural history of these lesions. There has 
been a tendency to combine categories in order to reduce interobserver variability 
(Miller 1999). The Bethesda system, for example, does not facilitate the study of 
natural history: the term “lesion” was adopted in preference to “neoplasia” since 
many of these entities are as likely to regress as they are to progress. Although 
there is some correspondence between the terminology used for cytological findings 
and histological diagnoses, these are imperfect. The Papanicolau categories, for 
example, have been shown not to have strict histological counterparts, and are no 
longer recommended for cytological reporting. 
 
In the cohort study described in this thesis, cervical smears were reported using the 
WHO system, and the results of histological assessments were reported using the 
original CIN terminology. Using these systems, the implication is that a smear 
containing mild dyskaryosis, for example, indicates an underlying histological 
abnormality of at worst CIN1, moderate dyskaryosis indicates CIN2, etc. Note also 
that the use of the term “koilocytic atypia” in the original CIN terminology refers to 
cytopathic changes resulting from HPV infection, which can be recognised under a 
microscope: these are sometimes reported as a histological diagnosis of “HPV”, as 
they were in the study described in this thesis. There is a clearly a straightforward 
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conversion between the original and the modified CIN terminology (the modified CIN 
terminology is used throughout this thesis). 
 
Table 2.2.1. Correspondence among reporting terminologies for cervical 
cytology and pathology reportsa. 
 
System Papanicolaou 
class system 
Dysplasia 
terminology 
(WHO system) 
SIL terminology 
(Bethesda system)
Original CIN 
terminology 
Modified CIN 
terminology 
Criteria Cytology 
(originally) Cytology Cytology 
Histology Histology 
Year of 
publication 1954 1953 1989 
1968 1990 
I Normal Within normal limits Normal Normal 
II Atypia (multiple qualifiers) 
Benign cellular 
changes (infection 
or repair) 
    
II Atypia (epithelial cell abnormalities)
ASCUS/AGCUS 
with qualifierb 
    
II or III  
Koilocytotic 
atypia, flat 
condyloma, 
without 
epithelial 
changes 
III Mild dysplasia/ dyskaryosis 
LSIL 
CIN grade 1 
Low grade CIN
III or IV 
Moderate 
dysplasia/ 
dyskaryosis 
CIN grade 2 
IV Severe dysplasia/ dyskaryosis CIN grade 3 
IV or V Carcinoma in situ
HSIL 
CIN grade 3 
High-grade CIN
Categories 
V Invasive carcinoma Invasive carcinoma
Invasive 
carcinoma 
Invasive 
carcinoma 
aMiller 1999, Nanda 2000, Franco 2002; bwhether a reactive, or a pre-malignant, or a malignant 
process is favoured. 
 
 
2.2.1.1 Cervical intraepithelial neoplasia 
 
Cervical intraepithelial neoplasia (CIN), regardless of grade, is asymptomatic and not 
visible, unaided, on examination (Hoffman 1996). According to the CIN histological 
classification system (original, or modified), lesions are graded primarily according to 
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the proportion of the epithelium which is occupied by basaloid, undifferentiated cells 
(figure 2.2.1.1) (Kiviat 1992): 
 
CIN1: CIN grade 1. The upper two thirds of the epithelium usually shows good 
differentiation, although some nuclear abnormalities persist up to the surface (if this 
were not the case, a corresponding cytological diagnosis would not be possible). 
Abnormalities of the nuclei are mild and are most marked in the basal third of the 
epithelium. Mitotic figures (mitotic figure: the microscopic appearance of a cell 
undergoing mitosis; a cell of which the chromosomes are visible by the light 
microscope) are present but not numerous; they are confined to the basal third of the 
epithelium, and abnormal forms are not expected. 
 
CIN2: CIN grade 2. The upper half of the epithelium shows differentiation and 
maturation, again with nuclear abnormalities (atypia) persisting to the surface. 
Abnormalities of the nuclei are more marked than they are in CIN1, and more 
abnormal nuclei are found higher in the epithelium than in CIN1. Mitotic figures, 
which may be abnormal, are present in the basal two-thirds of the epithelium. 
 
CIN3: CIN grade 3. Maturation is confined to the superficial third of the epithelium, or 
is completely absent. Nuclear abnormalities are marked throughout the whole 
thickness of the epithelium. Mitotic figures are present throughout the epithelium and 
may be numerous, with many abnormal configurations. 
 
Determining whether CIN is present in a cervical biopsy is difficult since there are 
benign and physiological changes which can be mistaken for CIN. Having 
determined that CIN is present, deciding the degree of CIN is also difficult due to the 
number of features which have to be considered. Inevitably, there is a degree of 
subjectivity involved in the interpretation of these features, which vary in a 
quantitative rather than in a qualitative way (Singer 1989). Reproducibility is 
therefore a legitimate concern. 
 
 
Figure 2.2.1.1 Schematic representation of the CIN histological classification 
system. 
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2.2.1.2 Cervical glandular intraepithelial neoplasia 
 
The pre-invasive stage of adenocarcinoma of the cervix is believed to comprise a 
continuous spectrum of one disease, similar to that of squamous cell carcinoma.  By 
analogy with CIN, the terminology adopted for this disease includes adenocarcinoma 
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in situ, cervical glandular atypia and cervical glandular intraepithelial neoplasia 
(CGIN) (Kumar 2000). These lesions arise from endocervical epithelium, but are 
much less common than CIN, and consequently much less is known about their 
natural history. There does, however, appear to be a definite association with the 
development of invasive adenocarcinoma (Hoffman 1996, Miller 1999). 
 
In the cohort study described in this thesis, no cases of CGIN or worse were 
identified, and so this disease will not be considered further. 
 
2.2.2 Acquisition of cervical abnormalities 
 
Cervical cytological abnormalities are very common, in particular in young women 
(Winer 2005). In the cohort study described in this thesis, among 1,075 women who 
were HPV DNA negative and cytologically abnormal at study entry, the cumulative 
risk at three years of any cytological abnormality was 28% (95% CI 25% to 32%). 
And of the 246 of these women who had at least one cytological abnormality, 93 had 
at least one further abnormality after having an intervening normal smear: 80 women 
had two “episodes” of cytological abnormality, 12 had three, and one had four 
(Woodman 2001). 
 
Risk factors for the acquisition of CIN are essentially identical to those for the 
acquisition of squamous cell carcinoma of the cervix, but with the strength of many 
associations being attenuated (Hoffman 1996). Risk factors for high-grade CIN 
(CIN2 and CIN3) may differ from those of low-grade CIN (CIN1 and lesser 
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histological abnormalities). For example, in a case-control study of women under the 
age of 40 years who were diagnosed with CIN, risk factors for CIN3 were found to be 
similar to those for invasive disease; CIN1 cases were similar to the controls; and 
women with CIN2 were intermediate between the two. Multiple sexual partners and 
age at first childbirth were strong risk factors for CIN2 and CIN3, as was smoking; 
however, smoking had only a weak association with CIN1 (Cuzick 1990). 
 
The single most important risk factor for cervical neoplasia of all grades is infection 
with certain types of cervical human papillomavirus (HPV) infection. Cervical HPV is 
a very common sexually transmitted infection, which accounts for the prominence of 
sexual behaviour characteristics in the known risk-factors for cervical neoplasia. The 
epidemiological evidence which lends support to a role for cervical infection with 
HPV in the aetiology of cervical neoplasia is now indisputable. Initially, this was 
largely based on studies with a case-control design: these consistently revealed a 
strong association between cervical neoplasia and the detection of HPV DNA in 
samples of exfoliated cervical cells taken at, or subsequent to, diagnosis of disease 
(Munoz 1992). Evidence from these cross-sectional studies has now been 
superseded by that obtained from longitudinal studies, which have again revealed 
strong associations between exposure to infection with cervical HPV and the risk of 
the acquisition, and progression, of cervical disease (Woodman 2002). Cervical HPV 
infection is discussed in greater detail in chapter 3. 
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2.2.3 Progression and regression of epithelial abnormalities of the cervix 
 
Determining an accurate estimate of rates of progression and regression for 
epithelial abnormalities of the cervix is not straightforward. In developed countries, in 
particular those with screening programmes for cervical cancer, all high-grade 
lesions which are detected are now treated, as are many low-grade lesions (see 
section 4.2.3). In general, therefore, the opportunity to observe the uninterrupted 
natural history of cervical disease is no longer possible. It is, however, clear that the 
vast majority of cervical lesions are transient, and are never destined to progress to 
invasive disease (Holowaty 1999). In the cohort study described in this thesis, the 
first episode of cervical cytological abnormality lasted 9 months (interquartile range 6 
to 14 months) before regressing to normal; episodes of cytological abnormality 
lasted longer as the severity of the initial smear in the episode of cytological 
abnormality increased (Woodman 2001). High-grade lesions have a much greater 
probability of progressing to invasive disease than do low-grade lesions, although 
the majority of these lesions also almost certainly regress (Holowaty 1999). One 
cohort study including 17,000 women which, unlike many previous studies, used an 
appropriate time-to-event analysis to estimate risks of progression and regression 
(see chapter 6), found that both mild and moderate dysplasia were more likely to 
regress than to progress, and that the risk of progression increased with increasing 
severity of dysplasia. For example, within five years, 25% of women with moderate 
dysplasia, a cytological diagnosis corresponding to a presumed histological 
diagnosis of CIN2, progressed to severe dysplasia or worse, compared to 63% who 
regressed within the same time period (Holowaty 1999). This report also cites six 
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other studies, with follow-up ranging from 24 to 78 months, all of which report 
progression for women with moderate dysplasia/CIN2. The risk of disease 
progression in these studies ranged from 11% to 53%. 
 
Time to progression from preclinical cervical disease to invasive cervical cancer has 
been estimated to be of the order of several years, if not decades: the age at which 
the maximum incidence of CIN occurs is around 25 to 34 years, at least two decades 
before the age at which the maximum incidence of cervical cancer occurs (Bosch 
2003). Therefore, not only do the majority of preclinical lesions regress without 
treatment, even those which progress to invasive cancer only do so after an interval 
of many years (Miller 1999). 
 
2.2.4 Invasive disease 
 
The term cervical cancer includes a number of different diseases. The most common 
invasive lesion is squamous cell carcinoma, comprising up to 85% of cases; 
adenocarcinomas account for a further 5% to 10%; the remaining rare lesions 
include adenosquamous lesions, adenoacanthomas, small-cell cancers, and 
sarcomas (Souhami 2005). 
 
Age at first sexual intercourse, number of sexual partners, use of oral 
contraceptives, high-parity, socioeconomic status, and smoking have all been 
implicated as risk factors for invasive cervical cancer (Castellsague 2003, 
International collaboration of epidemiological studies of cervical cancer (ICESCC) 
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2006a, 2006c and 2007a). However, the importance of these risk factors may vary 
according to age. In a two-to-one matched case-control study of 121 British women 
diagnosed with cervical cancer under the age of 40 years, only aspects of sexual 
behaviour were found to be important risk factors, and not other cofactors often 
identified in studies of older women. Age at first sexual intercourse and lifetime 
number of sexual partners were found to be the most important risk factors: weak 
associations with smoking and fruit consumption were “explained” by sexual 
behaviour; parity, educational attainment, and social class, were not significant risk 
factors (Cuzick 1996). 
 
2.2.5 Squamous cell neoplasia 
 
Squamous cell neoplasia includes the most common precancerous and cancerous 
conditions of the cervix, from the lowest grade of CIN, to advanced invasive 
squamous cell cervical cancer (SCCC). Risk factors for SCCC include: younger age 
at first sexual intercourse; increasing number of sexual partners; increasing parity; 
younger age at first full-term pregnancy; increasing duration of oral contraceptive 
use; a history of sexually transmitted diseases; low socioeconomic status; and 
smoking cigarettes (Miller 1999, Green 2003, Castellsague 2003, ICESCC 2006a 
and 2006b). 
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2.2.6 Adenocarcinoma of the cervix 
 
The majority of adenocarcinomas of the cervix arise from the endocervical 
epithelium, frequently within the endocervical canal (Souhami 2005). Precursors of 
this cancer are therefore more likely to be missed by cervical cytology tests (see 
section 2.1). These cancers also tend to produce fewer early symptoms, and are 
therefore more likely to be diagnosed at a later stage, than SCCC. Risk factors for 
adenocarcinoma include: younger age at first sexual intercourse; increasing number 
of sexual partners; increasing parity; younger age at first full-term pregnancy; and 
oral contraceptive use; smoking does not appear to be a risk factor for 
adenocarcinoma (Green 2003, Castellsague 2006, ICESCC 2006a, 2006c and 
2007a). 
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Chapter 3 
 
CERVICAL HUMAN PAPILLOMAVIRUS INFECTION 
 
 
 
 
 
Orientation 
 
In this chapter I: 
 
• describe the human papillomavirus 
 
• describe the natural history of cervical human papillomavirus infections 
 
• describe the role of cervical human papillomavirus in the acquisition of cervical 
abnormalities 
 
 
 
 
 
3.1 CERVICAL HUMAN PAPILLOMAVIRUS 
 
Cervical human papillomavirus (HPV) infection is a very common sexually 
transmitted infection. Infection with high-risk types of HPV is now considered to be a 
necessary, but not sufficient, cause of cervical cancer (Munoz 2000). HPV is a 
necessary cause since almost 100% of cervical cancers are positive for HPV DNA 
(Walboomers 1999, Parkin 2006). However, it is clearly not a sufficient cause 
because, while the majority of women appear to acquire cervical HPV infection soon 
after the onset of sexual activity (Collins 2002, Winer 2008), very few subsequently 
develop cervical cancer. Aetiological factors, additional to cervical HPV infection, are 
therefore required. 
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3.1.1 Viruses 
 
Viruses are submicroscopic obligate intracellular parasites: they are parasites which 
can have no mode of existence other than moving from one host-cell to the next 
(Cann 2001). Viruses lack the genetic information which encodes the apparatus 
necessary for the generation of metabolic energy, or for protein synthesis. They are 
therefore absolutely dependent upon the host-cell for these functions. Viruses have 
no ulterior motive: they are “designed” merely for the effective transmission of a 
nucleic acid genome from one host-cell to another. Once inside a host-cell, they co-
opt the cellular machinery in order to replicate themselves for transmission to a new 
host-cell. 
 
Viruses vary enormously in size, shape, and the number, and nature, of the 
molecules from which they are constructed (Flint 2004). There is thus no “typical” 
virus, or virus structure. However, in general, viruses comprise an RNA- or DNA-
genome enclosed in an outer protective “coat” of proteins, called the capsid. The 
capsid may itself consist of sub-units called capsomeres. On exit from a cell, some 
viruses also acquire an envelope surrounding the capsid, formed from structural 
components of the host-cell.  
 
3.1.2 The human papillomavirus 
 
Human papillomaviruses (HPV) are epitheliotropic viruses of the family 
Papillomaviridae (De Villiers 2004), with DNA genomes and non-enveloped 
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icosahedral capsids (Severson 2001, Doorbar 2006). Over 120 genotypes have now 
been identified, of which at least 118 have been fully sequenced, and approximately 
40 types are associated with lesions of the anogenital tract (which includes, but is 
not restricted to, the cervix) (Peitsaro 2002, De Villiers 2004).  
 
3.1.2.1 Organisation of the HPV genome 
 
The HPV genome consists of double-stranded, circular, DNA, the size of which 
varies according to HPV type, but they are all typically around 8,000 base-pairs in 
length (Mahdavi 2005). For example, the total HPV16 genome is 7,904 basepairs in 
length (PubMed accession number NC_001526), compared with 7,857 for the 
HPV18 genome (PubMed accession number NC_001357). The HPV genome codes 
for eight proteins, E1, E2, E4, E5, E6, E7 (the early proteins), L1 and L2 (the late 
proteins) (Mahdavi 2005); these genes overlap in the genome. A non-coding region 
of about 1,000 base pairs, called the upstream regulatory region or the long control 
region, separates the early and late gene clusters (Severson 2001) (figure 3.1.2.1). 
The viral genome does not encode a unique DNA polymerase, which is required for 
DNA replication, and therefore the virus must depend upon the replication machinery 
of the host-cell for the generation of viral progeny (Alani 1998). 
 
Comment: With respect to gene nomenclature, the apparently missing E3 gene is 
present only in a few papillomaviruses which infect animals; similarly there are E8, 
L3, and L4 genes, which are encoded by only a few papillomavirus types. 
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Figure 3.1.2.1. Schematic representation of the HPV16 genome. E1 to E7 are 
the early genes, L1 and L2 the late genes, and LCR the long control region (or 
the upstream regulatory region). 
 
 
 
 
3.1.2.1.1 Late genes 
 
The Late (L) genes encode the viral capsid proteins: the L1 and L2 genes code for 
the major and minor viral capsid proteins, respectively. The HPV capsid comprises 
360 copies of the L1 protein, organized into 72 pentavalent capsomeres, with one 
copy of L2 at the centre of the pentavalent capsomeres, at the virion vertices 
(Doorbar 2006). The L1 and L2 genes are not expressed in precancerous or 
malignant cells, but these structural proteins are important in immunological settings, 
30 
 
such as vaccine development (Zur Hausen 2002), and in neutralizing antibody 
assays (see sections 16.6, 16.7 and chapter 17). 
 
3.1.2.1.2 Early genes 
 
The early (E) genes function primarily in episomal replication. 
 
E1 is a regulatory protein, which plays a pivotal role in initiating viral-DNA replication 
and regulation of viral-gene expression, and is thus essential for permissive infection 
(Severson 2001). 
 
E2 is a regulatory protein, which codes for a protein responsible for viral replication 
and transcription (Mahdavi 2005). 
 
E4 appears to have a role in disrupting the cytoskeleton integrity of the host-cell, and 
thus in helping the assembly, maturation, and release, of the virus (Doorbar 2006). 
Despite its name, E4 is expressed late in the virus-replicating cycle (Severson 2001). 
 
E5 has been implicated in cellular transformation (Severson 2001, Mahdavi 2005): it 
induces some transformed phenotypes in established cells, and can increase the 
proliferative capacity of human keratinocytes (Flint 2004). 
 
E6 is an oncogene. The E6 gene of high-risk HPV types encodes a transforming 
protein which is capable of immortalizing epithelial cells and is thought to play a role 
31 
 
in the initiation of the oncogenic process (Flint 2004). The protein products of this 
gene interfere with the normal function of the p53 tumour suppressor gene: HPV E6 
binds with p53, leading to its dysfunction, and thereby impairing its ability to block 
the cell-cycle when DNA errors occur. E6 also protects the cell from apoptosis 
(Mahdavi 2005). 
 
E7 is an oncogene. The E7 gene of high-risk HPV types encodes a transforming 
protein capable of immortalizing epithelial cells, and is thought to play a role in the 
initiation of the oncogenic process. The protein-product of this gene binds to 
retinoblastoma protein (pRb), and activates genes which start the cell-cycle, leading 
to tissue proliferation (Mahdavi 2005). High-risk HPV E7 proteins bind to pRb with 
much greater efficiency than do low-risk HPV E7 proteins. 
 
E1 and E2 are negative regulators of E6 and E7 expression: viral integration into the 
host-cell genome typically occurs within the viral E1 or E2 genomes, thereby 
disrupting these genes, and leading to the loss of repression of E6 and E7 
transcription (Severson 2001). E6 and E7 are consistently found to be expressed in 
HPV-associated cervical cancers. Although continued expression of E6 and E7 is 
not sufficient for malignant conversion of squamous cells, continued expression of 
these genes appears to be necessary for maintaining the transformed phenotype. It 
has been shown that only the E6 and E7 genes of high-risk HPV types are able to 
immortalize human cells in tissue culture (Zur Hausen 2002). 
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3.1.2.2 Classification of HPV types 
 
Genotyping of HPV, or the classification of HPV into types, is based on the DNA 
sequences of the L1, E6, and E7 genes (Mahdavi 2005), analysed by either 
hybridization techniques, or by direct sequence comparison: a difference of 10% or 
more in sequence with respect to previously established strains, is sufficient to 
define a new type (Mahdavi 2005); subtypes differ by between 2% and 10%; and 
variants differ by less than 2%. For example, HPV16 and HPV18 share only 50% 
homology at the nucleotide level. 
 
HPV types differ according to their tissue affinity and pathogenicity. Therefore, they 
can also be classified into subtypes which infect stratified squamous or mucosal 
epithelia; or more typically, and of more direct relevance to this thesis, according to 
their observed association with cervical cancer in epidemiological studies. 
Oncogenic, or high-risk, types are those types most frequently detected at the time 
of diagnosis of cervical cancer, for example HPV16 and HPV18; non-oncogenic, or 
low-risk, types, for example HPV6 and HPV11, are less likely to be detected in 
association with cervical cancer (Mahdavi 2005). Intermediate-, or medium-risk, 
types are also sometimes separately distinguished. 
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3.1.2.3 The HPV life-cycle 
 
All viruses have life-cycles which, for convenience of description, can be divided into 
distinct phases: attachment, penetration, uncoating, expression, assembly, 
maturation, and release (Cann 2001).  
 
The papillomavirus life-cycle differs from that of all other virus families: infection 
requires the availability of epidermal or mucosal epithelial cells which are still able to 
proliferate, i.e. basal-layer cells (Zur Hausen 2002). All known HPVs are exclusively 
epitheliotropic; they do not infect or express their genes in the underlying dermis 
(Mahdavi 2005). 
 
Basal cells in the cervical squamous epithelium rest on the basement membrane, 
which is supported by the dermis. HPV is thought to access the basal cells through 
micro-abrasions in the cervical epithelium (figure 2.1), since only undifferentiated, 
basal, replicating keratinocytes are infected by HPV (Woodman 2007). A viral 
receptor which mediates the attachment of HPV virions to the host-cell has yet to be 
definitively identified (Alani 1998). Penetration into a host-cell of attached virions is a 
slow process, with a half-life of hours, and occurs via endocytosis (Mahdavi 2005). 
Once inside the cell, uncoating occurs, and the viral genome is released from the 
virion, allowing viral DNA to be transported into the nucleus, where the cellular DNA 
replication machinery is located. All but one of the early HPV genes, E1, E2, E5, E6 
and E7, are then expressed, and the viral DNA replicates from episomal DNA. It is 
thought that the virus maintains its genome as a low-copy-number episome in the 
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basal cells of the epithelium (typically quoted as 10 to 200 copies per cell, or 50 to 
100); the contribution of E6 and E7 to basal cell proliferation during in vivo infection 
is currently uncertain, and it has been suggested that expression of E1 (and possibly 
also E2) may be sufficient for the maintenance of viral episomes in basal cells 
(Doorbar 2005). 
 
Normal squamous human epithelia grow as stratified layers, where only cells in the 
basal-layers are able to actively divide (Hebner 2006). After division of infected 
basal-cells, some progeny remain in the basal-layer as infected cells; others detach 
and move away from the basement membrane towards the suprabasal-layers of the 
epithelium, and undergo cellular differentiation to become epithelial cells (Mahdavi 
2005). In the upper layers of the epithelium (the midzone and the superficial zone) 
the viral genome is replicated further, increasing to several thousand copies per cell 
(Wilson 2005), and the late genes L1 and L2, and the “early” gene E4, are 
expressed (Woodman 2007). Progeny virions are assembled in the nucleus when L1 
and L2 proteins encapsidate the viral genomes, which are then free to mature. 
 
Virus replication and assembly is tightly linked to the differentiation of epithelial cells 
(Mahdavi 2005): infectious virions are produced only in the terminally-differentiated 
cell (i.e. cells which will not differentiate further). The virus-laden squamous cells are 
then shed, from which the virus is released to initiate a new infection.  
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3.1.3 The acquisition of cervical HPV infection 
 
There is compelling evidence to suggest that a cervical HPV infection, as distinct 
from HPV infections at more superficial sites which may follow vertical or horizontal 
transmission, is only acquired as a result of penetrative vaginal sexual intercourse 
(Ley 1991, Andersson-Ellstrom 1996a, Koch 1997). The male sexual partner is thus 
the vector of HPV infection. The majority of women appear to acquire cervical HPV 
infection soon after the onset of sexual activity. In an analysis of 242 women from 
the cohort study described in this thesis who were recruited within six months of first 
sexual intercourse, and who were censored on acquiring a second sexual partner, 
46% were found to be HPV-positive within three-years of first sexual intercourse 
(Collins 2002). In a repeat of this analysis in 130 university students aged 18 to 22 
years recruited within three months of first sexual intercourse, 50% were found to be 
HPV-positive within three years of first sexual intercourse (Winer 2008). 
 
Risk factors for the acquisition of cervical HPV infection are similar to those for the 
acquisition of cervical cancer and its precursors, as might be anticipated since HPV 
infection is in the causal pathway for these conditions. Reported risk factors have 
included various aspects of a woman’s sexual behaviour, in particular: age at first 
sexual intercourse; lifetime number of sexual partners; recent number of sexual 
partners; history of other sexually transmitted diseases; and oral contraceptive use; 
other factors included the sexual behaviour of a woman’s male sexual partner(s), 
and cigarette smoking, dietary factors, and human immunodeficiency virus status 
(Burk 1996, Moscicki 2001, Schiffman 2003, Baseman 2005, Vaccarella 2006a, 
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Vaccarella 2006b). There is evidence that risk factors differ according to oncogenic 
potential: the association between low-risk HPV types and sexual behaviour is not as 
pronounced as that with high-risk HPV types (Kjaer 1997, STD-2000-Richardson, 
Vaccarella 2006b). Reports vary, but use of condoms may be protective against the 
acquisition of HPV infection: however, it is probably only consistent use which 
provides protection (Winer 2006). 
 
The prevalence of cervical HPV infection varies with age. For example, in 3,305 
cytologically normal cervical smears taken from women aged between 15 and 69 
years in the general population of Amsterdam, the Netherlands, prevalence was 
highest (20%) in women aged 25 to 29 years, declining rapidly thereafter (Jacobs 
2000). Other studies have reported similar results (Burk 1996a, Castle 2006). 
 
Longitudinal, cross-sectional, and case-control studies have shown that HPV16 is 
the most common type of HPV infection, followed by HPV18 (Woodman 2001, Winer 
2003). 
 
3.1.4 Persistence of HPV infection 
 
HPV infections can be categorised into latent, subclinical, and clinical, infections. 
Latent HPV infections can only be detected by virological means, and cause no 
clinical signs. Subclinical HPV infections can be detected by pathology techniques, 
e.g. cytopathological changes seen (under the microscope) in cervical smears, or by 
colposcopically-directed biopsy and histological studies, but not by unaided 
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examination. Clinical HPV infections are defined as those which result in visible 
lesions (by the naked eye), or which display clinical symptoms, for example genital 
warts (De Sanjose 1992). 
 
Most young women with cervical HPV infection appear to resolve their infection 
spontaneously in a very short time: in the cohort described in this thesis, median 
duration of an incident cervical HPV infection of any type was 13.7 months (inter-
quartile range 8.0 to 25.4), with some differences among specific types (Woodman 
2001). However, many viruses establish persistent infections which are 
characterized by continuous low- or high-levels of viral replication (for example the 
human immunodeficiency virus (HIV) and the hepatitis B virus) or by periodic 
reactivation of a latent infection following apparently disease-free intervals (for 
example the herpes simplex virus (HSV)) (Woodman 2007). Although it is now 
widely believed that a persistent infection with a high-risk HPV type is necessary for 
the development of high-grade cervical intraepithelial neoplasia (CIN) or invasive 
disease, the term “persistence” has often been loosely defined when testing this 
hypothesis. A fundamental problem relates to inferences drawn from observations 
made at indeterminate points during the natural history of the infection. In these 
circumstances, the distinction between a persistent and a transient infection is 
arbitrary to the extent that it is dependent on both the timing of the samples in 
relation to the natural history of the infection, and the time interval between the 
samples: the shorter the interval between tests, the more likely it is that an infection 
will be defined as persistent. 
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It is now clear that epithelial abnormalities of the cervix can be evident shortly after 
the first detection of HPV DNA in cervical samples (Woodman 2001). This is not to 
deny that HPV can establish a persistent infection, nor that a persistent cervical HPV 
infection is necessary for the development of invasive cervical disease. However, it 
remains to be determined whether persistent infections are characterized by the 
continuing detection of HPV, or by a state of latency during which the virus remains 
undetectable, only to reappear later. A mechanism for latency has not yet been 
established, nor is it clear whether the differences between a latent and an active 
cervical infection are qualitative or quantitative. However, a woman cannot be 
defined as having a persistent infection in any meaningful virological sense just 
because she tests positive for HPV on two occasions, some months apart, and 
therefore she should not, on the basis of this evidence, be considered to be at a high 
risk of cervical cancer. Nor can a woman who tests positive for a specific HPV type 
necessarily be considered to have cleared her infection when she first tests negative 
for that type. A clearer understanding of these issues is essential for the effective 
implementation of screening strategies which include HPV testing. 
 
3.1.5 HPV-mediated progression from pre-cancerous lesions to cervical cancer 
 
There is now overwhelming epidemiological and laboratory evidence linking cervical 
HPV infection with the acquisition of cervical cytological abnormalities, and of 
cervical cancer. Low-risk HPV types, such as types 6 and 11, cause benign genital 
warts; high-risk HPV types, such as types 16 and 18, are associated with the 
development of high-grade cervical abnormalities, and of cervical cancer. HPV16 is 
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the type most frequently detected at the time of diagnosis of squamous-cell cancer, 
followed by HPV18; HPV18 is the type most strongly associated with 
adenocarcinoma of the cervix (Woodman 2003). HPV16 is the type most commonly 
linked with cancer, since it is present in 50% of cervical cancers and high-grade CIN 
(and in 25% of low-grade CIN) (Koutsky 2002), and is estimated to account for 
approximately 60% of cervical cancers, with HPV18 adding another 10% (Harper 
2004). 
 
Not all viral genomes which are transported to the nucleus of the host-cell remain as 
episomal DNA. HPV can be found in cervical material in episomal forms, integrated 
forms (in which the viral genome becomes inserted into the host-cell genome), or in 
mixed forms which contain both. Although integration into the host-cell genome is 
effectively the end of the life-cycle for a virus, this change of physical-state from a 
“free” to a “captured” piece of DNA has implications for the malignant potential of the 
virus. Low-grade intraepithelial lesions support productive viral replication and 
shedding; only a fraction of these lesions will progress to high-grade cervical 
intraepithelial neoplasia. The integration of the HPV genome into the host-cell 
chromosomes is associated with the progression of untreated lesions. Viral 
integration into the host-cell genome often occurs downstream of the E6 and E7 
genes, in the E1 or E2 region of the virus genome (both the host cell and viral 
genomes are affected by integration); disruption of these coding regions results in a 
loss of negative-feedback control of E6 and E7 oncogene expression by the viral 
regulatory E1 or E2 proteins, which can no longer be manufactured by the cell, since 
their DNA sequence has been disrupted. Oncogene (i.e. E6 and E7) expression is 
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thus free to proceed unchecked. The prevalence in exfoliated cervical cells, or in 
cervical tissue, of episomal or integrated forms of HPV, or both, varies with the 
severity of disease, the infecting HPV type, and the method used to determine the 
physical-state of the virus (Woodman 2007). Development of invasive cancer 
requires additional genetic events, facilitated by E6- and E7-mediated inactivation of 
the genome guardians p53 and pRb, genomic instability, and suppression of 
apoptosis (Mahdavi 2005). 
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Chapter 4 
 
THE PREVENTION OF CERVICAL CANCER 
 
 
 
 
 
Orientation 
 
In this chapter I: 
 
• define primary- and secondary-prevention 
 
• describe strategies for the secondary-prevention of cervical cancer, and attempts 
to improve the efficiency of these strategies 
 
• discuss primary-prevention strategies based on HPV vaccines 
 
 
 
 
 
4.1 PRIMARY- AND SECONDARY-PREVENTION 
 
Primary-prevention of a targeted disease refers to measures taken to prevent that 
disease occurring in susceptible individuals: for example vaccination against certain 
types of human papillomavirus in young women to prevent the occurrence of cervical 
cancers associated with those types. Successful primary prevention is potentially the 
most cost-effective form of health care, since it eliminates not only the disease itself 
but also the sequelae of that disease.  
 
Secondary-prevention refers to measures taken to identify and treat asymptomatic 
subjects who already have preclinical disease, and thereby prevent the progression 
of disease in these already-diseased individuals. Secondary-prevention aims to 
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minimize the impact of disease. Successful secondary-prevention relies upon the 
targeted disease having a relatively long preclinical phase, and upon the availability 
of an effective treatment: there has to be an opportunity to identify the disease at an 
early stage, and the disease must be treatable, or the treatments must be capable of 
altering the natural history of the disease in an advantageous way. 
 
4.2 SECONDARY-PREVENTION OF CERVICAL CANCER 
 
A cervical cancer screening programme which uses cytological tests, or other 
methods, to identify women at high-risk of cervical cancer, is an example of a 
secondary-prevention initiative. 
 
4.2.1 Screening tests for cervical cancer 
 
In developing countries, where health facilities may be basic, visual inspection is, of 
necessity, one approach adopted for the detection of cervical cancer at an early 
stage. Direct visual inspection (or cervicoscopy) requires only a speculum, good 
light, and the use of dilute acetic acid. After swabbing the cervix with acetic acid, 
areas of dysplasia are stained white. Aided visual inspection, which is aimed at 
detecting cervical intraepithelial neoplasia grade 3 as well as early cancer, requires, 
in addition, a small magnifying instrument with which to view the acetic acid-stained 
cervix (Miller 1999, Wright 2003). 
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In developed countries, where health facilities are limited only by the allocation of 
resources, cervical cytological screening at regular intervals is the established 
method of screening for cervical cancer. The objective of screening in this case is 
primarily to detect precursors of cervical cancer, i.e. to identify disease which, if left 
untreated, would develop into cancer. The majority of cervical cancers, and therefore 
their precursors, arise in the transformation zone (see section 2.1.1). In cervical 
cytological screening, exfoliated cervical cells are collected using a device and 
sampling technique designed to sample cells from the entire transformation zone: a 
sample which does not contain endocervical cells, indicating that the entire 
transformation zone was not sampled, is considered inadequate. Sampling devices 
include the Ayre’s spatula, as used in the cohort study described in this thesis, 
cervical brushes, cervical swabs, etc. According to the original practice, the 
cytological material which is collected is then “smeared” evenly on to a glass slide 
(hence cervical smear), and a fixative applied. The smear is then transferred to a 
laboratory where it is examined under a microscope (“read”) by a cytopathologist for 
indications of cytological abnormalities. To aid interpretation of the smear result, an 
adequate “history” must accompany the smear e.g. details of the woman’s menstrual 
cycle, current hormonal treatments etc. 
 
There is now an alternative to the conventional smear, liquid-based cytology. The 
sample is taken, as described above, using a brush device, which is then either 
placed into liquid preservative in its entirety, or the cells on the brush are rinsed into 
the preservative. The liquid sample is then sent to the laboratory for preparation of a 
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cellular monolayer for examination. Examination of samples is currently (September 
2008) manual, but it may be possible to automate this in future. 
 
No screening test is perfect, and cervical smears are no exception. Cervical cytology 
screening involves taking smears in a standardised way, transferring the cytological 
material sampled to another medium, storage of the sample, and interpretation of the 
smear. Clearly this procedure is subject to error at a number of stages. The 
percentage of false-negative smears varies from 15% to 50%, while the percentage 
of false-positives is approximately 10%. This means that the sensitivity of cytology 
for cervical cancer is quite low (50% to 85%), although the specificity is quite high 
(approximately 90%) (Miller 1999, Franco 2002). The lack of sensitivity of an 
individual test is compensated for by repeating the tests after a relatively short time 
interval (Rozendaal 1996). And even if a smear is taken, and reported, without error 
or misinterpretation, cervical smears have detection rather than diagnostic accuracy: 
once a smear has been reported as positive, further tests are required for 
confirmation of the presence of disease. Nevertheless, taking cervical smears is 
minimally-intrusive, presents little or no risk to the woman, and has proven to be 
acceptable to the majority of women in developed countries. 
 
4.2.2 Criteria for effective cervical cancer screening programmes 
 
The aim of a cervical cancer screening programme is to reduce mortality from 
cervical cancer by identifying and treating women with cervical cancer precursors 
before they develop invasive cancer, and thereby prevent death due to cervical 
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cancer. The availability of a suitable screening test is clearly a crucial requirement, 
but this alone will not guarantee the success of a cervical screening programme. The 
essential crtiteria which must be met by an organised cervical screening programme 
are as follows (Miller 1999):  
 
• Individual women in the target population are identifiable. 
• Measures are available to guarantee high-coverage and high-attendance, 
such as personal letters of invitation. 
• Adequate facilities exist for obtaining cervical smears, and adequate 
laboratory facilities are available to examine them 
• An organised quality control programme for obtaining and interpreting cervical 
smears is in place 
• Adequate facilities exist for the diagnosis and appropriate treatment of any 
confirmed neoplastic lesions identified 
• A carefully designed (and agreed upon) referral system is in place for the 
management of any abnormality found, and for providing information about 
normal screening tests. 
• The evaluation and monitoring of the complete programme is organised 
effectively. 
 
4.2.3 The NHS cervical screening programme 
 
An example of a population-based cervical screening programme is the NHS 
cervical screening programme (NHSCSP) in the UK. Ad hoc cervical screening 
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began in the UK in the mid-1960s. However, it was hoped that the introduction of the 
National Cervical Screening Programme in 1988 would not only increase population 
coverage, but also reduce the over-screening of women who are at low-risk of 
cervical cancer. 
 
The NHS call and recall system is a national computerised system which 
automatically invites women who are registered with a general practitioner (GP) for 
cervical screening. Approximately four million women are now screened each year, 
with coverage approaching nearly 80% of the target population (NHSCSP website, 
September 2008). Originally, all women aged between 20 and 64 years were invited 
for screening at time intervals of three to five years; there were regional variations in 
screening intervals. Currently (September 2008), all women aged between 25 and 
64 years are invited for screening, with those under 50 routinely invited every three 
years and those over 50 every five years; women aged 65 years or over are also 
invited if they have not been screened since the age of 50, or if they have had recent 
abnormal cervical smears; and opportunistic screening of women who attend their 
GP, or a family planning clinic, for other reasons, is also encouraged, by means of 
incentive payments. Some other programmes invite women to attend for the first 
time once they become sexually active.  
 
The NHS call-recall system keeps track of smear results and any follow-up of 
abnormal smears, and recalls women for screening at the appropriate interval. 
Women with normal smears remain on routine recall. Women with cervical smears 
containing borderline nuclear abnormalities (BNA) or mild dyskaryosis, are recalled 
47 
 
for repeat smears at intervals of six months. Women who have three consecutive 
smears containing BNA, or two consecutive smears containing mild dyskaryosis, are 
referred for colposcopic assessment; women who have any smear containing 
moderate or severe dyskaryosis are immediately referred for colposcopic 
assessment (see section 5.2.3 for how this differs from the protocol used in the 
cohort study described in this thesis). Women who have smears suspected of 
containing invasive cancer, or glandular neoplasia, are (urgently) referred to a 
gynaecological oncologist: these women are not considered further here. Women 
only return to routine recall once they have had three consecutive normal smears, 
taken at six-month intervals. 
 
Colposcopic assessment is the standard method for evaluating the cervix following 
the detection of cytological abnormalities. A colposcope is a device for viewing the 
cervix under magnification: the cervix is swabbed with acetic acid to highlight 
abnormal areas, and biopsies of these areas are taken for histological assessment. 
In the NHSCSP, either a punch biopsy is taken or an excision biopsy, usually using a 
diathermy loop. As with cytology, for a satisfactory colposcopic assessment, the 
entire transformation zone must be visualised (Hoffman 1996). 
 
Women can be treated upon request at their first colposcopic assessment: an 
excision biopsy aims to remove the abnormality completely. Otherwise, only women 
who have histologically-confirmed disease are offered treatment. The NHS 
guidelines suggest that women with CIN1 can either be treated immediately, or kept 
under close colposcopic surveillance; in contrast, women with CIN2 or CIN3 should 
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be treated immediately. Treatment is usually given under general, rather than local, 
anaesthetic. Once a woman has been treated for CIN, she is followed-up, either in 
clinic or in primary care, with at least three smears being taken in the five-year 
period following treatment.  
 
Smears are taken using an appropriate sampling device and technique; as of August 
2008, liquid-based cytology, with manual interpretation, is in use. Quality assurance 
procedures are in place at all appropriate stages of the screening programme, and 
the programme is subject to regular audit. 
 
4.2.4 Effectiveness of cervical cancer screening programmes 
 
Screening for cervical cancer was introduced, in the UK and elsewhere, without 
awaiting evidence from prospective randomised controlled trials; such trials will not 
now be undertaken. In lieu of such trials, the decreasing mortality rate from cervical 
cancer is taken as evidence that screening is effective. 
 
One study used routine statistics to assess the impact of screening on the incidence 
of, and mortality from, cervical cancer in England following the introduction of the 
NHS call-recall system (Quinn 1999). This study found that the overall incidence of 
invasive disease remained stable up to the end of the 1980s (figure 1.1.2 suggests 
similar results for Great Britain), but thereafter fell continuously. Mortality from 
cervical cancer in England has been decreasing since 1950 (figure 1.2.2 suggests 
similar results for the UK since 1970 at least), but the authors claim that this 
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accelerated at the end of the 1980s. Other studies using similar methods have 
reached similar conclusions regarding the efficacy of cervical screening, both in the 
UK (Peto 2004) and in young women in European countries (Levi 2000). The 
position of cervical screening programmes now seems unassailable. 
 
4.2.5 Efficiency of cervical cancer screening programmes 
 
Cervical cancer screening programmes may be effective in reducing mortality from 
cervical cancer, but they do so at the expense of substantial over-diagnosis and 
unnecessary treatment. Although the treatment of pre-malignant changes in the 
cervix is therapeutically efficacious, it is also procedurally inefficient. This situation 
has arisen because of uncertainties surrounding the natural history of CIN. 
 
Cytological and histological examinations cannot reliably distinguish the few women 
with abnormal smears who will progress to invasive cancer, from the vast majority of 
those whose abnormalities will spontaneously regress (see section 2.2.3). Therefore 
it is necessary to treat all abnormalities which exceed a certain severity. For 
example, in Japan 35 million cervical smears are performed annually, with evidence 
of cervical cancer revealed in approximately 2,000 women (Tanaka 2004). In the US, 
for each new case of invasive cervical cancer found by using cytological smears, 
there are approximately 50 other cases of abnormal smears consistent with 
precursor lesions; to this must be added twice as many equivocal or borderline 
abnormalities (Franco 2002). Even in developing countries, where 83% of cases 
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occur and where cervical cancer accounts for 15% of all female cancers, the risk of 
cervical cancer before the age of 65 years is only 1.5% (Parkin 2005).  
 
The identification and treatment of cytological abnormalities of uncertain malignant 
potential is an expensive undertaking. For example, in England the cost of cervical 
screening, including the cost of treating cervical abnormalities, is estimated to be 
approximately £157 million a year (NHSCSP website, September 2008). 
Presumably, in Japan, where ten times as many smears are taken annually, the cost 
of the programme is in excess of £1 billion. Improving the efficiency of their 
cytological screening programmes should therefore be a priority for any health 
system. 
 
4.2.6 Improving the efficiency of cervical cancer screening programmes 
 
Infection with high-risk types of the human papillomavirus (HPV) is the most 
important risk factor for cervical cancer (see chapter 3). Therefore, it has been 
suggested that adding testing for the presence of cervical infection with HPV to 
cervical screening programmes can be used to improve the efficiency of these 
programmes. If HPV testing can be used to identify women at low-risk of acquiring 
cervical cytological abnormalities, or to identify those women with abnormalities who 
are at low-risk of progression to high-grade CIN, or worse, then efficiency gains can 
be realised by screening these women less frequently. 
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Several randomised controlled trials have now reported on the effectiveness of either 
adding HPV testing to conventional cervical cytology screening, or replacing 
conventional screening by HPV testing, outright. A trial undertaken in Sweden has 
reported that in women aged 32 to 38 years, the addition of HPV testing, using a 
PCR-enzyme immunoassay detecting 14 high-risk types, to conventional cytology, 
screening significantly reduced the incidence of CIN2 and CIN3 compared to 
conventional cytology alone (Naucler 2007). A similar trial in the Netherlands has 
reported that in women aged 29 to 56 years, the addition of the same HPV test as 
used in the previous trial to conventional cytology screening significantly reduced the 
incidence of CIN3, or worse, compared to conventional cytology alone (Bulkmans 
2007). A trial undertaken in Canada in women aged 30 to 69 years found that the 
hybrid capture 2 HPV test, used alone, had greater sensitivity for detecting CIN2 and 
CIN3 than conventional cytology (Mayrand 2007); a similar conclusion was reached 
by another trial of this HPV test undertaken in Italy in women in the same age-range 
(Ronco 2008). A trial investigating this issue is currently underway in the UK (the 
ARTISTIC trial), and is due to report in 2009 (NHSCSP website, September 2008). 
Of course none of these trials address the prevention of the primary end-point of 
cervical screening programmes, i.e. mortality from cervical cancer. 
 
Other triage strategies relying upon HPV testing include identifying women with 
“persistent” infections with high-risk types; measuring HPV viral load; and the 
detection of integrated forms of HPV. The difficulties with the concept of persistent 
infections have been described earlier (section 3.1.4); the difficulties with using 
measurements of HPV viral load will be described subsequently (see section 23.7). It 
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has been proposed that the identification of integrated forms of HPV could be a 
useful biomarker for progressive disease. There are several problems with this 
proposal. First, the identification of small numbers of integrated forms of HPV in a 
background of mainly episomal forms will always be a technical challenge when only 
exfoliated cells are available for analysis. Second, if integrated genomes are often 
transcriptionally silent, or become so shortly after integration, then their detection 
might have limited prognostic usefulness (see section 3.1.5 for a discussion of the 
physical state of HPV). 
  
4.3 PRIMARY-PREVENTION OF CERVICAL CANCER 
 
We now appear to be entering the era of the primary-prevention of cervical cancer, 
beginning with the approximately 70% of cervical cancers associated with the two 
most common high-risk HPV types, type 16 and type 18. 
 
Two prophylactic vaccines targeting HPV have now been developed. GARDASIL® is 
a quadrivalent vaccine against HPV16, HPV18, HPV6, and HPV11, marketed by 
Merck and Company; Cervarix® is a bivalent vaccine against HPV16 and HPV18, 
marketed by GlaxoSmithKline PLC. These vaccines have been evaluated in several 
multi-centre, randomised, double-blind, placebo-controlled, clinical trials (Villa 2005, 
Mao 2006, FUTURE II study group 2007a, Garland 2007, Paavonen 2007): data 
from the cohort reported in this thesis were used to inform the sample size 
calculation for some of these trials. 
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The vast majority of cervical HPV infections will not be followed by a diagnosis of 
cervical cancer, and for those which are, the time interval between the acquisition of 
the initial infection and the diagnosis of invasive disease is of the order of decades 
(see section 2.2.3). Therefore, the phase III trials evaluating these vaccines have 
used intermediate virological- and disease-outcomes as surrogates for estimating 
the impact of the vaccines on the incidence and mortality of invasive cervical cancer. 
One trial evaluating the quadrivalent vaccine used co-primary composite disease 
outcome measures: the incidence of genital warts, vulvar or vaginal intraepithelial 
neoplasia, or cancer; and the incidence of cervical intraepithelial neoplasia, 
adenocarcinoma in situ, or cancer associated with HPV types 6, 11, 16 and/or 18 
(Garland 2007). Another used a single primary composite disease outcome 
measure: the incidence of CIN2, CIN3, adenocarcinoma in situ, or invasive 
carcinoma of the cervix, associated with the detection of HPV16 or HPV18 DNA. The 
trial evaluating the bivalent vaccine used the incidence of CIN2 or worse associated 
with HPV16 and/or HPV18 as its primary composite disease outcome measure 
(Paavonen 2007). 
 
All three phase III trials have reported a significant reduction in the incidence of their 
primary outcome(s) in the vaccinated arm compared to the placebo arm, and both 
vaccines appear to offer almost 100% protection against high-grade cervical 
intraepithelial neoplasia (HGCIN), or worse, associated with HPV16 and HPV18. 
 
These exciting results have persuaded many of the need for a population-based 
vaccination programme, including the UK Department of Health: as of September 
54 
 
2008, a national programme of HPV vaccination has been introduced in the UK 
(NHSCSP website, September  2008). Initially, the Cervarix® vaccine, given as three 
injections over six months, is being offered to girls aged 12 to 13 years, i.e. prior to 
the presumed onset of sexual activity. This will be followed by a catch-up 
programme which, by the year 2011, will result in vaccination having been offered to 
all girls up to 18 years of age. Women over the age of 18 years, i.e. after the 
presumed age of onset of sexual activity, will not be offered vaccination. 
 
However, there are issues surrounding the vaccines which remain unresolved. A full 
cost-benefit analysis of a HPV vaccination programme must consider the impact of 
vaccination on the overall incidence of disease in the population, and not just that of 
disease associated with vaccine types. For example, a combined analysis of four 
randomised controlled trials (two phase II, and two phase III), reported a 44% 
reduction in the overall incidence of HGCIN following vaccination with the 
quadrivalent vaccine (Future II study group 2007b) (see table 4.3). This falls far short 
of the 100% protection popularly perceived to be offered by the vaccine, but this is 
not surprising, given that this analysis included women who were already 
seropositive to, or HPV DNA-positive for, vaccine types, or both, at study entry. 
Unfortunately, neither the combined analysis of the quadrivalent vaccine, nor the 
interim analysis of the phase III trial of the Cervarix® vaccine, reported the reduction 
in the overall incidence of HGCIN in women who were naïve for both types targeted 
by the vaccine, at study entry. However, one of the trials contributing to the 
combined analysis does separately report results for women who resemble those 
who are likely to be targeted for vaccination (Future II study group 2007a). This trial 
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found only a 27% reduction in the overall incidence of HGCIN among 9,396 women 
who tested negative for HPV16 and HPV18 at enrolment. This finding, which has 
received little attention, is critical to any cost-benefit analysis.  
  
If the overall reduction in the incidence of HGCIN is less than that predicted, then the 
benefits of a vaccination programme will also be less than anticipated. The apparent 
shortfall in the reduction in the incidence of HGCIN may have arisen because of an 
overestimate of the contribution of vaccine types to the overall incidence of HGCIN: 
the attribution of causality to a specific HPV type will always be problematic when 
contemporaneous, or sequential, infection with more than one HPV type is common, 
and more than one HPV type precedes the diagnosis of the outcome (Woodman 
2001, Gravitt 2007). 
 
However, a plausible alternative explanation has been offered for the possible 
continuing  increase in the overall incidence of HGCIN among vaccinated women 
(Sawaya 2007). The disappointing performance of the vaccine is consistent with the 
possibility that other oncogenic HPV types have “filled the biological niche” left after 
the elimination of HPV16 and HPV18. It is therefore now of considerable interest to 
know which HPV types continue to cause HGCIN in women vaccinated against 
HPV16 and HPV18. This information, which surely is readily available, will be critical 
when considering prospects for second-generation vaccines, but has yet to be 
published. 
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Table 4.3. Protective efficacy of Gardasil® against HPV types 6, 11, 16, 
and/or 18-associated high-grade CIN (HGCIN), and HGCIN associated with 
any HPV type, in “all comers”, and in those naïve for one or more types 
targeted by the vaccine. 
 
Population Reduction in the incidence of 
HGCIN1  associated with HPV 
types 6, 11, 16, and/or 18 (95% CI) 
Reduction in 
incidence of all 
HGCIN1 (95% CI) 
Naïve 99% (93 to 100)2 27% (4 to 44)3 
All comers 44% (31 to 55)2 18% (7 to 29)2 
1High-grade CIN; 2FUTURE II study group 2007b; 3FUTURE II study group 2007a 
 
 
There are still many issues to be resolved before a primary-prevention programme 
based on HPV vaccination can replace, outright, cervical cytology screening 
(Woodman 2007). Therefore screening will remain the main method of preventing 
cervical cancer for the foreseeable future (Miller 1999). 
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Chapter 5 
 
STUDY DESIGN 
 
 
 
 
 
Orientation 
 
In this chapter I describe: 
 
• the study design, study population, and study procedures, for the cohort study 
which forms the basis for this thesis 
 
• the collection of socio-demographic and behavioural data from study subjects 
 
• the collection and assessment of study samples 
 
• data considerations 
 
 
 
 
 
5.1 STUDY AIM 
 
When it was designed, the aim of the study described in this thesis was to determine 
the natural history and aetiology of early cervical neoplasia, in young women. 
 
5.2 STUDY DESIGN 
 
This was a prospective cohort study, with follow-up until the diagnosis of high-grade 
cervical intraepithelial neoplasia (CIN). 
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5.2.1 Setting 
 
A single family planning clinic (a Brook Advisory Centre) in Birmingham, UK. 
 
5.2.2 Study population 
 
Between March 1988 and September 1992, 2,011 women aged between 15 and 19 
years, who were likely to be available for long-term follow-up because of their 
continuing need for contraceptive supplies, were recruited by research nurses. 
 
5.2.3 Study protocol 
 
The study protocol is illustrated in figure 5.2.3a, and a schematic representation of 
the study design is illustrated in figure 5.2.3b. All women found to have cervical 
cytological abnormality, irrespective of the degree of severity of that abnormality, 
were immediately referred to a dedicated research clinic for colposcopic 
assessment, where a sample of colposcopically abnormal epithelium was removed 
for histological examination. Colposcopic and cytological surveillance was 
maintained in these women, and treatment was postponed, until there was 
histological evidence of high-grade CIN (CIN2 or CIN3), at which point women were 
treated and then left the study (Woodman 2001).  
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5.2.3.1 Follow-up 
 
Follow-up was six-monthly. Women asked to return to the study at intervals of six 
months, until the end of follow-up in August 1997. If they did not return for a follow-
up visit, they were sent a letter reminding them. 
 
5.2.3.1.1 Follow-up in the absence of cervical cytological abnormality 
 
Women who were found to be free of cytological abnormality were asked to return 
six months later. Women found to have an inadequate smear were invited to return 
as soon as possible for a repeat smear. 
  
5.2.3.1.2 Follow-up in the presence of cervical cytological abnormality 
 
All women found to have cervical cytological abnormality, irrespective of degree of 
severity, were immediately referred to a dedicated research clinic for colposcopic 
examination. The first appointment at the colposcopy clinic was made as soon as 
possible after the first detection of abnormality, often within one month, and certainly 
within less than six months. Once a woman had acquired a cytological abnormality, 
she remained on colposcopic and cytological surveillance every six months until 
there was no evidence of abnormality, defined as three consecutive negative 
colposcopic assessments and three consecutive negative smears. The woman then 
returned to cytological surveillance every six months. If another cervical cytological 
abnormality was subsequently detected, the same procedure applied. 
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5.2.3.1.3 End of follow-up 
 
Women could request treatment for histologically-confirmed abnormality at any time. 
However, the study protocol called for treatment to be postponed until there was 
histological evidence of CIN3, at which point women were recalled for treatment 
(there was of course a delay between taking the biopsy and receipt of the associated 
histological report), and thereafter left the study. During the initial period of the study, 
this was the procedure followed; however, subsequently, all cases of high-grade CIN 
were treated, i.e. CIN2 as well as CIN3. At the completion of the study, all women 
with evidence of histological abnormality were invited to return for treatment. 
 
5.2.3.1.4 Treatment 
 
Women were treated by either loop diathermy or laser cone biopsy. In loop 
diathermy, a thin, shaped, piece of wire (the loop) is heated and then used to cut 
through abnormal tissue, allowing it to be removed in one piece. Laser cone biopsy 
uses a laser to remove tissue. 
 
5.2.4 Ethical considerations 
 
The study protocol was approved by the appropriate ethical committee. 
5.2.4 Consent 
 
Informed oral consent was obtained from all women. 
 
Figure 5.2.3a. The study protocol. 
 
 
 aCervical intraepithelial neoplasia grade 1, 2 or 3; bthis is a histological diagnosis, not a virological 
diagnosis, of cervical human papillomavirus (see section 2.2.1). 
Cytological and 
colposcopic follow-up at 
intervals of six months
Cytology abnormal Follow-up smears 
at intervals of six 
months
Treat CIN2 or CIN3
Cytology abnormal Cytology normal
CIN2 or CIN3a HPVb or CIN1 
Normal 
histology and 
colposcopy
Immediate colposcopic 
and 
histological assessment
Normal cytology 
and 
colposcopy 
x3 
Initial cytological assessment 
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Figure 5.2.3b. Schematic representation of the study design. 
 
 
aCervical intraepithelial neoplasia 
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6/12 <6/12 6/12 6/12 
Visit 4 
 
 
5.3 COLLECTION OF DEMOGRAPHIC AND BEHAVIOURAL DATA 
 
On recruitment, all women were interviewed in-person: two medically-qualified and 
experienced female researchers conducted the majority of interviews during 
consecutive periods of the study (P Blomfield, H Winter), supplemented by two 
female research nurses: a structured questionnaire (appendix 1) was completed by 
the interviewer, and a detailed social, sexual, and behavioural risk factor profile at 
study entry was assembled (initially women who were 20 years old were also 
intended to be recruited: the wording on page five was unaltered when this intention 
was abandoned). At each subsequent visit to the study, women were re-interviewed, 
and changes in risk factors were collected using a second structured questionnaire 
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(appendix 2) (however, in practice, the interviewer didn’t always take the first 
questionnaire to the interview).  
 
On rare occasions, women were not interviewed for the first time contemporaneously 
with the taking of their first cervical smear; for example their visit to the Brook clinic 
may have coincided with menstruation, or they may not have been psychologically 
prepared to have a smear, etc. If a woman had a smear which was reported to be 
inadequate, she was invited back to the study for a repeat smear as soon as 
possible. Usually, this was within four months of the inadequate smear; when she 
returned to the study for a repeat smear she was not necessarily re-interviewed: this 
meant that the occurrence of an inadequate smear resulted in an extended period 
between data-collection interviews (the usual, or designed, six months, plus the time 
interval between the date of the inadequate smear and the date of the repeat 
smear). 
 
5.4 SAMPLE COLLECTION 
 
5.4.1 Cytological samples 
 
At each visit, two cervical cytological samples were taken using the same wooden 
Ayre’s spatula. The first sample was used to prepare a cervical smear for immediate 
cytological evaluation and reporting: a 360o rotation of the transformation zone was 
performed, then the material collected was applied to a slide. The second sample was 
stored for future virological examination: a 360o rotation of the transformation zone 
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was performed using the same spatula as was used to take the first sample, then the 
end of the spatula was broken off and placed into a sterile sample of phosphate-
buffered saline. The solution was refrigerated both before and after use, and then 
transferred to the laboratory as soon after the sample was taken as feasible. During 
the final 12 months of the study there was some concern regarding reports that the 
use of a wooden spatula could affect either the nature, or the detection, of viral DNA, 
and so cotton-tipped orange sticks were used for taking the second (virological) 
sample. The sampling technique was identical to that used with the spatula; the first 
sample (the one used as a cervical smear for immediate reporting) was still obtained 
using the Ayre's spatula. In the laboratory, cells from the virological sample were 
pelleted and stored at -40oC for future testing. 
 
5.4.2 Blood samples 
 
At each visit, women were requested to provide a blood sample. A sample of 
approximately 10ml of peripheral blood was taken by venipuncture. Serum was 
collected from the blood sample by centrifugation and stored at -40oC for future 
analysis. 
 
5.4.3 Histological samples 
 
If there was colposcopic evidence of abnormal epithelium, a punch biopsy was 
removed for immediate histological examination; a second histological specimen 
was then taken from an immediately adjacent area of abnormal epithelium, and 
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stored for future histological studies. Whilst on colposcopic follow-up, further 
histological specimens were only taken when there was considered to be evidence 
of the progression of disease. 
 
5.5 CLINICAL ASSESSMENT 
 
Two researchers, in consecutive periods, were responsible for interviewing the 
majority of study subjects, taking cervical cytological samples, and performing 
colposcopic assessments (including the taking of histological samples)  (P Blomfield, 
H Winter). 
 
5.5.1 Cervical cytological assessments 
 
All cervical cytological material was examined and reported by one cytologist (M 
Yates) using standard report forms for the NHS cervical screening programme, and 
employing the WHO dysplasia reporting system (see section 2.2.1).  
 
5.5.2 Colposcopic assessments 
 
Two researchers, in consecutive periods, performed all colposcopic assessments (P 
Blomfield, H Winter). 
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5.5.3 Histological assessments 
 
All histological material was examined by one pathologist (TP Rollason) and 
reported using the original CIN terminology (see section 2.2.1). 
 
5.5.4 Virological assessments 
 
Two methods for detecting HPV DNA were used for testing cervical samples from 
the cohort study described in this thesis: one was used to test all available samples, 
the other to test only a specific subset. 
 
5.5.4.1 HPV testing using GP5+/GP6+ general primer-mediated PCR 
 
After all clinical follow-up had ended, all cervical (virological) samples were tested for 
the presence of HPV DNA using a polymerase chain reaction (PCR) (see section 
21.1.1 for a description of PCR). Testing was carried out by a single laboratory 
scientist (J Selby) at the Department of Clinical Virology, Central Manchester 
Healthcare Trust, Manchester, during the period 1998 to 1999. 
 
First, the presence of human DNA was determined by performing a PCR using 
primers for β-globin; this assay was discontinued when 97.8% of the first 2,997 
samples tested were found to be β-globin positive (Woodman 2001). Thereafter, it 
was assumed that all samples contained human DNA and therefore that a HPV 
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DNA-negative result would only arise as a result of the sample in fact being HPV 
DNA-negative. 
 
Cervical samples were tested for the presence of HPV DNA using general primer 
(GP5+/GP6+) mediated PCR. Amplified product was detected by electrophoresis 
through a 2% agarose gel, followed by ethidium bromide staining, and visualisation 
under ultraviolet illumination. All gels were then subject to Southern-blot transfer 
followed by hybridisation (under low-stringency conditions) with a digoxygenin 
labelled generic HPV probe. Samples found to be HPV-positive after ethidium 
bromide staining were then subject to further PCR tests using type-specific primers 
for “two” HPV types considered low-risk (6/11) [these types could not be further 
distinguished] and six HPV types considered high-risk (16, 18, 31, 33, 52 and 58) 
because of their association with cervical neoplasia.   
 
A further presumptive typing of certain HPV-positive samples found to be non-
reactive with the type-specific PCR tests was achieved, either by restriction-enzyme 
analysis of PCR product obtained after DNA amplification using the degenerate HPV 
primers (MY09/MY11), or by sequencing the GP5+/GP6+ PCR product.  Repeat 
Southern-blot analysis using type-specific digoxygenin-labelled probes for HPV 
types 16, 18, and 33, was carried out on those samples found to be HPV-negative 
following ethidium bromide staining, but HPV-positive after hybridisation of the PCR 
product with a digoxygenin-labelled generic probe.  The use of additional tests 
resulted in 60 samples from 40 women being assigned a numeric type (i.e. one of 
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the types specifically tested for: 6/11, 16, 18, 31, 33, 52, 58) not identified by type-
specific PCR. 
 
5.5.4.2 Measurement of HPV viral load 
 
As described in the previous section, all cervical (virological) samples were tested for 
the presence of HPV DNA using a GP5+/GP6+ general primer-mediated PCR. 
However, a subset of samples was also tested for HPV16, or HPV18, viral load, or 
both. The method for measuring viral load is described in detail in section 21.2. The 
measurement of viral load was carried out by a single laboratory scientist (C 
Constandinou-Williams) at the Institute for Cancer Studies, University of 
Birmingham, Birmingham, during the period 2005 to 2006. 
 
5.5.5 Immunological assessments 
 
Sera samples from a subset of women were tested for their neutralizing antibody 
response to HPV16 and HPV18. The method for measuring the neutralizing antibody 
response is described in detail in chapter 17. Testing was carried out by a single 
laboratory scientist (K Wen) at the Institute for Cancer Studies, University of 
Birmingham, Birmingham, during 2006. 
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5.6 DATA CONSIDERATIONS 
 
5.6.1 Database construction 
 
The questionnaires (appendices 1 and 2) were designed to directly code information 
as it was collected. Questionnaires were entered onto two databases, one each for 
the retrospective and prospective questionnaires, with data entered by a limited (but 
unknown to the candidate) number of research staff. Construction and completion of 
these databases occurred during a period prior to the candidate’s association with 
this study. However the candidate has been extensively involved in the editing of 
existing databases, and the design, collation, and management, of new databases. 
 
The results from HPV testing using GP5+/GP6+ general primer-mediated PCR were 
entered into a Microsoft Access database, constructed and maintained by the 
laboratory technician who undertook the testing, with additional entries made by her 
supervisor (A Bailey). 
 
The raw results from the testing of HPV16 and HPV18 viral load were entered into 
several Microsoft Excel spreadsheets, one for each assay, by the laboratory scientist 
who undertook the assay. These were then processed and combined into a single 
dataset in Microsoft Excel, by the candidate. 
 
The raw results from testing for the neutralizing antibody response were output into a 
Microsoft Excel spreadsheet, one for each virus type in each assay, by the 
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laboratory technician who undertook the assay. These were then processed by the 
candidate and combined into a single dataset, also in Microsoft Excel.  
 
The final study database combining these five separate data sources is maintained 
in the software system Cache by the candidate, and interrogated using the 
programming language M (Cache ObjectScript). 
 
5.6.2 Data editing 
 
Given the extensive nature of the data collected by the questionnaires, and the 
various types of samples collected, a considerable amount of data editing was 
required for the various databases ultimately constructed. With the exception of the 
data cleaning which occurred during the initial quality checks undertaken for the 
questionnaire databases, for the most part data editing was conducted either by, in 
conjunction with, or under the supervision of, the candidate. In particular, all 
variables and outcomes used in analyses presented in this thesis were scrutinised 
for internal consistency by the candidate, as well as consistency with the hardcopy 
questionnaires.  
 
5.7 PUBLICATIONS 
 
Data from this cohort study have now been published in ten reports, including four 
based on the work described in this thesis (Blomfield 1998, Woodman 2001, Collins 
2002, Woodman 2003, Collins 2005, Woodman 2005, Steele 2008, Collins 2009, 
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Constandinou-Williams 2009, Collins 2010). These reports are described in table 
5.7. The candidate was a co-author on all of these papers, except the first. 
 
Table 5.7. Publications based on the cohort study described in this thesis. 
Publication Largest 
Population 
Described 
Description 
Blomfield 1998 1,219 Analysis to determine whether women at risk of cervical abnormality can be identified. Opportunistic analysis. 
Woodman 2001 2,011 Analysis of the natural history of cervical HPV
a infection in young 
women. Main report on the cohort study described in this thesis. 
Collins 2002 242 Describes the incidence of cervical HPV infection in women during their first sexual relationship. Opportunistic analysis. 
Woodman 2003 1,075 Investigation of the possibility that HPV18 is associated with rapidly progressing CINb. Opportunistic analysis. 
Collins 2005 474 
Analysis of the association between the proximity of first sexual 
intercourse to menarche and the risk of cervical HPV infection. 
Opportunistic analysis. Opportunistic analysis. Based on work 
described in this thesis. 
Woodman 2005 1,023 
Investigation into the role of sexual behaviour in the acquisition 
of asymptomatic Epstein-Barr virus infection. Opportunistic 
analysis. 
Steele 2008 42 
Describes the measurement of the humoral immune response to 
HPV16 and HPV18 infections following an incident cervical 
HPV16 or HPV18 infection, using a pseudovirion-based 
neutralizing antibody assay. Subject of a new grant application 
based on the original cohort. Based on work described in this 
thesis. 
Collins 2009 66 
Analysis of the integration of cervical HPV16 and HPV18 
infections. Subject of a new grant application based on the 
original cohort. 
Constandinou-
Williams 2009 60 
Describes the measurement of HPV16 and HPV18 viral load 
following an incident cervical HPV16 or HPV18 infection using 
quantitative (real-time) PCR. Subject of a new grant application 
based on the original cohort. Based on work described in this 
thesis. 
Collins 2010 1,485 
Analysis of the association between cigarette smoking and the 
incidence of cervical HPV infection, the duration of those 
infections, and the incidence of high-grade CIN. Addresses a 
secondary objective of the original cohort study. Based on work 
described in this thesis. 
aHuman papillomavirus; bcervical intraepithelial neoplasia. 
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Summary 
 
When it was designed, the aim of the study described in this thesis was to determine 
the natural history and aetiology of early cervical neoplasia, in young women. This 
was a prospective cohort study. 2,011 women aged 15 to 19 years were recruited 
from a single Brook Advisory Centre (a family planning clinic) in Birmingham, United 
Kingdom, between 1988 and 1992, and asked to re-attend at intervals of six months: 
follow-up ended on 31st August 1997. At recruitment, a standardised interview 
questionnaire was used to construct a detailed social, sexual, and behavioural risk-
factor profile, including smoking. Risk factor profiles were updated at each follow-up 
visit using a second standardised interview questionnaire. Women were asked to 
provide a blood sample at each visit. At each visit two cervical cytological samples 
were taken using the same Ayres spatula: the first was used to prepare a smear for 
immediate cytological evaluation; the second was placed into 10 ml of phosphate-
buffered saline and stored at -80°C for subsequent virological examination. All 
women in whom a cytological abnormality was identified were immediately referred 
to a dedicated research clinic for histological examination, irrespective of the severity 
of that abnormality. Also at each visit,  women were asked to provide a serum 
sample. Colposcopic and cytological surveillance were maintained in these women 
and treatment was postponed until there was histological evidence of high-grade 
cervical intraepithelial neoplasia (CIN: CIN2 or CIN3), at which point women left the 
study. The study was approved by the appropriate research ethics committee, and 
informed oral consent was obtained from all women. After all clinical follow-up had 
ended, cervical samples were tested for the presence of HPV DNA using a general 
primer (GP5+/GP6+) mediated polymerase chain reaction (PCR) and further PCR 
tests were done with type-specific primers on samples which were HPV-positive. 
Data from this cohort study have now been published in 10 reports. 
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Chapter 6 
 
STATISTICAL  AND METHODOLOGICAL CONSIDERATIONS 
 
 
 
 
 
Orientation 
 
In this chapter I: 
 
• describe the statistical nature of the data collected in the study described in this 
thesis 
 
• describe time-to-event data, and interval-censoring 
 
• discuss the process used to select methods for the analysis of the study 
described in this thesis 
 
• describe the methods used to analyse interval-censored time-to-event data in this 
thesis 
 
• discuss issues relating to time-varying covariates which are common to many  
analyses in this thesis 
 
• discuss issues relating to missing data which are common to many analyses in 
this thesis 
 
 
 
 
 
6.1 STATISTICAL CHALLENGES OF THE ANALYSIS OF THE STUDY 
DESCRIBED IN THIS THESIS 
 
When it was designed, the aim of the cohort study described in this thesis was to 
determine the natural history and aetiology of early cervical neoplasia, in young 
women. Repeated measurements on cytological, histological, virological, and 
serological, status were made, as well as on several behavioural risk factors (figure 
6.1).   
 
Figure 6.1. Statistical challenges of the analysis of the study described in this 
thesis. 
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The data from the cohort study described in this thesis present the following 
challenges: 
 
• Several possible outcomes 
 
There were several possible outcomes for the cohort study described in this thesis: 
illustrative examples are given in table 6.1a. The prevalence at study entry of 
cervical HPV infection, and of cervical cytological abnormality, are just two examples 
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of cross-sectional outcomes, and clearly there are several possible others; but most 
of the outcomes in table 6.1a involve an element of follow-up. Some of the outcomes 
in table 6.1a are explanatory, or intermediate, for others. For example, cervical HPV 
infection may generate an immune response to that infection, which, in turn, may 
“explain” the subsequent clearance of that infection, or lead to changes in HPV viral 
load. 
 
Table 6.1a. Examples of potential outcomes for the cohort study described 
in this thesis. 
 
Outcome 
Prevalence at study entry of cervical HPV infection, of any type, or of types 
6/11, 16, 18, 31, 33, 52 or 58 
Acquisition during follow-up of an incident cervical HPV infection, of any type or 
of types 6/11, 16, 18, 31, 33, 52 or 58 
Acquisition during follow-up of an incident cervical HPV infection of a type not 
present at study entry 
Time to clearance of an incident cervical HPV infection, of any type, or of a 
specific type 
Acquisition and clearance of a second, or subsequent, cervical HPV infection, 
of any type, or of a specific type 
Prevalence at study entry of cervical cytological abnormality 
Acquisition of an incident cervical cytological abnormality, of any severity, or of 
a specific severity 
Time to clearance of an incident cervical cytological abnormality, of any 
severity, or of a specific severity 
Acquisition and clearance of a second or subsequent cervical cytological 
abnormality, of any severity, or of a specific severity 
Acquisition of incident histologically-confirmed cervical abnormalities of any 
severity, or of a specific severity 
Time to acquisition of cervical cytological abnormality following the first 
detection of HPV DNA of any type, or of a specific type. 
Time to progression of cervical cytological abnormality 
HPV16 and HPV18 viral load, and how this changes during follow-up 
The humoral immune response to cervical HPV infection, of any type, or of a 
specific type, and how this changes during follow-up 
Time from acquisition of an incident cervical HPV16 or HPV18 infection until 
seroconversion to that type 
Time from seroconversion to cervical HPV16 or HPV18 infection until clearance 
of infection with that type 
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• Outcome data of different types 
 
The cohort study described in this thesis generated data of several different types. 
The two which concern the analyses presented in this thesis are time-to-event data, 
and longitudinal data. Time-to-event data was interval-censored. Such data require 
special techniques. 
 
• Repeated observations 
 
Measurements were made on the same woman on several occasions over time. 
Data were not balanced: different numbers of observations were made on each 
subject, with a different time interval between consecutive observations for each pair 
of observations and for each subject (see section 6.3.3.1). The time interval between 
the first cervical cytological abnormality and the first colposcopy (which followed 
“immediately”) was systematically shorter than any other interval between visits (see 
section 5.2.3.1.2). 
 
• Time-varying covariates 
 
Explanatory, and exposure, covariates were updated at each visit, yielding a mixture 
of time-fixed and time-varying covariates, for both explanatory variables and 
exposure status. 
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• Multiple exposures 
 
There were several possible exposure variables: examples are given in table 6.1b. 
Some exposures were potentially dependent, e.g. interaction between exposure to 
cervical HPV infection and smoking, or between exposure to cervical HPV16 
infection and to cervical infections with other HPV types.  
 
Table 6.1b. Examples of exposure variables for the cohort study described 
in this thesis. 
 
Exposure variable 
Changes in HPV viral load during follow-up 
Age at starting smoking 
Smoking status at study entry 
Changes in smoking status during follow-up 
Age at first sexual intercourse, or at menarche 
Acquisition of a new sexual partner during follow-up 
Changes in sexual behaviour during follow-up 
Characteristics of sexual partners 
HPV status at study entry, with respect to any type or an individual type 
Changes in cervical HPV status during follow-up, with respect to any type or 
an individual type 
Cervical cytological status at study entry 
Changes in cervical HPV viral load during follow-up 
 
• Measurements on different types of scale 
 
Cervical HPV DNA, cytological, and histological, status, and measures of the 
immune response to HPV infection, can all be considered as both binary and 
categorical measurements, but with an assumed underlying continuous process. In 
the case of HPV status, measurements on the continuous process were also 
available for two HPV types in a limited number of women (see chapter 21 on viral 
load).  
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• Measurements subject to misclassification 
 
Explanatory, exposure, and outcome, variables were all potentially subject to 
misclassification. Many explanatory variables were self-reported. Cytological and 
histological assessment were based on objective criteria; nevertheless tests could 
give false-positive or false-negative results, due to sampling, or observer, error. The 
colposcopist only took a biopsy for histological evaluation when there was evidence 
of disease progression, a subjective decision on their part.  
 
• Missing observations 
 
There were missing explanatory variables, “exposure” variables, and measurements 
of outcomes. There were difficulties in distinguishing which observations were 
missing because women were requested to return to the study every six months, but 
were not given specific appointment schedule: a woman who returned to the study 
after nine months may or may not generate a “missing” observation at six months in 
the true sense. 
 
Not all of the challenges described above are of concern in this thesis, and some will 
only be discussed in the relevant chapters. Other challenges apply to many of the 
analyses presented in this thesis, and will be discussed here in general terms, with 
more specific details given in the appropriate chapters. 
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6.2 DEFINITION OF TIME-TO-EVENT DATA 
 
Time-to-event data (also referred to as failure-time data, or survival data) consists of 
measurements of the time to the occurrence of an event of interest in a sample of 
study subjects. In this thesis, there are many examples of time-to-event data. 
 
The essential elements of a time-to-event are a well-defined origin from which time is 
measured, typically an event such as birth or diagnosis of disease (the origin event); 
the time of occurrence of an unambiguous event or outcome, such as death (the 
outcome event); and a measurement scale for time, such as calendar time or age. A 
time-to-event can be measured on a continuous or on a discrete scale, and it is not 
necessary for the event to be considered a “failure” in any sense: the event could be 
the development of a disease, a positive response to a treatment, relapse of 
disease, or death, in which case the time-to-event is more commonly known as the 
survival time. A typical example of a time-to-event measured on a continuous scale 
is the lifetime of an individual, the interval from date of birth to date of death, 
measured in calendar time. As an example of a discrete time-to-event, suppose that 
a subject is tested for the presence of antibodies to a virus every hour on the hour: 
the time-to-event in this case could then be taken as the number of hours which 
elapse until antibodies are first detected, measured on the scale 0, 1, 2, 3 hours, etc. 
 
Time-to-event studies are follow-up studies in which individuals are followed until the 
occurrence of an event. Technically this distinguishes them from longitudinal studies, 
in which study subjects are measured on more than one occasion, with exposure 
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and outcome data obtained at each occasion. However, clearly a longitudinal study 
can also generate time-to-event data, as in the longitudinal cohort study described in 
this thesis. In the analyses presented in this thesis, it is assumed that the event of 
interest, which varies according to the objectives of the analysis, is irreversible, and 
that once a subject has experienced the event they are removed from further 
consideration; in general, this is not always a requirement. 
 
6.3 CENSORING 
 
What distinguishes time-to-event data from other types of data is the occurrence of 
censoring. Censoring occurs when the time of occurrence of the outcome event is 
either not known, or is known only approximately. To deal appropriately with 
censoring in the analysis of time-to-event data, the study design which generated 
that data must be considered. There are several types of censoring which must be 
carefully distinguished, but they fall into three broad categories. 
 
6.3.1 Left-censoring 
 
Left-censoring arises when the event of interest occurs before the subject is first 
observed in the study. For example, in a study of the time from the date of the 
detection of the first cervical HPV infection (assumed known) to the date of the first 
acquisition of cervical cytological abnormality, some women may already have 
cervical abnormality when they are first recruited. Therefore their exact time-to-event 
will be unknown: but what is known is that their time-to-event is less than that 
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observed, in this case the time interval between the acquisition of cervical HPV 
infection and recruitment. 
 
6.3.2 Right-censoring 
 
Right-censoring occurs when subjects do not experience the event of interest before 
the end of the observation period: all that is known is that their time-to-event is 
greater than the duration of the observation period. 
 
For example, in an analysis of the time from recruitment until the acquisition of high-
grade CIN, most women in the cohort study described in this thesis had not had a 
diagnosis of high-grade CIN by the end of the follow-up period. Therefore their exact 
time-to-event was unknown: all that was known was that their time-to-event was 
greater than that observed, in this case the time interval between recruitment and 
the end of follow-up. 
 
6.3.3 Interval-censoring 
 
Interval-censoring occurs when an event is known only to have occurred within an 
interval of time, but the exact time of occurrence of that event is unknown: the 
associated time-to-event is said to be interval-censored. In this case the observed 
time-to-event is actually an interval of times rather than a single time i.e. the time-to-
event is known only approximately. 
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For example, in this thesis, I describe measurements made on cervical HPV 
infection, cervical cytological abnormalities, and cervical histological abnormalities, 
all three of which are asymptomatic. For example, since cervical HPV infection is an 
asymptomatic condition, its onset can only be detected by taking cervical samples 
from a woman periodically, and then testing these samples for the presence of HPV 
DNA (figure 6.3.3). In this case, the time from the date of study entry to the date of 
the first detection of cervical HPV infection will not be known exactly. However, it will 
be known that the time at which cervical HPV infection was first acquired lies in the 
interval between: the date of the cervical sample which first tested positive for HPV 
DNA; and the date of the sample taken at the immediately preceding visit, which was 
the last sample taken that was known to be HPV DNA-negative. Time from date of 
study entry to date of first detection of cervical HPV infection is therefore interval-
censored.  
 
Figure 6.3.3. Example of interval-censored observations on the time to 
acquisition of cervical HPV infection.  
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Interval-censoring is a generalisation of left- and right-censoring; or alternatively, left- 
and right-censoring are special cases of interval-censoring. In practice, time-to-event 
data can be subject to any combination of left-, right-, or interval-censoring, and the 
time of occurrence of the origin event can also be interval-censored. 
 
6.3.3.1 Types of interval-censoring 
 
There are several types of interval-censoring, which arise from different study 
designs. The applicability of different methods of analysis to data from these different 
study designs depends on the assumptions made about the observation scheme. 
 
Current status data. Under the simplest observation scheme, only one observation 
is made on each subject. This observation scheme gives rise to perhaps the most 
extreme form of interval-censored time-to-event data, known as current status data. 
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These data arise when every subject is measured (observed) on a single occasion, 
although the time (with respect to an origin event) at which the measurement is 
made may vary for each subject. In this case all times-to-event are interval-
censored. With this censoring scheme, the time-to-event is never known exactly: for 
each subject, either the outcome is known to have occurred before the measurement 
time, or the outcome is not observed. Within the context of this thesis, methods for 
the analysis of current status data are of no relevance, and will not be considered 
further. 
 
Grouped interval-censored data. When repeated observations are made on every 
subject under study at a common and fixed set of time points (e.g. every hour on the 
hour), then the time-to-event data generated are called grouped interval-censored 
data. The same number of observations can be made on all subjects, with the 
intervals between observations being of equal length (an X indicates an 
observation): 
1. X - - - - - X - - - - - X - - - - - X - - - - - X - - - - - X 
2. X - - - - - X - - - - - X - - - - - X - - - - - X - - - - - X 
3. X - - - - - X - - - - - X - - - - - X - - - - - X - - - - - X 
 
Or, the same number of observations can be made on all subjects, with the time 
intervals between observations being of different lengths, with given intervals being 
of the same length for each subject: 
 
             1. X - - - - - - - - - X - - - - - X - - - X - - - - - - X - - - - - - - - - - - - - - - - X 
             2. X - - - - - - - - - X - - - - - X - - - X - - - - - - X - - - - - - - - - - - - - - - - X 
3. X - - - - - - - - - X - - - - - X - - - X - - - - - - X - - - - - - - - - - - - - - - - X 
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The two designs above give rise to balanced data, and what has been called parallel 
data: the number of observations is fixed by design, and this may be allowed to vary 
for individuals, so long as this variation is pre-specified (Hougaard 2000). In contrast, 
longitudinal data arise when the number of observations is allowed to be random. A 
different number of observations can be made on each subject, with the time 
intervals between the observations being of equal lengths: 
 
1. X - - - - - X - - - - - X - - - - - X - - - - - X 
2. X - - - - - X - - - - - X - - - - - X - - - - - X - - - - - X 
3. X - - - - - X - - - - - X - - - - - X 
 
Or a different number of observations can be made on each subject, with the time 
intervals between observations being of different lengths, but with given time 
intervals being of the same length for each subject: 
 
1. X - - - - - - - - - X - - - - - X - - - X - - - - - - X 
2. X - - - - - - - - - X - - - - - X - - - X - - - - - - X - - - - - - - - - - - - - - - - X 
3. X - - - - - - - - - X - - - - - X - - - X 
 
In theory many studies would be expected to generate grouped interval-censored 
data by design, in particular the cohort study described in this thesis. However, the 
ideal of a common and fixed set of time points at which observations are made is 
rarely achieved in practice: observations tend to be asynchronous, with time 
intervals between observations varying both within a specific subject, and between 
different subjects. In the study described in this thesis, for example, women could 
not be compelled to return at intervals of six months, and could not be compelled to 
remain in the study until a set amount of follow-up had been completed. This meant 
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that women returned to the study at intervals of between four and eight months after 
the previous visit, assuming that they didn’t miss a visit and return after 12 months, 
for example; the time interval between the date of the first visit at which a cervical 
cytological abnormality was detected and the date of the subsequent smear (which 
was taken in a colposcopy clinic) was systematically shorter than other time intervals 
between study visits; an inadequate smear meant a rapid return to the study for a 
repeat smear; and some women made more visits than others, before they stopped 
returning to the study completely. 
 
Asynchronous interval-censored data. For studies generating this type of data, 
either the same number of observations are made on all subjects, with the time 
intervals between observations being of different length, and with given time 
intervals being of different lengths for each subject: 
 
1. X - - - - - - - - - X - - - - - X - - - X - - - - - - X - - - - - - - - - - - - - - - - X 
2. X - - - - - X - - - - X- - - - - - - - X - - - X  - - - - - - - - - - X 
3. X - - - - - - - - - - - - - - - X - - - - X - - - X - - - X - - - - - - - - X 
 
 
Or, more commonly, a different number of observations are made on each subject, 
with the time intervals between observations being of different lengths, and with 
given time intervals being of different lengths for each subject: 
 
1. X - - - - - - - - - X - - - - - X - - - X - - - - - - X - - - - - - - - - - - - - - - - X 
2. X - - - - - X - - - - X- - - - - - - - X - - - - - - - - - - X 
3. X - - - X - - - - X 
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This is the situation which arose in the cohort study described in this thesis. In each 
of the above illustrations, observations may or may not continue after the event of 
interest has occurred, depending on the event of interest. For example, in cohort 
study described in this thesis, samples were only tested for HPV DNA after all visits 
had been made and all samples had been collected. Therefore, for an analysis of 
time to first cervical infection with HPV, observations would unknowingly have 
continued beyond the event of interest, i.e. the first detection of cervical HPV 
infection. In contrast, for an analysis of the time to the first detection of cervical 
cytological abnormality, status of the previous observation, i.e. the previous smear 
result, would have been known prior to the next observation being made; 
observations on this outcome would therefore knowingly have continued beyond the 
event of interest. For an analysis of the time to the diagnosis of high-grade CIN, 
once the outcome was reached, further observations ceased, by design. 
 
In some circumstances it may be possible to ignore variation in time interval lengths, 
in which case a grouped interval-censored analysis will provide satisfactory results. 
The analysis of grouped interval-censored data is easily handled by standard 
methods (Carstensen 1996). However, this observation scheme is not directly 
relevant to the data considered in this thesis and so methods for the analysis of this 
type of interval-censored time-to-event data will not be discussed further. For the 
analysis of the data the study described in this thesis, more general methods are 
needed. 
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Doubly censored data. Usage of the term “doubly censored” is not consistent. It 
has been used to mean: the time of occurrence of the origin event is interval-
censored, with the outcome event either being observed exactly, or being right-
censored (e.g. Law 1992); or the data consist of left-censored, right-censored and 
exact observations (e.g. Samuelsen 1994); or the origin event and outcome event 
are both interval-censored (e.g. Kim 1993). The latter definition is the most useful 
definition in the context of this thesis. 
 
6.4 THE STATISTICAL ANALYSIS OF INTERVAL-CENSORED TIME-TO-EVENT 
DATA 
 
The aim of an analysis of time-to-event data is to describe how the risk of the 
occurrence of an event of interest changes over time. Except in the simplest of 
situations, the analysis of time-to-event data requires specialised statistical methods, 
for two reasons. First, time-to-event data tends to be non-normally distributed, and in 
particular positively-skewed. This means that the vast number of statistical 
techniques available which are based on the assumptions of normally distributed 
data are not directly applicable to time-to-event data. Second, in practice, in most 
studies which generate time-to-event data, those data are subject to censoring. 
Censoring requires appropriate handling to ensure that the data are analysed 
efficiently using a method which produces unbiased estimates of statistics of 
interest. 
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Many powerful methods for the analysis of right-censored time-to-event data have 
now been developed: the basic methods are available in all of the major statistical 
packages (e.g. SPSS, SAS, Stata), with more advanced techniques available in 
specialist statistical packages (e.g. S-plus, R). In contrast, methods for the analysis 
of interval-censored time-to-event data, whilst now becoming more common, have 
developed relatively slowly over the past 40 years. One popular approach to the 
analysis of interval-censored time-to-event data is to ignore the interval-censoring: in 
particular, recognition of the requirement for specific methods for analysing such 
data has not yet become widespread in the medical literature. This may reflect 
genuine ignorance on the part of most investigators, or it may have a more 
pragmatic explanation: many of the methods for the analysis of interval-censored 
time-to-event data are quite basic at present, with counterparts of the rich array of 
techniques which are available for right-censored time-to-event data yet to become 
widely available; software for analysing these data has only recently started to 
become accessible to the non-specialist. 
 
6.4.1 Estimation of survival functions with interval-censored time-to-event data 
 
For time-to-event data, the “survival” function provides a summary of how the risk of 
the occurrence of an event of interest changes over time. Theoretically, from the 
survival function can be derived all of the other functions which can be used to 
describe time-to-event data, in particular the hazard function, the density function 
and the cumulative distribution function (CDF). For right-censored time-to-event 
data, the Kaplan-Meier (KM) method is usually used to estimate the survival 
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function. For interval-censored time-to-event data, an analogue of the KM estimator 
is the nonparametric (generalized) maximum likelihood estimator (NPMLE). This was 
first discussed by Peto (Peto 1973) and Turnbull (Turnbull 1976), whose papers can 
be taken as the starting point(s) for the development of the statistical literature on the 
analysis of interval-censored time-to-event data. Both authors proposed algorithms 
for deriving the NPMLE of the CDF for continuous interval-censored time-to-event 
data, but Turnbull’s estimator is applicable in more general situations i.e. the 
assumptions made by the Turnbull estimator are less restrictive than those made by 
the Peto estimator. 
 
6.4.1.1 The non-parametric maximum likelihood estimator 
 
Unlike for the KM estimator, there is no closed formula for the NPMLE with interval-
censored time-to-event data, which must therefore be derived via an iterative 
algorithm. This is done using methods for multinomially-distributed data, after having 
formulated the problem in terms of a discrete survival analysis (Lawless 2003). 
Several algorithms may be used to estimate the NPMLE. Turnbull used a self-
consistency algorithm. With this approach, the observed data are used to construct 
disjoint time intervals which can gain possible probability masses; outside these 
intervals, the estimator is undefined (the original construction of the intervals 
receiving positive probability mass was flawed, and was subsequently corrected 
(Allioum 1996)). The estimator is therefore very unusual: it is a decreasing and very 
“rough” function, consisting of a series of horizontal lines and/or points, with gaps 
between the lines and/or points on the time axis. This is difficult to interpret visually, 
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and often the lines and/or points in the graph of the estimator are extended and 
joined to form a continuous step-function, similar in appearance to the KM estimator. 
However, this is aesthetically pleasing, rather than technically correct (but the same 
is true of the KM estimator), and since the extension of the lines can be performed in 
several ways, the visual representation is not necessarily unique (one book gives an 
algorithm which does not suffer from this visually difficult interpretation, but it is not 
clear why this algorithm is fundamentally different (Klein 1997)). In addition, methods 
based on the analysis of discrete time-to-event data can be numerically unstable 
because discrete hazards are probabilities which need to be constrained between 
zero and one (Goetghebeur 2000). Therefore, different approaches to estimating the 
NPMLE, or altering convergence criteria, may produce visually, if not statistically, or 
numerically, different representations of the estimator. Further, neither standard 
maximum likelihood estimation, nor martingale theory, is directly applicable to 
interval-censored time-to-event data measured on a continuous scale, and the 
method has not been shown to provide a consistent estimate of the variance of 
survival estimates for continuous time-to-event data in a general setting (Petroni 
1994). 
 
The Turnbull, or other, non-parametric maximum likelihood estimator has yet to 
attain the wide acceptance of the KM estimator. Given the unusual nature of the 
estimator, and the difficulties with its estimation and interpretation, this seems 
unlikely to change. So why use this type of estimator? The disadvantages are 
outweighed by the fact that no restrictive assumptions are made about the 
underlying distribution from which the observed data are generated. The estimator 
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can therefore be used to suggest a possible parametric model, which will rarely be 
known a priori, or, as with any nonparametric method, to help assess the robustness 
of conclusions drawn from a parametric analysis (Davison 1997). 
 
6.4.1.2 “Smoothing” the non-parametric maximum likelihood estimator 
 
The NPMLE is a “rough” estimator. In reality, we would expect the true survival 
function (and its CDF) to be a “smooth” function. There are methods available for 
smoothing estimators of certain of the survival functions. One approach is to use 
splines to estimate the survival function, or one of its associated functions, directly 
(Kooperberg 1995, Kooperberg 1997) (see later). Another is to “penalize” the 
likelihood function to force it to be smooth. 
 
The penalized maximum likelihood method (for which a FORTRAN programme is 
available, called PHMPL), defines the NPMLE as the function which maximizes the 
penalized likelihood (Joly 1998, Joly 1999). A “smoothing parameter” is introduced 
into the likelihood, which takes large values for rough functions, thereby “penalizing” 
the likelihood. The likelihood is then maximised over the class of all functions of the 
appropriate form, to yield the maximum penalised likelihood estimator (MPLE). 
However, the MPLE cannot be calculated directly, it must be approximated; in this 
case, splines are used. Splines are piecewise polynomial functions which can be 
combined, in a linear fashion, to approximate a function over an interval. A spline 
function is completely defined by a sequence of increasing “knots” on the time-axis 
(t1,..., tl), and the coefficients θ = (θ1,...,θl)T of the splines. PHMPL uses splines of 
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order four (called cubic splines), and allows a minimum of five, and a maximum of 
25, knots: in theory, the more knots that are used, the better the approximation. The 
recommended method is to start with a small number of knots and increase this 
number until the graph (sic) of the hazard function remains unchanged, which seems 
a little subjective. The smoothing parameter can be specified empirically, or it can be 
determined automatically. Explanatory variables can be included in a proportional 
hazards model, but PHMPL will not allow for the incorporation of time-varying 
covariates. 
 
6.4.1.3 Comparison of estimates derived from an analysis of interval-censored 
time-to-event data with those derived from the Kaplan-Meier analysis of right-
censored time-to-event data: in the cohort study described in this thesis 
 
The method used to analyse data should correspond to the underlying process 
which generated that data. However, as stated earlier, many investigators have 
failed to observe this general rule. Investigators who ignore the true nature of their 
data tend to use imputation of some type to convert their interval-censored data into 
“exact” (or more likely at worst right-censored) time-to-event data. If the interval-
censoring is recognised, midpoint imputation (stating that the event occurred in the 
middle of the interval in which the event is known to have occurred) is likely to be 
used (as indeed the candidate did in Woodman 2001 and Woodman 2003); if not, 
right-imputation is most likely to be used, for example using the date of diagnosis as 
the time at which the event occurred for an asymptomatic condition measured at 
intervals (see figure 6.3.3). Standard methods for use with right-censored time-to-
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event data are then used to analyse the resulting data. But what impact does this 
have on statistical inferences? 
 
To compare the Turnbull NPMLE, MPLE, and KM estimator, I undertook three 
analyses: one with a large number of events in a small population, one with a large 
number of events in a large population, and one with a small number of events in a 
large population. These were, respectively: the analysis of the incidence of cervical 
HPV infection in women recruited within six months of first sexual intercourse and 
before they acquired their second sexual partner (242 women, 78 incident cervical 
HPV infections) (Collins 2002); the analysis of the incidence of cervical cytological 
abnormality in women who were cytologically normal and negative for cervical HPV 
DNA at recruitment, and who had further follow-up (1,075 women, 246 incident 
cervical cytological abnormality events) (Woodman 2001); and the analysis of high-
grade CIN in the same women as used in the previous analysis (1,075 women, 28 
incident high-grade CIN events) (Woodman 2001). The NPMLE was calculated 
using the ICE macro in the statistical package SAS. The MPLE was obtained using 
the FORTRAN programme PHMPL, with the maximum number of knots used (25), 
and with linear interpolation of the estimator to obtain estimates at specific points in 
time. Three versions of the KM estimator were calculated, one each assuming the 
event of interest occurred at the left-hand end of the interval, at the right-hand end, 
or at the midpoint. The results of the comparison with the Turnbull NPMLE are 
presented in table 6.4.1.3 (note that cumulative risk is the complement of survival i.e. 
one minus survival).  
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Estimates based on the assumption that an event occurs at the left or right limits of 
the interval will, in theory, produce the most extreme estimates of the survival 
function (and therefore the cumulative risk function); these estimates should then 
form an interval within which estimates produced by making any other interpolation 
assumption will lie. In particular, this interval is expected to contain the true survival 
estimate, and the estimate based on the midpoint assumption, is considered to be 
the “best” estimate, in some (unspecified) sense. 
 
In the analysis of the incidence of cervical HPV infection, the NPMLE estimate does 
tend to lie between the left and right KM estimates, except at 24 months, where it 
lies below both limits. At other time points, the midpoint estimate provides a 
reasonable, although not always the best (among the three estimates investigated), 
approximation. The MPLE always lies between the left and right limits. In the 
analysis of the incidence of cervical cytological abnormalities, all three versions of 
the KM estimator underestimate the risk of acquiring cervical cytological abnormality, 
as estimated by the NPMLE, from 24 months onwards, with a substantial 
discrepancy at 60 months (this may be due to small numbers at risk by this stage). 
The MPLE estimate always lies between the left and right KM limits. In the analysis 
of the incidence of high-grade CIN, all three versions of the KM estimator 
underestimate the risk of acquiring high-grade CIN, as estimated by both the NPMLE 
and MPLE, up to 48 months, but overestimate the risk at 60 months. 
 
In all cases, the confidence interval associated with the NPMLE is substantially wider 
than the confidence intervals around any of the three versions of the KM estimator. 
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However, the confidence intervals for the MPLE are comparable in width to those for 
the three versions of the KM estimator. The paper presenting the PHMPL method 
states that it generates confidence bands for the penalized likelihood estimators, and 
thus for the survival estimates; the instructions for the PHMPL computer programme 
calls these statistics confidence limits (Joly 1999). If they are in fact confidence 
bands, this makes the narrow confidence intervals difficult to understand. 
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Table 6.4.1.3. Comparison of estimates of cumulative risk obtained using 
methods appropriate to interval-censored time-to-event data, with those 
obtained using interpolated data, and the Kaplan-Meier estimator. The 
cumulative risk (CR) of: cervical HPV infection following first sexual intercourse in 
women recruited within six months of first sexual intercourse whilst they had only 
one sexual partner; cervical cytological abnormality (CA) in women who were 
cytological normal and HPV DNA negative at recruitment, and who had further 
follow-up; and the analysis of high-grade CIN (HGCIN) in the same women. 
Estimates obtained using the Turnbull NPMLE (T), the MPLE (P), and the Kaplan-
Meier estimator, assuming that events occur at the left-hand end of the interval (L), 
at the midpoint (M), or at the right-hand end (R). Number of women (n) and number 
of events (e) are also presented. n=number of subjects, e=number of events. 
 
HPV (n=242, e=78) CA (n=1075, e=246) HGCIN (n=1075, e=28) Time 
(months) 
Method
CR (%) 95% CI CR (%) 95% CI CR (%) 95% CI 
T 0.0 − 0.0 − 0.0 − 
P 0.0 − 0.0 − 0.0 − 
L 15.3 10.8 to 19.8 8.4 6.7 to 10.0 0.0 − 
M 0.0 − 0.0 − 0.0 − 
0 
R 0.0 − 0.0 − 0.0 − 
T 24.6 3.9 to 45.3 13.4 0.6 to 26.2 1.2 0.0 to 2.9 
P 25.5 18.9 to 31.6 11.4 9.4 to 13.4 1.4 0.8 to 2.1 
L 27.1 21.0 to 33.2 15.3 13.1 to 17.5 0.2 0.3 to 1.5 
M 26.7 20.6 to 32.8 11.5 9.5 to 13.4 0.8 0.2 to 1.4 
12 
R 23.5 17.6 to 29.4 9.0 7.2 to 10.8 0.4 0.0 to 0.8 
T 34.2 18.5 to 49.8 22.0 10.6 to 33.3 2.4 0.0 to 5.1 
P 38.2 30.0 to 45.4 20.8 17.9 to 23.5 2.5 1.5 to 3.5 
L 39.3 31.5 to 47.1 21.8 19.1 to 24.6 1.3 0.5 to 2.1 
M 38.3 30.5 to 46.1 21.3 18.5 to 24.1 1.4 0.6 to 2.2 
24 
R 36.9 29.1 to 44.7 20.2 17.4 to 22.9 1.5 0.7 to 2.3 
T 45.4 27.1 to 63.7 31.2 11.2 to 51.3 3.3 0.1 to 6.5 
P 45.1 34.8 to 53.9 27.7 24.3 to 30.9 3.1 2.0 to 4.3 
L 42.5 33.9 to 51.1 27.3 24.1 to 30.6 2.5 1.3 to 3.7 
M 45.6 36.8 to 54.4 28.4 25.0 to 31.8 1.8 0.8 to 2.8 
36 
R 51.0 41.4 to 60.6 28.5 25.0 to 32.0 1.7 0.7 to 2.7 
T 49.8 30.3 to 69.3 35.6 23.5 to 47.7 3.6 0.0 to 8.3 
P 48.4 37.2 to 57.6 32.2 28.1 to 36.0 3.4 2.1 to 4.8 
L 44.8 35.4 to 54.2 31.3 27.4 to 35.1 3.2 1.6 to 4.8 
M 50.0 40.0 to 60.0 33.2 29.2 to 37.2 2.8 1.4 to 4.2 
48 
R 53.0 43.0 to 63.0 34.3 30.2 to 38.4 3.0 1.6 to 4.4 
T 58.9 34.3 to 83.5 55.5 39.7 to 71.3 3.6 0.0 to 8.3 
P 54.2 40.7 to 64.7 37.2 31.5 to 42.3 3.5 1.5 to 5.5 
L 51.5 39.5 to 63.5 34.2 29.7 to 38.7 4.5 2.3 to 6.7 
M 57.2 44.5 to 69.9 37.9 32.8 to 43.1 4.5 2.3 to 6.7 
60 
R 59.5 47.3 to 71.7 40.6 35.4 to 45.8 3.8 2.0 to 5.6 
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6.4.1.4 Comparison of estimates derived from an analysis of interval-censored 
time-to-event data with those derived from the Kaplan-Meier analysis of right-
censored time-to-event data: in other studies 
 
Others have also examined the impact of imputation of time-to-event data on 
statistical inferences, in the context of univariate, multivariate, and doubly-interval-
censored, analyses (Law 1992). 
 
Samulesen et al. (Samuelsen 1994) found that the NPMLE was substantially less 
than the KM estimate, but NPMLE estimates were closer to KM estimates using 
midpoint- rather than endpoint-imputation; in their multivariate analysis, there was 
very little difference between the estimates produced by the three methods, or their 
standard errors, but there were differences for certain covariates. 
 
In the analysis of a randomised controlled trial of 262 patients treated for gastric 
cancer, Nakazato et al. (Nakazato 1994) used methods suitable for right-censored 
time-to-event data, with right-endpoint imputation at the date of first detection of 
gastric cancer, to analyse interval-censored disease-free survival (DFS) times. In 
this study, follow-up was at every two weeks during the first month, then once a 
month to three months, every three months for one year, and thereafter every six 
months to five years. Subsequently, this data was reanalysed using methods 
appropriate to interval-censored time-to-event data (Sakamoto 1997). First the 
authors found that the biggest discrepancy in DFS rates between two analyses using 
the KM method, one with left-hand, the other right-hand, imputation, was only 1.2%. 
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Clearly, this will depend on the event rate, as seen in table 6.4.1.3. Similarly, 
although estimated regression coefficients and their standard errors were all slightly 
higher in the analysis using interval-censored time-to-event data, there were no 
substantial differences between this analysis and the original analysis. However, in 
their repeat analysis a parametric Weibull regression model was used, possibly 
because this was the only way the authors could proceed with an interval-censored 
analysis, given the stage of development of available software at that time. If this 
parametric assumption was not justified, it is difficult to interpret their conclusions. In 
the context of a Weibull model, Odell et al. (Odell 1992) found that when the hazard 
rate is flat (i.e. when the risk of an event occurring is essentially constant over time), 
or when the proportion of interval-censored data in a dataset is small (with most 
time-to-event data being exact, or right-censored), an analysis based on midpoints is 
adequate. 
 
Goggins et al. (Goggins 1998) reached a different conclusion for the semiparametric 
Cox model with interval-censored time-to-event data. Using simulation, they found 
that midpoint- or right-imputation produced bias in parameter estimates from the 
proportional hazards model, and underestimated standard errors. Kim et al. (Kim 
2002) reached similar conclusions in the context of multivariate interval-censored 
time-to-event data. 
 
The problem with single imputation, i.e. imputing only one time-to-event for each 
subject, such as midpoint, left- and right-endpoint imputation, is that it treats the 
imputed values as if they were known exactly. Inevitably, this will underestimate the 
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true variability in time-to-event data. Multiple imputation, on the other hand, attempts 
to overcome this problem by replacing each of the original interval observations with 
two or more “exact” values, thereby yielding multiple data sets. These data sets are 
then analysed separately using a standard method for right-censored time-to-event 
data, and the results combined in such a way as to take proper account of the 
variability in the original data set (Pan 2000). Sun (Sun 2006) used an approach 
involving multiple imputation to analyse two different datasets; Sun then compared 
the results against results obtained using the KM method with midpoint imputation, 
and the Cox regression model, and found very little difference overall. Nevertheless, 
Sun’s discussion is concluded by reiterating that an imputation approach can 
produce biased estimates, the precision of estimates may be overstated, and the 
effects of covariates may be measured incorrectly. Whether any or all of these 
adverse factors have arisen in an analysis of a specific dataset cannot be 
determined with any certainty. 
 
6.4.2 What is the most appropriate way to analyse interval-censored time-to-
event data in the cohort study described in this thesis? 
 
So, can an imputation method, in particular one using midpoint-imputation, be used 
to make inferences based on the interval-censored time-to-event data generated by 
the cohort study described in this thesis? Unfortunately, the answer seems to be “it 
depends”. An imputation approach appears to yield satisfactory results, provided the 
time intervals between measurements are short compared to the mean time-to-
event, i.e. the closer the actual observation scheme is to observations made in 
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continuous time, the better are the results of imputation within the interval (Collett 
2003). Based on the limited examples presented in table 6.4.1.3, the MPLE and KM 
estimate are quite close, even when the KM estimate differs from the NPMLE; the CI 
around the estimates also seem very narrow, since one would anticipate some 
concession to the fact that interval-censored observations must always be less 
precise than exact observations. Similarly, the imputation procedure described by 
Sun, while more complicated than midpoint-imputation, produces results which do 
not differ substantially from those produced by the midpoint analysis described. 
Given the added complexity of implementing these approaches, and the suspicion 
(on the candidates part, at least) that they yield spuriously precise estimates, they 
appear to offer little or no advantage compared to performing an analysis suitable to 
right-censored time-to-event data with midpoint imputation. It therefore appears that 
the best approach to dealing with interval-censored time-to-event data for the cohort 
study described in this thesis is to perform a nonparametric analysis appropriate to 
interval-censored time-to-event data; and then to check the results for consistency 
by using the more easily implemented methods which are available for right-
censored time-to-event data, obtained via midpoint-imputation. Any large 
discrepancies between the results of these two analyses can then be investigated in 
an attempt to determine the reason (that being said, it is the results of the interval-
censored analysis which should be accepted). However, it remains to identify 
suitable methods for the analysis of interval-censored time-to-event data when 
covariates are available. 
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6.5 IDENTIFICATION OF METHODS FOR THE ANALYSIS OF INTERVAL-
CENSORED TIME-TO-EVENT DATA FROM THE COHORT STUDY DESCRIBED 
IN THIS THESIS 
 
A search of the literature was undertaken with the aim of identifying methods for the 
analysis of interval-censored time-to-event data with: time-varying covariates; 
varying times between observations, both within and between individuals; varying 
numbers of observations for different individuals; and for which it would be possible 
for the candidate to implement in practice. Suitable methods were those for which 
there were existing computer programmes, or those which did not require extensive 
computer programming. 
 
All available published papers relating to methods used in the analysis of  interval-
censored time-to-event data were identified via a search of the PubMed database, 
and electronic journals databases at the Universities of Manchester and 
Birmingham; the term “interval-censored” was used in searches. The reference lists 
of the papers identified were then also searched. Two hundred and ten papers which 
were potentially relevant were identified: 54 were subsequently considered to be 
irrelevant for the purposes of this thesis (e.g. only applicable to current status data); 
65 were considered to be essentially of only theoretical interest, or to require 
excessive computer programme development time; and 17 were of indirect interest 
(e.g. review papers, or examples of applications of methods for interval-censored 
time-to-event data to real-life data). This left 74 to be examined in detail. Thirty-one 
were of potentially practical use, i.e. with computer programmes available, or 
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requiring easily-programmed techniques, and allowed for variation in the number 
and timing of measurements on each subject. Ten of these 31 papers presented 
methods for estimating time-to-event functions, including two which allowed for the 
inclusion of time-fixed covariates only; six discussed the comparison of survival 
curves, with time-fixed covariates; and 15 presented methods for the regression 
analysis of interval-censored time-to-event data. Of the 15 papers dealing with 
regression analysis: three were based on methods making parametric assumptions 
(one allowed for the inclusion of time-fixed covariates only, two for time-varying 
covariates); and 12 presented nonparametric, or semiparametric, methods. Of these 
12, eight allowed for the inclusion in the analysis of time-fixed covariates only, and 
four allowed for the inclusion of time-varying covariates, of which however, two 
assumed that discrete time-to-event data were of interest. The remaining two 
methods were considered for use with the data described in this thesis; Cox 
regression with midpoint imputation provided a benchmark against which results 
generated by the two methods identified were compared. 
 
I now briefly describe the two methods identified. 
 
6.5.1 Regression methods for analysing interval-censored time-to-event data: 
HARE 
 
HARE (the acronym is derived from HAzard Regression) is an adaptive regression 
method for analysing interval-censored time-to-event data in the presence of 
covariates (Kooperberg 1995, Kooperberg 1997). In HARE, linear or cubic splines 
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(see section 6.4.1.2) and tensor products are used to estimate the logarithm of the 
conditional hazard function (conditional upon covariates). Unknown parameters in a 
model are estimated using maximum likelihood; selection of the final model is either 
fully automatic, incorporating the stepwise addition and deletion of covariates using 
the Bayesian Information Criterion; or specific models can be investigated by forcing 
certain covariates into a model. Proportional hazards models assume that the 
conditional hazard function is a multiplicative function of time and covariates; with 
HARE, this assumption is not made, although proportional hazards models can be 
fitted as a special case. HARE places no restriction on the number, or frequency, of 
observations made on subjects, and allows both of these to vary between subjects. 
HARE can be used to analyse time-varying covariates, provided, as with other 
regression models with this capability, covariate values are known for each at-risk 
subject at each event time. However, HARE models the complete conditional hazard 
function, so time-varying covariates present a great numerical challenge than time-
varying covariates usually do. A computer programme in the statistical package S-
Plus is available for implementing HARE. 
 
HARE appeared to be an ideal method for analysing the data generated by the 
cohort study described in this thesis. In practice, implementing HARE proved 
problematic, with difficulty repeating apparently identical analyses on different 
occasions (sometime a result would be obtained, and sometimes it would not; 
however, whenever a result was obtained, it was always identical for identical 
analyses). It is unclear why this was the case. It is most likely to have been due to 
the performance of the computer(s) used to run the analyses, but may also have 
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been due to the statistical package used, flaws in the HARE programme itself, or the 
competence of the user. HARE was therefore only used in one set of analyses in this 
thesis. 
 
6.5.2 Regression methods for analysing interval-censored time-to-event data: 
PJS 
 
This method (the acronym PJS is mine, and is taken from the initials of the author) is 
a semi-parametric proportional hazards regression model for analysing interval-
censored time-to-event data in a generalized linear model (GLM) framework (Smith 
1997). This is a major advantage of the method, since it means that it falls within the 
mainstream of statistics, unlike HARE for example, which is highly specialized in 
nature. Covariates are incorporated parametrically (c.f. Cox regression), but the 
hazard function is either modeled empirically (a semi-parametric model), or is 
specified parametrically (a parametric model). This method makes no restrictive 
assumptions with respect to the observation scheme: subjects may be seen at 
irregular time intervals and/or on a varying number of occasions. The unit of analysis 
for this method is the interval between consecutive observation times. Each subject 
contributes a set of binary variables which indicate whether a failure occurred during 
each of the intervals of observation, prior to the known occurrence of the failure 
event, or to the end of the last time interval. These binary indicators are then 
modeled in a GLM. The logarithm of the baseline hazard function is modeled 
empirically (i.e. based on the observed data) as a smooth function. The suggested 
method is to model the logarithm of the baseline hazard function as an appropriate 
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function of the midpoints of the intervals of observation. For example, the logarithm 
of the baseline hazard function can be approximated by a quadratic polynomial in 
the interval midpoints. Alternatively, the baseline hazard function can be specified 
parametrically. However, in this case, it is not clear why the PJS method offers any 
advantage over the standard parametric methods for interval-censored time-to-event 
data. The PJS method allows for the incorporation of time-varying covariates defined 
on each interval of observation: therefore, a decision has to be made about how to 
code a covariate which varies throughout an interval (see section 6.6.1).  
 
6.5.3 Regression methods for analysing interval-censored time-to-event data: 
Other methods 
 
The PJS method is not the only method which has been proposed for the analysis of 
interval-censored time-to-event data which is based on GLM. For example 
Carstensen (Carstensen 1996) and Farrington (Farrington 1996) both present semi-
parametric methods for modeling interval-censored time-to-event data as a GLM, 
when patients are seen at irregular time intervals and/or on a varying number of 
occasions. As with the PJS method, models in the Carstensen and Farrington 
methods are based on an empirical estimate of the hazard function, with covariates 
incorporated parametrically. Both Carstensen and Farrington describe approaches 
for incorporating time-fixed covariates, but also state that time-varying covariates 
may be incorporated, with differing degrees of difficulty. For both the Carstensen and 
Farrington methods, models are fitted as GLM, with the contribution to the likelihood 
from a single individual equivalent to the likelihood from at most two independent 
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Bernoulli trials. This differs from the PJS method, since even when only fixed 
baseline covariates are included in the analysis, all intervals for each subject are 
used so that both the baseline hazard function can be estimated, and time-varying 
covariates can be included. Both the Carstensen and the Farrington method assume 
a piecewise-constant hazard function: the time axis is divided into a fixed number of 
intervals of varying width, independent of the time intervals yielded by the interval-
censored observations, and within these fixed intervals the hazard function is 
assumed to be a non-negative constant. The potential advantage of a piecewise-
constant hazards function is that, as the number of intervals used to model the 
hazard function increases, the model becomes more non-parametric in nature (in 
other words, this is the next-best-thing to a non-parametric method), which allows for 
flexibility in modeling, while retaining the advantages of parametric methods for 
hypothesis testing and estimation (Lindsey 1998). In the Farrington method, as the 
number of observations on subjects increases, the number of parameters in the 
discrete-time model increases, but for the additive and multiplicative models, the 
number of parameters remains constant; in the Carstensen method, the number of 
parameters used to estimate the hazard function remains under the analysts control. 
This last point is an important consideration when analysing a large cohort, such as 
the cohort of 2,011 women described in this thesis; with the PJS method, the 
number of parameters also remains constant as the number of observations 
increases. 
 
The Farrington method was rejected for use in the analysis of the cohort study 
described in this thesis on grounds of the requirement for substantial computer 
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programming to implement the method, as well as the extensive amount of work 
perceived to be required to include time-varying covariates in a model. In contrast, 
the Carstensen method was considered suitable, initially, since it appeared to be 
relatively straightforward to implement, and the incorporation of time-varying 
covariates seemed straightforward. An attempt was therefore made to use this 
method. However, when the data was analysed as a set of at most two records per 
subject, a mixture of positive- and negative-intensities (or estimates of the hazard 
function) was obtained, without including any covariates. Given that the hazard 
function is strictly non-negative by definition, this is clearly not satisfactory. When the 
data was coded as a set of binary outcomes with only one non-negative covariate 
per record (as suggested by the author to overcome this problem), all parameters 
were negative. This was the case whether analysing time to diagnosis of high-grade 
CIN (28 outcomes in 1,075 women) or HPV (407 outcomes in 1,075 women). 
Seaman et al. (Seaman 2001) also attempted to use this method and seem to have 
had the same problem. The authors state: “however, the generalized linear model 
computer algorithm may converge to an impossible solution, because it does not 
take into account the parameter constraints that exist when the survival model is 
formulated in this way as a generalized linear model [however, this is why 
Carstensen suggested coding the data with only one non-negative covariate per 
record]. In fact, I attempted to use Carstensen’s method, but found that negative 
estimates of the hazard function were produced for some time periods, even before 
covariates were introduced. I decided not to pursue this method any further. 
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The PJS method was found to be entirely satisfactory in terms of both ease of 
implementation, and consistency of results with the Cox model using midpoint-
interpolated right-censored time-to-event data. This method has been used in 
preference to HARE in all relevant analyses in this thesis, save the first undertaken 
(see chapters 8, 9, 10 and 11). 
 
6.6 TIME-VARYING COVARIATES IN TIME-TO-EVENT ANALYSES 
 
Covariates whose values change over time are called time-dependent, or time-
varying, covariates, for example temperature during the day, or smoking status 
during follow-up in the cohort study described in this thesis; covariates whose values 
do not change with time are called time-independent, or time-fixed, covariates, for 
example sex, or cytological status at recruitment into the cohort study described in 
this thesis. Time-varying covariates may be more plausible causal factors and better 
explain observed outcomes than time-fixed covariates (Bacchetti 2002). However, 
time-varying covariates present practical challenges in terms of: assigning them a 
value; the ability to include them in an analysis; their description; and their 
interpretation. 
 
6.6.1 Assigning a value to a time-varying covariate 
 
When including a time-varying covariate in an analysis, a decision must usually be 
made as to how to assign a value to that covariate. In particular, with a longitudinal 
repeated-measurements design, time-varying covariates are updated only at distinct 
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points in time, although the underlying process which they measure is likely to be a 
“smooth” continuously varying process. Therefore, the most representative, or 
relevant, value for that covariate during the interval between which the 
measurements are made must be decided upon. This decision will vary according to 
the covariate, and the study hypothesis, but tends to be based on a limited range of 
options. For example: previous measured value; current value; mean value; 
cumulative value; maximum value attained to date, etc. 
 
The value(s) of some time-varying covariates may be missing: subjects with missing 
values could be excluded from an analysis, but this is likely to be very inefficient, 
especially if values are missing only intermittently (see section 6.7.1). If the subjects 
are to be retained in the analysis, their missing values must be assigned a value in 
some way. Possible approaches are: to impute the missing value using the most 
recent measurement available, for categorical covariates; to interpolate between 
adjacent measurements, for continuous covariates; or to use several adjacent 
measurements to assign a value, for continuous covariates.  
 
These are general issues with assigning a value to a time-varying covariate. How 
time-varying covariates were assigned values, and how missing values were dealt 
with, in specific analyses of the cohort study described in this thesis, are discussed 
in the relevant sections of the thesis. 
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6.6.2 Including and describing time-varying covariates in an analysis 
 
Not all statistical methods for the analysis of time-to-event data will allow for the 
inclusion of time-varying covariates. For example, the nonparametric maximum 
likelihood estimators for both right-censored and interval-censored time-to-event 
data, the KM and Turnbull estimators, respectively, can only be estimated for time-
fixed covariates. And there is no equivalent graphical, or tabular, representation 
which will capture the effects of a time-varying covariate “at a glance” in the same 
way as a graph of the KM or Turnbull estimator will. 
 
Only methods capable of including time-varying covariates were considered for use 
in relevant analyses in this thesis.  
 
6.6.3 Interpretation of time-varying covariates 
 
Time-varying covariates can be categorised into groups according to the ability of 
study subjects, or investigators, to influence their values, either directly or indirectly: 
the greater the ability, the more challenging the question of interpretation. 
 
An external time-varying covariate is one which can be measured without regard to 
the status of the study subject (Kalbfleisch 2002). External covariates cannot be 
influenced by study subjects, or manipulated by investigators, and generally present 
few problems with respect to statistical inferences. There are different types of 
external time-dependent covariate (Singer 2003). A defined covariate is one for 
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which values are predetermined for every subject under study. Most defined 
covariates are functions of time e.g. time itself, or calendar age. An ancillary 
covariate is a random covariate whose values are determined by a stochastic (i.e. 
random) process independent of any particular study subject. For example a time-
varying environmental exposure, such as temperature: knowing the temperature on 
a given date at a certain time does not convey any information about the status with 
respect to any given outcome of a study subject at that time. 
 
An internal time-varying covariate is one for which the status of the study subject 
determines whether the covariate can be measured (Kalbfleisch 2002). For example, 
number of cigarettes smoked per day by a person is an internal time-varying 
covariate: this covariate changes over time in a way which cannot be determined in 
advance, and which can be changed by the subject themselves, either as a result of 
external influences, or merely on a whim. Knowing that a person smoked a certain 
number of cigarettes on a certain date implies that the person was alive on that date; 
knowledge of the variable therefore conveys knowledge of survival status.  
 
Internal time-varying covariates present difficulties of interpretation. One of the 
strengths of a longitudinal study design is that it establishes temporality, i.e. that the 
cause, as measured by the covariate, precedes the effect, as measured by the 
outcome variable. In contrast, a cross-sectional study, where the predictor (i.e. the 
covariate of interest) and outcome are measured contemporaneously, can never 
establish temporality with certainty. If a longitudinal analysis links outcomes with 
contemporaneous values of time-varying covariates, this effectively converts a 
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longitudinal analysis into a cross-sectional analysis. Therefore, even though a 
longitudinal analysis may demonstrate an association between a time-varying 
covariate and an outcome, this would not necessarily establish temporality. There 
are two types of time-varying covariate for which temporality may be an issue, state- 
and rate-dependent covariates  (Singer 2003). 
 
A time-varying covariate is state dependent if its values at a given time are affected 
by whether the subject has experienced the event of interest at that time. HPV viral 
load, and the first detection of cervical cytological abnormality, may be an example 
of this: the risk of acquiring cytological abnormality may increase with increasing viral 
load; but cytological abnormality may also facilitate an increase in HPV replication, 
and therefore an increase in HPV viral load. This is further complicated by the 
relative sensitivities of the two methods of measurement. The detection of cytological 
abnormality is relatively insensitive, whereas qPCR is very sensitive at detecting 
HPV. Therefore, a time-varying covariate measuring HPV viral load may 
demonstrate changes resulting from the acquisition of the outcome well before it is 
possible to detect the outcome itself.  
 
A time-varying covariate is rate-dependent if its values at time t are affected by an 
individual’s value of hazard at time t. Consider the relationship between the stress 
experienced by an aircraft pilot and the risk of an aircraft accident. Stress increases 
with workload and with knowledge of risk. A person under stress is more likely to 
make a mistake; thus the risk of an accident (and therefore the underlying hazard of 
an accident) increases as stress increases. The workload of a pilot, and the risk of 
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an accident, are greatest at take off and at landing, but are negligible in between. A 
pilot is well aware of this fact, and so the pilot’s stress levels follow the same pattern, 
hence pilot-stress is a rate-dependent covariate.  
 
To avoid difficulties with interpretation, covariate processes should be predictable. A 
predictable process is a stochastic (random) process whose value at time t is known 
infinitesimally before t, if not sooner. A time-fixed covariate measured at baseline is 
predictable, since once it is measured it is known at all subsequent times. Measuring 
a covariate simultaneously with the event of interest is analogous to placing a bet on 
a race just as the winner crosses the line (Therneau 2002). Therefore, ideally time-
varying covariates should take values from earlier chronological times, i.e. prior 
status on a potential predictor of the risk of a given outcome should be linked with 
current status on that outcome (Singer 2003). 
 
In practice, the best way to deal with time-varying covariates is to adopt the usual 
approach to complicated issues in statistical analysis: see how sensitive the 
conclusions are to different assumptions and definitions, and attempt to reach a 
consensus amongst the various possible conclusions. How time-varying covariates 
were interpreted in specific analyses of the cohort study described in this thesis is 
discussed in the relevant sections of the thesis. 
 
6.7 MISSING VALUES 
 
In any longitudinal analysis involving repeated measurements, the assumption is 
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made that each subject’s observed data are a random sample from the underlying 
process of interest within that subject. However, in practice, most longitudinal studies 
will include some subjects for whom data is missing for one or more of the repeated 
measurements. 
 
6.7.1 General description 
 
Missing values arise whenever one or more of the sequences of measurements on 
subjects within the study population are incomplete, in the sense that intended 
measurements are not taken, are lost, or are otherwise unavailable (Diggle 2000). 
Missing values result in unbalanced data. However, although missing data requires 
special handling from a statistical point of view, the existence of missing data does 
not, in itself, necessarily present a problem in an analysis. However, the nature of 
the missing values must also be considered: it must be determined whether the fact 
that values are missing bears any relationship to the study hypothesis. If the missing 
values have arisen as a result of systematic sources, this may invalidate statistical 
inferences (Singer 2003). 
 
Little describes procedures for the statistical analysis of data which are subject to 
missing values, and provides a now widely-accepted hierarchy of missing value 
mechanisms (Little 2002). The crucial distinction in likelihood-based analyses is 
between informative and non-informative, or random, missing values; in the latter 
case the missing value mechanism is referred to, suggestively, as ignorable. 
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The first mechanism, missing completely at random (MCAR), means that the 
observed values can be considered to be a random sample of those values which 
would have been observed had there been no missing data. MCAR data may be 
analysed by any method which can handle unbalanced data. Therefore, if missing 
data are unavoidable, this is the ideal type to have. Longitudinal data are MCAR if 
the probability of data being missing on any given occasion is independent of: (1) the 
time at which the measurement is made; (2) the values of covariates; (3) the value of 
the (missing) outcome (Singer 2003). To establish that data are MCAR it must be 
shown that the probability of data being missing at a given point in time is unrelated 
to the contemporaneous (but missing) value of the associated outcome. Because the 
contemporaneous value of the associated outcome is unobserved, this can only be 
established by a theoretical argument. Therefore, any reasonable potential 
association invalidates the MCAR assumption. 
 
The second mechanism, missing at random (MAR), is less ideal, but also less 
restrictive in its assumptions, than MCAR, and still allows valid statistical inferences 
to be made. When data are MAR the probability of data being missing can depend 
on any observed data, for either the covariates or any outcome values; it cannot, 
however, depend on any unobserved values of either covariates or outcome. 
 
If data is not missing at random (NMAR), the third mechanism, standard statistical 
methods based on likelihood principles cannot be used without accounting for the 
missing data mechanism. 
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Whether missing values occur intermittently or as “dropouts” is also an important 
consideration. Missing values occur as dropouts if, whenever a measurement at time 
t is missing, so are all measurements which should have been made after time t; 
otherwise the missing values are said to be “intermittent”. It may be reasonable to 
assume that intermittent missing values arise as a result of reasons unrelated to the 
measurement process, and are therefore MCAR. Dropouts arise as a result of 
subjects being withdrawn from a study prematurely. This can often be assumed to 
be related to the measurement process, in which case the missing data mechanism 
is said to be informative (Diggle 2000, Singer 2003). 
 
6.7.2 Missing values in the study described in this thesis 
 
The assumption has been made throughout all analyses based on the cohort study 
described in this thesis, that dropouts are non-informative, and that missingness is 
ignorable. Ignorable missingness permits valid statistical inferences; the burden of 
establishing that missingness is ignorable lies with the researcher (Singer 2003).  
 
6.7.2.1 Observation scheme 
 
In the cohort study described in this thesis, it is difficult to say for certain which 
missing values are dropouts in the sense described above. The study design did not 
specify the number of visits which each study subject was expected to make, only 
the desired frequency of those visits; and women could not be, and would not have 
been, compelled to return to the study. Some women only ever made one visit to the 
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study, whereas others remained on follow-up for several years; some women 
returned regularly at intervals of six months, others returned regularly but at intervals 
of their own choosing, and others returned irregularly. Dropout, due to inconvenience 
or to loss of interest in the study, may have occurred. There certainly does not 
appear to be an association between the number of visits made and the results of 
any study measurements of which the woman would have been aware, but this can 
never be established with certainty. 
 
6.7.2.2 Missing HPV observations 
 
Cervical HPV infection status can be considered to be both an exposure variable 
and an outcome, depending on the analysis: the method for dealing with missing 
values when HPV is used as an exposure variable is described in the appropriate 
sections of this thesis. In this study cytological samples were only tested for HPV 
DNA after all visits had been made and all clinical follow-up had ended. Neither a 
woman, nor any of the clinicians involved in her care, would have been aware of the 
woman’s HPV status at any point during the follow-up phase of the study, i.e. on or 
after recruitment to the study. Therefore, any missing observations are unlikely to 
have been directly related to cervical HPV status. 
 
Missing observations on cervical HPV status were mostly intermittent, given that a 
woman’s observation status is assumed to be known completely (dropouts are 
difficult to identify). Reasons an observation was missing include the following: a 
sample may not always have been taken at a visit; a sample for HPV DNA analysis 
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may not have been taken when an inadequate smear was repeated; the sample may 
have been physically lost or misplaced, for example some samples which were 
missing in the GP5+/GP6+ analysis were subsequently found and were included in 
the HPV viral load analysis; others included in the GP5+/GP6+ analysis could not be 
traced for inclusion in the viral load analysis. The sample may have been lost via 
failures in storage procedures: for example, some samples arrived in the laboratory 
with no material, or had clearly been stored inadequately, and so could not be 
tested. 
 
It would appear to be safe to conclude that missing measurements of cervical HPV 
status are at the very least MAR, if not MCAR. 
 
6.7.2.3 Missing cytological and histological status measurements 
 
Cervical cytological abnormality is essentially asymptomatic, but cervical cytological 
status was known to both the woman and the clinicians responsible for her care, 
after only a slight delay. Therefore, prior cytological status could, in theory, have 
influenced whether or not a subsequent measurement was missing. Histological 
measurements were only made following the detection of cytological abnormality, 
and therefore the issue of missingness of these measurements are closely related. 
 
Some missing observations on cervical cytological and histological status were 
clearly intermittent (see section 6.7.1), with women missing one scheduled visit and 
either attending shortly after, or returning at the next scheduled visit. Similarly, a visit 
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with an inadequate smear may nevertheless have provided a sample which was 
evaluable for HPV status, thus generating a “missing” sample for cytological status, 
but not for HPV status. Ignorable missingness appears to be a safe assumption in 
these cases. 
 
Non-informative dropout is likely to have occurred following increasing familiarity with 
study procedures, but for some cervical cytological outcomes, e.g. having a severe 
cervical cytological abnormality following an abnormality of a lower severity, 
informative dropout is a distinct possibility. All women were made fully aware of the 
design and objectives of the study when they agreed to participate. Therefore they 
would have known that any cytological abnormality they experienced would have 
been followed-up in the first instance without treatment, but nevertheless they would 
have been kept under close clinical surveillance; and that the frequency of study 
visits would not change according to their cervical cytological status, only the nature 
of the surveillance. This should have meant that the detection of a cervical 
cytological abnormality would not have affected the likelihood that a woman would 
return to the study. However, whereas cytological smears were taken in the Brook 
Advisory Centre (the family planning clinic), to which women would likely be 
returning for contraceptive supplies anyway, colposcopic assessments were 
performed in a different, and possibly less convenient, location. And agreement to 
participate in the study when cytological abnormality was a theoretical possibility is 
of course very different from being faced with the reality. The colposcopic 
assessments and histological diagnoses which followed the detection of a cytological 
abnormality were surely more intrusive and alarming in nature than having a 
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cytological smear was. Declining to participate in the study on the grounds of 
inconvenience certainly seems possible. However, refusing to return to the study 
because of concern over a diagnosis of cytological or histological abnormality seems 
counterintuitive, since women could address their concerns by requesting treatment 
at any point. Very few women exercised this right. Therefore, informative 
missingness, whilst theoretically unlikely, can never be ruled out entirely. 
 
 
Summary 
 
The study described in this thesis provides repeat observations on both outcome 
status and covariates, with, for each woman: correlation between observations; a 
variable number of observations; and a variable time interval between each 
observation. Outcomes are measured on both continuous and binary scales, can be 
either single events in time or multiple events measured at several points in time. For 
time-to-event data, outcomes are interval-censored, which require the use of special 
analytical methods. Covariates include both time-fixed and time-varying types, which 
are also known only to change within an interval. The study described in this thesis 
is also subject to “missing data”, the nature of which must be dealt with appropriately 
to ensure that valid statistical inferences are made. 
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Chapter 7 
 
THESIS AIM AND OBJECTIVES 
 
 
 
 
7.1 AIM  
 
To describe the natural history of cervical human papillomavirus (HPV) infection and 
its relationship to the acquisition of epithelial abnormalities of the cervix in a cohort of 
young women. 
 
7.2 OBJECTIVES  
 
• To investigate if the adolescent cervix is inherently more susceptible to HPV 
infection. 
 
o To measure the association between the time interval between date of 
menarche and date of first sexual intercourse and the risk of acquiring 
an incident cervical infection with HPV DNA of any type. 
 
• To investigate the association between cigarette smoking and the risk of cervical 
HPV infection, the natural history of this infection, and the subsequent 
development of epithelial abnormalities of the cervix. 
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o To determine the association between exposure to cigarette smoking 
and the risk of acquiring an incident cervical infection with HPV DNA of 
any type, HPV16 and HPV18. 
 
o To determine the association between exposure to cigarette smoking 
and the duration of an incident cervical infection with HPV DNA of any 
type, HPV16, and HPV18. 
 
o To determine the association between exposure to cigarette smoking 
and the risk of acquiring incident high-grade cervical intraepithelial 
neoplasia 
 
• To investigate how the natural history of cervical HPV infection varies with the 
humoral immune response. 
 
o To evaluate the performance of an assay for the measurement of the 
neutralizing antibody response to cervical infection with HPV16 and 
HPV18. 
 
o To describe the kinetics of the neutralizing antibody response in a 
cohort of young women who were recruited soon after first sexual 
intercourse, and who first tested positive for HPV16 DNA, or HPV18 
DNA, or both, in cervical samples during follow-up. 
 
124 
 
• To investigate how the natural history of cervical HPV infection varies with viral 
load, and to determine the association between HPV viral load and the 
acquisition of epithelial abnormalities of the cervix. 
 
o To evaluate the performance of an assay for the measurement of 
HPV16 and HPV18 viral load 
 
o To describe how the distribution of HPV viral load varies with the 
infecting HPV type in cervical samples. 
 
o To describe how viral load changes over time for women with incident 
cervical HPV16, or HPV18, infections 
 
o To describe the relationship between HPV16 and HPV18 viral load in 
cervical samples and the detection of epithelial abnormalities of the 
cervix. 
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Chapter 8 
 
PROXIMITY OF MENARCHE TO FIRST SEXUAL INTERCOURSE 
AND THE RISK OF CERVICAL HPV INFECTION 
 
INTRODUCTION 
 
 
 
 
The process of squamous metaplasia, during which columnar epithelium in the 
cervix is replaced by squamous epithelium, begins during puberty and is ongoing 
throughout the reproductive years (see section 2.1.1). One mechanism by which this 
process is thought to occur is by reserve-cell hyperplasia. Reserve cells, i.e. 
undifferentiated epithelial cells, proliferate around the exposed endocervical glands 
and ultimately replace the columnar epithelium with squamous epithelium. It has 
been suggested that reserve cells in adolescent and young women are especially 
vulnerable to human papillomavirus (HPV) infection (Singer 1989). 
 
Cross-sectional studies have suggested that, compared with women who delay the 
start of their sexual career, those who first have sexual intercourse soon after 
menarche are more susceptible to cervical HPV infection and thus have a greater 
risk of cervical neoplasia (Shew 1994, Kahn 2002a). However, these studies are 
limited in so far as outcomes are first defined some years after the woman’s first 
sexual experience, and therefore after the first possible exposure; at this point in 
time, it is not possible to distinguish the effects of early-, late- and cumulative-
exposures to HPV. The longer the time interval between date of first sexual 
intercourse and date of first sampling to test for the presence of HPV DNA in cervical 
samples, the more likely it is that a woman will have acquired, and then cleared, at 
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least one cervical HPV infection before first sampling, or possibly have established a 
latent infection, following which HPV may be only transiently detectable in cervical 
samples (Wallin 1999). Clearly, the occurrence of outcomes of interest in the interval 
immediately following the onset of sexual activity, and those factors which bear on it, 
can only be described when observations are made during this interval.  
 
I investigate, using longitudinal data, the risk of acquiring cervical HPV infection 
associated with the proximity of first sexual intercourse to menarche, during the first 
sexual relationship, in women who first had a cervical sample taken within twelve 
months of the start of their sexual career: both outcome and exposure are thus 
measured during the most relevant period. 
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Chapter 9 
 
PROXIMITY OF MENARCHE TO FIRST SEXUAL INTERCOURSE 
AND THE RISK OF CERVICAL HPV INFECTION 
 
METHODS 
 
 
 
Orientation 
 
In this chapter I: 
 
• define the outcome used in the analysis of the proximity of menarche to first 
sexual intercourse and the risk of cervical HPV infection 
 
• define the study population for the analysis 
 
• describe the statistical methods used in the analysis 
 
• define covariates used to measure sexual behaviour 
 
 
 
 
 
9.1 RESTATEMENT OF OBJECTIVES 
 
To investigate if the adolescent cervix is inherently more susceptible to HPV infection. 
Specifically, to measure the association between the time interval from date of menarche to 
date of first sexual intercourse and the risk of acquiring an incident cervical infection with 
HPV of any type. 
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9.2 DEFINITION OF OUTCOME 
 
The outcome for this analysis is the acquisition of an incident cervical HPV infection 
of any type, subsequent to the date of first sexual intercourse, and prior to the 
acquisition of a second sexual partner. In this analysis, the method used to detect 
HPV DNA was the GP5+/GP6+ general primer-mediated PCR system (see section 
5.5.4.1). 
 
9.3 STUDY POPULATION 
 
The study population for this analysis is a subset of the full cohort of 2,011 women 
recruited to the main study, comprising all women who were recruited within twelve 
months of first having had sexual intercourse and who had yet to acquire a second 
sexual partner. The study population comprises 474 women. 
 
9.4 STATISTICAL METHODS 
 
Methods appropriate to the analysis of interval censored time-to-event data were 
used in analyses of time-to-event data. 
 
Time-to-event was measured from the date of first sexual intercourse until the date 
of the first acquisition of a cervical infection with HPV DNA of any type. Given that 
cervical HPV infection is a sexually transmitted infection, women were assumed to 
be HPV DNA-negative on their date of first sexual intercourse. Subsequent 
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observations on HPV status were interval censored: time of acquisition of a cervical 
infection with HPV DNA of any type was known only to lie in the interval between the 
date of the first test which yielded a HPV-positive result and the date of the 
immediately preceding test which yielded a HPV-negative result, or the date of first 
sexual intercourse if the woman was HPV-positive in her first evaluable sample. 
Time-to-event was right-ensored on the earliest of: date of acquisition of a second 
sexual partner; date of diagnosis of high-grade cervical intraepithelial neoplasia; or 
the date of the last visit. Time-to-event was thus restricted to the period when a 
woman had only had one sexual partner.  
 
Turnbull’s generalisation of the product-limit estimator for interval censored data was 
used to estimate the cumulative risk of an incident cervical HPV infection of any type 
following first sexual intercourse, and to construct confidence intervals based on the 
logarithm of the hazard function (Turnbull 1976). Multivariate analyses were 
undertaken using HARE (HAzard REgression), an adaptive regression method for 
analysing interval-censored time-to-event data in the presence of covariates 
(Kooperberg 1997). Interactions were tested for, and although not so constrained, all 
models constructed using HARE were proportional hazards models. See section 
6.5.1 for a more detailed discussion of these statistical methods. 
 
9.5 DEFINITION OF SEXUAL BEHAVIOUR-RELATED STUDY VARIABLES 
 
A detailed sexual-behaviour history was collected at study entry for all women using 
an interviewer-completed questionnaire (see section 5.3); these details were then 
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updated at each visit using another interviewer-completed questionnaire recording 
changes since the previous visit (see appendices 1 and 2 for these two 
questionnaires). 
 
Covariates available for analysis were: the time interval between the date at 
menarche and the date of first sexual intercourse; age at first sexual intercourse; age 
at menarche; age of sexual partner; sexual experience of partner; and use of barrier 
contraception.  
 
9.5.1 Age at first sexual intercourse 
 
This is the calendar age at which a woman first experienced penetrative vaginal 
sexual intercourse.  
 
All women were sexually active prior to the end of follow-up. Age at first sexual 
intercourse was recorded on the questionnaire collected at the first interview for the 
vast majority of women (appendix 1). However, among the full cohort of all 2,011 
women recruited, 21 had yet to have sexual intercourse at their first interview, and 
so their age at first sexual intercourse was recorded prospectively. 
 
At their first interview, women were asked two questions relevant to their age at first 
sexual intercourse. One question, “How old were you when you first had vaginal 
intercourse”, elicited an explicit age in years. “Loss of virginity” is typically a 
memorable event, so age at first sexual intercourse is likely to have been accurately 
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recalled. However, the other question, “When did you first have intercourse?”, was 
recorded as a date, accurate to nearest month and year. Although this date is 
probably less memorable than age at first sexual intercourse, it could be used as a 
means of verifying the recorded age. During follow-up, women were asked the date 
on which they had acquired any new sexual partners since their previous interview, 
recorded as a full date. Given this date, age at first sexual intercourse could be 
calculated.  
 
9.5.2 Age of first sexual partner 
 
This is the calendar age of the woman’s first male sexual partner on the date at 
which the woman first experienced penetrative vaginal intercourse.  
 
Recorded ages were accepted at face value. At their first interview and during follow-
up, women were always asked the age of their sexual partner. However, their 
responses are subject to difficulties with recall, and possibly with the partner lying 
about their age. One additional potential source of confusion is that women 
occasionally appeared to give the current age of their current partner, rather than the 
age of that partner on the date they first had sexual intercourse with that partner.  
 
9.5.3 Age at menarche 
 
This is the calendar age of the woman when she first menstruated.  
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Age at menarche was recorded on the questionnaire collected at the woman’s first 
interview, as an age in years (appendix 1). Getting their first “period” is typically a 
memorable event for a woman, so age at menarche is likely to have been accurately 
recalled. 
 
9.5.4 Use of barrier contraception 
 
This is a binary variable recording whether a woman ever used barrier contraception 
with her partner during sex. 
 
For each of their sexual relationships, women were asked whether they had used 
barrier contraception during that relationship, and, if so, for how long, i.e. the length 
of the period during the relationship when barrier contraception was used. Note that, 
as defined here, this is not strictly speaking a baseline variable since it is defined as 
use at any time prior to the first evaluable sample. 
 
9.5.5 Sexual experience of partner 
 
This is a categorical variable, with categories “experienced”, “inexperienced” and 
“unknown”, recording whether or not the woman thought that her sexual partner was 
already sexually experienced prior to first sexual intercourse with her. 
 
At her first interview, for each of her sexual partners prior to that date, women were 
asked whether they thought that this partner was a “virgin” at the start of their sexual 
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relationship. During the prospective phase of the study, women were not asked 
about the sexual experience of their partners. 
 
9.5.6 Gynaecological age 
 
In general, this is a term coined to denote the elapsed time since date at menarche. 
This analysis focuses specifically on gynaecological age at first sexual intercourse, 
the time interval between the date at menarche and the date of first sexual 
intercourse. 
 
The year and month when first sexual intercourse occurred was known, or at least 
recorded,  for all women; the assumption was made that first sexual intercourse 
occurred at the midpoint of the month, and therefore date of first sexual intercourse 
was accurate to within 15 days. Age at menarche (AM) was known, or at least 
recorded, but the exact date on which menarche occurred is known rarely, if ever, in 
studies of this nature, and therefore the assumption was made that menarche 
occurred on the day before her (AM+1)st birthday. Age at menarche is therefore the 
minimum possible age, but note that if menarche had instead been located on the 
day of the AMth birthday, this would have yielded identical risk estimates of hazards 
ratios, given the method used to estimate these quantities. Age at menarche and 
age at first sexual intercourse were identical for one woman, whose gynaecological 
age was set to zero. 
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Chapter 10 
 
PROXIMITY OF MENARCHE TO FIRST SEXUAL INTERCOURSE 
AND THE RISK OF CERVICAL HPV INFECTION 
 
RESULTS 
 
 
 
 
 
Orientation 
 
In this chapter I: 
 
• describe the sexual behaviour characteristics of the study population and the 
association among these variables 
 
• investigate, in univariate analyses, association between sexual behaviour 
characteristics and the risk of acquiring a cervical HPV infection of any type 
 
• investigate, in univariate analyses, the association between the proximity of first 
sexual intercourse to menarche and the risk of acquiring a cervical HPV infection 
of any type 
 
• investigate, in multivariate analyses, the association between the proximity of first 
sexual intercourse to menarche and the risk of acquiring a cervical HPV infection 
of any type 
 
 
 
 
 
10.1 SEXUAL BEHAVIOUR CHARACTERISTICS OF THE STUDY POPULATION 
 
The frequency distribution of the sexual behaviour characteristics of the 474 women 
comprising the study population used in the analysis described in these chapters of 
the thesis are shown in table 10.1a. The median calendar age of a woman’s first 
sexual partner was 19 years (range 15 to 42); 14 (3.0%) women had a sexual 
partner aged 25 years or older. The median calendar age of a woman at first sexual 
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intercourse was 17 years (range 13 to 19). The median calendar age of a woman at 
menarche was 13 years (range 8 to 16). Most women used barrier contraception at 
some point during their first sexual relationship. Just over half of the women believed 
that their partner was already sexually experienced prior to first sexual intercourse 
with them, but a substantial proportion of women were unsure. 
 
Table 10.1a. Frequency distribution of the sexual behaviour 
characteristics of the study population. 
 
Characteristic Number of 
women (n=474) 
% 
   
Calendar age of first sexual partner (years)   
≤17 109   23.0
18    88   18.6
19    76   16.0
20    50   10.5
21    48   10.1
22    35     7.4
≥23    43     9.1
   
Calendar age at first sexual intercourse (years)   
≤15    65   13.7
16 155   32.7
17 138   29.1
18    82   17.3
19    34     7.2
   
Calendar age at menarche (years)   
≤11    70   14.8
12 114   24.1
13 160   33.8
≥14 130   27.4
   
Use of barrier contraception   
No 126   26.6
Yes 348   73.4
   
Sexual experience of partner   
Inexperienced 136   28.7
Experienced 245   51.7
Unknown    93   19.6
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The frequency distribution of gynaecological age at first sexual intercourse for the 
study population used in this analysis is shown in table 10.1b. The median 
gynaecological age at first sexual intercourse of the women was 3.3 years (range 0 
to 9.3). 
 
Table 10.1b. Frequency distribution of gynaecological 
age at first sexual intercourse. 
 
Gynaecological age at first 
sexual intercourse (years)a 
Number of 
women 
(n=474) 
% 
[ 0 , 1 ) 21 4.4 
[ 1 , 2 ) 67 14.1 
[ 2 , 3 ) 104 21.9 
[ 3 , 4 ) 127 26.8 
[ 4 , 5 ) 84 17.7 
[ 5 , 6 ) 46 9.7 
[ 6 , 7 ) 18 3.8 
≥7 7 1.5 
a[x, y) is a mathematical convention meaning values ≥x 
and <y. 
 
 
 
 
 
Summary 
 
The median age of a woman’s first sexual partner was 19 years (range 15 to 42); 14 
(3.0%) women had a sexual partner aged 25 years or older; median age at first 
sexual intercourse was 17 years (13 to 19); median age at menarche was 13 years 
(8 to 16); most women used barrier contraception at some point during their first 
sexual relationship; just over half of the women believed that their partner was 
already sexually experienced prior to first sexual intercourse with them, but a 
substantial proportion of women were unsure; and median gynaecological age at 
first sexual intercourse was 3.3 years (0 to 9.3). 
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10.2 THE ASSOCIATION BETWEEN GYNAECOLOGICAL AGE AT FIRST 
INTERCOURSE AND THE SEXUAL BEHAVIOUR CHARACTERISTICS OF THE 
STUDY POPULATION 
 
10.2.1 The association between gynaecological age at first sexual intercourse 
and calendar age at first sexual intercourse 
 
The association between gynaecological age and calendar age at first sexual 
intercourse is shown in table 10.2.1. These variables are positively-correlated: as 
gynaecological age at first sexual intercourse increases, calendar age at first sexual 
intercourse increases (correlation coefficients: Pearson’s=0.51; Spearman’s=0.52; 
Kendall’s Tau=0.40; ptwo-sided<0.01 in each case). This is as expected, given the 
definition of gynaecological age at first sexual intercourse and the narrow calendar 
age range within which women were eligible for recruitment into the study.  
 
Table 10.2.1. The association between gynaecological age at first sexual 
intercourse and calendar age at first sexual intercourse.  
 
Gynaecological age at first sexual intercourse (years)a Calendar 
age at first 
sexual 
intercourse 
(years) 
[ 0 , 2 )b [ 2 , 3 ) [ 3 , 4 ) [ 4 , 5 ) ≥ 5 Total 
≤15 29 (33) 21 (20) 12 (9) 3 (4) 0 (0) 65 (14) 
16 39 (44) 50 (48) 41 (32) 15 (18) 10 (14) 155 (33) 
17 15 (17) 25 (24) 54 (43) 29 (35) 15 (21) 138 (29) 
18 5 (6) 5 (5) 18 (14) 27 (32) 27 (38) 82 (17) 
≥19 0 (0) 3 (3) 2 (2) 10 (12) 19 (27) 34 (7) 
Total 88 (19) 104 (22) 127 (27) 84 (18) 71 (15) 474 (100)
aFrequency counts, i.e. number of women, with percentages in brackets. Percentages are 
calculated based on column totals, with the exception of those in the final row, which are 
percentages of the row total; b[x, y) means ≥x and <y. 
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10.2.2 The association between gynaecological age at first sexual intercourse 
and age of first sexual partner 
 
The association between gynaecological age at first sexual intercourse and the age 
of the woman’s first (and for this analysis, only) sexual partner, is shown in table 
10.2.2. These variables are only slightly positively correlated (correlation coefficients: 
Pearson’s=0.19; Spearman’s=0.17; Kendall’s Tau=0.12; ptwo-sided<0.01 in each case), 
with no consistent trend noticeable. 
 
Table 10.2.2. The association between gynaecological age at first sexual 
intercourse and calendar age of first sexual partner.  
 
Gynaecological age at first sexual intercourse (years)a Age of 
first 
sexual 
partner 
(years) 
[ 0 , 2 )b [ 2 , 3 ) [ 3 , 4 ) [ 4 , 5 ) ≥ 5 Total 
≤16 9 (10) 11 (11) 6 (5) 4 (5) 3 (4) 33 (7) 
17 18 (20) 22 (21) 18 (14) 13 (15) 5 (7) 76 (16) 
18 11 (13) 22 (21) 24 (19) 18 (21) 13 (18) 88 (19) 
19 20 (23) 17 (16) 16 (13) 8 (10) 15 (21) 76 (16) 
20 5 (6) 8 (8) 16 (13) 10 (12) 11 (15) 50 (11) 
21 10 (11) 6 (6) 18 (14) 8 (10) 6 (8) 48 (10) 
22 7 (8) 5 (5) 12 (9) 4 (5) 7 (10) 35 (7) 
≥23 8 (9) 13 (13) 17 (13) 19 (23) 11 (15) 68 (14) 
Total 88 (19) 104 (22) 127 (27) 84 (18) 71 (15) 474 (100)
aFrequency count (number of women) with percentage in brackets. Percentages are 
calculated based on column totals, with the exception of those in the final row, which are 
percentages of the row total; b[x, y) means ≥x and <y. 
 
 
10.2.3 The association between gynaecological age at first sexual intercourse 
and calendar age at menarche 
 
The association between gynaecological age at first sexual intercourse and calendar 
age at menarche is shown in table 10.2.3. These variables are negatively-correlated: 
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as gynaecological age at first sexual intercourse increases, calendar age at 
menarche decreases (correlation coefficients: Pearson’s=–0.70; Spearman’s=–0.66; 
Kendall’s Tau=–0.52; ptwo-sided<0.01 in each case). This is as expected, given the 
definition of gynaecological age at first sexual intercourse and the narrow calendar 
age range within which women were eligible for recruitment into the study.  
 
Table 10.2.3. The association between gynaecological age at first sexual 
intercourse and calendar age at menarche.  
 
Gynaecological age at first sexual intercourse (years)a Age at 
menarche 
(years) [ 0 , 2 )
b [ 2 , 3 ) [ 3 , 4 ) [ 4 , 5 ) ≥ 5 Total 
≤11 0 (0) 1 (1) 12 (9) 18 (21) 39 (55) 70 (15) 
12 4 (5) 20 (19) 41 (32) 29 (35) 20 (28) 114 (24) 
13 17 (19) 50 (48) 54 (43) 27 (32) 12 (17) 160 (34) 
≥14 67 (76) 33 (32) 20 (16) 10 (12) 0 (0) 130 (27) 
Total 88 (19) 104 (22) 127 (27) 84 (18) 71 (15) 474 (100) 
aFrequency counts  (number of women) with percentages in brackets. Percentages are 
calculated based on column totals, with the exception of those in the final row, which are 
percentages of the row total; b[x, y) means ≥x and <y. 
 
 
10.2.4 The association between gynaecological age at first sexual intercourse 
and the use of barrier contraception 
 
The association between gynaecological age at first sexual intercourse and the use 
of barrier contraception with the first sexual partner is shown in table 10.2.4. The 
association between these two variables is not statistically significant. 
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Table 10.2.4. The association between gynaecological age at first sexual 
intercourse and the use of barrier contraception.  
 
Gynaecological age at first sexual intercourse (years)a Use of barrier 
contraception [ 0 , 2 )b [ 2 , 3 ) [ 3 , 4 ) [ 4 , 5 ) ≥ 5 Total 
No 23 (26) 21 (20) 35 (28) 24 (29) 23 (32) 126 (27)
Yes 65 (74) 83 (80) 92 (72) 60 (71) 48 (68) 348 (73)
Total 88 (19) 104 (22) 127 (27) 84 (18) 71 (15) 474 (100)
aFrequency counts (number of women) with percentages in brackets. Percentages are calculated 
based on column totals, with the exception of those in the final row, which are percentages of the 
row total; b[x, y) means ≥x and <y. 
 
10.2.5 The association between gynaecological age at first sexual intercourse 
and sexual experience of partner 
 
The association between gynaecological age at first sexual intercourse and sexual 
experience of the first sexual partner is shown in table 10.2.5. The association 
between these two variables is not statistically significant. 
 
 
Table 10.2.5. The association between gynaecological age at first sexual 
intercourse and sexual experience of the first sexual partner.  
 
Gynaecological age at first sexual intercourse (years)a Sexual 
experience of 
the first 
partner 
[ 0 , 2 )b [ 2 , 3 ) [ 3 , 4 ) [ 4 , 5 ) ≥ 5 Total 
Experienced 26 (30) 38 (37) 34 (27) 21 (25) 17 (24) 136 (29) 
Inexperienced 44 (50) 50 (48) 67 (53) 46 (55) 38 (54) 245 (52) 
Unknown 18 (21) 16 (15) 26 (21) 17 (20) 16 (23) 93 (20) 
Total 88 (19) 104 (22) 127 (27) 84 (18) 71 (15) 474 (100)
aFrequency counts (number of women) with percentages in brackets. Percentages are calculated 
based on column totals, with the exception of those in the final row, which are percentages of the 
row total; b[x, y) means ≥x and <y. 
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10.2.7 The association between age of sexual partner and sexual experience of  
that partner 
 
A woman with an older sexual partner was more likely to state that her partner was 
sexually experienced than a woman with a younger sexual partner; a woman’s 
knowledge, or perception, of her partners’ sexual experience decreased slightly as 
the age of her sexual partner increased. 
 
 
 
Summary 
 
Gynaecological age and calendar age at first sexual intercourse were positively-
correlated (Pearson’s correlation coefficient=0.51). Gynaecological age at first 
sexual intercourse and age of first sexual partner were only slightly positively-
correlated (Pearson’s correlation coefficient=0.19). Gynaecological age at first 
sexual intercourse and calendar age at menarche were negatively-correlated 
(Pearson’s correlation coefficient=–0.70). The associations between gynaecological 
age at first sexual intercourse and both the use of barrier contraception with the first 
sexual partner, and the sexual experience of that partner, were not statistically 
significant. A woman with an older sexual partner was more likely to state that her 
partner was sexually experienced than a woman with a younger sexual partner. 
 
 
 
10.3 UNIVARIATE ANALYSIS 
 
With the exception of gynaecological age at first sexual intercourse, all ”continuous” 
variables in the following analyses are nevertheless highly discrete, taking only a 
very small number of integer values: continuous is thus somewhat of a misnomer. 
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10.3.1 Incident cervical HPV infections 
 
The median duration of follow-up was 22 months, and the median number of visits 
was three. During follow-up, 145 (31%) of the 474 women became HPV-positive; the 
cumulative risk of cervical HPV infection three years after first sexual intercourse 
was 45.0% (95% CI 37.9% to 51.2%). 
 
10.3.1.1 HPV types detected in the first HPV DNA-positive cervical sample 
 
The frequency distribution of the HPV types detected in the first HPV DNA-positive 
cervical sample is shown in table 10.3.1.1. Eighty six (59%) of the first HPV-positive 
samples were non-informative with respect to HPV type: just over half of all cervical 
HPV infections were uncharacterized types (unknown types which, however, were 
known to not be among the specific types tested for), with a further 7% being 
“positive” (HPV-positive samples which were not, or could not be, tested for specific 
types).  Among the 59 women for whom at least one numerical HPV type could be 
detected in their first HPV-positive cervical sample, the most frequently detected 
numerical type was HPV16, present in the samples of 28 (19%) women, followed by 
HPV18, in 16 (11%). HPV6/11, a low-risk type(s), was the only numerical type 
present for seven women.   
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Table 10.3.1.1. HPV types detected in the first HPV DNA-
positive cervical sample 
 
Types detected in the 
first HPV-positive 
cervical sample 
Number of 
women (%) 
(n=145) 
Risk 
categorya 
58 2 (1) H 
52 2 (1) H 
33 6 (4) H 
31 3 (2) H 
18 10 (7) H 
18;Type Xb 1 (1) H 
16 16 (11) H 
16;58 1 (1) H 
16;31 1 (1) H 
16;31;Type Xb 1 (1) H 
16;18 3 (2) H 
16;18;33 1 (1) H 
16;18;31 1 (1) H 
16; 6/11 3 (2) H 
16;52;6/11 1 (1) H 
6/11 7 (5) L 
   
Uncharacterized types 76 (52) U 
Positive 10 (7) U 
aH=high, L=low, U=unknown: conventionally accepted categories 
based on previous reports of association with cervical cancer; 
bUncharacterized types: unknown types which, however, were 
known to not be among the specific types tested for. 
 
 
10.3.2 Calendar age at first sexual intercourse 
 
The results of the univariate regression analysis of the association between calendar 
age at first sexual intercourse and the risk of an incident cervical HPV infection of 
any type in women who were first sampled within twelve months of the start of their 
sexual career is shown in table 10.3.2. When analysed as a continuous variable, 
there was a significant association between calendar age at first sexual intercourse 
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and the risk of an incident cervical HPV infection, with an increase in the hazards 
ratio of 21% (1.21-1.00) for every year of increase in age at first sexual intercourse. 
 
There did not appear to be a non-linear effect with this variable. When calendar age 
at first sexual intercourse was treated as a categorical variable with five categories 
(an arbitrary categorisation based upon “reasonable” numbers of women in each 
category), it remained a significant predictor. 
 
Table 10.3.2. Univariate regression analysis of the association 
between calendar age at first sexual intercourse and the risk of an 
incident cervical HPV infection of any type. 
 
Calendar 
age at first 
sexual 
intercourse 
(years) 
Number of 
women 
% Number 
HPV-positive
Hazards ratio 
(95% CI)a 
≤15    65   13.7   14 1.00 ( Reference )
16 155   32.7   39 1.16 (0.63 to 2.14)
17 138   29.1   52 1.89 (1.05 to 3.40)
18    82   17.3   29 1.49 (0.79 to 2.82)
19    34     7.2   11 2.47 (1.12 to 5.44)
     
Continuous 
(per year)b 474 100.0 145 1.21 (1.05 to 1.40)
aDerived from a fixed univariate HARE analysis; bvariable analysed as a centred 
continuous variable. 
 
 
 
10.3.3 Age of first sexual partner 
 
The results of the univariate regression analysis of the association between the age 
of the first sexual partner and the risk of an incident cervical HPV infection of any 
type, in women who were first sampled within twelve months of the start of their 
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sexual career, is shown in table 10.3.3. When analysed as a continuous variable, 
there was a significant association between the age of the first sexual partner and 
the risk of an incident cervical HPV infection of any type, with an increase in the 
hazards ratio of 8% (1.08-1.00) for every year of increase in age of sexual partner. 
 
There was some evidence of non-linear effects for age of sexual partner: when a 
transformed variable was constructed by subtracting the mean age of the sexual 
partner for all women in the study population (19 years) from the age of the sexual 
partner observed for the woman, the square of this variable was of borderline 
significance (p=0.062 (Wald test)) when added to a model containing the age of the 
sexual partner (transformed) alone; however the coefficient of this variable was very 
small. When age of partner was treated as a categorical variable with seven 
categories (an arbitrary categorisation based upon “reasonable” numbers of women 
and events in each category), it remained a significant predictor of the risk of an 
incident cervical HPV infection of any type; but it is doubtful whether an 8.4% 
increase for each year of age of partner is a true description of the relationship, 
possibly reflecting non-linear effects for this variable. It appears that a dichotomous 
categorisation with ≥22 compared to <22 may be the best categorisation for this 
variable. 
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Table 10.3.3. Univariate regression analysis of the association between 
the age of the first sexual partner and the risk of an incident cervical 
HPV infection of any type. 
 
Age of first 
sexual 
partner 
(years) 
Number of 
women 
% Number 
HPV-positive
Hazards ratio 
(95% CI)a 
≤17 109   23.0   26 1.00 ( Reference ) 
18    88   18.6   23 1.08 (0.61 to 1.89) 
19    76   16.0   14 0.87 (0.45 to 1.66) 
20    50   10.5   17 1.21 (0.66 to 2.24) 
21    48   10.1   16 1.35 (0.72 to 2.51) 
22    35     7.4   20 3.03 (1.69 to 5.44) 
≥23    43     9.1   29 2.52 (1.48 to 4.29) 
     
Continuousb 474 100.0 145 1.08 (1.05 to 1.13) 
aDerived from a fixed univariate HARE analysis; bvariable analysed as a centred continuous 
variable. 
 
10.3.4 Age at menarche 
 
The results of the univariate regression analysis of the association between calendar 
age at menarche and the risk of an incident cervical HPV infection of any type, in 
women who were first sampled within twelve months of the start of their sexual 
career, is shown in table 10.3.4. When analysed as a continuous variable, age at 
menarche was not significantly associated with the risk of an incident cervical HPV 
infection of any type; the point estimate of the hazards ratio suggests a slight 
decrease in risk as age at menarche increases. 
 
There was some evidence of non-linear effects for age at menarche; when a 
transformed variable was constructed by subtracting the mean age at menarche for 
all women in the study population (13 years) from the woman’s age at menarche, the 
square of this variable was of borderline statistical significance (Wald-test p-
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value=0.053) when added to a model containing this variable alone; however this 
model was not itself statistically significant. Analysing age at menarche as a 
categorical variable with four categories (an arbitrary categorisation based on 
“reasonable” numbers of women and numbers of events in each category) 
suggested some fluctuation in the hazards ratio, although it did not yield a 
statistically significant predictor, either overall or on a category-specific basis. 
 
Table 10.3.4. Univariate regression analysis of the association 
between calendar age at menarche and the risk of an incident 
cervical HPV infection of any type. 
 
Age at 
menarche 
(years) 
Number of 
women 
% Number 
HPV-positive
Hazards ratio 
(95% CI)a 
≤11    70   14.8   22 1.00 ( Reference )
12 114   24.1   29 0.78 (0.44 to 1.38)
13 160   33.8   55 1.11 (0.67 to 1.86)
≥14 130   27.4   39 0.87 (0.51 to 1.49)
     
Continuousb 474 100.0 145 0.97 (0.86 to 1.10)
aDerived from a fixed univariate HARE analysis; bvariable analysed as a centred 
continuous variable. 
 
 
10.3.5 Use of barrier contraception 
 
The results of the univariate regression analysis of the association between use of 
barrier contraception during the first sexual relationship and the risk of an incident 
cervical HPV infection of any type in women who were first sampled within twelve 
months of the start of their sexual career, are shown in table 10.3.5. Use of barrier 
contraception at any time prior to the date of the first evaluable sample was not 
significantly associated with the risk of an incident cervical HPV infection; the point 
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estimate of the hazards ratio suggests that the use of barrier contraception results in 
a decrease in risk (i.e. barrier contraception is protective against cervical HPV 
infection, as might be expected).  
 
Table 10.3.5. Univariate regression analysis of the association 
between the use of barrier contraception during the first sexual 
relationship and the risk of an incident cervical HPV infection of any 
type. 
 
Use of barrier 
contraception 
Number of 
women 
% Number 
HPV-
positive 
Hazards ratio 
(95% CI)a 
Never 126   26.6   39 1.00 ( Reference ) 
Ever 348   73.4 106 0.92 (0.64 to 1.33)
aDerived from a fixed univariate HARE analysis; bvariable analysed as a centred 
continuous variable. 
 
10.3.6 Sexual experience of partner 
 
The results of the univariate regression analysis of the association between the 
sexual experience of the first sexual partner and the risk of an incident cervical HPV 
infection of any type, in women who were first sampled within twelve months of the 
start of their sexual career, is shown in table 10.3.6. There was a significant 
association between the sexual experience of the woman’s first sexual partner and 
the risk of an incident cervical HPV infection of any type. Women with sexually 
experienced partners were almost three times as likely to acquire an incident 
cervical HPV infection of any type as those with inexperienced partners; women who 
did not know whether their partner was sexually experience were at twice the risk. 
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Twenty six (19%) of the 136 women with supposedly sexually inexperienced 
partners acquired an incident cervical HPV infection of any type. Assuming that, in 
common with women, men only acquire HPV via sexual transmission, this result 
casts some doubt on the ability of women to distinguish sexually experienced from 
sexually inexperienced partners. Of course some of the male sexual partners may 
have had other sexual partners after the start of their sexual relationship with this 
woman (for those acquiring cervical HPV infections, the median interval (months) 
between date of first sexual intercourse and date of first detection of cervical HPV 
infection was 20.40, 2.92 and 9.99 for women with inexperienced, experienced and 
unknown experience partners, respectively). The unknown category is clearly a 
mixture of experienced and inexperienced partners, and so it is probably unwise to 
try and combine this group with either the experienced or unexperienced groups, 
alone. Note that 67% of women who were first sampled within six months of the start 
of their sexual career (n=242) reported that they believed that their partner was 
sexually experienced, compared with 52% in this study population (n=474), with the 
difference being in the unknown rather than the sexually inexperienced category.  
 
Table 10.3.6. Univariate regression analysis of the association between the 
sexual experience of the first sexual partner and the risk of an incident 
cervical HPV infection of any type. 
 
Sexual 
experience of 
partner 
Number of 
women 
% Number 
HPV-
positive 
Hazards ratio 
(95% CI)a 
Inexperienced 136   28.7   26 1.00 ( Reference ) 
Experienced 245   51.7   89 2.79 (1.80 to 4.33)
Unknown    93   19.6   30 1.98 (1.17 to 3.36)
aDerived from a fixed univariate HARE analysis; bvariable analysed as a centred continuous 
variable. 
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10.3.7 Gynaecological age at first sexual intercourse 
 
Gynaecological age at first sexual intercourse is measured on a continuous scale, 
and initially it was analysed as a continuous variable. It was then further analysed as 
both a categorical variable, and as a series of binary variables, with different 
gynaecological ages at first sexual intercourse used for dichotomisation. The results 
of these univariate analyses of the association between gynaecological age at first 
sexual intercourse and the risk of an incident cervical HPV infection of any type, in 
women who were first sampled within twelve months of the start of their sexual 
career, are shown in table 10.3.7.  
 
When analysed as a continuous variable, there was a significant association 
between gynaecological age at first sexual intercourse and the risk of an incident 
cervical HPV infection, with an increase in the hazards ratio of 12.9% (1.129≈1.13-
1.00) for every year of increase in gynaecological age at first sexual intercourse. 
When a transformed variable (GAC) was constructed by subtracting the mean 
gynaecological age at first sexual intercourse for all women in the study population 
(3.3 years) from the observed gynaecological age at first sexual intercourse, the 
square of this variable was significant (p=0.03) when added to a model containing 
this variable alone, indicating a departure from linearity. However, in practice the 
effect of departures from linearity appear to be slight: model GAC gives an increase 
in the hazards ratio of 12.9% for each year of increase in the interval, compared to 
13.2% for model GAC+GAC2. This is also consistent with the fact that a model 
containing GAC alone is selected using the automated model-building option with 
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HARE. On the grounds of parsimony, results from the linear model are therefore 
accepted. 
 
Three of the five variables which were constructed to analyse gynaecological age at 
first sexual intercourse as a categorical variable yielded significant predictors of the 
risk of an incident cervical HPV infection of any type, with an increased risk 
associated with greater gynaecological age at first sexual intercourse. The 
exceptions were the dichotomous variables based on comparing ≥4 or ≥5 with a 
complementary reference group: the direction of the effect was the same, with 
women having gynaecological age ≥5 years being at no greater risk than women 
with gynaecological age <5; similarly for ≥4 versus <4. 
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Table 10.3.7. Univariate regression analysis of the association between 
gynaecological age at first sexual intercourse and the risk of an incident 
cervical HPV infection of any type. 
 
Gynaecological 
age at first 
sexual 
intercourse 
(years) 
Number of 
women 
% Number HPV 
positive 
Hazards ratio 
(95% CI)a 
Continuous (per 
year)b 
474 100.0 145 1.13 (1.02 to 1.25) 
     
<2   88 18.6 19 1.00 (  Reference )
2-3 104 21.9 28 1.16 (0.65 to 2.07) 
3-4 127 26.8 47 1.89 (1.11 to 3.22) 
4-5  84 17.7 28 2.10 (1.17 to 3.76) 
≥5  71 15.0 23 1.63 (0.89 to 2.98) 
     
<2   88   18.6   19 1.00 (  Reference )
≥2 386   81.4 126 1.66 (1.01 to 2.71) 
     
<3 192   40.5   47 1.00 (  Reference )
≥3 282   59.5   98 1.72 (1.22 to 2.44) 
     
<4 319   67.3    94 1.00 (  Reference )
≥4 155   32.7    51 1.34 (0.96 to 1.89) 
     
<5 403   85.0 122 1.00 (  Reference )
≥5   71   15.0    23 1.09 (0.70 to 1.70) 
aDerived from a fixed univariate HARE analysis; bvariable analysed as a centred continuous 
variable. 
 
 
 
 
 
Summary 
 
In univariate analyses, the hazards ratio (HR) of cervical HPV infection increased 
significantly with age at first sexual intercourse (HR=1.21 (95% CI 1.05 to 1.40) per 
year), partner age (HR=1.08 (95% CI 1.05 to 1.13) per year), and when women 
reported a sexually experienced partner (HR=2.79 for an experienced compared to 
an inexperienced sexual partner; 95% CI 1.80 to 4.33); the interval between 
menarche and first sexual intercourse (gynaecological age at first sexual 
intercourse) was a significant predictor of the risk of infection, with an increase in the 
HR of 12.9% for every year of increase in this interval (95% CI 2.1% to 24.9%). 
 
153 
 
10.4 MULTIVARIATE ANALYSIS 
 
Forward and backward stepwise multivariate regression analyses identified as 
significant independent predictors of incident cervical HPV infection of any type: 
gynaecologic age at first sexual intercourse; age of sexual partner; sexual 
experience of partner; and use of barrier contraception. Calendar age at first sexual 
intercourse and calendar age at menarche were not significant predictors. In this 
section, I consider how each of these variables influences the association between 
gynaecological age at first sexual intercourse and the risk of an incident cervical 
HPV infection of any type. 
 
10.4.1 Gynaecological age at first sexual intercourse and the use of barrier 
contraception 
 
In a multivariate regression analysis, use of barrier contraception was identified as 
an independent predictor of the risk of incident cervical HPV infection of any type, 
but the magnitude of its effects were small and its deletion from the final model had 
little impact on the estimates of effects of the remaining variables. Barrier 
contraception will therefore not be considered further. 
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10.4.2 Gynaecological age at first sexual intercourse, calendar age of sexual 
partner and sexual experience of partner 
 
The results of a multivariate regression analysis of the association between 
gynaecological age at first sexual intercourse and the risk of an incident cervical 
HPV infection of any type, controlling for age and sexual experience of partner, in 
women who were first sampled within twelve months of the start of their sexual 
career, are shown in table 10.4.2. 
 
Although gynaecological age at first sexual intercourse was found to be an 
independent predictor of the risk of incident cervical HPV infection of any type, when 
analysed as a continuous variable, it was of borderline statistical significance, and 
when analysed as a categorical variable the confidence intervals for each category 
included the null value of one, although the increasing risk with increasing 
gynaecological age at first sexual intercourse is still apparent. The same set of 
independent predictors were identified when gynaecologic age at first sexual 
intercourse was dichotomised into ≥3 years versus <3 years, but in this case 
gynaecological age was clearly significant (p=0.009); however the variable 
comparing ≥2 years versus <2 years was not. In all models, age of sexual partner 
was selected as a significant predictor. 
 
In a model containing gynaecological age at first sexual intercourse and calendar 
age of sexual partner, both treated as continuous variables, gynaecological age at 
first sexual intercourse was not statistically significant, but there was some evidence 
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of an interaction between the two variables. When gynaecological age at first sexual 
intercourse was dichotomised into ≥3 years versus <3 years, age of sexual partner 
“explained” some of the effect of gynaecological age at first sexual intercourse, but 
gynaecological age at first sexual intercourse remained statistically significant; age 
of sexual partner also remained statistically significant, with a slightly reduced 
hazards ratio, and there was no evidence of an interaction. When non-linear effects 
of age of sexual partner were included, the hazards ratio for this dichotomisation of 
gynaecological age at first sexual intercourse was reduced only slightly, with the 
non-linear effect of age of sexual partner remaining statistically significant. In this 
model, the hazards ratio for gynaecological age at first sexual intercourse was closer 
to that from the model containing only independent effects, than to that from the 
model containing the interaction, which is surprising since one would expect the 
categorical variable to ‘capture’ in some sense the non-linear effect of age of sexual 
partner: there was no interaction between the variables when both were analysed as 
categorical. However, the hazards ratios for gynaecological age at first sexual 
intercourse categorised as  ≥3 years versus <3 years, were very similar in all three 
models. 
 
Although age of sexual partner and sexual experience of partner may be expected to 
be positively-correlated, they were both still significant predictors of the risk of 
acquiring an incident cervical HPV infection of any type when included in a model 
together, and there was no evidence of an interaction. In a model including 
gynaecological age at first sexual intercourse, either as a continuous variable alone 
or with non-linear effects, and sexual experience of partner, the significance of 
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gynaecological age at first sexual intercourse was not explained by sexual 
experience of partner. In a model including gynaecological age at first sexual 
intercourse as a continuous variable with non-linear effects, experience and age of 
sexual partner as a categorical variable, the variables measuring gynaecological age 
at first sexual intercourse remained significant. 
 
When gynaecological age at first sexual intercourse was categorised into three 
categories [0,2), [2,3), [3,∞), (the non-dichotomous categorisation of this variable 
with the greatest statistical significance in a univariate regression analysis), the 
significance of this variable dropped just below the 5% level, i.e. gynaecological age 
at first sexual intercourse became non-significant, after controlling for age of sexual 
partner, either as a continuous or as a categorical variable. When age of sexual 
partner was categorised into a dichotomous variable with categories ≥22 years and 
<22 years, gynaecological age at first sexual intercourse with the three categories 
became significant once more. Again, gynaecological age at first sexual intercourse 
with this categorisation remained significant when only experience of sexual partner 
was included. 
 
157 
 
Table 10.4.2. Multivariate regression analysis of the association between 
gynaecological age at first sexual intercourse and the risk of an incident 
cervical HPV infection of any type. 
 
Gynaecological 
age at first 
sexual 
intercourse 
(years) 
Number of 
women 
% Number HPV 
positive 
Hazards ratio 
(95% CI)a 
Continuous 
(per year)b 474 100.0 145 1.10 (0.99 to 1.22) 
     
<2   88 18.6 19 1.00 ( Reference ) 
2-3 104 21.9 28 1.07 (0.61 to 1.90) 
3-4 127 26.8 47 1.62 (0.96 to 2.72) 
4-5  84 17.7 28 1.74 (0.98 to 3.09) 
≥5  71 15.0 23 1.42 (0.78 to 2.58) 
     
<2   88   18.6   19 1.00 (  Reference )
≥2 386   81.4 126 1.55 (0.95 to 2.51) 
     
<3 192   40.5   47 1.00 (  Reference )
≥3 282   59.5   98 1.58 (1.11 to 2.25) 
     
<4 319   67.3    94 1.00 (  Reference )
≥4 155   32.7    51 1.27 (0.90 to 1.78) 
     
<5 403   85.0 122 1.00 (  Reference )
≥5   71   15.0    23 1.06 (0.68 to 1.67) 
aderived from a fixed multivariate HARE analysis, controlling for age of partner as a centred 
continuous variable, and sexual experience of partner; bvariable analysed as a centred 
continuous variable. 
 
 
10.4.3 Gynaecological age at first sexual intercourse and calendar age at first 
sexual intercourse 
 
Given the positive correlation between gynaecological age at first sexual intercourse 
(G) and calendar age at first sexual intercourse (A) (section 10.2.1) and also the 
association between calendar age at first sexual intercourse and the risk of an 
incident cervical HPV infection of any type (K) (section 10.3.2), it is possible that the 
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association observed between gynaecological age at first sexual intercourse and the 
risk of an incident cervical HPV infection of any type is merely a (weaker) reflection 
of the former association, i.e. that the association between K and the variable G-A is 
merely a consequence of the association between K and G, with the subtraction of A 
being of no effect, except possibly to attenuate the observed association. 
 
The results of a multivariate regression analysis of the association between 
gynaecological age at first sexual intercourse and the risk of an incident cervical 
HPV infection of any type, controlling for calendar age at first sexual intercourse, age 
of sexual partner and sexual experience of partner, is presented in table 10.4.3. 
 
Table 10.4.3. Multivariate regression analysis of the association between 
gynaecological age at first sexual intercourse and the risk of an incident cervical 
HPV infection of any type, controlling for calendar age at first sexual 
intercourse, and for calendar age at first sexual intercourse, age of partner and 
sexual experience of partner. 
 
Hazards ratio (95% CI) Gynaecolog
ical age at 
first sexual 
intercourse 
(years) 
Number of 
women 
% Number 
HPV 
positive Uncontrolled Controlled for AFIa Controlled for 
AFI+PAb+PXc 
              
Continuous 
(per year) 474 100 145 1.13 (1.02 to 1.25) 1.17 (0.88 to 1.54) 1.21 (1.12 to 1.31)
              
<2 88 19 19 1.00 (  Reference ) 1.00 (  Reference ) 1.00 (  Reference )
≥2 386 81 126 1.66 (1.01 to 2.71) 1.15 (0.58 to 2.27) 1.20 (1.11 to 1.30)
              
<3 192 41 47 1.00 (  Reference ) 1.00 (  Reference ) 1.00 (  Reference )
≥3 282 60 98 1.72 (1.22 to 2.44) 1.08 (0.66 to 1.77) 1.12 (1.04 to 1.21)
              
<4 319 67 94 1.00 (  Reference ) 1.00 (  Reference ) 1.00 (  Reference )
≥4 155 33 51 1.34 (0.96 to 1.89) 1.22 (0.87 to 1.69) 1.26 (1.17 to 1.37)
              
<5 403 85 122 1.00 (  Reference ) 1.00 (  Reference ) 1.00 (  Reference )
≥5 71 15 23 1.09 (0.70 to 1.70) 1.12 (0.83 to 1.52) 1.17 (1.08 to 1.26)
aCalendar age at first sexual intercourse; bage of sexual partner; csexual experience of the woman’s 
sexual partner (as stated by the woman). 
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In univariate analyses of the association between gynaecological age at first sexual 
intercourse and the risk of an incident cervical HPV infection of any type, 
gynaecological age at first sexual intercourse was a significant predictor of risk when 
it was included in a model as either a centred continuous variable or as a categorical 
variable dichotomised into ≥2 years versus <2 years or ≥3 years versus <3 years. 
However, all of these variables were no longer statistically significant once the model 
had been controlled for calendar age at first sexual intercourse. Compared to it’s 
magnitude in the univariate (uncontrolled) analysis, the magnitude of the hazards 
ratio for gynaecological age at first sexual intercourse decreased when this variable 
was measured as a categorical variable dichotomised into ≥2 years versus <2 years 
or ≥3 years versus <3 years. This is what one might expect if the observed 
association between gynaecological age at first sexual intercourse and the risk of an 
incident cervical HPV infection of any type was due to the association between 
calendar age at first sexual intercourse and the risk of cervical HPV infection 
(although there are other explanations). However, the magnitude of the hazards ratio 
for gynaecological age at first sexual intercourse increased compared to it’s 
magnitude in the univariate analysis when this variable was measured as a either a 
centred continuous variable, or as a categorical variable dichotomised into ≥5 years 
versus <5 years;  when this variable was measured as a categorical variable 
dichotomised into ≥4 years versus <4 years, the hazards ratio was attenuated only 
slightly, essentially remaining the same. However, when the analysis was controlled 
for age of sexual partner and sexual experience of partner, in addition to calendar 
age at first sexual intercourse, all hazards ratios increased slightly compared to their 
values in the analysis controlling for calendar age at first sexual intercourse alone, 
160 
 
and every variable measuring gynaecological age at first sexual intercourse became 
statistically significant 
 
The association between gynaecological age at first sexual intercourse and the risk 
of an incident cervical HPV infection of any type does not appear to be due to the 
association between calendar age at first sexual intercourse and the risk of cervical 
HPV infection. No matter how gynaecological age at first sexual intercourse is 
measured in this analysis, there appears to be an increase, not a decrease, in the 
risk of an incident cervical HPV infection of any type with increasing gynaecological 
age at first sexual intercourse 
 
10.4.4 Gynaecological age at first sexual intercourse and calendar age at 
menarche 
 
Analysing these two variables simultaneously presents difficulties, because the study 
population is restricted to women who first had intercourse within a short interval 
before recruitment, at which time they were between the ages of 15 and 19 years, 
but menarche occurred between the ages of eight and 16 years; so a cross-
tabulation of these two variables reveals many zero-cells, and cells with no, or few, 
events. 
 
In a multivariate regression analysis in which gynaecological age at first sexual 
intercourse and calendar age at menarche were treated as continuous variables, 
age at menarche was not statistically significant. There was an interaction between 
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these variables, but given that both have non-linear effects, it may only be 
appropriate to look at models where both variables are categorical. Age at 
menarche, when analysed as a categorical variable, was not significant when 
gynaecological age at first sexual intercourse was treated as a continuous variable, 
and there was no evidence of an interaction. Age at menarche, when analysed as a 
categorical variable, was not significant when gynaecological age at first sexual 
intercourse was categorised into [0,2), [2,3), [3,∞); the model failed to converge 
when looking for an interaction in this analysis. 
 
10.4.5 Age of partner and calendar age at first sexual intercourse 
 
Women whose first coital episode was at a later age were more likely to form 
relationships with older men, and the association between incident cervical HPV 
infection of any type and calendar age at first sexual intercourse was no longer 
significant when this variable was controlled for in the multivariate analysis. 
 
 
 
Summary 
 
In a multivariate analysis, compared with women who first had sexual intercourse 
within three years of menarche, those who postponed first sexual intercourse 
beyond this time had a greater risk of cervical infection with HPV of any type 
(HR=1.58; 95% CI 1.11 to 2.25), after controlling for age and sexual experience of 
partner. 
 
Women who first have intercourse soon after menarche are not at greater risk of 
cervical HPV infection than women who delay the onset of sexual activity. The 
adolescent cervix does not appear to be inherently more susceptible to HPV 
infection. 
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Chapter 11 
 
PROXIMITY OF MENARCHE TO FIRST SEXUAL INTERCOURSE 
AND THE RISK OF CERVICAL HPV INFECTION 
 
DISCUSSION 
 
 
 
 
I have described, using longitudinal observations, how the risk of acquiring cervical 
HPV infection of any type varies with the time interval between menarche and first 
sexual intercourse in 474 women aged 15 to 19 years recruited within twelve months 
of first sexual intercourse and before the acquisition of a second sexual partner. One 
hundred and forty-five women became HPV-positive; the cumulative risk of acquiring 
a cervical HPV infection of any type three years after first sexual intercourse was 
45% (95% CI 38% to 51%). In univariate analyses, the hazards ratio (HR) of 
acquiring an incident cervical HPV infection of any type increased significantly with 
increasing age at first sexual intercourse (per year of increase in age, HR=1.21; 95% 
CI 1.05 to 1.40), partner age (per year of increase in age, HR=1.08; 95% CI 1.05 to 
1.13), and when women reported a sexually experienced partner (for women with an 
experienced compared to an inexperienced partner, HR=2.79; 95% CI 1.80 to 4.33); 
the time interval between date of menarche and date of first sexual intercourse was 
a significant predictor of infection, with an increase in the HR of 13% for every year 
of increase in this time interval (95% CI 2% to 25%). In a multivariate analysis, 
compared with women who first had intercourse within three years of menarche, 
those who postponed first sexual intercourse beyond this time had a greater risk of 
infection (HR=1.58; 95% CI 1.11 to 2.25), after controlling for age and sexual 
experience of partner. 
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The results described in this thesis demonstrate that the risk of an incident cervical 
HPV infection of any type increases as the time interval between menarche and first 
sexual intercourse increases, after controlling for other determinants of infection.  
This finding is biologically plausible, given that the life-cycle of HPV is dependent on 
host-cell replication and differentiation, which are characteristic of the squamous 
metaplasia occurring in the cervical transformation zone (see sections 2.1.1 and 
3.1.2.3); basal cells, the target cells for HPV infection, are most accessible in the 
transformation zone which, in young women, increases in size with time from 
menarche, independent of sexual and other reproductive factors (Jacobson 1999, 
Howley 2001). 
 
Findings from this analysis contradict those from studies which suggest that a short 
interval between menarche and first sexual intercourse increases the risk of HPV 
infection (Shew 1994, Kahn 2002a). In these studies, women were first sampled 
some years after first sexual intercourse and, as the authors of these reports 
concede, there is no evidence that infection was acquired during the hypothesised 
period of increased vulnerability. In contrast, the study population used in the 
analysis described in this thesis comprises women first sampled within a year of first 
sexual intercourse and, unlike the studies cited, was also restricted to women who 
had had only one sexual partner. By restricting the analysis to the period prior to the 
start of the second sexual relationship, confounding due to multiple sexual partners 
is eliminated. This additional restriction allowed a more precise examination of the 
role of the “male factor” in the acquisition of cervical HPV infection of any type (Kjaer 
2001, Kahn 2002b). 
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The study population for this analysis comprises all women who were recruited 
within twelve months of first having sexual intercourse, and who had yet to acquire a 
second sexual partner. To be eligible, women were not required to be in a sexual 
relationship during the entire period they were followed-up, nor were women who 
had only a brief sexual relationship with their first partner distinguished from those 
with longer relationships. The period 12 months was chosen because we had 
previously found that the median time to acquisition of the (presumed) first cervical 
HPV infection was over three years, and the median duration of cervical HPV 
infection was 13.7 months (range 8.0 to 25.4) (Woodman 2001). It was therefore 
unlikely that a woman recruited so soon after first sexual intercourse would have 
both acquired and cleared her first cervical HPV infection before she was first tested 
for the presence of HPV DNA. Estimates of the cumulative risk of the incidence of 
cervical HPV infection of any type were stable when the study population was based 
on either a six-month interval between first sexual intercourse and study entry, as 
used in a previous analysis (Collins 2002), or a twelve-month interval, as used in the 
analysis described in this thesis. This provides reassurance that the larger sample 
size provided by the “twelve-month population” did not compromise the greater 
proximity of first sexual intercourse and study entry in the “six-month population”. 
 
Times-to event were measured from date of first sexual intercourse until the date of 
the first detection of a cervical HPV infection of any type. Women were assumed to 
be negative for cervical infection with HPV DNA of any type on their date of first 
sexual intercourse: cervical HPV infection is a sexually transmitted infection acquired 
as a result of penetrative vaginal intercourse. Date of first sexual intercourse is thus 
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a woman’s first opportunity to acquire this sexually transmitted disease, and so this 
assumption appears reasonable. 
 
Older sexual partners were more likely to be reported as sexually experienced and, 
among women with sexually experienced partners, the risk of acquiring a cervical 
HPV infection of any type increased with increasing age of sexual partner. The 
“sexual experience of partner” variable was based on information collected from the 
woman: she was asked whether she knew, or thought, her partner had previous 
sexual experience prior to the start of her sexual relationship with that partner. 
However, the nature of that sexual experience was not further ascertained, e.g. 
penetrative sexual intercourse was not distinguished from other types of sexual 
activity. Responses had to be accepted at face value, with no opportunity to verify 
the accuracy of this variable with the partners themselves: there are no data on the 
partner’s number of sexual partners. 
 
It was necessary to define use of barrier contraception as use at any time prior to 
study entry, since first use was not reported consistently. The assumption is made 
that use of barrier contraception is a marker for low-risk sexual behaviour, and 
consistent condom use has been reported to be protective against the acquisition of 
cervical HPV infection (Winer 2006). In the analysis described in this thesis, use of 
barrier contraception (which primarily means condoms, but not exclusively) was 
slightly protective, but the association was neither strong nor statistically significant. 
Given that many women were also using oral contraceptives, barrier contraception 
may only have been used intermittently: data was not collected with sufficient 
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resolution to determine whether this was the case. Thus, only limited inferences are 
possible with this variable. 
 
The work in this chapter of the thesis was published in 2005 (Collins 2005: see 
appendix 3). Subsequently, a similar study citing this work (for ease of reference, the 
“repeat study”) was undertaken in 130 university women aged 18 to 24 years who 
reported first sexual intercourse within three months of enrolment into the study, or 
during follow-up, and who had further follow-up after first sexual intercourse (Winer 
2008). Biological samples were taken at time intervals of four months, with sexual 
behaviour updated at intervals of two-weeks via a web-based diary. HPV DNA was 
detected using PCR. 
 
In a univariate analysis, the repeat study found an association with gynaecological 
age at first sexual intercourse in the opposite direction to that found in the study 
described in this thesis: women reporting menarche two to five years before first 
sexual intercourse were more likely to acquire HPV than women reporting menarche 
eight to 14 years before first sexual intercourse (HR 2.57; 95% CI 1.13 to 5.82); 
women with a gynaecological age at first sexual intercourse of six years were at a 
substantially reduced risk of acquiring an incident cervical HPV infection of any type, 
although this category was not significantly different from the null value. When the 
woman’s sexual partner’s number of previous sexual partners, gynaecological age at 
first sexual intercourse, and sexual partner’s age were entered into a multivariate 
model, gynaecological age at first sexual intercourse was not statistically significant. 
As in the study described in this thesis, in univariate analyses women with sexually 
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experienced partners and older sexual partners were more likely to acquire genital 
HPV infection, but age at first sexual intercourse was not a significant risk factor for 
the acquisition of genital HPV infection. 
 
The authors of the repeat study did not undertake an analysis appropriate to interval-
censored time-to-event data. The results of the interval censored analyses used in 
the analysis described in this thesis were tested for “plausibility” using Cox 
proportional hazards regression, assuming that events occurred at the midpoint of 
an interval in which the first detection of HPV was known to have occurred (see 
section 6.4); the authors of the repeat study imputed the time of event at the right-
hand end of the interval. There were no material differences between the results of 
the interval censored and the midpoint analyses in the analysis described in this 
thesis. And given that the repeat study used a shorter time interval between study 
visits than that used in the study described in this thesis (four compared to six 
months), the conclusions reached by the authors of the repeat study are also likely 
to have remained materially unaltered had they undertaken an analysis appropriate 
to interval-censored time-to-event data, provided that late-occurring events were not 
overly influential (see section 6.4.1.3). That being said, it is not clear why the authors 
of the repeat study did not undertake the appropriate analysis, with the example of 
the publication based on the analysis described in this thesis before them. 
 
The cumulative incidence of genital HPV infection 36 months after reporting a first 
sexual partner was 49% (95% CI 36% to 64%), similar to that found in the study 
described in this thesis for cervical HPV infections of any type, specifically. 
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Interestingly, five women were reported to have tested positive for HPV before first 
sexual intercourse, and were excluded from the repeat study; four were positive for a 
single type (types 6, 51, 53, and 66), and one for multiple types (types 40, 61, and 
66): the authors of the repeat study state that there are plausible explanations for 
this, although they don’t provide them. Presumably, these infections were at 
superficial sites, rather than cervical HPV infections. Indeed, the repeat study only 
describes genital HPV infections, obtained by combining results from self-collected 
vaginal swabs and clinician-collected cervical and vulvovaginal swabs; cervical HPV 
infections are not separately distinguished. Therefore the repeat study was unable to 
address the hypothesis of interest directly. 
 
The authors of the repeat study state that “previous studies have suggested that the 
interval between menarche and first intercourse is related to the risk of HPV 
infection, but the directions of the observed associations have been inconsistent. 
Given that 95% of participants in the repeat study were at least 5 years past 
menarche at the time of first intercourse, we were unable to assess whether short 
intervals between menarche and first intercourse increase the risk of infection from a 
first partner”. 
 
This appears to be an attempt by the authors of the repeat study to overstate the 
novelty of their findings. The previous studies cited are that based on the work 
described in this thesis, and the two studies which the work described in this thesis 
has now superseded, for reasons stated both above and in the published paper. In 
fact, the criticism which the authors correctly level at their own work is precisely the 
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weakness which the work in this thesis is uniquely able to address. The mean 
gynaecological age at first sexual intercourse in the study population on which this 
thesis was based was 3.4 years (range 0 to 9), compared to 6.9 (range 2 to 14) in 
the repeat study. The study described in this thesis, and reported in the published 
paper, was thus able to assess whether short intervals between menarche and first 
sexual intercourse increased the risk of acquiring cervical HPV infection from a first 
sexual partner. 
 
The observations described in this thesis suggest that the adolescent cervix is not at 
greater risk of cervical HPV infection per se. Postponement of first sexual 
intercourse will not reduce a woman’s risk of acquiring a cervical HPV infection, and 
the risk is high even among women engaged in low-risk sexual behaviour. 
 
11.1 PUBLICATION 
 
As stated above, a paper based on the work described in chapters 8, 9, 10 and 11 of 
this thesis was published in 2005 (Collins 2005). This paper is reproduced in 
appendix 3. 
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Chapter 12 
 
SMOKING, CERVICAL HPV INFECTION, AND THE RISK OF 
CERVICAL NEOPLASIA 
 
INTRODUCTION 
 
 
 
 
 
Orientation 
 
In this chapter I discuss: 
 
• the mechanisms by which smoking may have an impact on the risk of acquiring 
cervical HPV infection and epithelial abnormalities of the cervix 
 
• the evidence of the association between smoking and epithelial abnormalities of 
the cervix 
 
• the evidence of the association between sexual behaviour and epithelial 
abnormalities of the cervix 
 
• the evidence of the association between smoking and cervical HPV infection 
 
• the limitations of previous studies which have investigated the association 
between smoking and epithelial abnormalities of the cervix, controlling for 
cervical HPV infection 
 
 
 
 
 
12.1 BACKGROUND 
 
Cervical human papillomavirus (HPV) infection is considered a necessary, but not 
sufficient, cause of cervical cancer, and attention is now focused on identifying 
cofactors which modulate the progression of cervical HPV infection to high-grade 
cervical intraepithelial neoplasia (CIN) and invasive disease (Castellsague 2003). 
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Cigarette smoking is one potential cofactor. Cigarette smoking may act through any 
of several biological mechanisms, either alone or in combination with other factors, 
to increase the risk of acquiring cervical HPV infection and cervical neoplasia. 
Smoking results in systemic exposure to compounds which damage DNA and 
increase the risk of cancer in various organs; in particular, these compounds are 
known to cause genomic damage in squamous epithelial cells (Castle 2002b). The 
components of tobacco smoke reach cervical cells via the bloodstream and by 
diffusion through tissue; high contents of the chemical components of cigarette 
smoke, e.g. nicotine, and its major metabolite cotinine, as well as other tobacco-
specific carcinogens, have been detected in the cervical mucus of smokers. These 
components may act as carcinogens (i.e. they may initiate the development of 
malignant tumours) or as mutagens (i.e. they may cause an increase in the rate of 
mutation), with high concentrations of these components leading to damage to the 
cervical epithelium, thus making it more susceptible to HPV infection. The order of 
exposures may therefore also be important (Olsen 1998). In vitro studies show that 
benzo[a]pyrene, a carcinogen found in cigarette smoke, can stimulate genome 
amplification and virion synthesis in cell lines productively infected with HPV (Alam 
2008). Or smoking may influence the course (persistence, viral load, extent) of a 
HPV infection via its impact on the immune response. Smoking has been associated 
with a “generalized suppression of the immune system”, which includes: decreases 
in the number of natural killer (NK) cells, and in NK cell activity; decreases in 
circulating levels of IgG and IgA; and reductions in numbers of cervical Langherans' 
cells (Giuliano 2002).  
172 
 
12.2 THE ASSOCIATION BETWEEN SMOKING, SEXUAL BEHAVIOUR, 
CERVICAL HPV INFECTION AND EPITHELIAL ABNORMALITIES OF THE 
CERVIX 
 
In this section I provide an overview of the evidence regarding the association 
between smoking and epithelial abnormalities of the cervix, and potential 
confounders of that association. 
 
12.2.1 Association between smoking and epithelial abnormalities of the cervix 
 
While it should be noted that not all studies have reported a statistically significant 
association between smoking and epithelial abnormalities of the cervix (Koutsky 
1992, Olsen 1995, Sasagawa 1997, Schiff 2000), the weight of evidence suggests 
that there is a positive association, at least for squamous disease. 
 
A meta-analysis has previously been undertaken of 72 epidemiological studies of 
cervical disease and cigarette smoking (Haverkos 2003). Thirty-nine of the studies 
had cervical cancer as an outcome, 23 non-malignant cervical disease, and 10 
included patients with both cancer and non-malignant disease. Of the 71 studies 
tabulated in the report of the meta-analysis (one study with an Asian population 
appears to be missing), 50 are case-control studies, 10 cross-sectional, and 11 
longitudinal studies. 
  
Results of the meta-analysis of the association between cervical disease and 
cigarette smoking are presented in table 12.2.1. Overall, a significant association 
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was found between cigarette smoking and both malignant and non-malignant 
disease. This was the case whether exposure status was measured as current 
smoking status, or as cumulative history of smoking, although the strongest 
associations were those between disease and current smoking status. Odds ratio 
estimates were all approximately equal to two, indicating only a small increase in 
risk. However, given the large number of smokers in the population, and the high 
rates of smoking amongst young women in particular, this increased risk has serious 
public health implications. 
 
 
Table 12.2.1. Results of a previously reported meta-analysis of 72 
epidemiological studies of cervical disease and cigarette smoking. 
  
Odds ratio; 95% CI; Number of studies Outcomes included 
Ever smokers Current smokers 
Cervical cancer 1.72 (1.63 to 1.82); n=31 2.25 (1.91 to 2.19); n=23
Non-malignant disease 1.87 (1.70 to 2.05); n=18 2.19 (1.99 to 2.41); n=20
Mixed disease 2.16 (1.89 to 2.46); n=9 2.45 (2.08 to 2.89); n=8 
Total 1.80 (1.72 to 1.88); n=58 2.13 (2.02 to 2.25); n=51
 
 
 
A similar “pooled” analysis of 23 epidemiological studies based on approximately 
14,000 women was undertaken more recently, with a substantial overlap between 
the studies involved in this pooled analysis and the earlier meta-analysis 
(International Collaboration of Epidemiological Studies of Cervical Cancer 2006a). 
However, the pooled analysis separately distinguished between squamous cell 
carcinoma of the cervix (SCCC) and adenocarcinoma, and reported associations for 
smoking exposures at a greater resolution. 
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Compared to women who had never smoked, women who were current smokers 
were at a significantly increased risk of both SCCC (RR=1.46; 95% CI 1.32 to 1.61) 
and CIN3 (RR=1.83; 95% CI 1.61 to 2.08). The risks for ex-smokers were lower for 
both disease outcomes, but there was no trend with time since stopping smoking. In 
analyses combining SCCC and CIN, in current smokers the risk of squamous 
disease increased with increasing number of cigarettes smoked per day, and with 
decreasing age at starting smoking; there was no such evidence for ex-smokers. 
There was no association between the risk of squamous disease and the duration of 
smoking. There was no association between smoking and the risk of 
adenocarcinoma, or adenocarcinoma in situ, irrespective of how smoking exposure 
was measured, with smoking appearing to have a slightly protective effect. 
 
Smoking may be a more important risk factor for CIN2 and CIN3 than for CIN1, 
suggesting that this exposure may act at a later stage during the pre-invasive phase 
of the natural history of cervical neoplasia (Cuzick 1990, Parazzini 1992, Schiffman 
1993, Brisson 1994, Ho 1998c, Franco 2002). 
 
12.2.2 The association between sexual behaviour and cervical disease 
 
Various aspects of sexual behaviour are known to be strong risk factors for cervical 
disease (see chapter 2), and sexual behaviour is also associated with smoking 
behaviour (International Collaboration of Epidemiological Studies of Cervical Cancer 
2006a). Therefore, we would anticipate that the association between smoking and 
cervical disease would be confounded by sexual behaviour. 
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Several studies which have attempted to control for confounding of the smoking-
cervical disease association by sexual behaviour have reported that smoking is an 
independent risk factor for CIN (Lyon 1983, La Vecchia 1986, Brock 1989, Cuzick 
1990, Gram 1992, Parazzini 1992, Munoz 1993, Becker 1994, Brisson 1994, De Vet 
1994, Nobbenhuis 1999, Mosckiki 2001, Franco 2002); some have also reported an 
increasing trend in the risk of CIN with increasing number of cigarettes smoked, and 
with increasing duration of smoking (Lyon 1983, La Vecchia 1986, Brock 1989, 
Becker 1994, Brisson 1994, De Vet 1994). In the pooled analysis, which includes 
some of these studies, four potential confounding factors were included in analyses: 
lifetime number of sexual partners, age at first sexual intercourse, parity, and oral 
contraceptive use. Only stratification by lifetime number of sexual partners altered 
the estimates of relative risk more than marginally. 
 
The association between sexual behaviour and the risk of cervical disease is almost 
certainly entirely due to the association between sexual behaviour and cervical HPV 
infection. Therefore the most appropriate control of confounding of the association 
between smoking and cervical disease by sexual behaviour is obtained by 
controlling for exposure to cervical HPV infection directly, rather than by using 
surrogate measures. 
 
12.2.3 The association between cervical HPV infection and smoking 
 
Is cervical HPV infection a potential confounder of the association between smoking 
and cervical disease? To determine this it must be shown that cervical HPV infection 
is associated with both smoking and cervical disease. Cervical HPV infection is the 
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pre-eminent risk factor for cervical disease in both smokers and non-smokers. The 
reported associations between smoking and the acquisition of HPV infections, or the 
duration of those infections, present a conflicting picture. One longitudinal study 
found no association between smoking and the prevalence of HPV at study entry 
(Kotloff 1998), whilst one did (Minkoff 2004). Four longitudinal studies have reported 
no association between the risk of an incident HPV infection and smoking, including 
one recruiting women aged 13 to 21 years from two family planning clinics (Ho 
1998b, Kotloff 1998, Mosckiki 2001, Sellors 2003). Two longitudinal studies have 
reported a statistically significant association, including one in HIV-seropositive and 
at-risk HIV-seronegative women, and one studying genital-tract HPV infections 
(Minkoff 2004, Winer 2003). Smoking has been reported to: have a significantly 
protective effect against persistent HPV infection in two studies (Hildesheim 1994, 
Ho 1998b); have no association in four studies (Kotloff 1998, Sellors 2003, Winer 
2003, Minkoff 2004); and to be associated with an increased duration of HPV 
infection, with a dose response with duration of smoking, in another (Giuliano 2002).  
 
Any reported association implies that cervical HPV infection has the potential to 
confound the measurement of the association between smoking and cervical 
disease, and so cervical HPV infection must be adequately controlled for in an 
analysis. 
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12.2.4 The association between smoking and cervical disease controlling for 
cervical HPV infection 
 
Case-control studies restricted to women who test positive for HPV DNA have 
consistently reported an increased risk of cervical neoplasia in smokers, with some 
reporting a dose-response effect (Olsen 1998, Kjaer 1998, Deacon 2000, Hildesheim 
2001, Plummer 2003, Harris 2004, McIntyre-Seltman 2005). A longitudinal study, 
restricted to women who tested positive for HPV DNA, has also reported an 
increased risk of CIN3 or worse in those who were smokers at enrolment (Castle 
2002b). Another longitudinal study, similarly restricted, has reported an increased 
risk of low-grade squamous intraepithelial lesions associated with daily smoking, but 
not with pack-years of smoking (Moscicki 2001). However, these studies are limited 
in so far as women were only tested for HPV on a single occasion, and therefore the 
duration of infection prior to the onset of disease is unknown. Residual confounding 
by time from first HPV exposure could still explain the excess risk associated with 
smoking, if women who smoke are more likely to have had an early exposure to 
HPV, and if early exposure is also a risk factor for disease. 
 
In the cohort study described in this thesis, it was possible to avoid residual 
confounding by time from first exposure to cervical HPV infection by making 
repeated measurements of smoking and HPV status in a cohort of young women, 
who were free of disease and HPV DNA-negative at study entry. Thus the design of 
the cohort study described in this thesis allowed not only the measurement of the 
risk of high-grade CIN in relation to changes in smoking and HPV status, but also the 
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exploration of the impact of smoking on the acquisition and duration of incident 
cervical HPV infections. 
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Chapter 13 
 
SMOKING, CERVICAL HPV INFECTION, AND THE RISK OF 
CERVICAL NEOPLASIA 
 
METHODS 
 
 
 
 
 
 
 
 
 
Orientation 
 
In this chapter I: 
 
 
• define the outcomes used in the analysis of smoking, cervical HPV infection, and 
the risk of epithelial abnormalities of the cervix 
 
• describe the study populations used in these analyses 
 
• describe the statistical methods used in these analyses 
 
• describe the collection of smoking data 
 
• describe the method used to interpolate dates of smoking “events” 
 
• describe the construction of variables used to measure exposure to smoking 
 
• describe the variables used to measure sexual behaviour 
 
• describe the construction of variables used to measure exposure to cervical HPV 
infection 
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13.1 RESTATEMENT OF OBJECTIVES 
 
To investigate the association between cigarette smoking and: the risk of incident 
cervical HPV infection; the natural history of incident cervical HPV infection; and the 
subsequent development of epithelial abnormalities of the cervix. 
 
o To determine the association between exposure to cigarette smoking 
and the risk of acquiring an incident cervical infection with HPV DNA of 
any type, HPV16, and HPV18. 
 
o To determine the association between exposure to cigarette smoking 
and the duration of an incident cervical infection with HPV DNA of any 
type, HPV16, or HPV18. 
 
o To determine the association between exposure to cigarette smoking 
and the risk of acquiring incident high-grade cervical intraepithelial 
neoplasia 
 
13.2 DEFINITION OF OUTCOMES 
 
The time to the acquisition of an incident cervical HPV infection of any type 
measured from the date of study entry until the date of the first detection of HPV 
DNA in a cervical sample. Equivalent definitions were used in the analyses of 
incident cervical HPV16 and HPV18 infections. 
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Duration of an incident cervical HPV infection measured from the date of the cervical 
sample in which HPV DNA was first detected until the date of the first subsequent 
sample which tested negative for HPV DNA. Equivalent definitions were used for the 
analysis of the duration of incident cervical HPV16 and HPV18 infections. 
 
Time to the diagnosis of incident high-grade cervical intraepithelial neoplasia (CIN) 
was measured from the date of study entry until the date of the first diagnosis of 
high-grade CIN (a histological diagnosis of CIN2 or CIN3). 
 
In these analyses, the method used to detect HPV DNA was the GP5+/GP6+ 
general primer-mediated PCR system (see section 5.5.4.1). 
 
13.3 STUDY POPULATION 
 
The study population for a given analysis varied according to the outcome analysed. 
 
13.3.1 The study population for the analysis of incident cervical HPV infections 
 
In analyses of incident cervical HPV infections, of any type, or of types 16 or 18, the 
study population was restricted to women who were HPV DNA-negative in their first 
evaluable cervical sample, cytologically normal in their first evaluable smear, and 
who had further follow-up after the earliest of these two events. 
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13.3.2 The study population for the analysis of the duration of incident cervical 
HPV infections 
 
13.3.2.1 The study population for the analysis of the duration of incident 
cervical HPV infections of any type 
 
Women who had an incident cervical HPV infection of any type, and who had further 
follow-up after the first detection of HPV DNA. 
  
13.3.2.2 The study population for the analysis of the duration of incident 
cervical HPV16 infections 
 
Women who had an incident cervical HPV16 infection, and who had further follow-up 
after the first detection of HPV16 DNA. 
 
13.3.2.3 The study population for the analysis of the duration of incident 
cervical HPV18 infections 
 
Women who had an incident cervical HPV18 infection, and who had further follow-up 
after the first detection of HPV18 DNA. 
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13.3.3 The study population for the analysis of incident high-grade CIN 
 
In analyses of incident high-grade CIN, the study population was restricted to women 
who were HPV DNA-negative in their first evaluable cervical sample, cytologically 
normal in their first evaluable smear, and who had further follow-up after this time. 
 
13.4 STATISTICAL METHODS 
 
Methods appropriate to the analysis of interval censored time-to-event data were 
used. 
 
Observations on the acquisition of cervical HPV infection of any type, or of types 16 
or 18, and the acquisition of high-grade CIN were interval censored; time of onset 
was known only to lie in the interval between the date of the visit at which they were 
first detected and the date of the immediately preceding visit. Similarly, time to 
clearance of HPV infection was known only to lie in the interval between the date of 
the visit at which HPV was last detected and the date of the immediately following 
visit. All outcomes were thus interval censored time-to-event data. 
 
Time to incident cervical HPV infection of any type was measured from the date of 
study entry until the interval containing the date of the first acquisition of HPV DNA of 
any type in a cervical sample, with censoring at the date of the end of follow-up. 
Equivalent definitions were used in the analysis of incident cervical HPV16 and 
HPV18 infections. 
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The duration of an incident cervical HPV infection of any type was measured from 
the date of the first detection of HPV DNA of any type in a cervical sample until the 
interval containing the date of the first subsequent sample which tested HPV DNA-
negative, with censoring at the end of follow-up. Equivalent definitions were used for 
the analysis of the duration of incident cervical HPV16 and HPV18 infections. 
 
The time to the diagnosis of incident high-grade CIN was measured from the date of 
study entry until the interval containing the date of the first diagnosis of high-grade 
CIN, with censoring at the date of the end of follow-up. 
 
The date of the end of follow-up was the earliest of: the date of diagnosis of high-
grade CIN; the date of treatment; the date of the last clinical follow-up (the latest of: 
the date of the last smear; the date of the last colposcopy visit). 
 
Estimates of the cumulative risk of an event of a given type were obtained using a 
non-parametric maximum likelihood estimator (Turnbull 1976) (see section 6.4.1). 
Estimates of hazards ratios were obtained in univariate and multivariate analyses 
using a semi-parametric method for modelling interval-censored time-to-event data 
with time-varying covariates, as a generalized linear model (see section 6.5.2 for 
further details of this method). 
 
Time-varying covariates were assigned their current values at each study visit. 
Construction of time-varying smoking exposure variables is described in following 
sections. When testing the statistical significance of linear trends of smoking 
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variables, an indicator variable for ever having smoked, or current smoking status, 
as appropriate, was also included: this is equivalent to restricting the analysis to 
ever, or current, smokers, respectively (Leffondre 2002). Sexual behaviour variables 
available for analysis (see section 13.8 below) were only retained in final models if 
they were significant in multivariate analyses which included smoking. 
 
Tests of statistical significance were conducted at the 5% two-sided significance 
level using likelihood ratio tests, and 95% confidence intervals (CI) were constructed 
as appropriate. 
 
13.5 THE COLLECTION OF SMOKING DATA 
 
Smoking data was collected via in-person interview, using one questionnaire at 
study entry to collect retrospective data, and another during follow-up to collect 
“prospective” data (see section 5.3 and appendices 1 and 2). Smoking status was 
self-reported, with no further objective verification. 
 
13.5.1 Retrospective data collection 
 
At recruitment, women were asked the following questions regarding their smoking 
history (see appendix 1): 
 
1) Have you ever regularly smoked cigarettes? 
2) How old were you when you started? 
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3) Do you still smoke? 
4) If you have given up, how old were you? 
5) How many cigarettes per day?  
6) Are the cigarettes filter, non-filter or handmade? 
 
The possible answers were: for questions 1 and 3, Y (yes) or N (no); for questions 2 
and 4, an age in years; for question 5, a number corresponding to a categorised 
range (1:1-9 2:10-19 3:20-29 4:30-39 5:40+); and for question 6, a number 
corresponding to one of the three categories (filter, non-filter or handmade). 
 
The use of the word “regularly” in question 1 was crucial: this should have eliminated 
the women who tried smoking once or twice, but then stopped. 
 
The recording of answers to question 6 was abandoned early during the study 
(hence this question does not appear on the questionnaire in appendix 1) since very 
few of these young women smoked anything other than filter-cigarettes. For 
example, within the study population for the incidence of cervical HPV infection: for 
951 women this field was left blank on the database, with 119, one and four in the 
filter, non-filter and handmade categories, respectively. 
 
In the coding rules for the entry of data onto the computerized database, it states 
that smoking (i.e. the answers to questions 1-6) is recorded in a field of 8 characters 
and gives the following example: a person who started smoking at age 16 and gave 
up at age 21, and who had smoked 15 filter cigarettes a day, would be coded 
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Y16N2121. This implies that even people who had given up smoking prior to study 
entry should have a value recorded for the amount they smoked prior to giving up 
(note that the restriction in age at recruitment was changed after these instructions 
were drawn up): this rule was not applied consistently. Of 91 women within the 
cohort of 1,075 who said that they were non-smokers at their first interview, but had 
been regular smokers in the past, 37 (41%) had no recorded value for the number 
they smoked. The vast majority of these women were among the last third recruited 
to the study, i.e. study numbers after 1241, or women recruited on or after 9th June 
1990. 
 
13.5.2 Prospective data collection 
 
At follow-up (prospective) interviews, women were asked the following questions 
regarding their smoking history (see appendix 2): 
 
7) Are you [a] cigarette smoker? 
8) Have you changed the number you smoke since [the] last visit? 
9) If smoking, how many per day? 
 
The answers possible were: for question 7, Y (yes) or N (no); for question 8, a 
number corresponding to a categorised change (1:stopped, 2:same, 3:started, 4:cut 
down and 5:increased); and for question 9, a number corresponding to a categorised 
range (1:1-9, 2:10-19, 3:20-29, 4:30-39 and 5:40+). 
 
188 
 
Note that the word “regular” no longer appears, and that there is no question 
regarding the type of cigarettes smoked. 
 
Question 8 was subsequently considered to be unreliable for various reasons. For 
example, it was felt that, when talking to health professionals, women were naturally 
inclined to say that they were smoking less than they were at the previous visit, even 
when there was no apparent change in the quantity smoked (i.e. they would give 
“socially desirable answers”). This variable was certainly internally inconsistent, with 
at least one woman saying she had cut down since the last visit when, according to 
the recorded information, she had been a non-smoker at the previous visit. Data 
collected in response to this question was not analysed. 
 
Comment: This questionnaire was supposed to be used to record changes in status 
since the previous visit: the questionnaire has ‘DETAILS-change only’ printed at the 
top of the first sheet. This policy was not adhered to, with sequences of identical 
results recorded for various questions; also, apparently, the questionnaire was not 
always taken to the interview with the woman, so it is not clear how this policy could 
have been adhered to. 
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13.6 INTERPOLATION OF “SMOKING EVENT” DATES 
 
A “smoking event” is defined as an occurrence of a change in smoking status e.g. 
starting or stopping smoking, or changing the number of cigarettes smoked per day. 
 
The smoking data has limited resolution for detecting smoking events. Distinguishing 
the number of times a woman started and stopped smoking was limited by the 
number of interviews she had, and the proximity of interviews to smoking events. For 
example, if a woman who was smoking at her first interview stopped for a period and 
then started smoking again before her second interview, this pattern of behaviour 
would have gone unrecorded. If, however, she had been interviewed during the brief 
period of time during which she had stopped smoking, the fact that she had stopped 
would have been recorded. 
 
The date on which a woman started smoking was interval censored: it was not 
known exactly. If she began smoking prior to her first interview, the date on which 
she started smoking was known to lie within a given year of age. Similarly, if once 
having started smoking, she subsequently stopped prior to her first interview, the 
date of this event was only known to lie within a given year of age for the woman. In 
some cases, women who reported that they had started and stopped smoking prior 
to recruitment, again reported that they were smoking at recruitment. 
 
Interpolation was used to determine an “exact” date for smoking events. The most 
complex interpolations occured in the retrospective data, with interpolation 
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depending on the proximity of the ages at which the woman started smoking, 
stopped smoking, and was recruited. The possible patterns of smoking and 
recruitment are shown in figure 13.6a: note that for ease of illustration only, events 
are shown as occurring in consecutive years of age. The dates of smoking events 
were interpolated by equally distributing the dates of events within the year of age 
(i.e. between the relevant consecutive birthdays) in which they were known to occur, 
with additional restrictions based on recruitment date and smoking status at that 
time. 
 
For example, in figure 13.6a panel a, there are three dates of smoking events to be 
interpolated between date of birthday Bdb and date of recruitment R: the date of first 
starting smoking, the date of stopping smoking and the date of starting smoking for 
the second time, since this woman was a smoker at recruitment. These three dates 
are determined by calculating the time interval in days (d) between the date of 
birthday Bdb and the date of recruitment, both of which are known exactly. This 
interval is then divided by the number of events plus one, in this case four. The nth 
event (n=1,2,3) thus occurs at the date given by Bdb+[n x (d/4)] (figure 13.6b panel 
b). Similarly, figure 13.6b panels b and c illustrate the interpolation of two and one 
smoking events, respectively. 
 
After recruitment, smoking events can only correspond to a single change in 
smoking status between interviews; consequently, all dates of smoking events are 
interpolated at the midpoint between the interview dates at which smoking status 
was determined. 
Figure 13.6a. The ten possible patterns of smoking events prior to 
recruitment. S=Started smoking; P=Stopped smoking; R=Recruitment, with 
smoking status at recruitment (+: smoking, –: not smoking); Bdi=Birthday, age 
i. 
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Figure 13.6b. Interpolation of smoking events prior to recruitment. S=Started 
smoking; P=Stopped smoking; R=Recruitment, with smoking status at recruitment 
(+: smoking, –: not smoking); Bdi=Birthday, age i. 
 
 
 
a) Three events in the same year of age. 
 
 
                                                       R-Bdb 
                
           Bdb                                                                                        R                      Bdc 
 
                         d                    d                    d                     d 
 
                                   S                     P                    S 
 
    where d = (R-Bdb)/4. 
 
 
b) Two events in the same year of age. 
 
 
                                                        R-Bdb 
                
           Bdb                                                                                        R                      Bdc 
 
                             d                             d                             d 
 
                                            S                            P                                               
 
    where d = (R-Bdb)/3, and d is measured in days. 
 
 
c) One event in a given year of age. 
 
 
 
                                                         R-Bdb 
                
           Bdb                                                                                        R                      Bdc 
 
                                     d                                          d 
 
                                                           S  
 
     where d = (R-Bdb)/2, and d is measured in days. 
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13.7. DEFINITION OF SMOKING-RELATED STUDY VARIABLES 
 
Interpolated smoking dates, as described in the previous section, were used to 
determine the values for all smoking exposure variables. Suppose a woman’s 
smoking status is known to change at the m times ti, i=1,2,...,m. For ease of notation, 
a change in smoking status is said to have occurred when smoking status is 
determined for the first time (i.e. at t1) and at end of follow-up (i.e. at tm). Define 
indicator variables Ej, j=1,2,...,m-1 for a woman’s smoking status in each of the 
intervals [ti, ti+1) (if T is in the period [a,b) then a≤T<b), i.e.: 
 
  Ej = 1    if the woman is a smoker during the period [ ti , ti+1) 
         0    if the woman is not a smoker during the period [ ti , ti+1) 
 
for j=1,2,...m-1. Figure 13.7 is an illustration of how the smoking status of a woman 
may vary with time (Note: a solid circle means that the point is included; an open 
circle means that the point is excluded). 
 
Figure 13.7. An illustrative example of how the smoking status of a woman 
may vary with time. ti,  i=1,2,...,8, are the times at which the womans smoking 
status is known to change; Ej, j=1,2,...,7, are indicators of current smoking status 
during the interval [tj, tj+1) (Ej=1 if the woman is a smoker, and 0 otherwise). 
 
 
 
t1 t2 t3 t4 t5 t6 t7 t8 
 Time 
E2=1 E3=0 E4=1 E5=0 E6=1 E7=0 E1=0 
Smoker 
Yes 
No 
 
 
13.7.1 Smoking status at study entry 
 
Two definitions of “smoking status at study entry” were used in analyses. The first 
definition distinguished ex-smokers, i.e. women who had once smoked but had since 
stopped, from women who had never smoked. With this definition, smoking status at 
study entry is a time-independent, i.e. time-fixed, categorical covariate with three 
levels, “never smoker”, “ex-smoker” and “current smoker”. At study entry: women 
who had never been regular smokers were categorised as “never smoker”; women 
who had been regular smokers, but who had stopped and were no longer regular 
smokers, were categorised as “ex-smokers”; women who were still regular smokers 
were categorised as “current smokers”. Women who were regular smokers at study 
entry, but who also stated that they had stopped smoking at some point prior to 
study entry, were still categorized as current smokers. 
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Some of the outcome variables analysed in this section of the thesis had a small 
total number of associated events; this meant that the ex-smoker category often had 
no events, so it was not possible to estimate risks for this category. To enable 
analysis of this variable for all outcomes, and to enable comparisons of risk 
estimates to be made across these outcomes, a second definition of “smoking status 
at study entry” was also used in analyses. The second definition combined women 
who had quit smoking prior to study entry with those who had never smoked, into a 
single “non-smoker” category. With this definition, smoking status at study entry is a 
time-fixed binary covariate with categories “non-smoker” and “current smoker”. 
 
Note that the second definition is sub-optimal in that the reference group (non-
smokers) combines women with some degree of exposure (current smokers and ex-
smokers) with those who have none (never-smokers); in contrast, the first definition 
has a clear-cut non-exposed reference group.  
 
13.7.2 Smoking history: ever versus never 
 
Smoking history (ever versus never) is a time-varying binary covariate. For the  
purposes of computation, it was defined as taking the value zero prior to the date of 
first starting smoking, and the value one thereafter. The value of this variable at time 
t is given by the indicator function S1(t): 
 
      S1(t)=I[ t ≥TS ] 
 
where t is time and TS is the time at which  the woman first started smoking. 
 
Figure 13.7.2 presents the graph of S1, calculated as the indicator function I[t ≥ t2], 
as a function of time for the woman illustrated in figure 13.7. 
 
Figure 13.7.2. The time-varying binary covariate “smoking history (ever versus 
never)” (S1(t)=I(t≥t2)) for the woman illustrated in figure 13.7 as a function of 
time. 
 
 
 
Smoking history: ever versus never 
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13.7.3 Current smoking status 
 
Current smoking status is a time-varying categorical covariate. Two definitions of this 
variable were used in analyses. The first definition combined women who had quit 
smoking (ex-smokers) with those who had never smoked (never-smokers), into a 
single “non-smoker category”. This definition yields a binary covariate taking the 
value zero for a non-smoker, and one for a current smoker, constructed using the 
following method. Define the time-varying indicator function Vi(t): 
 
               Vi(t) = I(ti ≤T< ti+1)                  i=1,2,...m-1 
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Then the current smoking status (binary) of the woman at time t, S2(t), is given by: 
 
                  m-1 
                                                  S2(t) =  Σ EiVi(t) 
                                                              i=1 
 
S2 takes the value zero for a non-smoker and one for a current smoker. The graph of 
S2 as a function of time for the woman illustrated in figure 13.7 is presented in figure 
13.7.3; note that this figure effectively reproduces figure 13.7. 
 
 
Figure 13.7.3a. The time-varying binary covariate “current smoking status” 
(S2(t)) for the woman illustrated in figure 13.7 as a function of time: two 
categories (0=non-smoker, 1=current smoker). 
 
 
 
0 
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Current smoking status 
t1 t2 t3 t4 t5 t6 t7 t8 
 Time 
 
 
The second definition distinguishes women who had smoked at some point in time 
but who were currently non-smokers (ex-smokers), from women who had never 
smoked (non-smokers). The second variable, a three-level categorical variable 
taking the value zero for a non-smoker, one for an ex-smoker, and two for a current 
smoker, was derived from the first variable using the following method. Define the 
time-varying indicator function T(t): 
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T(t) = I(S2(t)>0) 
 
Then the current smoking status (three-categories) of the woman at time t, S3(t), is 
given by: 
S3(t) = 2S2(t)T(t)+S1(t)(1–T(t)) 
 
The graph of S3 as a function of time for the woman illustrated in figure 13.7 is 
presented in figure 13.7.3b. 
 
 
Figure 13.7.3b. The time-varying categorical covariate “current smoking 
status” (S3(t)) for the woman illustrated in figure 13.7 as a function of time: 
three categories (0=never-smoker, 1=ex-smoker, 2=current smoker). 
 
 
 
t1 t2 t3 t4 t5 t6 t7 t8 
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 Time 
Current smoking status 
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13.7.4 The time since first starting smoking 
 
The time since first starting smoking is a time-varying covariate measuring the total 
amount of time since a woman first became a smoker; the value of this variable thus 
increases even during the periods of time when the woman was a non-smoker. The 
time since first starting smoking at time t (S4(t)) is defined as follows: 
 
S4(t)=(t–TS)S1(t) 
where t is current time and TS is the time at which the woman first started smoking. 
The graph of S4 as a function of time for the woman illustrated in figure 13.7 is 
presented in figure 13.7.4. 
 
 
Figure 13.7.4. The time-varying continuous function “the time since first 
starting smoking” (S4(t)) for the woman illustrated in figure 13.7 as a function 
of time. 
 
 
 
t1 t2 t3 t4 t5 t6 t7 t8 
0 
t8 - t2 
 Time 
The time since first starting smoking 
 
Time since first starting smoking is only well-defined for women who have started 
smoking at some point; for women who have never smoked it is not defined (a value 
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of zero would be incorrect). This variable was therefore analyzed as a continuous 
covariate in a model which also included a time-varying covariate indicating whether 
a woman had ever smoked, effectively restricting the analysis to ever-smokers for 
this variable, but allowing maximum information to be used for other variables in the 
analysis. 
 
This variable was also analysed as a categorical covariate with categories chosen 
because they were “logical”, iin this case multiples of whole years, and had 
“sufficient” numbers of events in each category; these categories were chosen prior 
to the estimation of risks. When analyzed as a categorical covariate, the reference 
category was never-smokers: this category is labelled “non-smokers”, which is 
strictly correct since all women are non-smokers until they start smoking, and only 
women who never start smoking remain in this category. 
 
13.7.5 The cumulative duration of smoking 
 
Smoking status can change over time, i.e. not all women who start smoking remain 
smokers thereafter; and some women who quit smoking subsequently re-start. Time 
since first starting smoking, as analyzed in the previous section, assumes that risk 
“accumulates” even while a woman is a non-smoker. In contrast, the cumulative 
duration of smoking distinguishes smoking and non-smoking time periods. The 
cumulative duration of smoking is a time-varying covariate measuring the total 
amount of time during which a woman has been an active smoker; the value of this 
variable remains constant during the periods of time when the woman was a non-
smoker. This variable is constructed using the following method. Define the time-
varying indicator function U(t): 
Ui(t) = I(t ≥ ti) 
Define: 
Vi(t) =  tUi(t)(1–Ui+1(t)) + ti+1Ui+1(t) 
Then, the cumulative duration of smoking at time t, S5(t), is given by: 
 
            m -1 
                                                       S5(t) =  Σ  (Vi(t) – ti )Ui(t)Ei 
             i=1 
 
The graph of S5 as a function of time for the woman illustrated in figure 13.7 is 
presented in figure 13.7.5. 
 
Figure 13.7.5. The time-varying covariate “the cumulative duration of smoking” 
(S5(t)) for the woman illustrated in figure 13.7 as a function of time. 
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This variable is well-defined for all women: women who have never smoked at a 
given point in time have a true cumulative duration of smoking of zero. 
 
The assumption that an increase from zero to one carries the same risk as an 
increase from four to five, for example, would need to be verified. In this case, the 
numerical change in the variable is the same, i.e. an increase of one, but a change 
from zero to one represents a change from never having smoked to starting smoking 
(a qualitative change), which may be expected to convey a greater increase in risk 
than merely continuing smoking, but at a higher rate. Therefore, this variable was 
also analyzed as a categorical covariate with categories chosen because they were 
“logical”, in this case multiples of whole years, and had “sufficient” numbers of 
events in each category; these categories were chosen prior to the estimation of 
risks. Never-smokers were used as the reference category. 
 
13.7.6 The duration of the current smoking episode 
 
The duration of the current smoking episode is a time-varying covariate measuring 
the total amount of time a woman has been smoking since she last started smoking. 
For current smokers, the current smoking episode was considered to have begun at 
the midpoint between the most recent date at which a woman reported having 
started to smoke, and the date of the preceding visit. So, if at time T a woman has 
made one or more unsuccessful attempts to quit smoking, but is a smoker at time T, 
the duration of the current smoking episode at time T is the interval between the date 
on which she started smoking for the second time, and time T. This variable is only 
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well-defined for women who are current smokers. This variable was therefore initially 
analysed as a continuous covariate together with a time-varying covariate indicating 
whether a woman was a current smoker, thereby effectively restricting the analysis 
to current smokers. 
 
This variable was also analysed as a categorical covariate with categories chosen 
because they were “logical”, in this case multiples of whole years, and had 
“sufficient” numbers of events in each category: these categories were chosen prior 
to the estimation of risks. Two versions of this variable were analyzed: one had non-
smokers as the reference category (a category which combined never- and ex-
smokers); the other had never-smokers alone as the reference category, with ex-
smokers in a separate category. 
 
13.7.7 Pack-years smoked 
 
Pack-years are a conventional measure of cumulative exposure to smoking over the 
lifetime of a woman, combining intensity and duration of smoking into one 
measurement, giving each equal weight. Pack-years smoked is a time-varying 
covariate: they are obtained by multiplying quantity smoked, which may vary over 
time, by the time for which that quantity was smoked, accumulating the resulting 
product over the lifetime of the woman, and expressing the result in suitable units. 
 
Figure 13.7 illustrates how a woman’s smoking status may change over time with 
respect to both status (smoker or non-smoker) and quantity smoked (smoking 
intensity). However, the situation is likely to be more complex than this illustration, 
since the amount a woman smokes, as well as her smoking status, may vary with 
time. Suppose the number of cigarettes a woman smokes per unit time is known to 
change at times t’i, i=1,2,...,m’ (once again, for ease of notation, a “change” is said to 
have occurred when the number smoked per unit time is determined for the first 
time, and at the end of follow-up) and let Qk, k=1,2,...m’-1 be variables measuring 
the number of cigarettes smoked per unit time during each of the intervals [ti, ti+1). 
Figure 13.7.7a illustrates this situation, which is slightly different from that illustrated 
in figure 13.7 since this woman does not stop smoking at time t7, but instead 
changes (increases, say) the quantity she smokes.  
 
 
Figure 13.7.7a. An illustration of how the smoking status of a woman may vary 
with time. t’i,  i=1,2,...,8 are the times at which the amount a woman smokes is 
known to change; Qk, k=1,2,...,7 are numbers of cigarettes smoked per unit time. 
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The number of cigarettes smoked per day was not recorded exactly, but was 
categorised into one of six categories (including a quantity of zero for non-smokers); 
the assumption was therefore made that the actual number of cigarettes smoked per 
day was equal to the midpoint of each category, i.e. 5, 15, 25, and 35 cigarettes per-
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day, respectively, for the first four categories, with the number smoked in the final 
(open-ended) category arbitrarily set to 45. This number was then assumed to apply 
from the date of the interview at which that quantity-category was collected, until the 
date of the day preceding the subsequent interview, at which point the quantity was 
updated. For women who, prior to study entry, had started smoking, stopped, and 
then started again, the assumption was made that the number of cigarettes smoked 
per day during the first smoking episode was the same as the number smoked when 
she started smoking for the second time. 
 
The cumulative quantity of cigarettes smoked is a time-varying covariate measuring 
the total number of cigarettes smoked by a woman; the value of this variable 
remains constant during the periods of time when the woman was a non-smoker. 
This variable was constructed using the following method. Define the time-varying 
indicator function U(t): 
 
Ui(t) = I(t ≥ ti) 
Define: 
Vi(t) =  tUi(t)[1–Ui+1(t)] + ti+1Ui+1(t) 
 
Then, the cumulative quantity of cigarettes smoked at time t is given by: 
 
          m’ -1 
                                                      S6(t) =  Σ  (Vi(t) – ti )Ui(t)Qi 
            i=1 
 
The graph of S6 as a function of time for the woman illustrated in figure 13.7.7a is 
presented in figure 13.7.7b. 
 
Figure 13.7.7b. The time-varying covariate “the cumulative quantity of 
cigarettes smoked” (S6(t)) for the woman illustrated in figure 13.7.7a as a 
function of time. 
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The cumulative quantity of cigarettes was then categorised using categories chosen 
to correspond to “pack-years”, where one pack-year corresponds to 
20*365.25=7,305 cigarettes. Note that a woman who smokes one pack of 20 
cigarettes every day for one year, has an exposure of one pack-year; as does a 
woman who smokes half as many cigarettes for twice as long. This variable is well-
defined for all women: women who have never smoked at a given point in time have 
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a number of pack-years of zero; there is thus no need to distinguish never-, ex-, and 
current-smokers.  
 
13.7.8 Current smoking intensity 
 
Current smoking intensity is a time-varying categorical covariate measuring the 
number of cigarettes smoked per day. Categories recorded for this variable were: 0, 
1 to 9, 10 to 19, 20 to 29, 30 to 39, and 40 or more. Due to the small number of 
events for some of the outcome variables, and to enable comparisons to be made 
across these outcomes, this variable was analyzed as a four-category variable, with 
never-smokers as reference category, ex-smokers in a separate category with a 
smoking intensity of 0, and categories 1 to 9 and 10 or more for current smokers. 
 
13.8 DEFINITION OF SEXUAL BEHAVIOUR-RELATED VARIABLES 
 
Variables measuring some aspect of sexual behaviour which were available for 
analysis were age at first sexual intercourse, age of oldest sexual partner (two 
versions: in total, and in the previous six months), lifetime number of sexual partners, 
all measured on a continuous scale; and the acquisition of a new sexual partner in 
the previous six months, measured as a categorical variable. The first three of these 
variables are self-explanatory: age at first sexual intercourse was a time-fixed 
covariate; the other two variables were time-varying, with values updated at each 
study visit. When values were missing, these variables took their last known value. 
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Acquisition of a new sexual partner in the previous six months was a time-varying 
binary covariate indicating whether a woman had acquired one or more new sexual 
partners in the previous six months. A return to a previous sexual partner was also 
counted as acquiring a new sexual partner, whether or not the woman had acquired 
another new (distinct) sexual partner in the interim. Sometimes, a woman would 
state that she had started a sexual relationship with one partner, had ended that 
relationship, but that subsequently she had “returned” to this original sexual partner. 
If she had acquired a new (distinct) sexual partner in the interim, she would be 
categorised as having acquired two sexual partners; if not, she would be categorised 
as having acquired one sexual partner. This is because the assumption was made 
that any current sexual relationship was monogamous for both partners; but that the 
male partner was sexually active, and therefore exposed to cervical HPV infections 
carried by additional sexual partners, whilst he was not in a relationship with the 
study woman. 
 
13.9 DEFINITION OF HPV EXPOSURE VARIABLES 
 
In some analyses in this section, cervical HPV infection is an outcome, but for the 
analysis of incident high-grade CIN, cervical HPV infection is an exposure variable: 
in this analysis, cervical HPV infection status was treated as an irreversible time-
varying indicator variable. The risk of cervical disease associated with exposure to 
cervical HPV infection is known to vary according to type; therefore controlling for 
HPV exposure using a variable measuring only exposure to any HPV type, may be 
suboptimal and provide insufficient control of this variable. Cervical HPV infection 
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status was therefore controlled by including in each analysis three separate time-
varying binary variables constructed to measure whether a woman had ever been 
exposed to cervical infection with HPV16, HPV18, or other HPV types; HPV16 and 
HPV18, the two most common high-risk HPV types, were detected in sufficient 
numbers to make this analysis feasible. 
 
For example, suppose a woman who was HPV DNA-negative in a cervical sample at 
study entry (T0), acquired HPV16 at time T1, acquired HPV18 at time T2 (T2>T1), 
acquired HPV of a type other than type 16 or type 18, at time T3 (T3>T2), was 
positive for both HPV16 and HPV18 (but no other types) at time T4 (T4>T3), and was 
HPV DNA-negative at times T5 and T6 (T5>T4, T6>T5). Table 13.9 illustrates the 
coding of the three HPV exposure variables as they change over time for this 
woman. As soon as HPV of the relevant type is detected, the status for that variable 
changes from 0 (unexposed) to 1 (exposed) and thereafter remains at 1, whatever 
additional changes in HPV status occur thereafter. This variable assumes that once 
a woman has been exposed to HPV, her risk status for high-grade CIN is 
permanently altered, even if she subsequently becomes HPV DNA-negative. 
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Table 13.9. Example of the coding of the set of three time-varying variables 
measuring HPV exposure as they were used in the analysis of incident 
high-grade CIN. This example relates to a woman who was HPV DNA-negative 
at study entry (T0), acquired HPV16 at time T1, HPV18 at time T2, HPV of 
another type at time T3, was positive for HP16 and HPV18 (but no other types) at 
time T4, and was HPV DNA-negative at times T5 and T6. 
 
Time HPV16 HPV18 Other HPV types 
T0 0 0 0 
T1 1 0 0 
T2 1 1 0 
T3 1 1 1 
T4 1 1 1 
T5 1 1 1 
T6 1 1 1 
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Chapter 14 
 
SMOKING, CERVICAL HPV INFECTION, AND THE RISK OF 
CERVICAL NEOPLASIA 
 
RESULTS 
 
 
 
 
 
Orientation 
In this chapter I: 
 
• describe the association between exposure to cigarette smoking and the risk of 
acquiring an incident cervical infection with HPV DNA of any type 
 
• describe the association between exposure to cigarette smoking and the risk of 
acquiring an incident cervical infection with HPV16 or HPV18 
 
• describe the association between exposure to cigarette smoking and the duration 
of an incident cervical infection with HPV of any type, HPV16, or HPV18 
 
• describe the association between exposure to cigarette smoking and the risk of 
acquiring incident high-grade cervical intraepithelial neoplasia 
 
 
 
 
 
14.1 THE INCIDENCE OF CERVICAL HPV INFECTION IN RELATION TO 
SMOKING HISTORY 
 
The study population for this analysis comprises 1,075 women who were HPV DNA-
negative in their first evaluable sample, cytologically normal in their first evaluable 
cervical smear, and who had further follow-up after this time. The study population is 
identical for the analysis of the incidence of cervical HPV infections of any type, 
HPV16 and HPV18; only the outcome changes for these analyses. 
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Note: When presenting analyses, to describe the distribution of a variable, or to 
convey some measure of the reliability of estimates, it is conventional to report 
numbers of subjects and the number of events they experience for each of the 
categories of that variable, or overall for continuous variables. For time-varying 
covariates, however, it is the history of how these quantities change over time which 
are relevant; these require a more extensive and complex presentation than space 
allows. Therefore, in this section, women were categorised at their observed event 
time, and it is these frequencies and number of events which are reported in tables.  
 
14.1.1 Univariate analysis 
 
This section presents the results of univariate analyses describing the association 
between each of the variables used to measure exposure to cigarette smoking and 
the risk of: an incident cervical HPV infection of any type; an incident cervical HPV16 
infection; and an incident cervical HPV18 infection.  
 
HPV16 and HPV18 are the two HPV types which are most frequently detected at the 
time of diagnosis of cervical cancer, and are therefore of particular interest. Within 
the cohort on which this thesis is based, these two high-risk types were also the 
most commonly detected types (at any time during follow-up), and were the only two 
types detected with sufficient frequency to enable their inclusion as outcomes in 
separate analyses. 
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14.1.1.1 Cervical HPV infection of any type 
 
Four hundred and seven women first acquired a cervical infection with HPV DNA of 
any type during follow-up. 
 
14.1.1.1.1 The univariate analysis of the association between smoking status 
at study entry and the risk of an incident cervical HPV infection of any type 
 
Three hundred and fifty six (33%) women were smokers at study entry, of whom one 
had stopped smoking at some point prior to study entry, but had since re-started. 
Seven hundred and nineteen (67%) women were non-smokers at study entry; 626 
(87%) had never been smokers compared with 93 (13%) who reported that they had 
been smokers prior to study entry, but had since stopped. Of the 626 women who 
had never smoked prior to study entry, 228 (36%) became HPV-positive during 
follow-up: HPV was first detected after first exposure to smoking in 19 (8%) of these 
women; coincident with first exposure to smoking in 17 (7%); and before first 
exposure to smoking in 192 (84%) (15 (8%) of whom were known to have begun 
smoking before the end of follow-up). Of the 449 women who had first become 
smokers at some point prior to study entry, 179 (40%) became HPV-positive in 
cervical samples during follow-up. 
 
The univariate analysis of the association between smoking status at study entry and 
the risk of an incident cervical HPV infection of any type is described in table 
14.1.1.1.1. The association between smoking status at study entry and the risk of an 
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incident cervical HPV infection of any type was not statistically significant using the 
definition of the exposure variable which explicitly accounts for changes in smoking 
status prior to study entry. When ex-smokers were combined with never-smokers, 
smoking status at study entry remains non-significant; however, when they were 
combined with current smokers (forming an “ever-smoker” category), smoking status 
at study entry became statistically significant. Current smokers at baseline had an 
approximately 20% increase in risk in all three analyses; in the analysis using the 
first definition, current and ex-smokers were at a similar risk. 
 
 
Table 14.1.1.1.1. The univariate analysis of the association between smoking 
status at study entry and the risk of an incident cervical infection with HPV 
DNA of any type.  
 
Smoking Status At 
Study Entry 
Number of 
Women (%)
Number of 
Events 
Hazards Ratio (95% CI) 
    
Never-smoker 626 (58.2) 228 1.00 (Reference) 
Ex-smoker   93 (  8.7)   38 1.26 (0.89 to 1.79) 
Current smoker 356 (33.1) 141 1.23 (0.99 to 1.52) 
      χ2=4.40; 2df; p=0.11a 
    
Non-smoker 719 (65.0) 266 1.00 (Reference) 
Current smoker 356 (35.0) 141 1.19 (0.97 to 1.46) 
      χ2=2.74; 1df; p=0.10a 
    
Non-smoker 626 (58.2) 228 1.00 (Reference) 
Ever smoker 449 (41.8) 179 1.23 (1.01 to 1.51) 
      χ2=4.38; 1df; p=0.04a 
aLikelihood ratio test: chi-squared statistic; degrees of freedom; p-value. 
 
 
In women who had never smoked prior to study entry, the cumulative risk of an 
incident cervical HPV DNA infection of any type at one, two and three years after 
study entry were 19.5%, 35.5% and 43.4% respectively. 
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 14.1.1.1.2 The univariate analysis of the association between age at starting 
smoking and the risk of an incident cervical HPV infection of any type 
 
Age at first starting smoking was analysed as both a time-fixed variable, fixed at 
study entry, and as a time-varying covariate. Four hundred and forty nine (41.8%) 
women had regularly smoked cigarettes at some point prior to study entry; the 
median age at starting smoking for these women was 15 years (range 9 to 19). 
 
The univariate analysis of the association between age at starting smoking, as 
recorded at study entry, and the risk of an incident cervical HPV infection of any 
type, is described in table 14.1.1.1.2. Among women who had ever smoked at study 
entry, there was a decrease in the risk of an incident cervical HPV infection of any 
type as age at starting smoking increased: the hazard ratios decreased by 6% (1.00-
0.94) for every year of increase in age at starting smoking; however, the association 
was not statistically significant. There was a statistically significant association 
between age at starting smoking at study entry and the risk of an incident cervical 
HPV infection of any type, when age at starting smoking was analysed as a 
categorical variable. However, there was no consistent pattern: statistical 
significance appears to be due to a single category, with no apparent trend in risk 
associated with age at starting smoking.  
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Table 14.1.1.1.2. The univariate analysis of the association between age at 
starting smoking as measured at study entry and the risk of an incident 
cervical infection with HPV DNA of any type.  
 
Age At Starting 
Smoking (at study 
entry) 
Number of 
Women (%) 
Number 
of Events
Hazards Ratio (95% CI) 
    
Continuous (per year)a 1075 (100) 407 0.94 (0.86 to 1.02) 
   χ2=2.04; 1df; p=0.15b 
    
Never-smoker 626 (58.2) 228 1.00 ( Reference ) 
≤13 100 (  9.3) 41 1.38 (0.98 to 1.94) 
14-15 182 (16.9) 83 1.38 (1.07 to 1.79) 
 ≥16 167 (15.5) 55 1.00 (0.74 to 1.34) 
   χ2=8.59; 3df; p=0.04b 
aIncludes a variable indicating “ever smoker” status at study entry; bLikelihood ratio test: chi-
squared statistic; degrees of freedom; p-value. 
 
 
 
14.1.1.1.3 The univariate analysis of the association between a history of ever 
having smoked and the risk of an incident cervical HPV infection of any type 
 
Nearly 50% of women had smoked cigarettes at some point prior to the first 
detection of HPV DNA of any type during follow-up. 
 
The univariate analysis of the association between a history of ever having smoked 
and the risk of an incident cervical HPV infection of any type is described in table 
14.1.1.1.3. Compared to women who had never smoked, women who had ever 
smoked had a small (39%=1.39-1.00), but statistically significant, increase in the risk 
of an incident cervical HPV infection of any type. 
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Table 14.1.1.1.3. The univariate analysis of the association between a 
history of ever having smoked and the risk of an incident cervical infection 
with HPV DNA of any type.  
 
Have you ever been 
a cigarette smoker? 
Number of 
Women (%)
Number of 
Events 
Hazards Ratio (95% CI) 
    
No 550 (51.2) 192 1.00 (Reference) 
Yes 525 (48.8) 215 1.39 (1.14 to 1.69) 
      χ2=10.79; 1df; p=0.001a 
aLikelihood ratio test: chi-squared statistic; degrees of freedom; p-value. 
 
 
 
14.1.1.1.4 The univariate analysis of the association between the time since 
first starting smoking and the risk of an incident cervical HPV infection of any 
type 
 
At the earliest of the date of the first detection of HPV DNA of any type in a cervical 
sample, or the date of the end of follow-up, the median time since first starting 
smoking was 43.1 months (range 2.2 to 157.0) in women who had ever smoked. 
  
The “univariate” association (the model actually contains more than one variable, but 
the focus of the analysis is on only one of those variables) between time since 
starting smoking and the risk of an incident cervical HPV infection of any type is 
described in table 14.1.1.1.4. There was a very slight and non-significant decrease in 
the risk of an incident cervical HPV infection of any type with increasing time since 
starting smoking, when this variable was analysed as a continuous variable, 
controlling for ever having smoked. The risk of an incident cervical HPV infection of 
any type decreased by 3% (1.00-0.97) for every increase of one year in time since 
starting smoking. When the variable was analysed as a categorical covariate, with 
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never-smokers as reference group, the time since first starting smoking was 
significantly associated with the risk of an incident cervical HPV infection of any type. 
However, there were only very slight differences between the risks estimated for 
each of the non-zero categories, suggesting that the association observed was a 
consequence of ever having smoked, rather than duration of smoking per se. 
 
 
Table 14.1.1.1.4. The univariate analysis of the association between the time 
since first starting smoking and the risk of an incident cervical infection with 
HPV DNA of any type.  
 
Time Since First 
Starting Smoking 
Number of 
Women (%)
Number of 
Events 
Hazards Ratio (95% CI) 
   
Continuous (per year)a 1075 (100) 407 0.97 (0.91 to 1.03) 
  χ2=1.05; 1df; p=0.31b 
   
Never-smoker 550 (51.2) 192 1.00 (Reference) 
( 0, 36 months)c 181 (16.8) 85 1.44 (1.11 to 1.87) 
[36, 72)c 242 (22.5) 91 1.31 (1.02 to 1.69) 
[72, +)c 102 (  9.5) 39 1.46 (1.01 to 2.09) 
  χ2=11.26; 3df; p=0.01b 
   
Never-smoker 550 (51.2) 192 1.00 (Reference) 
( 0, 36 months)c 181 (16.8) 85 1.44 (1.11 to 1.87) 
[36, 72)c 242 (22.5) 91 1.31 (1.02 to 1.69) 
[72, 84)c 40 (  3.7) 18 1.44 (0.87 to 2.38) 
[84, +)c 62 (  5.8) 21 1.47 (0.91 to 2.36) 
    χ2=11.26; 4df; p=0.02b 
aModel includes a time-varying indicator variable indicating “ever smoker” status; bLikelihood ratio 
test: chi-squared statistic; degrees of freedom; p-value; c[a, b) is a mathematical convention 
denoting the interval ≥a to <b. 
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14.1.1.1.5 The univariate analysis of the association between the cumulative 
duration of smoking and the risk of an incident cervical HPV infection of any 
type 
 
At the earliest of the date of the first detection of HPV DNA of any type in a cervical 
sample, or the date of the end of follow-up, the median cumulative duration of 
smoking was 35.6 months (range 2.2 to 157.0) among women who had ever 
smoked.  
 
The univariate analysis of the association between the cumulative duration of 
smoking and the risk of an incident cervical HPV infection of any type is described in 
table 14.1.1.1.5. There was a slight non-significant decrease in the risk of an incident 
cervical HPV infection of any type with increasing cumulative duration of smoking, 
when this variable was analysed as a continuous variable, controlling for ever having 
smoked. The risk of an incident cervical infection decreased by 4% (1.00-0.96) for 
every year of increase in the cumulative duration of smoking. When the variable was 
analysed as a categorical covariate, with never-smokers as reference group, 
cumulative duration of smoking was significantly associated with the risk of an 
incident cervical HPV infection of any type. However, there were only very slight 
differences between the risks estimated for each of the categories, with no trend 
apparent. Note that this analysis differs from that in section 14.1.1.1.4 because not 
all women smoked continuously once they had started to smoke. As expected, 
cumulative duration of smoking is highly correlated with time since starting smoking: 
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the risks estimates associated with the latter are slightly less extreme, but the 
pattern of risk estimates is similar. 
 
 
Table 14.1.1.1.5. The univariate analysis of the association between the 
cumulative duration of smoking and the risk of an incident cervical infection 
with HPV DNA of any type.  
 
Cumulative Duration 
Of Smoking 
Number of 
Women (%) 
Number of 
Events 
Hazards Ratio (95% CI)
   
Continuous (per year) 1075 (100.0) 407 0.96 (0.90 to 1.02) 
  χ2=1.64; 1df; p=0.20b 
    
Never-smoker 550 (51.2) 192 1.00 (Reference) 
( 0, 36 months)c 251 (23.3) 113 1.50 (1.18 to 1.90) 
[36, 72)c 205 (19.1) 75 1.20 (0.92 to 1.57) 
[72, +)c 69 (   6.4) 27 1.57 (1.03 to 2.40) 
   χ2=13.45; 3df; p=0.004b 
aModel includes a time-varying indicator variable indicating “ever smoker” status; bLikelihood ratio 
test: chi-squared statistic; degrees of freedom; p-value; c[a, b) is a mathematical convention denoting 
the interval ≥a to <b. 
 
 
14.1.1.1.6 The univariate analysis of the association between the duration of 
the current smoking episode and the risk of an incident cervical HPV infection 
of any type  
 
The duration of a smoking episode was measured from the date a woman reported 
smoking until the first date subsequent to this on which she reported stopping 
smoking. At the earliest of the date of the first detection of HPV DNA of any type in a 
cervical sample, or the date of the end of follow-up, the median duration of the 
current smoking episode was 34.8 months (range 1.2 to 157.0), among women who 
were current smokers at that time. 
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The univariate analysis of the association between the duration of the current 
smoking episode and the risk of an incident cervical HPV infection of any type is 
described in table 14.1.1.1.6. There was a very slight non-significant decrease in the 
risk of an incident cervical HPV infection of any type with increasing duration of 
current smoking episode, when this variable was analysed as a continuous variable, 
and the analysis was controlled for current smoking status. The risk of an incident 
cervical HPV infection of any type decreased by 3% (1.00-0.97) for every increase of 
year in time since the start of the current smoking episode. When the variable was 
analysed as a categorical covariate with non-smokers as reference group, there 
were very slight differences between the risks estimated for each of the non-zero 
categories. When the variable was analysed as a categorical covariate with never-
smokers as reference group, there were very slight differences between the risks 
estimated for each of the non-zero categories and the risk for ex-smokers: inclusion 
of ex-smokers in the non-smokers category in the previous analysis “diluted” the risk 
estimates, but only slightly. 
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Table 14.1.1.1.6. The univariate analysis of the association between the 
duration of the current smoking episode and the risk of an incident cervical 
infection with HPV DNA of any type.  
 
Duration Of Current 
Smoking Episode 
Number of 
Women (%)
Number of 
Events 
Hazards Ratio (95% CI) 
    
Continuous (per year)a 1075 (100) 407 0.97 (0.90 to 1.04) 
   χ2=0.75; 1df; p=0.39b 
    
Nonsmoker 679 (63.2) 243 1.00 (Reference) 
( 0, 24 months)c 132 (12.3) 60 1.41 (1.06 to 1.88) 
[24, 48)c 120 (11.2) 52 1.26 (0.93 to 1.70) 
[48, +)c 144 (13.4) 52 1.22 (0.90 to 1.66) 
   χ2=6.96; 3df; p=0.07b 
    
Never-smoker 550 (51.2) 192 1.00 (Reference) 
Ex-smoker 129 (12.0) 51 1.41 (1.03 to 1.93) 
( 0, 24 months)c 132 (12.3) 60 1.50 (1.12 to 2.01) 
[24, 48)c 120 (11.2) 52 1.34 (0.98 to 1.82) 
[48, +)c 144 (13.4) 52 1.30 (0.95 to 1.78) 
   χ2=11.44; 4df; p=0.02b 
aModel includes a time-varying indicator variable indicating “current smoking” status; bLikelihood 
ratio test: chi-squared statistic; degrees of freedom; p-value; c[a, b) is a mathematical convention 
denoting the interval ≥a to <b. 
 
 
14.1.1.1.7 The univariate analysis of the association between pack-years 
smoked and the risk of an incident cervical HPV infection of any type 
 
This analysis was restricted to the 1,038 (out of 1,075) women for whom the quantity 
smoked was known throughout follow-up. At the earliest of the date of the first 
detection of HPV DNA of any type in a cervical cytological sample, or the date of the 
end of follow-up, the median pack-years smoked was 1 pack-year (range 0.1 to 8) in 
women who had ever smoked prior to that time. 
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The univariate analysis of the association between pack-years smoked and the risk 
of an incident cervical HPV infection of any type is described in table 14.1.1.1.7. 
When analysed as a continuous variable, the hazards ratio decreased by 8% (1.00-
0.92) for every increase of one pack year, but the association was not statistically 
significant. There was no evidence of a departure from linearity for this variable. 
However, when analysed as a categorical variable, the risk estimates showed no 
consistent pattern across categories: women who had smoked less than one pack-
year, or between two and three pack-years, were at a significantly increased risk of 
an incident cervical infection with HPV DNA of any type (the confidence intervals 
around the hazards ratios exclude 1), but women in the intervening category were 
not at a significantly increased risk; women who had smoked more than three pack-
years had no detectable increase in risk compared with women who had never 
smoked.  
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Table 14.1.1.1.7. The univariate analysis of the association between pack-years 
smoked and the risk of an incident cervical infection with HPV DNA of any 
type.  
 
Pack-years Smoked Number of 
Women (%) 
Number of 
Events 
Hazards Ratio (95% CI) 
Continuous (per pack-
year)a 1038 (100) 394 0.92 (0.80 to 1.05) 
   χ2=1.66; 1df; p=0.20b 
    
Never-smoker 550 (51.2) 192 1.00 (Reference) 
(0 , 1)c 232 (22.4) 110 1.59 (1.25 to 2.01) 
[1 , 2)c 143 (13.8) 50 1.16 (0.84 to 1.58) 
[2 , 3)c 73 (7.0) 30 1.50 (1.01 to 2.21) 
[3 , +)c 40 (3.9) 12 1.03 (0.56 to 1.90) 
   χ2=15.84; 4df; p=0.003b 
aModel includes a time-varying indicator variable indicating ”ever smoker” status; bLikelihood ratio 
test: chi-squared statistic; degrees of freedom; p-value; c[a, b) is a mathematical convention denoting 
the interval ≥a to <b. 
 
 
14.1.1.1.8 The univariate analysis of the association between current smoking 
status and the risk of an incident cervical HPV infection of any type  
 
The univariate analysis of the association between current smoking status and the 
risk of an incident cervical HPV infection of any type is described in table 14.1.1.1.8. 
Current smoking status was significantly associated with the risk of an incident 
cervical HPV infection of any type. Current smokers and current ex-smokers had a 
small (38%=1.38-1.00) but significantly increased risk of an incident cervical HPV 
infection of any type compared to women who had never smoked. As expected, the 
magnitude of this risk was similar to that seen for the “smoking history (ever versus 
never)” variable: these two variables are highly correlated, since for any woman who 
never smokes, or whose smoking status changes only once (the majority of women), 
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the variables are identical. When never-smokers and ex-smokers were combined 
into the reference group, this variable remained statistically significant. 
 
 
Table 14.1.1.1.8. The univariate analysis of the association between current 
smoking status and the risk of an incident cervical infection with HPV DNA 
of any type.  
 
Current Smoking Status Number of 
Women (%)
Number of 
Events 
Hazards Ratio (95% CI)
Never-smoker 550 (51.2) 192 1.00 (Reference) 
Ex-smoker 129 (12.0) 51 1.41 (1.04 to 1.93) 
Current smoker 396 (36.8) 164 1.38 (1.12 to 1.70) 
      χ2=10.82; 2df; p=0.004a 
    
Non-smoker 679 (63.2) 243 1.00 (Reference) 
Current smoker 396 (36.8) 164 1.29 (1.06 to 1.58) 
      χ2=6.32; 1df; p=0.01a 
aLikelihood ratio test: chi-squared statistic; degrees of freedom; p-value. 
 
 
14.1.1.1.9 The univariate analysis of the association between current smoking 
intensity and the risk of an incident cervical HPV infection of any type 
 
This analysis was restricted to the 1,038 (out of 1,075) women for whom quantity 
smoked was known throughout follow-up. 
 
At the earliest of the date of the first detection of HPV DNA of any type in a cervical 
cytological sample, or the date of the end of follow-up, most women who were 
current smokers were smoking between one and nine cigarettes per day. 
 
The univariate analysis of the association between current smoking intensity and the 
risk of an incident cervical infection with HPV DNA of any type is shown in table 
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14.1.1.1.9. When analysed as a categorical variable, current smoking intensity was 
significantly associated with the risk of an incident cervical infection with HPV DNA 
of any type. However, this seems to reflect the risk associated with being a current 
smoker rather than smoking intensity per se: among current smokers, there was no 
significant association between current smoking intensity and the risk of an incident 
cervical HPV infection of any type. 
 
Table 14.1.1.1.9. The univariate analysis of the association between current 
smoking intensity and the risk of an incident cervical infection with HPV 
DNA of any type. 
 
Current Smoking 
Intensity 
Number of 
Women (%) 
Number of 
Events 
Hazards Ratio (95% CI)
    
Continuous (per 
category)a 1038 (100) 394 0.97 (0.82 to 1.14) 
   χ2=0.16; 1df; p=0.69b 
    
Never-smoker 550 (53.0) 192 1.00 ( Reference ) 
0 per day 104 (10.0) 40 1.41 (1.04 to 1.93) 
1 to 9 per day 196 (18.9) 92 1.48 (1.15 to 1.90) 
10 or more per day 188 (18.1) 70 1.26 (0.96 to 1.67) 
      χ2=11.81; 3df; p=0.008b 
aThe increase in risk for every increase of one in category of smoking intensity; bLikelihood ratio test: 
chi-squared statistic; degrees of freedom; p-value. 
 
 
 
Summary 
 
There are several possible ways of measuring exposure to smoking in the study 
described in this thesis. In univariate analyses, most of the alternative exposure 
variables measuring exposure to smoking were significantly associated with the risk 
of an incident cervical HPV infection of any type, although the magnitude of the risk 
estimates were typically small. 
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14.1.1.2 HPV16 infection 
 
One hundred and ten women acquired an incident cervical infection with HPV16 
during follow-up. 
 
Note: In the tables, frequencies and numbers of events are reported at the time of 
occurrence of an event. Therefore, since “HPV of a specific type” events are less 
common than “HPV of any type” events (110 and 64 for HPV16 and HPV18, 
respectively, compared with 407 for HPV of any type), women in the type-specific 
analyses are often followed-up for longer before experiencing an event. Therefore 
they have greater opportunity to change smoking status. This accounts for the 
apparent “discrepancy” between the number of women in specific categories of the 
smoking variable in the type-specific analyses and the “all-types-combined” analysis. 
 
14.1.1.2.1 The univariate analysis of the association between smoking status 
at study entry and the risk of an incident cervical HPV16 infection  
 
The univariate analysis of the association between smoking status at study entry and 
the risk of an incident cervical HPV16 infection is described in table 14.1.1.2.1. The 
association between smoking status at study entry and the risk of an incident 
cervical HPV16 infection was not statistically significant using any of the three 
possible definitions of this exposure variable. 
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Table 14.1.1.2.1. The univariate analysis of the association between smoking 
status at study entry and the risk of an incident cervical infection with HPV16.  
 
Smoking Status At 
Study Entry 
Number of 
Women (%)
Number of 
Events 
Hazards Ratio (95% CI)
    
Never-smoker 626 (58.2) 62 1.00 (Reference) 
Ex-smoker   93 (  8.7) 10 1.22 (0.62 to 2.38) 
Current smoker 356 (33.1) 38 1.08 (0.72 to 1.63) 
      χ2=0.40; 2df; p=0.82a 
    
Non-smoker 719 (65.0) 72 1.00 (Reference) 
Current smoker 356 (35.0) 38 1.06 (0.71 to 1.57) 
      χ2=0.08; 1df; p=0.78a 
    
Non-smoker 626 (58.2) 62 1.00 (Reference) 
Ever smoker 449 (41.8) 48 1.11 (0.76 to 1.62) 
      χ2=0.29; 1df; p=0.59a 
aLikelihood ratio test: chi-squared statistic; degrees of freedom; p-value. 
 
 
14.1.1.2.2 The univariate analysis of the association between age at starting 
smoking and the risk of an incident cervical HPV16 infection 
 
The univariate analysis of the association between age at starting smoking, as 
measured at study entry (i.e. this was a time-fixed variable whose value was 
measured at study entry), and the risk of an incident cervical infection with HPV16 is 
shown in table 14.1.1.2.2. Age at first starting smoking was analysed as both a time-
fixed variable, fixed at study entry, and as a time-varying covariate, updated during 
follow-up. In neither analysis was there a statistically significant association between 
age at starting smoking and the risk of an incident cervical HPV16 infection. 
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Table 14.1.1.2.2. The univariate analysis of the association between age at 
starting smoking as measured at study entry and the risk of an incident 
cervical infection with HPV16.  
 
Age At Starting 
Smoking (at study 
entry) 
Number of 
Women (%) 
Number 
of Events
Hazards Ratio (95% CI) 
    
Continuous (per year)a 1075 (100) 110 1.02 (0.87 to 1.20) 
   χ2=0.06; 1df; p=0.80b 
    
Never-smoker 626 (58.2) 62 1.00 ( Reference ) 
≤13 100 (  9.3) 9 0.95 (0.47 to 1.91) 
14-15 182 (16.9) 22 1.21 (0.74 to 1.97) 
 ≥16 167 (15.5) 17 1.09 (0.64 to 1.87) 
   χ2=0.69; 1df; p=0.88b 
aIncludes a variable indicating “ever smoker” status at study entry; bLikelihood ratio test: chi-
squared statistic; degrees of freedom; p-value. 
 
 
14.1.1.2.3 The univariate analysis of the association between a history of ever 
having smoked and the risk of an incident cervical HPV16 infection  
 
The univariate analysis of the association between a history of ever having smoked 
and the risk of an incident cervical infection with HPV16 is shown in table 14.1.1.2.3. 
Women who had ever smoked had a small (40%=1.40-1.00) but non-significant 
increase in the risk of an incident cervical HPV16 infection compared to women who 
had never smoked. 
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Table 14.1.1.2.3. The univariate analysis of the association between a 
history of ever having smoked and the risk of an incident cervical 
infection with HPV16.  
 
Have you ever been 
a cigarette smoker? 
Number of 
Women (%) 
Number of 
Events 
Hazards Ratio (95% CI) 
    
No 539 (50.1) 48 1.00 (Reference) 
Yes 536 (49.9) 62 1.40 (0.96 to  2.05) 
      χ2=3.14; 1df; p=0.08a 
aLikelihood ratio test: chi-squared statistic; degrees of freedom; p-value. 
 
 
14.1.1.2.4 The univariate analysis of the association between the time since 
first starting smoking and the risk of an incident cervical HPV16 infection 
 
At the earliest of the date of the first detection of HPV16 in a cervical cytological 
sample, or the date of the end of follow-up, the median time since first starting 
smoking was 49.1 months (range 2.2 to 188.0) in women who had ever smoked. 
  
The univariate analysis of the association between the time since first starting 
smoking and the risk of an incident cervical infection with HPV DNA of any type is 
shown in table 14.1.1.2.4. There was a small but statistically significant decrease in 
the risk of an incident cervical HPV16 infection with increasing time since starting 
smoking, when this variable was analysed as a continuous variable, controlling for 
ever having smoked. The risk of an incident cervical HPV16 infection decreased by 
12% (1.00-0.88) for every increase of one year in the time since starting smoking. 
When the variable was analysed as a categorical covariate, with never-smokers as 
reference group, time since first starting smoking was not significantly associated 
with the risk of an incident cervical HPV16 infection. Note that this is a reversal in the 
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situation which occurred in the analysis of the incidence of a cervical infection with 
HPV DNA of any type. 
 
 
Table 14.1.1.2.4. The univariate analysis of the association between the time 
since first starting smoking and the risk of an incident cervical infection with 
HPV16.  
 
Time Since First 
Starting Smoking 
Number of 
Women (%) 
Number of 
Events 
Hazards Ratio (95% CI)
   
Continuous (per year)a 1075 (100) 407 0.88 (0.79 to 0.99) 
  χ2=4.45; 1df; p=0.03b 
   
Never-smoker 539 (50.1) 48 1.00 (Reference) 
( 0, 36 months)c 146 (13.6) 22 1.52 (0.91 to 2.54) 
[36, 72)c 237 (22.0) 30 1.57 (0.99 to 2.49) 
[72, +)c 153 (14.2) 10 0.92 (0.45 to 1.89) 
  χ2=5.33; 3df; p=0.15b 
   
Never-smoker 539 (50.1) 48 1.00 (Reference) 
( 0, 36 months)c 146 (13.6) 22 1.52 (0.91 to 2.54) 
[36, 72)c 237 (22.0) 30 1.58 (1.00 to 2.49) 
[72, 84)c 47 (  4.4) 5 1.22 (0.48 to 3.11) 
[84, +)c 106 (  9.9) 5 0.72 (0.27 to 1.92) 
    χ2=6.01; 4df; p=0.20b 
aModel includes a time-varying indicator variable indicating “ever smoker” status; bLikelihood ratio 
test: chi-squared statistic; degrees of freedom; p-value; c[a, b) is a mathematical convention denoting 
the interval ≥a to <b. 
 
 
14.1.1.2.5 The univariate analysis of the association between the cumulative 
duration of smoking and the risk of an incident cervical HPV16 infection  
 
At the earliest of the date of the first detection of HPV16 in a cervical sample, or the 
date of the end of follow-up, the median cumulative duration of smoking was 41.0 
months (range 2.2 to 178.7) among women who had ever smoked.  
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The univariate analysis of the association between the cumulative duration of 
smoking and the risk of an incident cervical infection with HPV16 is shown in table 
14.1.1.2.5. There was a significant decrease in the risk of an incident cervical HPV16 
infection with increasing cumulative duration of smoking when this variable was 
analysed as a continuous variable, controlling for ever having smoked. The risk of an 
incident cervical infection with HPV16 decreased by 12% (1.00-0.88) for every year 
of increase in the cumulative duration of smoking. When the variable was analysed 
as a categorical covariate, with never-smokers as reference group, cumulative 
duration of smoking was not significantly associated with the risk of an incident 
HPV16 overall; however, women who had smoked for a total of at most 36 months 
were at a significantly greater risk of acquiring an incident cervical HPV16 infection 
than women who had never smoked. A trend in risk with increasing smoking duration 
was apparent, although numbers of events were small in the last category in 
particular. 
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Table 14.1.1.2.5. The univariate analysis of the association between the 
cumulative duration of smoking and the risk of an incident cervical infection 
with HPV16.  
 
Cumulative Duration 
Of Smoking 
Number of 
Women (%) 
Number of 
Events 
Hazards Ratio (95% CI)
   
Continuous (per year) 1075 (100.0) 110 0.88 (0.78 to 0.99) 
  χ2=5.06; 1df; p=0.02b 
    
Never-smoker 539 (50.1) 48 1.00 (Reference) 
( 0, 36 months)c 227 (13.6) 34 1.76 (1.13 to 2.74) 
[36, 72)c 200 (22.0) 21 1.20 (0.72 to 2.01) 
[72, +)c 109 (  4.4) 7 0.92 (0.40 to 2.10) 
   χ2=6.43; 3df; p=0.09b 
aModel includes a time-varying indicator variable indicating “ever smoker” status; bLikelihood ratio 
test: chi-squared statistic; degrees of freedom; p-value; c[a, b) is a mathematical convention 
denoting the interval ≥a to <b. 
 
 
14.1.1.2.6 The univariate analysis of the association between the duration of 
the current smoking episode and the risk of an incident cervical HPV16 
infection  
 
At the earliest of the date of the first detection of HPV16 in a cervical sample, or the 
date of the end of follow-up, median duration of the current smoking episode was 
38.8 months (range 1.2 to 157.0) among women who were current smokers at this 
time. 
 
The univariate analysis of the association between the duration of the current 
smoking episode and the risk of an incident cervical infection with HPV16 is shown 
in table 14.1.1.2.6. There was a significant decrease in the risk of an incident 
cervical HPV16 infection with increasing duration of the current smoking episode, 
when this variable was analysed as a continuous variable controlling for current 
234 
 
smoking status. The risk of an incident cervical infection decreased by 13% (1.00-
0.87) for every increase of one year in time since the start of the current smoking 
episode. When this variable was analysed as a categorical covariate with either non-
smokers or never-smokers as reference group, it was also significant; however, a 
clear-cut trend with increasing duration was not apparent. 
 
 
Table 14.1.1.2.6. The univariate analysis of the association between the 
duration of the current smoking episode and the risk of an incident cervical 
infection with HPV16.  
 
Duration Of Current 
Smoking Episode 
Number of 
Women (%) 
Number 
of Events 
Hazards Ratio (95% 
CI) 
    
Continuous (per year)a 1075 (100) 110 0.87 (0.76 to 1.00b) 
   χ2=4.05; 1df; p=0.04c 
    
Non-smoker 677 (63.0) 66 1.00 (Reference) 
( 0, 24 months)d 123 (11.4) 22 1.81 (1.11 to 2.95) 
[24, 48)d 107 (10.0) 7 0.61 (0.28 to 1.33) 
[48, +)d 168 (15.6) 15 1.01 (0.57 to 1.77) 
   χ2=8.20; 3df; p=0.04c 
    
Never-smoker 539 (50.1) 48 1.00 (Reference) 
Ex-smoker 138 (12.8) 18 1.77 (1.03 to 3.05) 
( 0, 24 months)d 123 (11.4) 22 2.05 (1.23 to 3.41) 
[24, 48)d 107 (10.0) 7 0.69 (0.31 to 1.52) 
[48, +)d 168 (15.6) 15 1.15 (0.64 to 2.06) 
   χ2=12.07; 4df; p=0.02c 
aModel includes a time-varying indicator variable indicating “current smoking” status; bTo two 
decimal places, but <1; cLikelihood ratio test: chi-squared statistic; degrees of freedom; p-value; 
d[a, b) is a mathematical convention denoting the interval ≥a to <b. 
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14.1.1.2.7 The univariate analysis of the association between pack-years 
smoked and the risk of an incident cervical HPV16 infection  
 
This analysis was restricted to the 1,038 (out of 1,075) women for whom the quantity 
smoked was known throughout follow-up. 
 
At the earliest of the date of the first detection of HPV16 in a cervical sample, or the 
date of the end of follow-up, the median pack-years smoked was 1.2 pack-years 
(range 0.05 to 7.93) in women who had ever smoked prior to that time. 
 
The univariate analysis of the association between pack-years smoked and the risk 
of an incident cervical infection with HPV16 is shown in table 14.1.1.2.7. There was 
a statistically significant association between pack-years of smoking and the risk of 
an incident cervical HPV16 infection. When analysed as a continuous variable, 
controlling for ever having smoked, the hazards ratio decreased by 26% (1.00-0.74) 
for every increase of one pack year.  However, when analysed as a categorical 
variable, although statistically significant, the risk estimates showed no consistent 
pattern across categories: women who had smoked less than one pack-year, or 
between two and three pack-years, were at an increased risk of HPV16, but women 
in the remaining categories were at A decreased risk, based on the point estimates. 
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Table 14.1.1.2.7. The univariate analysis of the association between pack-years 
smoked and the risk of an incident cervical infection with HPV16.  
 
Pack-years smoked Number of 
Women (%) 
Number of 
Events 
Hazards Ratio (95% CI)
    
Continuous (per 
pack-year)a 1038 (100) 108 0.74 (0.57 to 0.96) 
   χ2=5.97; 1df; p=0.01b 
    
Never-smoker 539 (52.0) 48   1.00 (Reference) 
(0 , 1)c 210 (21.0) 36 1.96 (1.27 to 3.03) 
[1 , 2)c 149 (14.0) 11 0.90 (0.46 to 1.73) 
[2 , 3)c 78 (7.3) 11 1.82 (0.94 to 3.55) 
[3 , +)c 62 (5.8) 2 0.39 (0.09 to 1.62) 
   χ2=15.34; 4df; p=0.004b 
aModel includes a time-varying indicator variable indicating ‘ever smoker’ status; bLikelihood ratio 
test: chi-squared statistic; degrees of freedom; p-value; c[a, b) is a mathematical convention 
denoting the interval ≥a to <b. 
 
 
 
14.1.1.2.8 The univariate analysis of the association between current smoking 
status and the risk of an incident cervical HPV16 infection  
 
The univariate analysis of the association between current smoking status and the 
risk of an incident cervical infection with HPV16 is shown in table 14.1.1.2.8. The 
association was not statistically significant overall. However, when the variable was 
analysed as a three-category variable, current ex-smokers had a significantly 
increased risk of HPV16 compared to women who had never smoked; current 
smokers did not, although confidence intervals around the risk estimates overlapped. 
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Table 14.1.1.2.8. The univariate analysis of the association between current 
smoking status and the risk of an incident cervical infection with HPV16.  
 
Current Smoking Status Number of 
Women (%)
Number of 
Events 
Hazards Ratio (95% CI)
    
Never-smoker 539 (50.1) 48 1.00 (Reference) 
Ex-smoker 138 (12.8) 18 1.77 (1.03 to 3.06) 
Current smoker 398 (37.0) 44 1.29 (0.86 to 1.95) 
      χ2=4.34; 2df; p=0.11a 
    
Non-smoker 677 (63.0) 66 1.00 (Reference) 
Current smoker 398 (37.0) 44 1.14 (0.78 to 1.67) 
      χ2=0.45; 1df; p=0.50a 
    
Never-smoker 539 (50.1) 48 1.00 (Reference) 
Ever-smoker 536 (49.9) 62 1.77 (1.03 to 3.06) 
      χ2=3.14; 1df; p=0.08a 
aLikelihood ratio test: chi-squared statistic; degrees of freedom; p-value. 
 
 
14.1.1.2.9 The univariate analysis of the association between the current 
smoking intensity and the risk of an incident cervical HPV16 infection 
 
This analysis was restricted to the 1,038 (out of 1,075) women for whom the quantity 
smoked was known throughout follow-up. 
 
At the earliest of the date of the first detection of HPV16 in a cervical sample, or the 
date of the end of follow-up, most women who were current smokers were smoking 
between one and nine cigarettes per day, but the median quantity smoked was 
between 10 and 19 cigarettes per day. 
 
The univariate analysis of the association between current smoking intensity and the 
risk of an incident cervical infection with HPV16 is shown in table 14.1.1.2.9. The 
238 
 
association was not statistically significant whether the variable was measured on a 
categorical or on a continuous scale. 
 
Table 14.1.1.2.9. The univariate analysis of the association between the current 
smoking intensity and the risk of an incident cervical infection with HPV16. 
 
Current Smoking 
Intensity 
Number of 
Women (%) 
Number of 
Events 
Hazards Ratio (95% CI)
    
Continuous (per 
category)a,b 1038 (100) 108 0.86 (0.64 to 1.15) 
   χ2=1.11; 1df; p=0.29c 
    
Never-smoker 539 (50.1) 48 1.00 ( Reference ) 
0 per day 114 (11.0) 16 1.77 (1.03 to  3.06) 
1 to 9 per day 188 (18.1) 23 1.28 (0.77 to  2.10) 
10 or more per day 197 (19.0) 21 1.32 (0.79 to  2.20) 
      χ2=4.35; 3df; p=0.23c 
aModel includes a time-varying indicator variable indicating “current smoking” status; bthe increase in 
risk for every increase of one in category of current smoking intensity; cLikelihood ratio test: chi-
squared statistic; degrees of freedom; p-value. 
 
 
 
14.1.1.3 HPV18 infection 
 
In univariate analyses, there were no statistically significant associations between 
smoking exposure and the risk of an incident cervical HPV18 infection. Hazards 
ratios tended to be closer to the null value of one than those seen in the analysis of 
HPV16 infection presented above. 
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Summary 
 
Time since starting smoking, the cumulative duration of smoking, the duration of the 
current smoking episode, and pack-years of smoking, were all statistically significant 
predictors of the risk of an incident cervical HPV16 infection; hazards ratios were 
typically small. There were no significant associations between smoking exposure 
and the risk of an incident cervical HPV18 infection, and measures of association 
tended to be closer to the null value than in the analysis of HPV16. 
 
 
 
 
14.1.2 Multivariate analysis 
 
This subsection presents the results of multivariate analyses describing the 
association between each of the variables used to measure exposure to cigarette 
smoking and the risk of incident cervical HPV infections of any type, and incident 
HPV16 and HPV18 infections, after controlling for variables measuring some aspect 
of sexual behaviour. 
 
Various aspects of sexual behaviour are known risk factors for cervical HPV infection 
(see section 3.1.3). Since high-risk sexual behaviour is also associated with 
smoking, sexual behaviour may confound the association between smoking and the 
risk of incident cervical HPV infection. A univariate analysis was therefore 
undertaken to identify potential confounders amongst the sexual behaviour 
variables. Variables measuring some aspect of sexual behaviour which were 
included in the analysis were: calendar age at first sexual intercourse; lifetime 
number of sexual partners; whether a woman had acquired a new sexual partner in 
the previous six months; the age of the woman’s oldest sexual partner; and the age 
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of the woman’s oldest sexual partner in the previous six months. The age of the 
(only) sexual partner was considered more reliable as a predictor of the sexual 
experience of that partner than the variable recording sexual experience of partner 
itself, which was therefore not included in analyses (see chapter 11). 
 
I first describe the distribution of the available sexual behaviour variables. 
 
14.1.2.1 Description of the sexual behaviour variables 
 
14.1.2.1.1 Age at first sexual intercourse 
 
The frequency distribution of calendar age at first sexual intercourse is shown in 
table 14.1.2.1.1. Strictly speaking, this variable is time-varying, and the ages in this 
table are those which were measured at the earliest of the date of the first detection 
of a cervical HPV infection of any type in a cervical sample, or the date of the end of 
follow-up. But note that there were only 21 virgins at study entry in the entire cohort 
of 2,011 women recruited into the study described in this thesis. 
 
The median age at first sexual intercourse was 16 years (range 5 to 20). 
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Table 14.1.2.1.1. Frequency distribution of the age at first sexual 
intercourse. 
 
Age at first sexual intercourse 
(years)a 
Frequencyb (n=1075) % 
5 1 0.1% 
11 1 0.1% 
12 7 0.7% 
13 34 3.2% 
14 119 11.1% 
15 227 21.1% 
16 357 33.2% 
17 211 19.6% 
18 98 9.1% 
19 17 1.6% 
20 3 0.3% 
aMeasured at the date of the first detection of HPV DNA of any type in a cervical 
sample; bNumber of women. 
 
 
14.1.2.1.2 Number of changes of sexual partner 
 
The frequency distribution of the number of changes of sexual partner during follow-
up is shown in table 14.1.2.1.2. This variable is time-varying, and the values in this 
table are those which were measured at the earliest of the date of the first detection 
of cervical HPV infection of any type in a cervical sample, or the date of the end of 
follow-up.  
 
Most women did not change sexual partner, or did not acquire new sexual partners, 
during follow-up. Among women who did change sexual partner, the median number 
of changes was 2 (range 1 to 17). 
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Table 14.1.2.1.2. Frequency distribution of the number of 
changes of sexual partner during follow-up. 
 
Number of changes of 
sexual partner during 
follow-upa 
Frequencyb 
(n=1075) 
% 
0 574 53.4% 
1 243 22.6% 
2 125 11.6% 
3 67 6.2% 
4 23 2.1% 
5 13 1.2% 
6 12 1.1% 
7 5 0.5% 
8 4 0.4% 
9 1 0.1% 
10 3 0.3% 
15 1 0.1% 
16 2 0.2% 
17 2 0.2% 
aMeasured at the date of the first detection of HPV DNA of any type in a 
cervical sample; bNumber of women. 
 
 
 
14.1.2.1.3 Age of a woman’s oldest sexual partner 
 
The frequency distribution of the age of a woman’s oldest sexual partner is shown in 
table 14.1.2.1.3. This variable is time-varying, and the ages in this table are those 
which were measured at the earliest of the date of the first detection of HPV infection 
of any type in a cervical sample, or the date of the end of follow-up. 
  
The median age of a woman’s oldest sexual partner was 21 years (range 15 to 50). 
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Table 14.1.2.1.3. Frequency distribution of the age of a 
woman’s oldest sexual partner. 
 
Age of oldest sexual partner 
(years)a 
Frequencyb 
(n=1075) 
% 
15 6 0.6% 
16 22 2.0% 
17 46 4.3% 
18 99 9.2% 
19 133 12.4% 
20 132 12.3% 
21 103 9.6% 
22 104 9.7% 
23 93 8.7% 
24 72 6.7% 
25 60 5.6% 
26 46 4.3% 
27 36 3.3% 
28 32 3.0% 
29 20 1.9% 
30 22 2.0% 
31 12 1.1% 
32 8 0.7% 
33 4 0.4% 
34 5 0.5% 
35 4 0.4% 
36 1 0.1% 
37 3 0.3% 
38 1 0.1% 
39 1 0.1% 
40 2 0.2% 
42 4 0.4% 
43 1 0.1% 
44 1 0.1% 
45 1 0.1% 
50 1 0.1% 
aMeasured at the date of the first detection of HPV DNA of any type in a 
cervical sample; bNumber of women. 
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14.1.2.2 Identification of sexual behaviour variables which may act as 
confounders of the association between smoking and the risk of an incident 
cervical HPV infection of any type 
 
The results of the univariate analysis to identify potential confounders of the 
association between smoking and the risk of an incident cervical HPV infection of 
any type are shown in table 14.1.2.2. In this table, all models are compared to the 
model called “Quadratic”, the model containing quadratic midpoint-modelling of the 
hazard function only (see section 6.5.2: this is the appropriate “null” model in this 
case). Differences in deviance between two nested models were referred to a chi-
squared distribution with degrees of freedom equal to the difference in degrees of 
freedom between the two respective models. Estimates of association are not 
presented: it is the existence of an association which is relevant in this analysis. 
 
By inspection, it can be seen that all variables were significantly associated with the 
risk of an incident cervical HPV infection of any type, except for age at first sexual 
intercourse; this was true whether this variable was analysed as a categorical or as a 
continuous covariate. In multivariate analyses including smoking, only those sexual 
behaviour variables which remained statistically significant were retained in the final 
model. 
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Table 14.1.2.2. Model deviance and degrees of freedom obtained from models 
analysing the association between the sexual behaviour variables and the risk 
of an incident cervical HPV infection of any type. 
 
Modela Deviance Degrees 
of 
freedom 
Significant
    
Null 2534.208 3240 - 
Quadratic 2517.961 3238 - 
    
Lifetime number of sexual partners (C)     2464.043 3233 Yes 
Lifetime number of sexual partners (V) 2484.147 3237 Yes 
    
Age at first sexual intercourse (C) 2514.9 3234 No 
Age at first sexual intercourse (V) 2516.568 3237 No 
    
Age of oldest sexual partner (C) 2475.495 3233 Yes 
Age of oldest sexual partner (V) 2489.347 3237 Yes 
    
New sexual partner in the previous 6 months (C) 2499.664 3237 Yes 
    
Age of oldest partner in previous 6 months (C) 2495.879 3233 Yes 
Age of oldest partner in previous 6 months (V) 2499.672 3237 Yes 
    
aC=Variable analysed as categorical covariate, V=Variable analysed as continuous covariate. 
 
 
14.1.2.3 HPV infection of any type 
 
For each of the variables used to measure exposure to smoking, only lifetime 
number of sexual partners and age of the oldest sexual partner were statistically 
significant in multivariate models examining the association between smoking and 
the risk of an incident cervical HPV infection of any type. Therefore, in this section 
the phrase “controlling for sexual behaviour” is used as shorthand to indicate that 
associations are controlled for these two sexual behaviour variables only. 
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14.1.2.3.1 The multivariate analysis of the association between smoking status 
at study entry and the risk of an incident cervical HPV infection of any type, 
after controlling for sexual behaviour 
 
The association between smoking status at study entry and the risk of an incident 
cervical HPV infection of any type was not statistically significant, after controlling for 
sexual behaviour, using any of the definitions of this exposure variable (table 
14.1.2.3.1). The slightly elevated risks seen in the uncontrolled analysis are 
essentially reduced to null in the controlled analysis. 
  
Table 14.1.2.3.1. The multivariate analysis of the association between smoking 
status at study entry and the risk of an incident cervical infection with HPV 
DNA of any type, after controlling for sexual behaviour.  
 
Smoking Status At 
Study Entry 
Number of 
Women (%)
Number of 
Events 
Hazards Ratioa (95% CI) 
    
Never-smoker 626 (58.2) 228 1.00 (Reference) 
Ex-smoker   93 (  8.7)   38 1.07 (0.75 to 1.52) 
Current smoker 356 (33.1) 141 1.01 (0.81 to 1.26) 
      χ2=0.15; 2df; p=0.96b 
    
Non-smoker 719 (65.0) 266 1.00 (Reference) 
Current smoker 356 (35.0) 141 1.00 (0.81 to 1.24) 
      χ2=0.00; 1df; p=0.99b 
    
Non-smoker 626 (58.2) 228 1.00 (Reference) 
Ever smoker 449 (41.8) 179 1.02 (0.83 to 1.26) 
      χ2=0.05; 1df; p=0.83b 
aControlling for lifetime number of sexual partners and age of oldest sexual partner; bLikelihood 
ratio test: chi-squared statistic; degrees of freedom; p-value. 
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14.1.2.3.2 The multivariate analysis of the association between the age at 
starting smoking (as recorded at study entry) and the risk of an incident 
cervical HPV infection of any type, after controlling for sexual behaviour  
 
The multivariate analysis of the association between age at starting smoking (as 
recorded at study entry) and the risk of an incident cervical HPV infection of any 
type, after controlling for sexual behaviour, is described in table 14.1.2.3.2. The 
association was not statistically significant. Compared to the uncontrolled analysis, in 
the analysis treating age at starting smoking as a continuous variable, the hazards 
ratio and p-value decreased slightly; the hazards ratio in the 16-or-over age category 
(≥16) also decreased. 
 
Table 14.1.2.3.2. The multivariate analysis of the association between the age 
at starting smoking (as recorded at study entry) and the risk of an incident 
cervical infection with HPV DNA of any type, after controlling for sexual 
behaviour.  
 
Age At Starting 
Smoking (at study 
entry) 
Number of 
Women (%) 
Number 
of Events
Hazards Ratioa (95% CI)
    
Continuous (per year)b 1075 (100) 407 0.93 (0.86 to 1.02) 
   χ2=2.47; 1df; p=0.12c 
    
Never-smoker 626 (58.2) 228 1.00 ( Reference ) 
≤13 100 (  9.3) 41 1.13 (0.80 to 1.60) 
14-15 182 (16.9) 83 1.15 (0.88 to 1.50) 
 ≥16 167 (15.5) 55 0.83 (0.62 to 1.13) 
   χ2=3.87; 3df; p=0.28c 
aControlling for lifetime number of sexual partners and age of oldest sexual partner; bIncludes a 
variable indicating “ever smoker” status at study entry; cLikelihood ratio test: chi-squared statistic; 
degrees of freedom; p-value. 
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14.1.2.3.3 The multivariate analysis of the association between a history of 
ever having smoked and the risk of an incident cervical HPV infection of any 
type, after controlling for sexual behaviour 
 
The multivariate analysis of the association between a history of ever having smoked 
and the risk of an incident cervical HPV infection of any type, after controlling for 
sexual behaviour, is described in table 14.1.2.3.3. The association was not 
statistically significant. The small (39%), but statistically significant, increased risk in 
women who had ever smoked compared to those who had never smoked seen in 
the univariate analysis, was reduced to a 15% (1.15-1.00) non-significant increase 
after controlling for sexual behaviour. 
 
Table 14.1.2.3.3. The multivariate analysis of the association between a history 
of ever having smoked and the risk of an incident cervical infection with HPV 
DNA of any type, after controlling for sexual behaviour. 
 
Have you ever 
been a cigarette 
smoker? 
Number of 
Women (%) 
Number of 
Events 
Hazards Ratioa (95% CI) 
No 550 (51.2) 192 1.00 (Reference) 
Yes 525 (48.8) 215 1.15 (0.93-1.41) 
      χ2=1.73; 1df; p=0.19b 
aControlling for lifetime number of sexual partners and age of oldest sexual partner; bLikelihood 
ratio test: chi-squared statistic; degrees of freedom; p-value. 
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14.1.2.3.4 The multivariate analysis of the association between the time since 
first starting smoking and the risk of an incident cervical HPV infection of any 
type, after controlling for sexual behaviour 
  
The multivariate analysis of the association between the time since first starting 
smoking and the risk of an incident cervical infection with HPV DNA of any type, 
after controlling for sexual behaviour, is described in table 14.1.2.3.4. The 
association was not statistically significant whether the variable was analysed as a 
continuous, or as a categorical, covariate. Compared with the univariate analysis, all 
hazards ratios were attenuated after controlling for sexual behaviour. 
 
Table 14.1.2.3.4. The multivariate analysis of the association between the time 
since first starting smoking and the risk of an incident cervical infection with 
HPV DNA of any type, after controlling for sexual behaviour. 
 
Time Since First 
Starting Smoking 
Number of 
Women (%) 
Number of 
Events 
Hazards Ratioa (95% CI) 
   
Continuous (per year)b 1075 (100) 407 0.95 (0.89 to 1.01) 
  χ2=2.55; 1df; p=0.11c 
   
Never-smoker 550 (51.2) 192 1.00 (Reference) 
( 0, 36 months)d 181 (16.8) 85 1.27 (0.97 to 1.65) 
[36, 72)d 242 (22.5) 91 1.06 (0.81 to 1.37) 
[72, +)d 102 (  9.5) 39 1.13 (0.78 to 1.65) 
  χ2=3.10; 3df; p=0.38c 
   
Never-smoker 550 (51.2) 192 1.00 (Reference) 
( 0, 36 months)d 181 (16.8) 85 1.27 (0.97 to 1.66) 
[36, 72)d 242 (22.5) 91 1.06 (0.81 to 1.37) 
[72, 84)d 40 (  3.7) 18 1.18 (0.71 to 1.95) 
[84, +)d 62 (  5.8) 21 1.10 (0.68 to 1.79) 
    χ2=3.14; 4df; p=0.53c 
aControlling for lifetime number of sexual partners and age of oldest sexual partner; bModel includes 
a time-varying indicator variable indicating “ever smoker” status; cLikelihood ratio test: chi-squared 
statistic; degrees of freedom; p-value; d[a, b) is a mathematical convention denoting the interval ≥a to 
<b. 
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14.1.2.3.5 The multivariate analysis of the association between the cumulative 
duration of smoking and the risk of an incident cervical HPV infection of any 
type, after controlling for sexual behaviour 
 
The multivariate analysis of the association between the cumulative duration of 
smoking and the risk of an incident cervical HPV infection of any type, after 
controlling for sexual behaviour, is shown in table 14.1.2.3.5. There was a small, but 
statistically significant, decrease in the risk of an incident cervical HPV infection of 
any type with increasing cumulative duration of smoking when this variable was 
analysed as a continuous variable. The association was not significant when this 
variable was analysed as a categorical covariate, and no clear-cut trend was 
apparent. In the univariate analysis, the reverse was true i.e. the categorical variable 
was a significant predictor of risk, but the continuous variable was not. 
 
Table 14.1.2.3.5. The multivariate analysis of the association between the 
cumulative duration of smoking and the risk of an incident cervical infection 
with HPV DNA of any type, after controlling for sexual behaviour.  
 
Cumulative Duration 
Of Smoking 
Number of 
Women (%) 
Number 
of Events 
Hazards Ratioa (95% CI)
    
Continuous (per year)b 1075 (100.0) 407 0.93 (0.87 to 1.00) 
   χ2=4.43; 1df; p=0.04c 
    
Never-smoker 550 (51.2) 192 1.00 (Reference) 
( 0, 36 months)d 251 (23.3) 113 1.31 (1.03 to 1.67) 
[36, 72)d 205 (19.1) 75 0.95 (0.72 to 1.27) 
[72, +)d 69 (   6.4) 27 1.14 (0.74 to 1.76) 
   χ2=6.06; 3df; p=0.11c 
aControlling for lifetime number of sexual partners and age of oldest sexual partner; bModel 
includes a time-varying indicator variable indicating “ever smoker” status; cLikelihood ratio test: chi-
squared statistic; degrees of freedom; p-value; d[a, b) is a mathematical convention denoting the 
interval ≥a to <b. 
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14.1.2.3.6 The multivariate analysis of the association between the duration of 
the current smoking episode and the risk of an incident cervical HPV infection 
of any type, after controlling for sexual behaviour 
 
The multivariate analysis of the association between the duration of the current 
smoking episode and the risk of an incident cervical infection with HPV DNA of any 
type, after controlling for sexual behaviour, is described in table 14.1.2.3.6. The 
association was not statistically significant, whether this exposure variable was 
analysed as either a categorical or as a continuous variable. In the univariate 
analysis, this variable was not significant when analysed as a continuous variable, or 
as a categorical variable with non-smokers as reference group, but was significant 
when ex-smokers were separately distinguished from never-smokers. The p-values 
for both categorical variables decreased after controlling for sexual behaviour, 
whereas that of the continuous variable increased. 
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Table 14.1.2.3.6. The multivariate analysis of the association between the 
duration of the current smoking episode and the risk of an incident cervical 
infection with HPV DNA of any type, after controlling for sexual behaviour. 
 
Duration Of Current 
Smoking Episode 
Number of 
Women (%) 
Number 
of Events 
Hazards Ratioa (95% CI) 
    
Continuous (per year)b 1075 (100) 407 0.95 (0.88 to 1.02) 
   χ2=2.10; 1df; p=0.15c 
    
Non-smoker 679 (63.2) 243 1.00 ( Reference ) 
( 0, 24 months)d 132 (12.3) 60 1.23 (0.92 to 1.65) 
[24, 48)d 120 (11.2) 52 1.06 (0.77 to 1.44) 
[48, +)d 144 (13.4) 52 0.96 (0.70 to 1.31) 
   χ2=2.19; 3df; p=0.53c 
    
Never-smoker 550 (51.2) 192 1.00 ( Reference ) 
Ex-smoker 129 (12.0) 51 1.22 (0.88 to 1.67) 
( 0, 24 months)d 132 (12.3) 60 1.28 (0.95 to 1.73) 
[24, 48)d 120 (11.2) 52 1.10 (0.80 to 1.52) 
[48, +)d 144 (13.4) 52 1.00 (0.72 to 1.39) 
   χ2=3.61; 4df; p=0.46c 
aControlling for lifetime number of sexual partners and age of oldest sexual partner; bModel 
includes a time-varying indicator variable indicating “current smoker” status; cLikelihood ratio test: 
chi-squared statistic; degrees of freedom; p-value; d[a, b) is a mathematical convention denoting 
the interval ≥a to <b. 
 
 
14.1.2.3.7 The multivariate analysis of the association between pack-years 
smoked and the risk of an incident cervical HPV infection of any type, after 
controlling for sexual behaviour 
 
This analysis was restricted to the 1,038 (out of 1,075) women for whom quantity 
smoked was known throughout follow-up. 
 
The multivariate analysis of the association between pack-years smoked and the risk 
of an incident cervical infection with HPV DNA of any type, after controlling for 
sexual behaviour, is described in table 14.1.2.3.7. When analysed as a continuous 
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variable, and after controlling for sexual behaviour, there was a statistically 
significant association, with a decrease in the risk of an incident cervical HPV 
infection of any type of 13% (1.00-0.87) for every increase of one in pack-years 
smoked; in the univariate analysis, the 8% decrease observed was not significant.  
 
In contrast, in the univariate analysis the association was highly significant when the 
variable was analysed as a categorical variable, but in the multivariate analysis the 
association was no longer significant. However, there was no evidence of a 
departure from linearity for the pack-years variable in this analysis. Therefore, once 
lifetime number of sexual partner and age of oldest sexual partner had been 
controlled for, there was a significant decrease in the risk of an incident cervical HPV 
infection of any type as pack-years smoked increased. 
 
Table 14.1.2.3.7. The multivariate analysis of the association between pack-
years smoked and the risk of an incident cervical infection with HPV DNA of 
any type, after controlling for sexual behaviour.  
 
Pack-years Smoked Number of 
Women (%) 
Number 
of Events
Hazards Ratio (95% CI)a 
    
Continuous (per pack-
year)b 1038 (100) 394 0.87 (0.76 to 1.00) 
   χ2=4.36; 1df; p=0.04c 
    
Never-smoker 550 (51.2) 192 1.00 (Reference) 
(0 , 1)d 232 (22.4) 110 1.36 (1.06 to 1.74) 
[1 , 2)d 143 (13.8) 50 0.99 (0.71 to 1.37) 
[2 , 3)d 73 (7.0) 30 1.15 (0.77 to 1.71) 
[3 , +)d 40 (3.9) 12 0.73 (0.39 to 1.37) 
   χ2=8.50; 4df; p=0.07c 
aControlling for lifetime number of sexual partners and age of oldest sexual partner; bModel 
includes a time-varying indicator variable indicating “current smoker” status; cLikelihood ratio test: 
chi-squared statistic; degrees of freedom; p-value; d[a, b) is a mathematical convention denoting 
the interval ≥a to <b. 
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14.1.2.3.8 The multivariate analysis of the association between current 
smoking status and the risk of an incident cervical HPV infection of any type, 
after controlling for sexual behaviour 
 
The multivariate analysis of the association between current smoking status and the 
risk of an incident cervical infection with HPV DNA of any type, after controlling for 
sexual behaviour, is shown in table 14.1.2.3.8. After controlling for sexual behaviour, 
the association between current smoking status and the risk of an incident cervical 
HPV infection of any type was not statistically significant; this is in contrast to the 
univariate analysis, where all three of the variables used to measure current smoking 
status were significant. 
 
Table 14.1.2.3.8. The multivariate analysis of the association between current 
smoking status and the risk of an incident cervical infection with HPV DNA of 
any type, after controlling for sexual behaviour.  
 
Current Smoking Status Number of 
Women (%)
Number of 
Events 
Hazards Ratioa (95% CI) 
    
Never-smoker 550 (51.2) 192 1.00 (Reference) 
Ex-smoker 129 (12.0) 51 1.22 (0.89 to 1.68) 
Current smoker 396 (36.8) 164 1.13 (0.90 to 1.41) 
      χ2=1.97; 2df; p=0.37b 
    
Non-smoker 679 (63.2) 243 1.00 (Reference) 
Current smoker 396 (36.8) 164 1.08 (0.87 to 1.33) 
      χ2=0.51; 1df; p=0.48b 
    
Never-smoker 550 (51.2) 192 1.00 (Reference) 
Ever-smoker 525 (48.8) 215 1.15 (0.93-1.41) 
      χ2=1.73; 1df; p=0.19b 
aControlling for lifetime number of sexual partners and age of oldest sexual partner; bLikelihood ratio 
test: chi-squared statistic; degrees of freedom; p-value. 
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14.1.2.3.9 The multivariate analysis of the association between current 
smoking intensity and the risk of an incident cervical HPV infection of any 
type, after controlling for sexual behaviour 
 
This analysis was restricted to the 1,038 (out of 1,075) women for whom quantity 
smoked was known throughout follow-up. 
 
The multivariate analysis of the association between current smoking intensity and 
the risk of an incident cervical infection with HPV DNA of any type, after controlling 
for sexual behaviour, is described in table 14.1.2.3.9. The association was not 
statistically significant: the significant association between the categorical variable 
and the risk of an incident cervical HPV infection of any type seen in the univariate 
analysis was “explained” by controlling for lifetime number of sexual partners and 
age of oldest sexual partner (sexual behaviour). 
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Table 14.1.2.3.9. The multivariate analysis of the association between current 
smoking intensity and the risk of an incident cervical infection with HPV DNA 
of any type, after controlling for sexual behaviour. 
 
Current Smoking 
Intensity 
Number of 
Women (%) 
Number of 
Events 
Hazards Ratioa 
(95% CI) 
    
Continuous (per 
category)b,c 1038 (100) 394 0.92 (0.78 to 1.08) 
   χ2=1.04; 1df; p=0.34d 
    
Never-smoker 550 (53.0) 192 1.00 ( Reference ) 
0 per day 104 (10.0) 40 1.22 (0.89 to 1.68) 
1 to 9 per day 196 (18.9) 92 1.25 (0.97 to 1.62) 
10 or more per day 188 (18.1) 70 0.99 (0.74 to 1.32) 
      χ2=4.16; 3df; p=0.24d 
aControlling for lifetime number of, and age of oldest, sexual partner; bModel includes a time-varying 
indicator variable indicating “current smoker” status; cthe increase in risk for every increase of one in 
category of smoking intensity; dLikelihood ratio test: chi-squared statistic; degrees of freedom; p-
value. 
 
 
14.1.2.4 HPV16 infection 
 
Only lifetime number of sexual partners was found to be associated with the 
incidence of cervical HPV16 infection in a univariate analysis. In analyses of the 
association between exposure to smoking and the risk of an incident cervical HPV16 
infection, after controlling for sexual behaviour, the duration of the current smoking 
episode and pack-years smoked were both found to be statistically significant 
predictors of risk. However, the associated estimates of effect (hazards ratios) were 
small in magnitude. 
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14.1.2.5 HPV18 infection 
 
There were no significant associations between sexual behaviour and the incidence 
of HPV18 infection in univariate analyses. Therefore analyses controlling for sexual 
behaviour were not necessary in this case. 
 
 
 
 
Summary 
 
In analyses of the association between exposure to smoking and the risk of an 
incident cervical HPV infection of any type, after controlling for sexual behaviour, the 
cumulative duration of smoking and pack-years smoked were found to be significant 
predictors of risk. Only lifetime number of sexual partners was found to be 
associated with the incidence of HPV16 infection in a univariate analysis, but after 
controlling for sexual behaviour, duration of current smoking episode and pack-years 
were both found to be significant predictors of risk: estimates of effect were all small 
in magnitude. There were no significant associations between sexual behaviour and 
the incidence of cervical HPV18 infection in univariate analyses, therefore analyses 
controlling for sexual behaviour were not performed. 
 
 
 
 
14.2 THE DURATION OF INCIDENT CERVICAL HPV INFECTION IN RELATION 
TO SMOKING HISTORY 
 
14.2.1 Univariate analysis 
 
In the analysis of the duration of incident cervical HPV infection, of any type or of 
types 16 and 18, the event of interest is clearing an HPV infection. Therefore, since 
a hazards ratio (HR) greater than one means the event of interest (clearance) is 
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more likely to occur, exposures with HR>1 are associated with infections of shorter 
duration, i.e. the event is more likely to occur, so the infection is more likely to be 
cleared, so the infection is more likely to be of short duration. In contrast, a HR<1 
indicates that the exposure is protective, and therefore the event of interest is less 
likely to occur, i.e. the relevant exposure is associated with infections of longer 
duration. 
 
14.2.1.1 HPV infection of any type 
 
The study population for this analysis comprises 328 women who had an incident 
cervical HPV infection of any type, and who had further follow-up after the first 
detection of HPV DNA, i.e. women had to have an incident infection to be able to 
clear that infection. 
 
14.2.1.1.1 The univariate analysis of the association between a history of ever 
having smoked and the duration of an incident cervical HPV infection of any 
type 
 
The univariate analysis of the association between a history of ever having smoked 
and the risk of clearing an incident cervical HPV infection of any type is described in 
table 14.2.1.1.1. The association was not statistically significant, with a hazards ratio 
very close to the null value of 1. 
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Table 14.2.1.1.1. The univariate analysis of the association between a 
history of ever having smoked and the risk of clearing an incident cervical 
infection with HPV DNA of any type.  
 
Have you ever been 
a cigarette smoker? 
Number of 
Women (%) 
Number of 
Events 
Hazards Ratio (95% CI) 
    
No 149 (45.4) 120 1.00 ( Reference ) 
Yes 179 (54.6) 149 1.05 (0.82 to 1.35) 
      χ2=0.17; 1df; p=0.68a 
aLikelihood ratio test: chi-squared statistic; degrees of freedom; p-value. 
 
 
14.2.1.1.2 The univariate analysis of the association between the time since 
first starting smoking and the duration of an incident cervical HPV infection of 
any type 
 
The univariate analysis of the association between the time since first starting 
smoking and the risk of clearing an incident cervical HPV infection of any type is 
described in table 14.2.1.1.2. The association was not statistically significant.  
 
Table 14.2.1.1.2. The univariate analysis of the association between the time 
since first starting smoking and the risk of clearing an incident cervical 
infection with HPV DNA of any type.  
 
Time Since First 
Starting Smoking 
Number of 
Women (%) 
Number of 
Events 
Hazards Ratio (95% CI)
   
Continuous (per year)a 328 (100.0) 269 0.97 (0.90 to 1.04) 
  χ2=1.05; 1df; p=0.31b 
   
Never-smoker 149 (45.4) 120 1.00 ( Reference ) 
( 0, 36 months)c 50 (15.2) 41 1.21 (0.84 to 1.76) 
[36, 72)c 75 (22.9) 63 0.96 (0.70 to 1.32) 
[72, +)c 54 (16.5) 45 1.06 (0.73 to 1.54) 
  χ2=1.42; 3df; p=0.70b 
aModel includes a time-varying indicator variable indicating “ever smoker” status; bLikelihood ratio 
test: chi-squared statistic; degrees of freedom; p-value; c[a, b) is a mathematical convention denoting 
the interval ≥a to <b. 
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14.2.1.1.3 The univariate analysis of the association between the cumulative 
duration of smoking and the duration of an incident cervical HPV infection of 
any type  
 
The univariate analysis of the association between the cumulative duration of 
smoking and the risk of clearing an incident cervical HPV infection of any type is 
described in table 14.2.1.1.3. There was a slight non-significant decrease in the risk 
of clearing an incident cervical HPV infection of any type with increasing cumulative 
duration of smoking, when this variable was analysed as a continuous variable, 
controlling for ever having smoked. When the variable was analysed as a categorical 
variable, the model failed to converge. Alternative categorisations of the variable 
also led to failure in convergence of the model. 
 
Table 14.2.1.1.3. The univariate analysis of the association between the 
cumulative duration of smoking and the risk of clearing an incident cervical 
infection with HPV DNA of any type.  
 
Cumulative Duration 
Of Smoking 
Number of 
Women (%) 
Number of 
Events 
Hazards Ratio (95% CI)
   
Continuousa (per year) 328 (100.0) 269 0.96 (0.90 to 1.02) 
  χ2=1.64; 1df; p=0.20b 
aModel includes a time-varying indicator variable indicating ‘ever smoker’ status; bLikelihood ratio 
test: chi-squared statistic; degrees of freedom; p-value. 
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14.2.1.1.4 The univariate analysis of the association between the duration of 
the current smoking episode and the duration of an incident cervical HPV 
infection of any type 
 
The univariate analysis of the association between the duration of the current 
smoking episode and the risk of clearing an incident cervical HPV infection of any 
type is described in table 14.2.1.1.4. The association was not statistically significant, 
and all hazards ratios were close to the null value of one, whether the exposure 
variable was measured on a continuous, or on a categorical, scale. 
 
Table 14.2.1.1.4. The univariate analysis of the association between the 
duration of the current smoking episode and the risk of clearing an incident 
cervical infection with HPV DNA of any type.  
 
Duration Of Current 
Smoking Episode 
Number of 
Women (%)
Number 
of Events
Hazards Ratio (95% CI)
    
Duration of current 
smoking episode (per 
year)a 
328 (100.0) 269 0.97 (0.90 to 1.05) 
   χ2=0.60; 1df; p=0.44b 
    
Non-smoker 192 (58.5) 158 1.00 ( Reference ) 
( 0, 24 months)c 41 (12.5) 36 1.14 (0.78 to 1.67) 
[24, 48)c 36 (11.0) 28 1.09 (0.72 to 1.66) 
[48, +)c 59 (18.0) 47 0.85 (0.61 to 1.21) 
   χ2=1.83; 3df; p=0.61b 
    
Never-smoker 149 (51.2) 120 1.00 ( Reference ) 
Ex-smoker 43 (12.0) 38 1.14 (0.78 to 1.66) 
( 0, 24 months)c 41 (12.5) 36 1.18 (0.80 to 1.74) 
[24, 48)c 36 (11.0) 28 1.12 (0.73 to 1.73) 
[48, +)c 59 (18.0) 47 0.89 (0.62 to 1.26) 
   χ2=2.29; 4df; p=0.68b 
aModel includes a time-varying indicator variable indicating “current smoking” status; bLikelihood 
ratio test: chi-squared statistic; degrees of freedom; p-value; c[a, b) is a mathematical convention 
denoting the interval ≥a to <b. 
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14.2.1.1.5 The univariate analysis of the association between pack-years 
smoked and the duration of  an incident cervical HPV infection of any type 
 
This analysis was restricted to the 319 women for whom the quantity smoked was 
known throughout follow-up. 
 
The univariate analysis of the association between pack-years smoked and the risk 
of clearing an incident cervical HPV infection of any type is described in table 
14.2.1.1.5. When analysed as a continuous variable, the hazards ratio decreased by 
7% (1.00-0.93) for every increase of one pack year, but the association was not 
statistically significant. When analysed as a categorical variable, the risk estimates 
showed no consistent pattern across categories, but a greater number of pack-years 
smoked was again associated with infections of longer duration. 
 
Table 14.2.1.1.5. The univariate analysis of the association between pack-
years smoked and the risk of clearing an incident cervical infection with HPV 
DNA of any type.  
 
Pack-years 
Smoked 
Number of 
Women (%) 
Number of 
Events 
Hazards Ratio (95% CI)
    
Cumulative quantity 
smoked (per pack-
year) 
319 (100.0) 262 0.93 (0.81 to 1.07) 
   χ2=1.00; 1df; p=0.32a 
    
Never-smoker 149 (46.7) 120 1.00 (Reference) 
(0 , 1)b 75 (23.5) 65 1.25 (0.91 to 1.71) 
[1 , 2)b 45 (14.1) 35 0.92 (0.62 to 1.36) 
[2 , 3)b 25 (  7.8) 22 0.95 (0.59 to 1.54) 
[3 , +)b 25 (  7.8) 20 0.88 (0.53 to 1.47) 
   χ2=3.24; 4df; p=0.52a 
aLikelihood ratio test: chi-squared statistic; degrees of freedom; p-value; b[a, b) is a mathematical 
convention denoting the interval ≥a to <b. 
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14.2.1.1.6 The univariate analysis of the association between current smoking 
status and the duration of an incident cervical HPV infection of any type  
 
The univariate analysis of the association between current smoking status and the 
risk of clearing an incident cervical HPV infection of any type is described in table 
14.2.1.1.6. Current smoking status was not significantly associated with the risk of 
clearing an incident cervical HPV infection of any type in any of these three 
analyses; current ex-smokers were more likely than current smokers to clear their 
infection, but the difference was negligible. 
 
Table 14.2.1.1.6. The univariate analysis of the association between current 
smoking status and the risk of clearing an incident cervical infection with 
HPV DNA of any type.  
 
Current Smoking Status Number of 
Women (%)
Number of 
Events 
Hazards Ratio (95% CI)
    
Never-smoker 149 (45.4) 120 1.00 ( Reference ) 
Ex-smoker    43 (13.1) 38 1.14 (0.78 to 1.66) 
Current smoker 136 (41.5) 111 1.03 (0.78 to 1.34) 
      χ2=0.46; 2df; p=0.79a 
    
Non-smoker 192 (58.5) 158 1.00 ( Reference ) 
Current smoker 136 (41.5) 111 1.00 (0.77 to 1.28) 
      χ2=0.0009; 1df; p=0.98a 
    
Never-smoker 149 (45.4) 120 1.00 ( Reference ) 
Ever-smoker 179 (54.6) 149 1.05 (0.82 to 1.35) 
      χ2=0.17; 1df; p=0.68a 
aLikelihood ratio test: chi-squared statistic; degrees of freedom; p-value. 
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14.2.1.1.7 The univariate analysis of the association between current smoking 
intensity and the duration of an incident cervical HPV infection of any type 
 
This analysis was restricted to the 319 (out of 328) women for whom the quantity 
smoked was known throughout follow-up. The model did not converge for this 
analysis; however, the frequency distribution of this variable and the number of 
clearance events in each category are shown in table 14.2.1.1.7. 
 
 
Table 14.2.1.1.7. The univariate analysis of the association between current 
smoking intensity and the risk of clearing an incident cervical infection with 
HPV DNA of any type. 
 
Current Smoking Intensity Number of Women (%) Number of Events 
   
Continuous (per category) 319 (100.0) 262 
   
Never-smoker 149 (46.7) 120 
0 per day 36 (11.3) 33 
1 to 9 per day 77 (24.1) 63 
10 or more per day 57 (17.9) 46 
   
 
 
14.2.1.2 HPV16 infection 
 
The study population for this analysis comprises 90 women who had an incident 
cervical HPV16 infection, and who had further follow-up after the first detection of 
HPV16 DNA. 
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14.2.1.2.1 The univariate analysis of the association between a history of ever 
having smoked and the duration of an incident cervical HPV16 infection 
 
The univariate analysis of the association between a history of ever having smoked 
and the risk of clearing an incident cervical HPV16 infection is described in table 
14.2.1.2.1. The association was not statistically significant: the risk of clearing an 
incident cervical HPV16 infection increased by 41% (1.41-1.00) for ever- relative to 
never-smokers, compared to only 5% for HPV infections of any type. 
 
 
Table 14.2.1.2.1. The univariate analysis of the association between a 
history of ever having smoked and the risk of clearing an incident cervical 
HPV16 infection.  
 
Have you ever been a 
cigarette smoker? 
Number of 
Women (%)
Number of 
Events 
Hazards Ratio (95% CI) 
    
No 38 (42.2) 31 1.00 ( Reference ) 
Yes 52 (57.8) 45 1.41 (0.87 to 2.28) 
      χ2=2.07; 1df; p=0.15a 
aLikelihood ratio test: chi-squared statistic; degrees of freedom; p-value. 
 
 
14.2.1.2.2 The univariate analysis of the association between the time since 
first starting smoking and the duration of an incident cervical HPV16 infection  
 
The univariate analysis of the association between the time since first starting 
smoking and the risk of clearing an incident cervical HPV16 infection is described in 
table 14.2.1.2.2. The association was not statistically significant.  
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Table 14.2.1.2.2. The univariate analysis of the association between the time 
since first starting smoking and the risk of clearing an incident cervical HPV16 
infection. 
  
Time Since First 
Starting Smoking 
Number of 
Women (%)
Number of 
Events 
Hazards Ratio (95% CI)
   
Continuous (per year)a 90 (100.0) 76 0.99 (0.87 to 1.13) 
  χ2=0.01; 1df; p=0.91b 
   
Never-smoker 38 (42.2) 31 1.00 ( Reference ) 
( 0, 36 months)c 17 (18.9) 15 1.33 (0.70 to 2.52) 
[36, 72)c 24 (26.7) 21 1.51 (0.83 to 2.74) 
[72, +)c 11 (12.2) 9 1.35 (0.61 to 3.00) 
  χ2=2.23; 3df; p=0.53b 
aModel includes a time-varying indicator variable indicating “ever smoker” status; bLikelihood ratio 
test: chi-squared statistic; degrees of freedom; p-value; c[a, b) is a mathematical convention 
denoting the interval ≥a to <b. 
 
 
14.2.1.2.3 The univariate analysis of the association between the cumulative 
duration of smoking and the duration of an incident cervical HPV16 infection.  
 
The univariate analysis of the association between the cumulative duration of 
smoking and the risk of clearing an incident cervical HPV16 infection is described in 
table 14.2.1.2.3. The association was not statistically significant, and all hazards 
ratios were small with wide confidence intervals. 
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Table 14.2.1.2.3. The univariate analysis of the association between the 
cumulative duration of smoking and the risk of clearing an incident cervical 
HPV16 infection.  
 
Cumulative Duration 
Of Smoking 
Number of 
Women (%) 
Number of 
Events 
Hazards Ratio (95% CI)
   
Continuous (per year) 90 (100.0) 76 1.01 (0.89 to 1.15) 
  χ2=0.03; 1df; p=0.86b 
    
Never-smoker 38 (42.2) 31 1.00 (Reference) 
( 0, 36 months)c 28 (13.6) 26 1.30 (0.75 to 2.24) 
[36, 72)c 18 (22.0) 13 1.83 (0.90 to 3.74) 
[72, +)c 6 (  4.4) 6 1.28 (0.50 to 3.31) 
   χ2=2.99; 3df; p=0.39b 
aModel includes a time-varying indicator variable indicating “ever smoker” status; bLikelihood ratio 
test: chi-squared statistic; degrees of freedom; p-value; c[a, b) is a mathematical convention 
denoting the interval ≥a to <b. 
 
 
14.2.1.2.4 The univariate analysis of the association between the duration of 
the current smoking episode and the duration of an incident cervical HPV16 
infection 
 
The univariate analysis of the association between the duration of the current 
smoking episode and the risk of clearing an incident cervical HPV16 infection is 
described in table 14.2.1.2.4. Overall, the association was not statistically significant, 
and all hazards ratios were close to the null value of 1, except the hazards ratio for 
women whose current smoking episode had lasted for four or more years. These 
women were at a nearly three-fold increased risk of clearing their infections 
compared to women who had never smoked, i.e. smoking had a protective effect in 
that smoking was associated with shorter periods of HPV16-positivity. However, the 
sample size in this category was small, and the confidence interval indicates that the 
increased risk is also consistent with the risks seen in the other smoking categories. 
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Table 14.2.1.2.4. The univariate analysis of the association between the 
duration of the current smoking episode and the risk of clearing an incident 
cervical HPV16 infection.  
 
Duration Of Current 
Smoking Episode 
Number of 
Women (%)
Number 
of Events 
Hazards Ratio (95% 
CI) 
   
Continuous (per year)a 90 (100.0) 76 1.08 (0.92 to 1.26) 
  χ2=0.88; 1df; p=0.35b 
    
Never-smoker 38 (42.2) 31 1.00 ( Reference ) 
Ex-smoker 16 (17.8) 16 1.24 (0.65 to 2.34) 
( 0, 24 months)c 11 (12.2) 9 1.31 (0.61 to 2.85) 
[24, 48)c 12 (13.3) 8 1.11 (0.49 to 2.49) 
[48, +)c 13 (14.4) 12 2.89 (1.25 to 6.68) 
   χ2=6.42; 4df; p=0.17b 
aModel includes a time-varying indicator variable indicating “current smoking” status; bLikelihood 
ratio test: chi-squared statistic; degrees of freedom; p-value; c[a, b) is a mathematical convention 
denoting the interval ≥a to <b. 
 
14.2.1.2.5 The univariate analysis of the association between pack-years 
smoked and the duration of  an incident cervical HPV16 infection 
 
This analysis was restricted to the 88 (out of 90) women for whom quantity smoked 
was known throughout follow-up. The univariate analysis of the association between 
pack-years smoked and the risk of clearing an incident cervical HPV16 infection is 
described in table 14.2.1.2.5. The association was not statistically significant.  
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Table 14.2.1.2.5. The univariate analysis of the association between pack-
years smoked and the risk of clearing an incident cervical HPV16 infection.  
 
Pack-years Smoked Number of 
Women (%)
Number of 
Events 
Hazards Ratio (95% CI)
    
Continuous (per pack-
year) 
88 (100.0) 74 0.98 (0.73 to 1.32) 
   χ2=0.02; 1df; p=0.89a 
    
Never-smoker 38 (43.2) 31 1.00 ( Reference ) 
(0 , 1)b 28 (31.8) 26 1.49 (0.86 to 2.58) 
[1 , 2)b 10 (11.4) 6 1.38 (0.54 to 3.53) 
[2 , 3)b 9 (10.2) 9 1.61 (0.70 to 3.69) 
[3 , +)b,c 3 (3.4) 2 0.94 (0.22 to 4.02) 
   χ2=2.90; 4df; p=0.57a 
 aLikelihood ratio test: chi-squared statistic; degrees of freedom; p-value; b[a, b) is a mathematical 
convention denoting the interval ≥a to <b; cthis categorisation was retained despite the small 
sample size to aid comparison with the “HPV of any type” analysis. 
 
 
14.2.1.2.6 The univariate analysis of the association between current smoking 
status and the duration of an incident cervical HPV16 infection 
 
The univariate analysis of the association between current smoking status and the 
risk of clearing an incident cervical HPV16 infection is described in table 14.2.1.2.6. 
Current smoking status was not significantly associated with the risk of clearing an 
incident cervical HPV16 infection in any of the three analyses using the different 
definitions of current smoking status. In contrast to the analysis of any HPV type, 
current ex-smokers were less likely than current smokers to clear a cervical HPV16 
infection. 
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Table 14.2.1.2.6. The univariate analysis of the association between current 
smoking status and the risk of clearing an incident cervical HPV16 infection.  
 
Current Smoking Status Number of 
Women (%)
Number of 
Events 
Hazards Ratio (95% CI)
    
Never-smoker 38 (42.2) 31 1.00 ( Reference ) 
Ex-smoker 16 (17.8) 16 1.24 (0.65 to 2.33) 
Current smoker 36 (40.0) 29 1.54 (0.90 to 2.63) 
      χ2=2.53; 2df; p=0.28a 
    
Non-smoker 54 (60.0) 47 1.00 ( Reference ) 
Current smoker 36 (40.0) 29 1.44 (0.88 to 2.36) 
      χ2=2.09; 1df; p=0.15a 
    
Never-smoker 38 (42.2) 31 1.00 ( Reference ) 
Ever-smoker 52 (57.8) 45 1.41 (0.87 to 2.28) 
      χ2=2.07; 1df; p=0.15a 
aLikelihood ratio test: chi-squared statistic; degrees of freedom; p-value. 
 
 
 
14.2.1.2.7 The univariate analysis of the association between current smoking 
intensity and the duration of an incident cervical HPV16 infection 
 
This analysis was restricted to the 88 (out of 90) women for whom the quantity 
smoked was known throughout follow-up. The univariate analysis of the association 
between current smoking intensity and the risk of clearing an incident cervical 
HPV16 infection is described in table 14.2.1.2.7. The association was not statistically 
significant. 
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Table 14.2.1.2.7. The univariate analysis of the association between current 
smoking intensity and the risk of clearing an incident cervical HPV16 
infection. 
 
Current Smoking 
Intensity 
Number of 
Women (%) 
Number of 
Events 
Hazards Ratio (95% CI)
    
Continuous (per 
category)a,b 
88 (100.0) 74 1.00 (0.69 to 1.44) 
   χ2=0.0005; 1df; p=0.98c 
    
Never-smoker 38 (43.2) 31 1.00 ( Reference ) 
0 per day 14 (15.9) 14 1.24 (0.65 to 2.34) 
1 to 9 per day 21 (23.9) 21 1.68 (0.89 to 3.16) 
10 or more per day 15 (17.0) 15 1.37 (0.68 to 2.77) 
      χ2=2.78; 1df; p=0.43c 
aModel includes a time-varying indicator variable indicating “current smoking” status; bthe 
increase in risk for every increase of 1 in category of smoking intensity; cLikelihood ratio test: 
chi-squared statistic; degrees of freedom; p-value. 
 
 
14.2.1.3 HPV18 infection 
 
The sample size was too small, and in particular “clearance events” were too few to 
carry out an analysis of the association between smoking exposure and the duration 
of incident HPV18 infections. 
 
14.2.2 Multivariate analysis of the association between smoking and the risk of 
clearing an incident cervical infection with HPV 
 
Multivariate analyses of the association between smoking and the risk of clearing 
either an incident cervical infection with HPV of any type, or with HPV16, controlling 
for sexual behaviour, were undertaken.  However, given that there were no 
significant associations to “explain” in the univariate analyses, and also that in no 
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instance did the hazards ratios from the univariate analysis change by more than 
10% in the corresponding multivariate analyses, there is nothing further of interest to 
report. 
 
 
Summary 
 
There were no statistically significant associations between any of the variables 
measuring exposure to smoking and the risk of clearing either an incident cervical 
HPV infection of any type, or of clearing an incident cervical HPV16 infection; there 
were too few clearance events to make the analysis of the clearance of incident 
cervical HPV18 infections worthwhile. Multivariate analyses revealed nothing 
noteworthy. 
 
 
 
14.3 THE INCIDENCE OF CERVICAL CYTOLOGICAL ABNORMALITY IN 
RELATION TO SMOKING HISTORY 
 
The association between smoking and cervical cytological abnormality is primarily of 
interest for those cytological abnormalities which ultimately progress to high-grade 
CIN. Given that cytological abnormality is a surrogate endpoint for high-grade CIN, 
and that sufficient data relating to high-grade CIN are available, no presentation of 
results relating to cytological abnormality will be given here. 
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14.4 THE INCIDENCE OF HIGH-GRADE CIN IN RELATION TO SMOKING 
HISTORY 
 
The study population for this analysis comprises 1,075 women who were HPV DNA-
negative in their first evaluable virological sample, cytologically normal in their first 
evaluable cervical smear, and who had further follow-up after this time. 
 
Twenty-eight women in the cohort of 1,075 were diagnosed with incident high-grade 
cervical intraepithelial neoplasia (CIN) during follow-up.  
 
14.4.1 Univariate analysis 
 
14.4.1.1 The univariate analysis of the association between smoking status at 
study entry and the risk of incident high-grade CIN 
 
Of the 626 women who had never smoked prior to study entry, 14 (2%) were 
diagnosed with high-grade CIN during follow-up: diagnosis was made after first 
exposure to smoking in two (14%) of these women and before first exposure to 
smoking in the remaining 12 (86%). Of the 449 women who had first become 
smokers at some point prior to study entry, 14 (3%) were diagnosed with high-grade 
CIN during follow-up. 
 
The univariate analysis of the association between smoking status at study entry and 
the risk of incident high-grade CIN is described in table 14.4.1.1. The association 
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between smoking status at study entry and the risk of incident high-grade CIN, after 
controlling for HPV infection, was not statistically significant, using any of the three 
definitions of this variable which were investigated. Women who were ex- or current 
smokers at study entry were at an increased risk of high-grade CIN compared to 
women who were never-smokers, but this increase was not significant. Women who 
were ex-smokers at study entry had a higher risk of high-grade CIN than women 
who were current smokers at study entry, but there was no significant difference 
between the point estimates of the hazards ratios. 
 
A woman was categorised as an ex-smoker immediately after she stopped smoking. 
Varying this definition by including a “lag-time” during which ex-smokers were still 
classified as current smokers, may have produced different estimates of risk. The 
two-category variable combining ex-smokers with never-smokers provides a lower 
bound on the hazards ratio for a variable constructed in this way. Similarly, by 
combining ex-smokers with current smokers, we obtain an upper-bound. The 
magnitude of the hazards ratio for ex-smokers alone suggests that, however the ex-
smokers are distributed between the never- and current-smokers, the resulting “lag-
time” variable will not yield a statistically significant hazard ratios. 
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Table 14.4.1.1. The univariate analysis of the association between 
smoking status at study entry and the risk of incident high-grade CIN.  
 
Smoking Status At 
Study Entry 
Number of 
Women (%)
Number of 
Events 
Hazards Ratio 
(95% CI) 
    
Never-smoker 626 (58.2) 14 1.00 (Reference) 
Ex-smoker   93 (  8.7)   3 1.77 (0.51 to 6.17) 
Current smoker 356 (33.1) 11 1.31 (0.59 to 2.91) 
      χ2=0.95; 2df; p=0.62a 
    
Non-smoker 719 (65.0) 17 1.00 (Reference) 
Current smoker 356 (35.0) 11 1.21 (0.57 to 2.61) 
      χ2=0.25; 1df; p=0.62a 
    
Non-smoker 626 (58.2) 14 1.00 (Reference) 
Ever-smoker 449 (41.8) 14 1.39 (0.66 to 2.93) 
      χ2=0.76; 1df; p=0.38a 
aLikelihood ratio test: chi-squared statistic; degrees of freedom; p-value. 
 
 
In women who had never smoked prior to study entry, the cumulative risks of 
incident high-grade CIN at one, two and three years after study entry were 19.5%, 
35.5% and 43.4% respectively. 
  
14.4.1.2 The univariate analysis of the association between the age at starting 
smoking and the risk of incident high-grade CIN 
 
Four hundred and forty nine (41.8%) women had regularly smoked cigarettes at 
some point prior to study entry; the median age at starting smoking for these women 
was 15 years (range 9 to 19). 
 
The univariate analysis of the association between the age at starting smoking, as 
recorded at study entry, and the risk of incident high-grade CIN is described in table 
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14.4.1.2. The association between the age at starting smoking at study entry and the 
risk of incident high-grade CIN was not statistically significant. When analysed as a 
categorical variable, no individual category was statistically significant, and although 
there was a suggestion of a decreasing risk with increasing age at starting smoking, 
the trend was not consistent. In contrast, when analysed as a continuous variable, 
the point estimate of the hazards ratio suggested an increasing risk with increasing 
age at starting smoking. There is a danger of over-interpreting these results: 
numbers of events are small, all confidence intervals are wide, and no individual 
estimates are statistically significant; this may be the best interpretation of these 
results. 
 
Table 14.4.1.2. The univariate analysis of the association between the age at 
starting smoking as measured at study entry and the risk of incident high-
grade CIN.  
 
Age At Starting 
Smoking (at study 
entry) 
Number of 
Women (%) 
Number 
of Events
Hazards Ratio (95% CI) 
    
Continuous (per year)a 1075 (100) 28 1.07 (0.78 to 1.45) 
   χ2=0.17; 1df; p=0.68b 
    
Never-smoker 626 (58.2) 14 1.00 ( Reference ) 
≤13 100 (  9.3) 4 1.74 (0.57 to 5.34) 
14-15 182 (16.9) 5 1.14 (0.41 to 3.18) 
 ≥16 167 (15.5) 5 1.48 (0.53 to 4.12) 
   χ2=1.18; 3df; p=0.76b 
aIncludes a variable indicating “ever smoker” status at study entry; bLikelihood ratio test: chi-
squared statistic; degrees of freedom; p-value. 
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14.4.1.3 The univariate analysis of the association between a history of ever 
having smoked and the risk of incident high-grade CIN 
 
The univariate analysis of the association between a history of ever having smoked 
and the risk of incident high-grade CIN is described in table 14.4.1.3. Just over half 
of all women had smoked cigarettes at some point prior to the first diagnosis of high-
grade CIN. Women who had ever smoked had a small but non-significant increase in 
the risk of incident high-grade CIN, compared to women who had never smoked. 
 
Table 14.4.1.3. The univariate analysis of the association between a history 
of ever having smoked and the risk of incident high-grade CIN.  
 
Have you ever been 
a cigarette smoker? 
Number of 
Women (%)
Number of 
Events 
Hazards Ratio (95% CI) 
    
No 535 (49.8) 12 1.00 (Reference) 
Yes 540 (50.2) 16 1.27 (0.60 to 2.69) 
      χ2=0.38; 1df; p=0.54a 
aLikelihood ratio test: chi-squared statistic; degrees of freedom; p-value. 
 
14.4.1.4 The univariate analysis of the association between the time since first 
starting smoking and the risk of incident high-grade CIN 
 
At the earliest of the date of first diagnosis of high-grade CIN and the end of follow-
up, median time since first starting smoking was 50.4 months (range 2.2 to 188.0) in 
women who had ever smoked. 
  
The univariate analysis of the association between the time since starting smoking 
and the risk of incident high-grade CIN is described in table 14.4.1.4. There was a 
very slight and non-significant decrease in the risk of incident high-grade CIN with 
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increasing time since starting smoking, when this variable was analysed as a 
continuous variable, controlling for ever having smoked. The risk of incident high-
grade CIN decreased by 6% (1.00-0.94) for every increase of one year in time since 
starting smoking. When the variable was analysed as a categorical covariate, with 
never-smokers as reference group, again the time since first starting smoking was 
not significantly associated with the risk of incident high-grade CIN. The trend 
suggested in the continuous analysis was not evident in the categorical analysis, but 
numbers of events were small and confidence intervals were all wide. In particular, 
the largest hazards ratio was seen for women for whom 72 to 84 months had 
elapsed since they started smoking, but the confidence interval indicates that the 
data are also consistent with a halving of risk. 
 
Table 14.4.1.4. The univariate analysis of the association between the time 
since first starting smoking and the risk of incident high-grade CIN.  
 
Time Since First 
Starting Smoking  
Number of 
Women (%) 
Number of 
Events 
Hazards Ratio (95% CI)
   
Continuous (per year)a 1075 (100) 28 0.94 (0.78 to 1.13) 
  χ2=0.46; 1df; p=0.50b 
   
Never-smoker 535 (49.8) 12 1.00 ( Reference ) 
( 0, 36 months)c 135 (12.6) 3 1.13 (0.31 to 4.11) 
[36, 72)c 232 (21.6) 6 1.31 (0.49 to 3.51) 
[72, +)c 173 (16.1) 7 1.31 (0.47 to 3.60) 
  χ2=0.43; 3df; p=0.93b 
   
Never-smoker 535 (49.8) 12 1.00 ( Reference ) 
( 0, 36 months)c 135 (12.6) 3 1.14 (0.31 to 4.16) 
[36, 72)c 232 (21.6) 6 1.33 (0.49 to 3.57) 
[72, 84)c 51 (  4.7) 3 2.07 (0.57 to 7.47) 
[84, +)c 122 (11.3) 4 0.96 (0.28 to 3.34) 
    χ2=1.32; 4df; p=0.86b 
aModel includes a time-varying indicator variable indicating “ever smoker” status; bLikelihood ratio 
test: chi-squared statistic; degrees of freedom; p-value; c[a, b) is a mathematical convention denoting 
the interval ≥a to <b. 
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14.4.1.5 The univariate analysis of the association between the cumulative 
duration of smoking and the risk of incident high-grade CIN 
 
At the earliest of the date of the first diagnosis of high-grade CIN and the date of the 
end of follow-up, the median cumulative duration of smoking was 40.7 months 
(range 2.2 to 178.7) among women who had ever smoked.  
 
The univariate analysis of the association between the cumulative duration of 
smoking and the risk of incident high-grade CIN is described in table 14.4.1.5. There 
was no statistically significant association when this variable was analysed as either 
a continuous or as a categorical variable. In the analysis in which cumulative 
duration of smoking was measured as a categorical variable, the largest hazards 
ratio was seen for women with a cumulative duration of smoking between 36 and 60 
months, but this was not significant. 
 
 
Table 14.4.1.5. The univariate analysis of the association between the 
cumulative duration of smoking and the risk of incident high-grade CIN.  
 
Cumulative Duration 
Of Smoking 
Number of 
Women (%)
Number of 
Events 
Hazards Ratio (95% CI)
   
Continuous (per year) 1075 (100) 28 0.99 (0.83 to 1.18) 
  χ2=0.01; 1df; p=0.91b 
   
Never-smoker 535 (49.8) 12 1.00 (Reference) 
( 0, 36 months)c 218 (20.3) 4 0.94 (0.30 to 2.92) 
[36, 72)c 204 (19.0) 7 1.56 (0.61 to 3.98) 
[72, +)c 104 (11.0) 5 1.30 (0.42 to 3.99) 
   χ2=1.07; 3df; p=0.79b 
aModel includes a time-varying indicator variable indicating ‘ever smoker’ status; bLikelihood ratio 
test: chi-squared statistic; degrees of freedom; p-value; c[a, b) is a mathematical convention 
denoting the interval ≥a to <b. 
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14.4.1.6 The univariate analysis of the association between the duration of the 
current smoking episode and the risk of incident high-grade CIN 
 
At the earliest of the date of the first diagnosis of high-grade CIN and the date of the 
end of follow-up, the median duration of the current smoking episode was 38.8 
months (range 1.2 to 157.0), among women who were current smokers at that time. 
 
The univariate analysis of the association between the duration of the current 
smoking episode and the risk of incident high-grade CIN is described in table 
14.4.1.6. The association was not statistically significant. The suggestion of a 
decreasing risk of incident high-grade CIN with increasing duration of the current 
smoking episode seen in the analysis in which duration of current smoking episode 
was measured as a continuous variable, was not evident in the analysis in which this 
exposure variable was analysed as a categorical variable: the hazards ratios for 
each category were comparable, with no trend evident. Numbers of events were too 
small to allow for an analysis of a categorical variable including an “ex-smoker” 
category. 
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Table 14.4.1.6. The univariate analysis of the association between the 
duration of the current smoking episode and the risk of incident high-grade 
CIN.  
 
Duration Of Current 
Smoking Episode 
Number of 
Women (%)
Number of 
Events 
Hazards Ratio (95% CI) 
    
Duration of current 
smoking episode (per 
year)a 
1075 (100) 28 0.91 (0.75 to 1.09) 
   χ2=1.12; 1df; p=0.29b 
    
Non-smoker 673 (62.6) 12 1.00 ( Reference ) 
( 0, 24 months)c 117 (10.9) 4 2.08 (0.67 to 6.48) 
[24, 48)c 110 (10.2) 5 2.93 (1.02 to 8.41) 
[48, +)c 175 (16.3) 7 1.93 (0.75 to 4.96) 
   χ2=4.83; 3df; p=0.18b 
aModel includes a time-varying indicator variable indicating “current smoking” status; bLikelihood 
ratio test: chi-squared statistic; degrees of freedom; p-value; c[a, b) is a mathematical convention 
denoting the interval ≥a to <b. 
 
 
14.4.1.7 The univariate analysis of the association between pack-years smoked 
and the risk of incident high-grade CIN 
 
This analysis was restricted to the 1,038 (out of 1,075) women for whom the quantity 
smoked was known throughout follow-up. At the earliest of the date of the first 
diagnosis of high-grade CIN and the date of the end of follow-up, median pack-years 
smoked was 1 pack-year (range 0.1 to 8) in women who had ever smoked prior to 
that time. 
 
The univariate analysis of the association between pack-years smoked and the risk 
of incident high-grade CIN is described in table 14.4.1.7. The association was not 
statistically significant. When analysed as a continuous variable, the hazards ratio 
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increased by 11% (1.11-1.00) for every increase of one pack year; when analysed 
as a categorical variable, neither the variable itself nor any individual category was 
significant. 
 
Table 14.4.1.7. The univariate analysis of the association between pack-years 
smoked and the risk of incident high-grade CIN.  
 
Pack-years Smoked Number of 
Women (%) 
Number of 
Events 
Hazards Ratio (95% CI)
    
Cumulative quantity 
smoked (per pack-
year) 
1038 (100) 27 1.11 (0.79-1.56) 
   χ2=0.35; 1df; p=0.55a 
    
Never-smoker 535 (51.5) 12 1.00 (Reference) 
(0 , 1)b 200 (19.3) 3 0.71 (0.20-2.53) 
[1 , 2)b 154 (14.8) 5 1.56 (0.54-4.44) 
[2 , 3)b 77 (7.4) 3 1.39 (0.38-5.07) 
[3 , +)b 72 (6.9) 4 1.77 (0.53-5.90) 
   χ2=2.05; 4df; p=0.73a 
aLikelihood ratio test: chi-squared statistic; degrees of freedom; p-value; b[a, b) is a mathematical 
convention denoting the interval ≥a to <b. 
 
 
14.4.1.8 The univariate analysis of the association between current smoking 
status and the risk of incident high-grade CIN 
 
The univariate analysis of the association between current smoking status and the 
risk of incident high-grade CIN is described in table 14.4.1.8. Current smoking status 
was significantly associated with the risk of incident high-grade CIN, with current 
smokers having a two-fold increased risk compared to women who were current 
non-smokers. There were no events among current ex-smokers, so an analysis 
including a three-category variable accounting for changes in smoking status could 
not be undertaken. Note that the third method of categorising this variable has been 
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presented earlier (see section 14.4.1.3), and is included here for completeness. 
Numbers of events were small, so this result needs to be interpreted with caution, 
e.g. being an ex-smoker is unlikely to be protective against high-grade CIN to the 
extent suggested here. 
 
 
Table 14.4.1.8. The univariate analysis of the association between current 
smoking status and the risk of incident high-grade CIN.  
 
Current Smoking Status Number of 
Women (%)
Number of 
Events 
Hazards Ratio (95% CI)
   
Never-smoker 535 (49.8) 12 1.00 (Reference) 
Ex-smoker 138 (12.8) 0 - 
Current smoker 402 (37.4) 16 - 
    
Non-smoker 673 (62.6) 12 1.00 (Reference) 
Current smoker 402 (37.4) 16 2.21 (1.04 to 4.67) 
      χ2=4.34; 1df; p=0.04a 
    
Never-smoker 535 (49.8) 12 1.00 (Reference) 
Ever-smoker 540 (50.2) 16 1.27 (0.60 to 2.69) 
      χ2=0.38; 1df; p=0.54a 
aLikelihood ratio test: chi-squared statistic; degrees of freedom; p-value 
 
 
14.4.1.9 The univariate analysis of the association between current smoking 
intensity and the risk of incident high-grade CIN 
 
This analysis was restricted to the 1,038 (out of 1,075) women for whom the quantity 
smoked was known throughout follow-up. At the earliest of the date of the first 
detection of HPV DNA of any type in a cervical sample and the date of the end of 
follow-up, the vast majority of women who were current smokers were smoking less 
than 19 cigarettes per day. 
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The univariate analysis of the association between current smoking intensity and the 
risk of incident high-grade CIN is described in table 14.4.1.9. When analysed as a 
categorical variable, the association between current smoking intensity and the risk 
of incident high-grade CIN was of borderline statistical significance. Note that never-
smokers and those currently smoking zero cigarettes per day (current ex-smokers) 
had to be combined into the same category, due to there being no events in the 
latter group. When analysed as a continuous variable (or equivalently, when a trend 
test was performed), the association was highly significant. 
 
 
Table 14.4.1.9. The univariate analysis of the association between current 
smoking intensity and the risk of incident high-grade CIN. 
 
Current Smoking 
Intensity 
Number of 
Women (%) 
Number of 
Events 
Hazards Ratio (95% CI)
    
Current smoking 
intensity (per category)a 1038 (100) 27 2.25 (1.37 to 3.69) 
   χ2=9.79; 1df; p=0.002b 
    
Non-smoker 649 (62.5) 12 1.00 ( Reference ) 
1 to 9 per day 191 (18.4) 5 1.59 (0.59 to 4.25) 
10 or more per day 198 (19.1) 10 2.87 (1.24 to 6.66) 
      χ2=5.69; 2df; p=0.06b 
aThe increase in risk for every increase of one in category of smoking intensity; bLikelihood ratio test: 
chi-squared statistic; degrees of freedom; p-value. 
 
 
 
 
Summary 
 
In univariate analyses of the association between smoking exposure and the risk of 
incident high-grade CIN, only current smoking status and current smoking intensity 
were found to be significant predictors of risk. The risk of high-grade CIN in current 
smokers was twice that in current non-smokers; and increased significantly with 
smoking intensity. 
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14.4.2 Multivariate analysis 
 
14.4.2.1 Controlling for HPV exposure 
 
14.4.2.1.1 The multivariate analysis of the association between smoking status 
at study entry and the risk of incident high-grade CIN, controlling for exposure 
to cervical HPV infection 
 
The multivariate analysis of the association between smoking status at study entry 
and the risk of incident high-grade CIN, controlling for exposure to cervical HPV 
infection of any type, is described in table 14.4.2.1.1. The association between 
smoking status at study entry and the risk of incident high-grade CIN, after 
controlling for cervical HPV infection, was not statistically significant, using any of the 
three definitions of this variable. In the multivariate (controlled) analysis, ex-smokers 
had the same hazards ratio (i.e. the same risk) as current smokers, whereas they 
appeared to be at greater risk in the univariate analysis; estimates of hazard ratios 
changed only slightly in the controlled, compared to the uncontrolled, analysis for the 
other two variables. 
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Table 14.4.2.1.1. The multivariate analysis of the association between 
smoking status at study entry and the risk of incident high-grade CIN, 
controlling for exposure to cervical HPV infection of any type.  
 
Smoking Status At 
Study Entry 
Number of 
Women (%)
Number of 
Events 
Hazards Ratio (95% CI)
    
Never-smoker 626 (58.2) 14 1.00 (Reference) 
Ex-smoker   93 (  8.7)   3 1.33 (0.37-4.76) 
Current smoker 356 (33.1) 11 1.30 (0.58-2.92) 
      χ2=0.49; 2df; p=0.78a 
    
Non-smoker 719 (65.0) 17 1.00 (Reference) 
Current smoker 356 (35.0) 11 1.25 (0.58-2.71) 
      χ2=0.31; 1df; p=0.58a 
    
Non-smoker 626 (58.2) 14 1.00 (Reference) 
Ever smoker 449 (41.8) 14 1.31 (0.62-2.78) 
      χ2=0.49; 1df; p=0.48a 
aLikelihood ratio test: chi-squared statistic; degrees of freedom; p-value 
 
 
14.4.2.1.2 The multivariate analysis of the association between age at starting 
smoking and the risk of incident high-grade CIN, controlling for exposure to 
cervical HPV infection 
 
The multivariate analysis of the association between age at starting smoking, as 
recorded at study entry, and the risk of incident high-grade CIN, controlling for 
exposure to cervical HPV infection of any type, is described in table 14.4.2.1.2. The 
association was not statistically significant. In each case, the point estimate of the 
hazards ratio decreased compared to that obtained in the univariate analysis, but 
changes between these analyses were slight. 
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Table 14.4.2.1.2. The multivariate analysis of the association between age at 
starting smoking, as measured at study entry, and the risk of incident high-
grade CIN, controlling for exposure to cervical HPV infection of any type.  
 
Age at Starting Smoking 
(at study entry) 
Number of 
Women (%) 
Number 
of Events 
Hazards Ratio (95% CI)
    
Continuous (per year)a 1075 (100) 28 1.02 (0.97 to 1.07) 
   χ2=0.55; 1df; p=0.46b 
    
Never-smoker 626 (58.2) 14 1.00 ( Reference ) 
≤13 100 (  9.3) 4 1.65 (0.53 to 5.12) 
14-15 182 (16.9) 5 1.11 (0.40 to 3.09) 
 ≥16 167 (15.5) 5 1.34 (0.47 to 3.90) 
   χ2=0.84; 3df; p=0.84b 
aIncludes a variable indicating “ever smoker” status at study entry; bLikelihood ratio test: chi-
squared statistic; degrees of freedom; p-value. 
 
 
14.4.2.1.3 The multivariate analysis of the association between a history of 
ever having smoked and the risk of incident high-grade CIN, controlling for 
exposure to cervical HPV infection of any type 
 
The multivariate analysis of the association between a history of ever having smoked 
and the risk of incident high-grade CIN, controlling for exposure to cervical HPV 
infection of any type, is described in table 14.4.2.1.3. The association was not 
statistically significant. Compared to the univariate analysis, the estimate of the 
hazards ratio decreased, but the change was slight. 
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Table 14.4.2.1.3. The multivariate analysis of the association between a 
history of ever having smoked and the risk of incident high-grade CIN, 
controlling for exposure to cervical HPV infection of any type.  
 
Have you ever been 
a cigarette smoker? 
Number of 
Women (%)
Number of 
Events 
Hazards Ratio (95% CI) 
    
No 535 (49.8) 12 1.00 (Reference) 
Yes 540 (50.2) 16 1.11 (0.52 to 2.37) 
      χ2=0.08; 1df; p=0.78a 
aLikelihood ratio test: chi-squared statistic; degrees of freedom; p-value. 
 
 
14.4.2.1.4 The multivariate analysis of the association between the time since 
first starting smoking and the risk of incident high-grade CIN, controlling for 
exposure to cervical HPV infection of any type 
 
The multivariate analysis of the association between the time since starting smoking 
and the risk of incident high-grade CIN, controlling for exposure to cervical HPV 
infection of any type, is described in table 14.4.2.1.4. The association was no 
statistically significant, whether this variable was analysed as a continuous, or as a 
categorical, variable. Compared to the univariate analysis, the hazards ratios are 
closer to the null value of 1, but the changes are slight. 
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Table 14.4.2.1.4. The multivariate analysis of the association between the 
time since first starting smoking and the risk of incident high-grade CIN, 
controlling for exposure to cervical HPV infection of any type.  
 
Time Since First 
Starting Smoking 
Number of 
Women (%)
Number 
of Events 
Hazards Ratio (95% CI)
   
Continuous (per year)a 1075 (100) 28 0.97 (0.78 to 1.20) 
  χ2=0.10; 1df; p=0.75b 
   
Never-smoker 535 (49.8) 12 1.00 ( Reference ) 
( 0, 36 months)c 135 (12.6) 3 1.00 (0.27 to 3.65) 
[36, 72)c 232 (21.6) 6 1.07 (0.40 to 2.88) 
[72, +)c 173 (16.1) 7 1.23 (0.44 to 3.45) 
  χ2=0.16; 3df; p=0.98b 
   
Never-smoker 535 (49.8) 12 1.00 ( Reference ) 
( 0, 36 months)c 135 (12.6) 3 1.01 (0.28 to 3.69) 
[36, 72)c 232 (21.6) 6 1.08 (0.40 to 2.90) 
[72, 84)c 51 (  4.7) 3 1.61 (0.44 to 5.93) 
[84, +)c 122 (11.3) 4 1.01 (0.29 to 3.55) 
    χ2=0.51; 4df; p=0.97b 
aModel includes a time-varying indicator variable indicating “ever smoker” status; bLikelihood ratio 
test: chi-squared statistic; degrees of freedom; p-value; c[a, b) is a mathematical convention 
denoting the interval ≥a to <b. 
 
 
14.4.2.1.5 The multivariate analysis of the association between the cumulative 
duration of smoking and the risk of incident high-grade CIN, controlling for 
exposure to cervical HPV infection of any type 
 
The multivariate analysis of the association between the cumulative duration of 
smoking and the risk of incident high-grade CIN, controlling for exposure to cervical 
HPV infection of any type, is described in table 14.4.2.1.5. The association was not 
statistically significant. After controlling for exposure to cervical HPV infection of any 
type, the hazards ratio for the “0 to 36 month” category (labelled (0, 36 months) in 
the table) was further from the null value of one than the uncontrolled estimate. 
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Table 14.4.2.1.5. The multivariate analysis of the association between the 
cumulative duration of smoking and the risk of incident high-grade CIN, 
controlling for exposure to cervical HPV infection of any type.  
 
Cumulative Duration 
Of Smoking 
Number of 
Women (%) 
Number of 
Events 
Hazards Ratio (95% CI)
   
Continuous (per year) 1075 (100) 28 1.04 (0.86 to 1.27) 
  χ2=0.19; 1df; p=0.66b 
   
Never-smoker 535 (49.8) 12 1.00 (Reference) 
( 0, 36 months)c 218 (20.3) 4 0.70 (0.22 to 2.22) 
[36, 72)c 204 (19.0) 7 1.48 (0.58 to 3.76) 
[72, +)c 104 (11.0) 5 1.30 (0.41 to 4.12) 
   χ2=1.57; 3df; p=0.67b 
aModel includes a time-varying indicator variable indicating “ever smoker” status; bLikelihood ratio 
test: chi-squared statistic; degrees of freedom; p-value; c[a, b) is a mathematical convention denoting 
the interval ≥a to <b. 
 
 
14.4.2.1.6 The multivariate analysis of the association between the duration of 
the current smoking episode and the risk of incident high-grade CIN, 
controlling for exposure to cervical HPV infection of any type 
 
The multivariate analysis of the association between the duration of the current 
smoking episode and the risk of incident high-grade CIN, controlling for exposure to 
cervical HPV infection of any type, is described in table 14.4.2.1.6. There was no 
significant association whether this variable was analysed as a continuous, or as a 
categorical, variable.  
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Table 14.4.2.1.6. The multivariate analysis of the association between the 
duration of the current smoking episode and the risk of incident high-grade 
CIN, controlling for exposure to cervical HPV infection of any type.  
 
Duration Of Current 
Smoking Episode 
Number of 
Women (%)
Number of 
Events 
Hazards Ratio 
(95% CI) 
    
Duration of current smoking 
episode (per year)a 1075 (100) 28 0.92 (0.75 to 1.12) 
   χ2=0.74; 1df; p=0.39b 
    
Nonsmoker 673 (62.6) 12 1.00 ( Reference ) 
( 0, 24 months)c 117 (10.9) 4 1.99 (0.63 to 6.22) 
[24, 48)c 110 (10.2) 5 2.76 (0.96 to 7.90) 
[48, +)c 175 (16.3) 7 1.94 (0.75 to 5.03) 
   χ2=4.45; 3df; p=0.22b 
aModel includes a time-varying indicator variable indicating ‘current smoking’ status; bLikelihood 
ratio test: chi-squared statistic; degrees of freedom; p-value; c[a, b) is a mathematical convention 
denoting the interval ≥a to <b. 
 
 
14.4.2.1.7 The multivariate analysis of the association between pack-years 
smoked and the risk of incident high-grade CIN, controlling for exposure to 
cervical HPV infection of any type 
 
The multivariate analysis of the association between pack-years smoked and the risk 
of incident high-grade CIN, controlling for exposure to cervical HPV infection of any 
type, is described in tables 14.4.2.1.7. When analysed as a continuous variable, the 
association between pack-years of smoking and the risk of incident high-grade CIN, 
controlling for exposure to cervical HPV infection of any type, was statistically 
significant. However, compared to the uncontrolled analysis, the increase in the 
hazards ratio for every increase of one pack year approximately doubled from 11% 
to 24% (1.24-1.00).  When analysed as a categorical variable, the risk estimates 
showed no consistent pattern across categories. 
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Table 14.4.2.1.7. The multivariate analysis of the association between pack-
years smoked and the risk of incident high-grade CIN, controlling for 
exposure to HPV.  
 
Pack-years Smoked Number of 
Women (%)
Number of 
Events 
Hazards Ratio (95% CI)
    
Cumulative quantity 
smoked (per pack-year) 1038 (100) 27 1.24 (0.86 to 1.78) 
   χ2=1.22; 1df; p=0.27a 
    
Never-smoker 535 (51.5) 12 1.00 ( Reference ) 
(0 , 1)b 200 (19.3) 3 0.52 (0.14 to 1.87) 
[1 , 2)b 154 (14.8) 5 1.71 (0.59 to 4.94) 
[2 , 3)b 77 (7.4) 3 1.18 (0.32 to 4.37) 
[3 , +)b 72 (6.9) 4 1.88 (0.56 to 6.37) 
   χ2=3.64; 4df; p=0.46a 
aLikelihood ratio test: chi-squared statistic; degrees of freedom; p-value; b[a, b) is a mathematical 
convention denoting the interval ≥a to <b. 
 
 
14.4.2.1.8 The multivariate analysis of the association between current 
smoking status and the risk of incident high-grade CIN, controlling for 
exposure to cervical HPV infection of any type 
 
The multivariate analysis of the association between current smoking status and the 
risk of incident high-grade CIN, controlling for exposure to cervical HPV infection of 
any type, is described in tables 14.4.2.1.8. After controlling for exposure to cervical 
HPV infection of any type, current smoking status remained significantly associated 
with the risk of incident high-grade CIN; the estimate of the hazards ratio remained 
essentially unchanged compared to that in the uncontrolled (univariate) analysis. 
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Table 14.4.2.1.8. The multivariate analysis of the association between current 
smoking status and the risk of incident high-grade CIN, controlling for 
exposure to cervical HPV infection of any type. 
 
Current Smoking Status Number of 
Women (%)
Number of 
Events 
Hazards Ratio (95% CI)
   
Never-smoker 535 (49.8) 12 1.00 (Reference) 
Ex-smoker 138 (12.8) 0 - 
Current smoker 402 (37.4) 16 - 
    
Non-smoker 673 (62.6) 12 1.00 (Reference) 
Current smoker 402 (37.4) 16 2.16 (1.02 to 4.59) 
      χ2=4.08; 1df; p=0.04a 
    
Never-smoker 535 (49.8) 12 1.00 (Reference) 
Ever-smoker 540 (50.2) 16 1.11 (0.52 to 2.37) 
      χ2=0.08; 1df; p=0.78a 
aLikelihood ratio test: chi-squared statistic; degrees of freedom; p-value. 
 
 
14.4.2.1.9 The multivariate analysis of the association between current 
smoking intensity and the risk of incident high-grade CIN, controlling for 
exposure to cervical HPV infection of any type 
 
The multivariate analysis of the association between current smoking intensity and 
the risk of incident high-grade CIN, after controlling for exposure to cervical HPV 
infection of any type, is described in table 14.4.2.1.9. After controlling for exposure to 
cervical HPV infection of any type, despite attenuation in the estimates of the 
hazards ratios compared to those in the uncontrolled analysis, the associations 
remained statistically significant. 
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Table 14.4.2.1.9. The multivariate analysis of the association between 
current smoking intensity and the risk of incident high-grade CIN, 
controlling for exposure to cervical HPV infection of any type. 
 
Current Smoking 
Intensity 
Number of 
Women (%)
Number 
of Events
Hazards Ratio (95% CI)
    
Current smoking intensity 
(per category)  
1038 (100) 27 1.94 (1.22 to 3.09) 
   χ2=8.19; 1df; p=0.004a 
    
Non-smoker 649 (62.5) 12 1.00 ( Reference ) 
1 to 9 per day 191 (18.4) 5 1.72 (0.64 to 4.63) 
10 or more per day 198 (19.1) 10 2.55 (1.09 to 5.95) 
      χ2=4.66; 2df; p=0.10a 
aLikelihood ratio test: chi-squared statistic; degrees of freedom; p-value. 
 
 
 
Summary 
 
In univariate analyses, the risk of incident high-grade CIN in current smokers was 
twice that of current non-smokers; and increased significantly with current smoking 
intensity; in multivariate analyses controlling for past or current exposure to cervical 
infection with HPV16 or HPV18 and other HPV types, these hazards ratios 
decreased slightly, but remained statistically significant. No association was found 
between the risk of incident high-grade CIN and the other smoking variables. 
 
 
 
 
14.4.2.2 Controlling for sexual behaviour 
 
There were no associations between the available sexual behaviour variables and 
the incidence of high-grade CIN. Statistical significance is not necessarily the sole 
criterion for including or excluding a potential confounder from an analysis. However, 
it is the confounding of the relationship between smoking and high-grade CIN by 
cervical HPV infection which is relevant in this analysis. Although recent sexual 
behaviour is the strongest determinant of HPV-positivity at any point in time (e.g. 
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number of recent sexual partners is associated with HPV status, but not with high-
grade CIN (Deacon 2000)), in this analysis I can measure HPV status directly. 
Therefore, controlling for cervical HPV infection status will accomplish controlling for 
confounding by sexual behaviour, directly. 
 
14.4.2.3 Effect of the inclusion of women with prevalent cervical HPV 
infections and/or prevalent cervical cytological abnormalities in the analysis of 
the incidence of high-grade CIN 
 
In the analysis presented above, all 1,075 women in the study population were 
recruited close to the onset of sexual activity, and were free of cytological 
abnormality and cervical HPV infection at study entry. Therefore, although some 
women are likely to have acquired and cleared a cervical HPV infection prior to study 
entry, the assumption has been made that in these women the first cervical HPV 
infection detected during the follow-up period of this study is their first such infection 
overall. The first detection of high-grade CIN during follow-up was certainly the first 
occurrence of this disease. The study population described in these chapters of the 
thesis (the 1,075 women) therefore provides the best opportunity of being able to 
describe the association between incident high-grade CIN and smoking. However, 
the number of women diagnosed with high-grade CIN in this study population is 
small (28 women). 
 
Another analysis was conducted in which study entry criteria were relaxed: women 
with cervical cytologically abnormalities, or who were HPV-positive in their cervical, 
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or both, at study entry, were also included in the study population. The final study 
population for this analysis comprised 1,485 women, 56 of whom progressed to 
high-grade CIN. In this analysis, estimates of hazards ratios associated with smoking 
were not substantially changed, and the significant predictors identified were 
identical (Table 14.4.2.3). 
 
Table 14.4.2.3. The association between smoking and the incidence of 
high-grade CIN in an analysis including women all women with further 
follow-up after study entry. 
 
 All women (n=1485, 56 events) 
  Crude HR (95% CI) Adjusted HR (95% CI)a 
Current smoking status   
Non-smoker 1.00 (Reference) 1.00 (Reference) 
Smoker 2.19 (1.29-3.74) 2.06 (1.20-3.52) 
 p=0.003 p=0.007 
   
Current smoking intensity   
Non-smoker 1.00 (Reference) 1.00 (Reference) 
1-9 per day 2.04 (1.06-3.92) 1.90 (0.99-3.66) 
10+ 2.35 (1.27-4.37) 2.21 (1.19-4.12) 
 p-trend=0.01 p-trend=0.008 
aadjusted for exposure to cervical infection with HPV16, HPV18 and other HPV types 
 
 
 
Summary 
 
Conclusions remained unaltered, and estimates of association were essentially 
identical, in an analysis in which the study population was expanded to include 
women with HPV infection or cytological evidence of cervical disease at study entry. 
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Chapter 15 
 
SMOKING, CERVICAL HPV INFECTION, AND THE RISK OF 
CERVICAL NEOPLASIA 
 
DISCUSSION 
 
 
 
 
Repeated measurements of smoking and cervical human papillomavirus (HPV) 
status were used to explore the impact of smoking on the acquisition and duration of 
incident cervical HPV infections, and to measure the risk of acquiring incident high-
grade cervical intraepithelial neoplasia (CIN), in relation to changes in smoking and 
cervical HPV status. Several ways of measuring exposure to cigarette smoking were 
investigated in the analyses described in this thesis. One of the strengths of the 
study population and study design described in this thesis was that, by including 
women with incident cervical HPV infections, it was possible to measure the impact 
of changes in smoking and cervical HPV infection status during follow-up on the risk 
of high-grade CIN, and also to avoid any residual confounding by time from first HPV 
exposure.  
 
15.1 THE INCIDENCE OF CERVICAL HPV INFECTION 
 
HPV is a necessary, but not sufficient, cause of cervical cancer. Smoking may act as 
a cofactor, for example by increasing the risk of acquiring a cervical HPV infection, 
or by prolonging the duration of an infection which has already been acquired. 
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In univariate analyses of the association between smoking and the risk of acquiring 
an incident cervical HPV infection of any type, most of the smoking exposure 
variables were significant predictors. The magnitude of the risk estimates (hazards 
ratios) were typically small. However, it is possible that many of the significant 
associations merely reflect the fact that “ever-smokers” are at greater risk of infection 
than “never smokers”. In univariate analyses, the time since starting smoking, the 
cumulative duration of smoking, the duration of the current smoking episode, and 
pack-years of smoking, were all significant predictors of the risk of acquiring incident 
cervical HPV16 infection. All, however, appear to be protective: the risk of incident 
infection with cervical HPV16 decreased as the magnitude of each of these variables 
increased. There were no significant associations between smoking exposure and 
the risk of an incident cervical HPV18 infection, and measures of association tended 
to be closer to the null value of 1 than in the analysis of HPV16. 
 
In multivariate analyses of the association between smoking exposure and the risk of 
an incident cervical HPV infection of any type, after controlling for sexual behaviour, 
amongst all available exposure variables, only cumulative duration of smoking and 
pack-years of smoking were found to be significant predictors. Again, both appear to 
be protective against cervical HPV infection. Amongst the sexual behaviour variables 
investigated, only lifetime number of sexual partners was found to be associated with 
the incidence of cervical HPV16 infection in a univariate analysis; after controlling for 
this variable, the duration of the current smoking episode and pack-years of smoking 
were both found to be significant protective factors. There were no significant 
associations between risk-factors measuring sexual behaviour and the incidence of 
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cervical HPV18 infection in univariate analyses, therefore multivariate analyses were 
not undertaken. 
 
In the study described in this thesis, the increased risk of acquiring a cervical HPV 
infection of any type associated with smoking was for the most part explained by the 
association between smoking and sexual behaviour. These findings are consistent 
with those of most other longitudinal studies of incident cervical HPV infection (Ho 
1998b, Moscicki 2001, Sellors 2003, Winer 2003, Minkoff 2004, Munoz 2004); 
although one such study reported an increased risk of incident HPV infection 
associated with smoking, it did not distinguish between cervical and vulvovaginal 
infections (Ho 1998b); another found an increased risk only in HIV-infected women 
(Minkoff 2004). 
 
However, the protective effect of variables incorporating some measure of the 
duration of smoking, even after controlling for sexual behaviour, is more difficult to 
interpret. Not all studies have reported variables measuring duration of smoking. 
One study found an increased, but non-significant, risk associated with increasing 
pack-years of smoking (Moscicki 2001); another merely states that this variable was 
not as “highly associated” as other smoking variables, and so was not considered 
further (Minkoff 2004). I am reluctant to over-interpret counterintuitive results when 
estimates of effect for successive categories are subject to substantial fluctuation, 
and there is no clear or convincing trend. Another unusual finding is that ex-smokers 
almost always have a higher risk (based on the point estimate, not necessarily 
statistical significance) of incident cervical HPV infections of any type or of type 16 
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than current smokers. Other authors who have observed this phenomenon have also 
been unable to explain this. 
 
The fact remains that these results do not support the hypothesis that smoking 
increases the risk of acquiring a cervical HPV infection.  
 
15.2 THE DURATION OF CERVICAL HPV INFECTION 
 
Because the cohort used in many of the analyses described in this thesis included 
women who tested negative for HPV DNA in cervical samples at study entry, we 
were able to estimate the time of onset of an episode of cervical HPV infection. This 
is an important consideration, because the duration of an infection cannot be 
measured in women who already test positive for HPV in cervical samples at study 
entry. 
 
There were no statistically significant associations between any of the smoking 
exposure variables and the risk of clearing an incident cervical HPV infection, either 
of any type, or of type 16; there were too few clearance events to make the analysis 
of the clearance of cervical HPV18 infections worthwhile. Multivariate analyses 
yielded no further insight. In analyses of the duration of incident cervical HPV16 
infection, although not statistically significant, hazards ratios tended to suggest that 
smoking increases the risk of clearing an infection, i.e. that smoking is associated 
with a shorter duration of cervical HPV16 infections. 
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Two other studies have reported that smoking has a significantly protective effect 
against persistent infection (Hildesheim 1994, Ho 1998b), but this finding is by no 
means consistent across studies. One study which reported that smoking prolongs 
the duration of HPV infection included only prevalent cases; of two studies which 
included both prevalent and incident cases, one found no significant association, and 
the other, a significant association only in HIV-negative women; and only then in 
those infected with high-risk HPV types (Giuliano 2002b, Richardson 2005, Koshiol 
2006). If smoking per se does not increase the risk of the acquisition of cervical HPV 
infection, and if it does not prolong the duration of infection, then other mechanisms 
may have to be invoked to explain the excess risk of cervical neoplasia associated 
with smoking.  
 
15.3 THE INCIDENCE OF HIGH-GRADE CIN 
 
In univariate analyses of the association between smoking exposure and the risk of 
incident high-grade CIN, current smoking status and current smoking intensity were 
found to be significant predictors of risk. The risk of incident high-grade CIN in 
current smokers was twice that in current non-smokers; and increased significantly 
with smoking intensity. In multivariate analyses controlling for past or current 
exposure to HPV16 and HPV18 and other HPV types, these hazards ratios 
decreased slightly, but remained significant. No association was found with the other 
smoking variables. An increased risk of cervical neoplasia has occasionally been 
associated with smoking duration, but only following periods of exposure which are 
substantially in excess of those observed in our cohort. 
302 
 
The magnitude of the association between current smoking status and the risk of 
incident high-grade CIN was consistent with that observed in case-control and 
longitudinal studies restricted to women who tested positive for HPV (Deacon 2000, 
Castle 2002b, Moscicki 2001). The pooled IARC analyses, which included 
thousands of CIN3 and cancer cases, found a similar two-fold elevation of risk 
(International Collaboration of Epidemiological Studies of Cervical Cancer 2006a) 
(see section 12.2.1). However, regardless of sample size, these studies cannot 
reveal the temporal relationship between exposure and outcome, nor can they 
resolve the issue of residual confounding by the time from first cervical HPV 
exposure, even when restricted to HPV-positive women. In contrast, the study 
design and choice of study population described in this thesis enabled these issues 
to be addressed. 
 
15.4 CHOICE OF STUDY POPULATION 
 
The cohort study described in this thesis deliberately recruited only young women 
because it was the intention to recruit women who were free of both cervical disease 
and cervical HPV infection at study entry; only with such a study population is it 
possible to study the temporal relationship between exposure and incident disease. 
Although the women in this study were recruited immediately before, or soon after, 
the onset of sexual activity, the possibility cannot be ruled out that some women may 
have already cleared a short-lived cervical HPV infection prior to study entry. 
However, it can be confidently asserted that any high-grade CIN detected during 
follow-up is incident disease. Conclusions remained unaltered, and estimates of 
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association were essentially identical, when the study population was expanded to 
include women with cervical HPV infection, or cytological evidence of cervical 
disease, or both, at study entry. 
 
15.5 CHOICE OF DISEASE ENDPOINT 
 
CIN2 may be considered a “soft” end point, in the sense that it represents a 
potentially equivocal diagnosis of pre-cancer, and therefore women with CIN2 may 
not be at-risk of progression. CIN represents a continuum of abnormality; therefore, 
at one end of the spectrum (the “high” end), some cases diagnosed as CIN2 may in 
fact be CIN1, or at the other end (the “low” end), CIN3. CIN3 is an unambiguous 
diagnosis since it corresponds to abnormality extending throughout the full thickness 
of the epithelium, and is considered true pre-cancer (see section 2.2.1.1). However, 
it is current clinical practice that women with CIN2 are treated, as a result of the low, 
but not negligible, risk of disease progression in women with CIN2 (see sections 
2.2.3 and 4.2.3). Furthermore, the incidence of high-grade CIN, as defined in this 
thesis, has been used as an outcome measure for clinical trials of HPV vaccines 
(see section 4.3). 
 
15.6 CONTROL OF CONFOUNDING BY EXPOSURE TO CERVICAL HPV 
INFECTION 
 
Cervical HPV infection is a strong predictor of the risk of progression of early cervical 
neoplasia to high-grade CIN. Many investigators have analysed HPV-positive and 
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HPV-negative women separately, or restricted the analysis to “HPV-positive” 
women. However, HPV status is not a static variable, nor is it clear why the risk of 
disease should be restricted to the period when a woman is HPV-positive, according 
to possibly insensitive detection methods. 
 
The study design used by the cohort study described in this thesis enabled a more 
appropriate and efficient approach to the analysis of the association between 
smoking and high-grade CIN, controlling for exposure to cervical infection with HPV 
DNA of any type. HPV status was not determined at study entry only, or at diagnosis 
only, as other investigators have chosen, or been obliged, to do. Instead, cervical 
HPV status was determined prospectively at each study visit, and the analysis then 
incorporated these changes over time. Thus, for example, a woman who had 
intermittent periods of HPV-positivity during follow-up, would effectively contribute 
“time-at-risk” to both the exposed and unexposed groups, as appropriate. The time-
varying binary indicators measuring HPV exposure status, the construction of which 
is described in section 13.9, ensured that the comparison group using these 
variables was women during the period of follow-up when they were HPV DNA-
negative. Similarly for smoking status, which was also updated during follow-up. 
Restricting the analysis to when a woman was HPV-positive would make inefficient 
use of the data obtained and inevitably, and unnecessarily, introduce exposure 
misclassification. For example, how should a woman who went from being HPV-
negative to HPV-positive, and back again, be treated? 
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Of course, the way in which I controlled for confounding by HPV exposure is not 
perfect, in at least one respect. Ideally, I would also have adjusted for exposure to 
other individual high-risk HPV types in the same way as I did for HPV16 and HPV18. 
However, numbers were insufficient to allow this to be done, even in the expanded 
cohort of 1,485 women. Adjustment for other aspects of cervical HPV exposure, or 
allowing for more complex changes in HPV exposure status, may have been 
possible, for example by allowing women to move between HPV-positive and HPV-
negative states, by estimating cumulative exposure, or by adjusting for time since 
first cervical HPV infection. However, the latter variable, at least, would be redundant 
in this context since analyses based on the incident cohort do not suffer from 
confounding by time since first exposure because this occurs during follow-up, and 
changes in status are accounted for as they are detected. 
 
15.7 CONTROL OF CONFOUNDING BY VARIABLES OTHER THAN CERVICAL 
HPV INFECTION 
 
Confounding has to be dealt with on a study-by-study basis: the lack of confounding 
in one study does not rule out confounding in others. In a study intended to minimize 
residual confounding, it may be inappropriate to eliminate non-statistically significant 
variables from the final model, since confounding does not depend on considerations 
of statistical significance alone. My approach was to retain in the final model only 
those variables which were significant in multivariate analyses including smoking 
variables; this approach was applied consistently for all analyses. The analyses in 
which the inclusion of a potential confounder changed an estimated hazards ratio by 
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more than 10%, regardless of the statistical significance of the variable itself, were 
also those in which that confounder was a significant predictor, and for which results 
have been presented. The exception was age at first sexual intercourse in the 
analysis of high-grade CIN. Age at first intercourse was not a significant independent 
predictor of high-grade CIN. However, inclusion of this variable in a model also 
controlling for exposure to cervical HPV infection, yielded greater point estimates of 
association and corresponding increases in significance for all of the smoking 
variables, but without altering conclusions. Because the study hypothesis relates to 
the association between smoking and high-grade CIN, controlling for exposure to 
cervical HPV infection, I decided that presenting results which also controlled for age 
at first sexual intercourse detracted from the clarity of the presentation. 
 
15.8 MECHANISTIC EXPLANATION FOR THE ROLE OF SMOKING IN THE 
AETIOLOGY OF CERVICAL DISEASE 
 
I stated earlier that smoking may act as a cofactor, either by increasing the risk of 
acquiring a cervical HPV infection, or by prolonging the duration of an infection. This 
is not to rule out the possibility that other mechanisms exist by which cervical HPV 
infection might influence disease progression. Alternative mechanisms have not 
been well defined, nor will they be unless and until existing explanations are shown 
to be inadequate. There is no incentive for pursuing mechanistic explanations unless 
and until it can first be shown that the association between smoking and cervical 
neoplasia is not simply a consequence of residual confounding from time from first 
cervical HPV exposure. However, having now shown that smoking does not increase 
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the risk of acquiring cervical HPV infection, once sexual behaviour is controlled for; 
nor that it prolongs the duration of cervical HPV infection, we are obliged to 
speculate regarding other, as yet inadequately characterised, mechanisms. The 
longitudinal studies necessary to show that such smoking-related changes increase 
the risk of disease initiation, or disease progression, have yet to be undertaken. 
 
The evidence for a possible impact of smoking on the humoral and local immune 
responses to cervical HPV infection is conflicting. One study reported that HPV16-
infected women were less likely to have type-specific antibodies if they were 
smokers; another, that a sequential rise in HPV16 antibody levels was more 
common in smokers than in non-smokers (Silverberg 2006, Wiley 2006).  Whereas 
some investigators have concluded that smoking reduces the number of 
intraepithelial Langerhans' cells in the uterine cervix, others have found no 
association (Campaner 2006, Nadais 2006). 
  
15.9 CONCLUSION 
 
Although cigarette smoking by adolescents continues to be an important public 
health problem, the modest risk of cervical neoplasia associated with smoking is 
unlikely to persuade many to quit. Early age at smoking initiation is reported to 
increase the risk of lung and breast cancer, independent of smoking duration or 
intensity (Wiencke 1999, Gram 2005). Although the interdependent effects of age at 
smoking initiation, duration of smoking, time since smoking cessation, and calendar 
age, are not easily disentangled, such an effect is biologically plausible because 
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these tissues continue to grow and develop into early adulthood (Leffondre 2002, 
Wiencke 2002). Empirical evidence of the long-term effects on these tissues of early 
smoking initiation will be difficult to obtain. However, the cervix can be sampled more 
easily than many other sites (in terms of both accessibility and the acceptability of 
the sampling technique), and were smoking-induced DNA damage shown to 
precede the development of a pre-malignant phenotype at this site, then it would 
provide more compelling evidence that the harmful effects of smoking can occur 
earlier than is commonly believed. 
 
15.10 PUBLICATION 
 
A paper based on the work described in chapters 12, 13, 14 and 15 of this thesis 
was published in January 2010 (Collins 2010: see appendix 4). 
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Chapter 16 
 
THE KINETICS OF THE HUMORAL IMMUNE RESPONSE TO 
INCIDENT CERVICAL HPV16 AND HPV18 INFECTIONS 
 
INTRODUCTION 
 
 
 
 
 
Orientation 
 
In this chapter I: 
 
• describe relevant aspects of the immune system 
 
• describe the immune response to HPV infection 
 
• provide an overview of the evidence in the literature relating to the kinetics of the 
immune response to cervical HPV infection 
 
• describe relevant aspects of the measurement of the humoral immune response 
to incident cervical HPV16 and HPV18 infections 
 
 
 
 
 
16.1 BACKGROUND 
 
The kinetics of the humoral immune response following an incident cervical HPV 
infection in naïve women, i.e. women who have never been exposed to HPV 
infection, are not well characterised. There are at least two major difficulties in 
arriving at such a characterisation. 
 
First, because cervical HPV infection is an asymptomatic condition, its time of onset 
can never be precisely determined. However, its time of onset can be approximated 
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by making frequent observations at short time intervals in women who are 
unexposed to cervical HPV infection at recruitment. These women should be 
recruited soon after they have first had sexual intercourse, because the longer the 
time interval between first sexual intercourse and study entry, the more likely it is 
that a woman will have acquired, and then cleared, at least one cervical HPV 
infection during this time (Woodman 2001, Collins 2002). 
 
The second difficulty relates to the assay used to measure the immune response to 
HPV infection. The most commonly used assay is the virus-like particle-based 
enzyme-linked immunosorbent assay, the VLP-ELISA. The integrity of the VLP-
ELISA depends on the maintenance of intact virus-like particles (VLP); disrupted or 
incorrectly-folded VLPs may lead to the detection of non-neutralizing and cross-
genotype-reactive antibodies, thus complicating the interpretation of results. 
Competitive radioimmunoassays (cRIA) which specifically measure HPV type-
specific neutralizing antibodies have also been developed. The cRIA is more 
sensitive than the ELISA, and is less likely to be influenced by impurities in the 
sample. However, like any serological assay based on competition, it will fail to 
detect serum antibodies that which to bind to, or compete with, the epitopes that bind 
the competing antibody. 
 
A sensitive and specific assay capable of measuring the functionally-relevant HPV 
type-specific neutralizing antibodies is required. 
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16.2 THE IMMUNE SYSTEM 
 
The immune response can be dichotomised into humoral immunity and cell-
mediated immunity: humoral immunity refers to those aspects of the immune 
response which are mediated by antibodies; cell-mediated immunity refers to those 
aspects which are mediated by cells, such as T-lymphocytes, macrophages and 
natural killer cells. Cell-mediated immunity is directed primarily against intracellular 
pathogens and is very effective at removing virus-infected cells, and intracellular 
bacteria, but also provides defence against fungi, protozoans, and larger parasites 
(Abbas 2003, Lydyard 2004, Stanley 2006). 
 
The immune system has both non-specific and specific components, innate 
immunity and adaptive immunity, respectively. These components function 
cooperatively. Innate immunity provides an early and rapid response to “insult”, or 
more specifically to infection, but it is not very specific, i.e. it may not distinguish 
subtle differences between different pathogens, and it responds in essentially the 
same way to repeated infections of the same type. In contrast, although the 
adaptive, or acquired, immune response takes longer to respond to antigen than the 
innate immune response, it is more powerful, versatile, specific, and “remembers” 
prior exposures. The adaptive immune response increases in magnitude and 
capability with successive exposures to the same antigen. The adaptive immune 
response, as with the immune response generally, has two branches, cell-mediated 
immunity and humoral immunity (Abbas 2003, Lydyard 2004). 
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16.2.1 Cell-mediated immunity 
 
The principal cells involved in cell-mediated immunity are T-lymphocytes, or T-cells. 
The principal mechanisms of innate immunity against viruses are inhibition of 
infection by type 1 interferons, and natural-killer-cell-mediated killing of infected cells 
(Abbas 2003, Andersen 2006, Lydyard 2004). In the cohort study described in this 
thesis, cell-mediated immunity to cervical HPV infection was not measured and so 
will not be considered further. 
 
16.2.2 Humoral immunity 
 
The principal components of the adaptive immune response are antibodies produced 
by B-lymphocytes, and by plasma cells, which also stimulate the production of 
chemical mediators of the immune response, such as complement and interferon. 
The principal cells involved in humoral immunity are B-lymphocytes, or B-cells, 
which produce large quantities of antibodies. Antibodies are highly-specific antigen-
binding molecules, which either remain attached to the B-cell as a receptor, or are 
released into the circulation to mediate elimination of antigen. 
 
There are five classes of antibody, each of which also has two or more subclasses: 
IgM (immunoglobulin M), IgD, IgA, which provides the first line of defence at mucosal 
surfaces, IgE, and IgG. IgG is found throughout the body, and is the main defence 
against blood-borne infectious agents. 
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Antibodies can act directly, i.e. on their own independently of a cellular intermediary, 
to neutralize certain antigens, such as viruses; they can coat (“opsonise”) a target 
antigen, and thereby enhance the activity of phagocytes; or lead to the direct killing 
of cells via antibody-dependent cellular cytotoxicity. In general, adaptive immunity 
against viral infections is mediated by, antibodies which block virus binding and entry 
into host-cells, and by cytotoxic T-lymphocytes, which eliminate the infection by 
killing infected cells (Abbas 2003, Lydyard 2004). 
 
16.3 DESCRIPTION OF THE IMMUNE RESPONSE TO CERVICAL HPV 
INFECTION 
 
Infection with an oncogenic HPV type (e.g. types 16 and 18) is a necessary but not 
sufficient cause of cervical cancer. Cervical HPV infection is extremely common, but 
most infections, particularly in young women, appear to be transient and of short 
duration (Woodman 2001). The immune system is clearly important in the control of 
cervical HPV infections, a fact which can be deduced directly from the increased 
incidence and duration of cervical HPV infections and squamous intraepithelial 
lesions of the cervix in immunosuppressed women (Vernon 1994, Zur Hausen 2002, 
Baseman 2005). Immune responses against HPV during the early stages of infection 
may be important in preventing reinfection, inhibiting viral spread, and preventing 
viral persistence (De Gruijl 1997). However, the kinetics of the immune response to 
cervical HPV infections have yet to be characterised. 
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16.3.1 Humoral immunity to cervical HPV infection 
 
The precise role of the humoral immune response in the mediation of cervical HPV 
infection, or of cervical neoplasia, has yet to be established, but has now been 
investigated in several studies. 
 
16.3.1.1 Cross-sectional studies examining humoral immunity to cervical HPV 
infection 
 
Evidence from cross-sectional studies regarding an association between cervical 
HPV infection and the immune response to that infection is ambiguous, since the 
cross-sectional study design does not enable the determination, with certainty, of the 
order in which exposure and outcome arrived. Cross-sectional studies will therefore 
not be considered further in this chapter. 
 
16.3.1.2 Longitudinal studies examining humoral immunity to cervical HPV 
infection 
 
Only longitudinal study designs, such as that used in the cohort study described in 
this thesis, are capable of defining the kinetics of the immune response to incident 
cervical HPV infection. In this section, I describe reports from longitudinal studies 
which have investigated some aspect of the immune response to cervical HPV 
infection; results relating to disease endpoints are not considered, since these are 
not the subject of analyses in this thesis and so cannot be put into context. I focus on 
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a subset of mature longitudinal studies: the names given to these studies are for 
convenience of reference only, and are not necessarily those with which the principal 
investigators endowed them. 
 
16.3.1.2.1 The Amsterdam cohort study 
 
This was a prospective cohort study describing the development, persistence, and 
progression, of CIN lesions in relation to the natural history of HPV infection, 
including the humoral immune response to that infection. The cohort consisted of 
353 women aged 18 to 55 years, who were routinely referred to a single colposcopy 
clinic in Amsterdam, The Netherlands. All women had mild to moderate or severe 
dyskaryosis at study entry and were followed at intervals of three to four months until 
they clinically progressed to CIN3. PCR was used to test for 14 high-risk HPV types. 
 
Results from this cohort study have now appeared in several publications (Remmink 
1995, De Gruijl 1996a, Rozendaal 1996, De Gruiijl 1996b, De Gruijl 1997, Bontkes 
1998a, Bontkes 1998b, Nobbenhuis 1999, Bontkes 1999a, Bontkes 1999b, De Gruijl 
1999, Bontkes 2000, Rozendaal 2000, VanDuin 2002). One of these investigated the 
humoral immune response against HPV16 VLPs, and its relationship with the 
clearance of HPV16 infection and cervical lesions (Bontkes 1999b). Cervical mucus 
samples from 125 women, and plasma samples from 100 women, respectively, were 
tested for IgA and IgG antibodies, using HPV16 L1/L2 VLP-based ELISA. Women 
were more likely to have a humoral IgA response when HPV16 DNA was not 
detected in the smear, than when it was, although this difference was not statistically 
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significant; in contrast, women were more likely to have a humoral IgG response 
when HPV16 DNA was detected. 
  
Although the sample size was relatively large, this was essentially a cross-sectional 
analysis of a longitudinal study and therefore has the weaknesses of a cross-
sectional study rather than the strengths of a longitudinal study. There are also many 
design flaws with this study: for example, it was not certain that women were free of 
the primary outcome at study entry, a pre-requisite for a cohort study; women were 
reported as being disease-free at study entry, yet a fifth were cytologically abnormal 
at this time; and the cytological classification of some women was inaccurate 
(Woodman 2002) (see section 20.3.2.2 for further discussion of some of the flaws 
with this study). In the study population used in the analyses described in this 
section of the thesis, all women were unambiguously free of cervical cytological 
abnormalities at study entry. 
 
16.3.1.2.2 The San Francisco cohort study 
 
This was a prospective cohort study investigating the early natural history of cervical 
HPV infection in women aged between 13 and 22 years recruited from one family 
planning clinic and one student health center in the San Francisco Bay area, USA. 
Several methods were used for the detection of HPV DNA in this study, with, for 
example, PCR used on only selected subsets of women. 
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Results from this cohort study have now appeared in several publications (Moscicki 
1998, Moscicki 1999, Scott 1999, Nakagawa 2000, Moscicki 2001, Nakagawa 2002, 
Moscicki 2004). One paper describes temporal changes in the humoral immune 
response to HPV16, using serial virus-like particle (VLP) antibody assays 
(Nakagawa 2002). However, this description is based on only eight women: it is at 
best suggestive. Four women had two HPV16 DNA-positive episodes; for two of 
these women, the second episode “occurred in the presence of high titers of HPV16 
VLP antibody”. The authors say “this brings into question the protective role of 
humoral immunity in preventing repeated infection”. They also found that all four of 
these women rapidly became HPV16 DNA-negative following the start of the second 
HPV16 episode, “suggesting the presence of immunological memory”. 
 
16.3.1.2.3 The New Brunswick cohort study 
 
This was a prospective cohort study investigating the natural history of cervical HPV 
infection, which recruited 608 students (mean age 20 years) from Rutger’s University 
in New Brunswick, USA. Women were followed-up for a maximum of three years, at 
intervals of six months. At each visit, a cervicovaginal lavage was done for use in 
HPV testing; PCR and southern blot were used to test for HPV DNA. Blood samples 
for the preparation of serum were collected at the annual visits initially, but also at 
the six-month visits in the last year of  the study.  
 
Results from this cohort study have now appeared in several publications (Burk 
1996b, Ho 1998b, Morrison 1998, Ho 2002, Kahn 2002a, Kahn 2002b, Ho 2004). 
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One report from this study investigated whether host immunity protected against 
subsequent infection, in a subset of 247 women who had further follow-up after their 
initial incident, or prevalent, HPV infection (Ho 2002). In this report, the authors 
found that the detection of persistent antibodies to HPV16 VLPs was associated with 
a reduced risk of subsequent HPV infection, and that type-specific persistent 
infection had a protective effect on subsequent infection with a HPV16-related type. 
A later report examined seroconversion to HPV16 VLPs (n=403, e (number of 
events)=25) and clearance (duration) of seroconversion to HPV16 VLPs (n=87, 
e=37) (Ho 2004). Women infected with HPV16 were more likely to seroconvert than 
those who were HPV-negative, or than those who were infected with other HPV 
types. There was no difference in the risk of seroconversion for women with 
“persistent” infection with HPV16, compared to those without. Among women who 
became seropositive, those who had no subsequent HPV infection had the highest 
chance of becoming seronegative; persistent HPV16 infection did not significantly 
alter the risk of becoming seronegative. 
 
This cohort study fulfils at least one of the ideal criteria required of a study designed 
to investigate the humoral immune response to HPV, i.e. frequent observations at 
short intervals in women who are recruited soon after first sexual intercourse. 
However, this study did not separately distinguish cervical from other lower genital 
tract infections (by design). Therefore, notwithstanding its relatively large sample 
size, this study can make only a limited contribution to the study of the humoral 
response to cervical HPV infections. In contrast, the study described in this thesis 
examined the humoral immune response to cervical HPV infections specifically. 
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16.3.1.2.4 The Guanacaste cohort study 
 
This was a population-based cohort study of the natural history of cervical neoplasia, 
which recruited over 10,000 women of all ages from Guanacaste, a rural province of 
Costa Rica with consistently high rates of invasive cervical cancer. Women were 
followed-up at intervals of between six months and one year, for a period of  several 
years (this study may be ongoing at the present time (August 2008)). The presence 
of HPV DNA was detected using PCR. 
 
Results from this cohort study have now appeared in several publications (Herrero 
1997, Ung 1999, Hildesheim 2001, Wang 2001, Gravitt 2003, Wang 2003, Castle 
2004, Viscidi 2004, Wang 2004a, Wang 2004b, Castle 2005a, Castle 2005b, Castle 
2006). In reports from this study investigating the immune response to HPV 
infection, only the sera samples taken at study entry and at the end of follow-up, five 
to seven years later, have been analysed. The investigators have reported that 55% 
of women who were HPV16-seropositive at baseline “remained” seropositive five to 
seven years later, and that there was an association between viral load at baseline 
and the risk of seroconversion to HPV16 at the end of follow-up (Wang 2004a). 
Seropositivity to either HPV16, HPV18, or HPV31, did not protect against 
subsequent infection with the specific type, or either of the other types; in fact, there 
was a significantly increased risk of infection with HPV18-related types among 
women seropositive for HPV16 or HPV31 at study entry (Viscidi 2004). 
 
320 
 
It is difficult to interpret these results: with such a long time interval between 
measurements of serostatus, these analyses cannot eliminate the possibility that 
women reverted to being seronegative in between the two measurements. The study 
described in this thesis made frequent measurements of serostatus at short time 
intervals, and was thus in a better position to ensure that any change in serostatus 
would be observed. 
 
16.3.1.2.5 The Copenhagen cohort study 
 
This was a population-based cohort study of women randomly selected from the 
general population of Copenhagen, Denmark. Women made two visits, the second 
“about” two years after the recruitment visit. Cervical samples for HPV DNA testing 
and blood samples for serological testing, were taken at both visits. 
 
Results from this cohort study have now appeared in several publications (Kjaer 
1996, Kjaer 1997, Kjaer 1998, Kjaer 2001, Kjaer 2002, Pastrana 2004). One report 
describes data relating to 100 women who were virgins at study entry, and 105 
monogamous women (mean age at recruitment approximately 24 years) (Kjaer 
2001). Among initially virgin women who first experienced sexual intercourse during 
the study period, nine had become HPV16 DNA-positive by the second of their two 
visits, of whom seven (78%) were seropositive to HPV16 VLPs; in contrast, only two 
of 13 women who had acquired an infection with HPV DNA of another type during 
follow-up seroconverted, as did one woman who was not HPV16 DNA-positive, but 
was positive to HPV DNA of another type, at study entry. Among women who were 
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monogamous at study entry, five had become HPV16 DNA positive at the second 
visit, of whom four (80%) were seropositive to HPV16 VLPs; seroconversion was 
also observed in three women who became positive for other types during follow-up, 
and at study entry, or during follow-up, in nine women in whom no HPV DNA was 
ever detected. This is difficult to interpret since there were only two visits, with a 
substantial interval between them: it is not possible to be confident about temporality 
with such a large time interval. In contrast, the ability to demonstrate temporality was 
one of the clear strengths of the design of the study described in this thesis. 
 
16.3.1.2.6 The Swedish Schoolgirl cohort study 
 
The was a cohort study (Andersson-Ellstrom 1996a, Andersson-Ellstrom 1996b) 
which recruited 98 women aged 15 to 17 years who were attending a secondary 
school in Karlstad, Sweden. Women were seen at intervals of six months. PCR was 
used to detect HPV DNA. 
 
One report on this study used HPV L1/L2 VLP ELISA to detect IgG antibodies to 
HPV16 and HPV33 VLPs (interestingly, “disrupted” BPV capsids were also included 
as negative-controls: see later) (Andersson-Ellstrom 1996b). Seven women who 
were initially HPV16 DNA-negative and seronegative to HPV16 VLPs, seroconverted 
during follow-up; five of these women were HPV16 DNA-positive at their final visit, 
including one woman known to be HPV16 DNA-positive at her second visit. Six 
women who were initially HPV16 DNA-negative and seronegative to HPV16 VLPs, 
and who subsequently acquired HPV16 DNA, also seroconverted during follow-up 
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(these two groups are not mutually exclusive). Unfortunately, despite the longitudinal 
nature of this study, and the presentation of results for individuals, sufficient details 
are not provided to establish the temporal relationship between the acquisition of 
HPV DNA and seroconversion. As discussed above, the study described in this 
thesis was in an advantageous position to establish temporality. 
 
16.3.1.2.7 The University of Washington cohort study 
 
This was a cohort study which recruited 603 female students who attended the 
University of Washington (UOW), Washington, USA, between 1990 and 1997. There 
are now several reports on this cohort, including five which focus on some aspect of 
the immune response to incident HPV infections (Xi 1995, Carter 1996, Xi 1997, 
Carter 2000, Hagensee 2000, Thomas 2000, Xi 2002, Onda 2003, Winer 2003, 
Buchinsky 2006). The UOW cohort study is of particular interest because, as well as 
fulfilling the ideal criteria required of a study designed to investigate the humoral 
immune response to HPV, it is possibly the most comparable cohort study to the 
study reported in this thesis, the Birmingham Brook Clinic cohort. 
 
16.4 COMPARISON OF THE “UNIVERSITY OF WASHINGTON” AND 
“BIRMINGHAM BROOK CLINIC SEROLOGY” COHORTS 
 
The final UOW cohort comprised 603 women, not all of whom contributed to the 
longitudinal analyses due to the inevitable exclusion of women from analyses 
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because of an imperfect correspondence between the available DNA and serum 
samples. For example, only 528 women entered one analysis (Xi 2002). 
 
The Birmingham Brook Clinic cohort study enrolled 2,011 women. The following 
women were then excluded: those who had an abnormal smear, or tested positive 
for HPV DNA in a cervical sample, at enrolment; and those who did not provide two 
or more sera, and cervical, samples which could be tested both cytologically and 
virologically. This left 554 women available for a longitudinal study of the immune 
response to incident cervical HPV infections. For ease of reference, these 554 
women will be referred to as the Birmingham Brook Clinic Serology cohort (BBS). 
 
16.4.1 Sexual experience 
 
The median age at study entry was 19 years in the UOW cohort  and 18 years in the 
BBS cohort. The median number of years of sexual activity prior to study entry was 
two for members of the BBS cohort; this statistic is not reported for the UOW cohort.  
One hundred and seventy one (28.2%) women in the UOW cohort were virgins at 
enrollment; all women in the BBS cohort were already sexually active at study entry. 
The median number of sexual partners at study entry was two in those women in the 
UOW cohort who were already sexually active at study entry, and two in the BBS 
cohort. 
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16.4.2 Frequency of sampling and duration of follow-up 
 
The median time interval between visits in the UOW cohort was 4.7 months, 
compared to 7 months in the BBS cohort; the median duration of follow-up in studies 
reporting on the immune response in the UOW cohort ranged from 26 to 39 months; 
it was 29 months for the BBS cohort. 
 
16.4.3 The prevalence of HPV infection and cervical cytological abnormality at 
study entry 
 
The prevalence of HPV infection in the UOW cohort was 19.7%; that of cervical 
cytological abnormality is not reported, nor is the presence of cytological abnormality 
listed among the exclusion criteria. All women in the BBS cohort tested negative for 
HPV DNA in cervical samples (prevalence 0%) and had a normal cervical smear at 
study entry. 
 
16.4.4 The number of incident HPV infections 
 
In the UOW cohort, the number of women with incident HPV16 infections included in 
the various analyses of the immune response ranged from 25 to 67; the only 
analysis of incident HPV18 infections included 35 women. The BBS cohort included 
72 women with incident cervical HPV16 infections and 40 with incident cervical 
HPV18 infections. 
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16.4.5 Detection of types other than HPV16 prior to the first detection of HPV16 
 
Approximately 43% of women with an incident HPV16 infection tested positive for a 
type other than HPV16 at enrolment in the UOW cohort; all women in the BBS 
cohort were HPV DNA-negative in cervical samples at enrolment. After enrolment, 
23% of women in the BBS cohort with an incident cervical HPV16 infection tested 
positive for a type other than HPV16 before HPV16 was first detected; this statistic is 
not reported for the UOW cohort. 
 
16.4.6 Availability of sera samples 
 
The mean number of sera samples available for women in the UOW cohort was 6.6, 
compared to 4.2 for the BBS cohort. The mean number of sera samples available for 
women in the BBS cohort with an incident cervical HPV16 infection was 5.3, and 5.8 
for those with an incident cervical HPV18 infection. 
 
16.4.7 Type of infection 
 
Regrettably, none of the papers describing the immune response to incident HPV 
infection among the UOW papers, distinguishes between women with cervical and 
vulval HPV infections. In contrast, the BBS cohort includes only women with incident 
cervical HPV infections (intentionally: infections at other sites were not tested for 
explicitly). 
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16.5 DISCUSSION OF LONGITUDINAL STUDIES 
 
Unlike the BBS cohort, the UOW cohort does not describe the kinetics of the 
immune response to incident cervical HPV infections specifically. The estimated time 
to seroconversion following an incident HPV16 infection also varies across the 
different reports based on the UOW cohort, with differences attributed to changes in 
sample size. Alternatively, the variation may reflect differences between the reports 
in terms of the methods used to measure or analyse time to seroconversion. It is 
also impossible to interpret reported associations between the occurrence of cervical 
cytological abnormality and seroconversion following an incident cervical HPV 
infection, given that an unspecified, but substantial, number of these infections did 
not involve the cervix. The BBS cohort includes a substantial number of women with 
incident cervical HPV16 and/or HPV18 infections; it is also a potentially “cleaner” 
cohort for investigating the immune to cervical HPV infections because it includes 
only women with such infections, all of whom tested negative for HPV DNA and had 
a normal cervical smear at study entry. The analysis of the immune response to 
cervical HPV infection in the cohort described in this thesis is therefore worth 
pursuing. 
 
16.5.1 Need for further studies 
 
Some of the cohort studies described above have now been analysed and reported 
extensively. While most of the cohorts are large, the study population for the analysis 
of the immune response to HPV infection has often been quite small. Overall, these 
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studies do not provide convincing evidence of temporality, i.e. that the immune 
response follows, rather than precedes, the detection of HPV DNA; and some of the 
more mature studies do not separately distinguish cervical from other lower genital 
tract infections. However, the main criticism which can be levelled at all of the 
studies described above relates to the assay used to measure the immune 
response. Measuring the HPV-specific immune response requires prior knowledge 
of the types of immunity that may be important, and different immunological assays 
often produce conflicting results (Crosbie 2006). In all of the studies discussed 
above, VLP-based ELISA was used to detect antibodies to HPV infection: however, 
this assay may not measure the functionally-relevant aspect of the humoral immune 
response, the neutralizing antibody response. 
 
16.6 THE NEUTRALIZING ANTIBODY RESPONSE TO HPV 
 
It is currently assumed that the protective humoral response to HPV infection is 
mediated via neutralizing antibodies (Doorbar 2005). Neutralizing antibodies prevent 
the infection of susceptible cells by HPV, by preventing the HPV virions from 
attaching to cellular receptors, thereby denying them access to the cell and therefore 
also denying them the opportunity to replicate. In natural infection in animals, the 
generation of anti-L1 (the major capsid protein: see section 3.1.2.1) neutralizing 
antibodies is associated with protection against challenge with infectious virus 
(Stanley 2006). However, a newly synthesised HPV virion is not released from a cell 
until it reaches the epithelial surface (Doorbar 2005), and is thus protected from 
interference by the humoral immune system of the host throughout the majority of its 
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life cycle. It is therefore unlikely that antibodies alone, neutralizing or otherwise, will 
be sufficient to clear an HPV infection once it has become established. 
 
16.7 MEASUREMENT OF THE HUMORAL IMMUNE RESPONSE  
 
16.7.1 HPV neutralization assays 
 
Neutralization assays are serological assays which measure the neutralizing-
antibody response to a virus. Some neutralization assays employ real viruses, but 
most use surrogates, in particular the virus-like particle-based enzyme-linked 
immunosorbent assay (VLP-based ELISA). 
 
16.7.1.1 VLP-based ELISAs 
 
Enzyme-linked immunosorbent assay (ELISA) is a widely used immunoassay for the 
detection of antigen. VLP-based ELISA’s are so-called because they use a virus like 
particle (VLP) as the target antigen. The capsid of every HPV type consists of two 
structural proteins, L1 and L2, which, although homologous across types, are 
nevertheless specific to a given type (see section 3.1.2.1). VLP are manufactured in 
vitro from these structural proteins: they resemble the virus from which they are 
derived, but contain no viral genome, and are therefore non-infectious. VLPs can, 
however, display conformationally-dependent surface epitopes, and so are expected 
to generate a similar immune response to the real virus which they mimic. 
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16.7.1.1.1 VLP-based ELISAs: Advantages 
 
VLP-based ELISA is now a well-established technique: it is sensitive, rapid to 
perform, and inexpensive. VLP-based ELISA is an economical assay for testing 
samples on a large scale, high-throughput, testing. 
 
16.7.1.1.2 VLP-based ELISAs: Disadvantages 
 
While VLP can be produced in large quantities using commercially-available 
expression systems, manufacturing stable VLP for some types of HPV, in particular 
for HPV18, is still not straightforward. VLP-based ELISA are reliant upon intact high-
quality VLP; disrupted or incorrectly-folded VLP may lead to the detection of non-
neutralizing and cross-genotype-reactive antibodies. Cross-reactions among 
phylogenetically-similar papillomaviruses have been reported, and multiple cross-
reactions between distinct types have been observed in a highly-infected population 
(Coursaget 2003). It is therefore potentially difficult to determine whether the assay 
is measuring a neutralizing, or a non-neutralizing, immune response, and to 
distinguish between an immune response to the target HPV type, to one of its 
closest genotypes, or to another HPV type. 
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16.7.1.2 Pseudovirus-based assays 
 
Early neutralization assays were technically demanding, expensive, low-throughput, 
and the limited in terms of the number of HPV types which could be assayed. Most 
assays now rely on the production of pseudovirions in vitro (Roden 1996, Unckell 
1997, Kawana 1998, Stauffer 1998, Touze 1998, Rossi 2000), yielding assays which 
are comparatively high-throughput (Pastrana 2004, Buck 2005). In theory, almost 
any type of HPV-pseudovirion, i.e. a PsV which mimics any of the HPV types, can be 
produced, although some types are easier to produce and more stable than others. 
 
Pseudovirions are similar to VLP, in that they are constructed of the L1 and L2 
proteins of the relevant virus, but they differ from VLP in that they also package a 
“genome”, which usually encodes a reporter or marker gene. Pseudovirions are 
infectious in the sense that they are capable of attaching themselves to the 
appropriate cell-surface receptors of a susceptible cell and delivering the 
pseudovirions genome into that cell, where gene expression of the genes encoded 
by the pseudovirus genome can occur. Measurement of the expression of reporter 
molecules allows quantification of how efficient an “infection” has been, and 
consequently how much neutralizing antibody is present in a test serum. 
 
 
331 
 
16.7.1.2.1 Pseudovirus-based assays: Advantages 
 
Pseudovirus-based assays measure the most functionally-relevant aspect of the 
immune response to viruses. There is no doubt that an appropriately conducted 
pseudovirus-based assay specifically measures neutralizing, as opposed to non-
neutralizing, antibodies: unlike VLP-based assays, the “genes” of a pseudovirion will 
only be expressed if the pseudovirus enters (infects) the cell, and co-opts the cellular 
DNA-replication machinery so that the gene which produces the marker molecule 
can be expressed. This assay is sensitive, and HPV type-specific. 
 
16.7.1.2.2 Pseudovirus-based assays: Disadvantages 
 
Neutralization assays are a relatively new technology. At present, they are 
cumbersome, time consuming, technically difficult to establish, i.e. get to work 
correctly at first, and perform, and are expensive. 
 
16.7.1.3 Justification for the assay used in this study 
 
In this study, an adaption of a neutralizing antibody assay originally developed by 
Pastrana et al. (Pastrana 2004) was used. This assay is described in detail in 
chapter 17. This assay is as sensitive as the commonly used VLP-based ELISA, is 
more HPV type-specific, and specifically measures neutralizing antibodies, the 
functionally-relevant antibodies. 
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Having first characterised the reproducibility of the neutralizing antibody assay, I 
then describe the kinetics of the neutralizing antibody response in a cohort of young 
women who were recruited soon after first sexual intercourse, and who first tested 
positive in cervical samples for HPV16 DNA, or HPV18 DNA, or both, during follow-
up. 
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Chapter 17 
 
THE KINETICS OF THE HUMORAL IMMUNE RESPONSE TO 
INCIDENT CERVICAL HPV16 AND HPV18 INFECTIONS 
 
METHODS 
 
 
 
 
 
Orientation 
 
In this chapter I: 
 
• describe the laboratory methods and procedures used to establish and carry out 
a neutralizing antibody assay 
 
• describe the way in which the neutralizing antibody assay was carried out in 
practice 
 
• provide a numerical example to illustrate the data produced by the neutralizing 
antibody assay and the method used to calculate the magnitude of the 
neutralizing antibody response 
 
• describe the statistical methods used to measure intra- and inter-assay reliability 
 
 
 
 
 
17.1 SEROLOGICAL SAMPLES 
 
At each visit, women were requested to provide a blood sample. Serum was 
collected from each blood sample, by centrifugation, and stored for future analysis. 
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17.2 THE DETECTION OF NEUTRALIZING ANTIBODIES TO HPV16 AND HPV18 
 
Neutralizing antibody assays detect functionally relevant antibodies which block 
infection of susceptible target cells. The assay used in this analysis employed 
structures which “simulate” the viruses of interest, called pseudovirions (PsV); these 
are essentially virus-like particles which also encapsidate a reporter-gene. Serum 
samples were tested for their ability to block the infection of target cells by these 
PsV.  
 
In this study we have used an adaption of a neutralizing antibody assay originally 
developed by Pastrana et al. (Pastrana 2004). A description of the laboratory 
methods used in conducting this assay is given below; a formal technical description 
appears in appendix 5. 
 
17.2.1 Preparation of pseudovirions 
 
To manufacture HPV type-specific PsV, 293TT cells were transfected with three 
plasmid vectors (a plasmid is a small extra-chromosomal DNA molecule which is 
capable of independent replication): one each encoding the major (L1) and minor 
(L2) capsid proteins of the relevant HPV type (see section 3.1.2.1), and one 
encoding a “reporter” molecule, in this case secreted (embryonic) alkaline 
phosphatise (SEAP). For reasons which will be explained subsequently, PsV of 
bovine papillomavirus type 1 (BPV1) were also manufactured, using two plasmid 
vectors: one encoding both of the capsid proteins of BPV1, and one encoding SEAP. 
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HPV16, HPV18 and BPV1 PsV were thus manufactured in essentially identical, but 
separate, processes. 
 
Once a cell has been transfected with a plasmid, it will begin to express the gene 
encoded by that plasmid. In this case, this will lead to the expression of the L1 and 
L2 proteins of the viruses of interest. The L1 and L2 proteins self-assemble into a 
PsV consisting of a capsid encapsulating the plasmid encoding SEAP. It is this 
SEAP-encoding piece of DNA which distinguishes a PsV from a virus-like particle 
(VLP): a VLP consists of an empty capsid, whereas a PsV also contains a DNA 
“genome”. Having been transfected, and the PsV allowed to assemble and mature, 
the 293TT cells are then disrupted to release the PsV, which are then isolated and 
purified. 
 
17.2.2 The Neutralizing antibody assay 
 
The principle behind the assay is illustrated in figure 17.2.2. 293TT cells are used as 
“target” cells in this assay (as well as being used in the manufacture of PsV). These 
cells possess the appropriate cell-surface receptors for infection by HPV, and 
therefore also the PsV which are designed to mimic HPV. If a solution of PsV and 
target cells is prepared, the PsV will “infect” the target cells and start to express the 
PsV genes, which in this case means the expression of SEAP (figure 17.2.2 part a). 
The target cells secrete SEAP into the surrounding culture medium. Quantitation is 
then possible, following the addition of a substrate for alkaline phosphatise, which 
produces a luminescent product which can be measured. However, if antibodies to 
the virus mimicked by the PsV, or more specifically a serum sample which is 
suspected of containing such antibodies, is also included in the solution being 
tested, then these antibodies can potentially “neutralize” the PsV before they infect 
the target cells, thereby preventing, or reducing, the expression of SEAP (figure 
17.2.2 part b). 
 
Figure 17.2.2. The principle behind the neutralizing antibody assay. 
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Developing and optimising the neutralizing antibody assay in the laboratory in which 
the assay was implemented took several months. Setting-up the assay required the 
concentrated effort of a laboratory technician for most of a working day; which was 
then followed by three days of incubation i.e. the assay components were mixed and 
were allowed to interact for three days; and finally, the processing of the well-plates 
for reading again consumed a substantial portion of a working day. At any given 
time, only a single laboratory technician was employed in conducting this assay. The 
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extensive amount of work required in the first and third steps of the assay, outlined 
above, severely limited the number of samples which could be analysed at any one 
time. The amount of time required to conduct the assay from start to finish, and the 
constraints of the working week, further limited the throughput of this assay. 
 
17.2.3 Determination of the amount of pseudovirus to use in the neutralizing 
antibody assay 
 
One of the final stages in the development of the neutralizing antibody assay was to 
determine the amount of PsV to use: if too many PsV were used, even sera 
containing high antibody titres would be unable to neutralize the PsV; if too few were 
used, the PsV would be neutralized by sera with even very low antibody titres. 
 
The production, purification and determination of the amount of PsV to use in the 
assays for each of the three viruses involved, i.e. HPV16, HPV18 and BPV1, 
consumed five months. 
 
17.3 CONDUCTING THE NEUTRALIZING ANTIBODY ASSAY 
 
To measure the neutralizing antibody response to HPV16 or HPV18 using the 
selected neutralizing antibody assay, it was necessary to conduct two assays 
simultaneously: one for the specific HPV type of interest, and another for the “non-
specific immune response”, which involved testing the sample for the neutralizing 
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antibody response to BPV1. Both assays were conducted in the same way, and the 
results interpreted in conjunction.  
 
17.3.1 Well-plate configuration 
 
The assay was conducted using a 96-well well-plate, comprising a grid of wells in an 
8-row-by-12-column configuration. Within laboratory limits, each non-empty well on 
the well-plate contained identical numbers of 293TT target cells, but the non-empty 
wells differed with respect to other factors (figure 17.3.1): 
 
1) Empty wells. 
 
The perimeter wells, i.e. the wells closest to the edge of the well-plate, were left 
empty, to avoid evaporation. Clearly, this restricted the number of informative wells 
on each well-plate in each assay, but was unavoidable since perimeter wells often 
produce erratic results with this assay. 
 
2) “Sample wells”. 
 
Each study sample was tested using all six of the internal wells of one column on the 
well-plate. These wells contained target cells and PsV in identical concentrations, 
but with increasing dilutions of study sample serum moving down the column. These 
dilutions were chosen (following the developmental assays described subsequently) 
because they were considered to cover the range within which the titres of the study 
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samples were likely to lie: the first well was at a dilution of 1-in-40, with three-fold 
increases in dilution in successive wells, i.e. dilutions of 1-in-120, 1-in-360, 1-in-
1080, 1-in-3240, and 1-in-9720. Assuming that the sample contains neutralizing 
antibodies, then moving down the column, wells contain progressively fewer 
antibodies and are therefore less likely to be able to neutralize the PsV. Therefore, 
the production of SEAP in wells will increase moving down the column, and the 
signal, i.e. the amount of SEAP measured, will increase. 
 
The minimum dilution used was 1-in-40 because Pastrana et al. (Pastrana 2004) 
found that below a dilution of 1-in-40, there was a high non-specific background 
reaction (non-specific inhibition). Therefore a titre of less than 1-in-40 is essentially 
“negative”, whereas a titre of 1-in-40 or above is “positive”, given a satisfactory 
comparison with the BPV1 titre (see section 7.3.2 point 6). 
 
Given that only the internal wells of the well-plate could be used, i.e. the wells other 
than the perimeter wells, and that each sample occupied all of the internal wells in a 
given column, each 96-well well-plate could be used to test a maximum of 10 study 
samples. In practice, this number was further reduced by the need to include wells 
used for  purposes other than testing samples directly. 
 
Note that it is not a requirement of this neutralizing antibody assay that all dilutions of 
the same sample must be analysed in the same column: the wells used for the 
different dilutions can appear in any order on the same well-plate. But for practical 
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reasons, it is simpler to have one column correspond to the same sample, and for 
consecutive wells to have consecutive dilutions. 
 
3) Positive- and negative-control wells. 
 
These wells contain target cells and PsV in identical concentrations, but with 
increasing dilutions of control sample serum moving down the column. Ideally a 
standard (validated) set of controls with known titres would be used (e.g. controls 
supplied by an external agency), but internal controls can be used if they can be 
validated.  
 
4) Maximum signal wells 
 
These wells contain target cells and PsV in identical concentrations. These wells do 
not contain any antibodies, and therefore the expression of SEAP in these wells is 
the maximum attainable, since the PsV can “infect” the target cells unimpeded. The 
mean signal from all relevant wells is used in calculations (see section 17.3.2).  
 
5) Background wells. 
 
These wells contain identical concentrations of target cells only. They provide a 
background signal for the well-plate i.e. a measure of the natural production of SEAP 
by 293TT cells. 
 
Figure 17.3.1. Well-plate configuration for conducting the neutralizing antibody 
assay. Three-fold dilutions assumed. 
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17.3.2 The result of the assay: determination of the 50% neutralization titre 
 
The measurement, or “result”, produced by this neutralizing antibody assay is called 
the “50% neutralization titre” (or just the “titre” for short). 
 
The result of the assay is based on the relative reduction in the expression of SEAP 
in the wells with serum added (sample wells), compared to the maximum expression 
possible. The 50% neutralization titre is the lowest dilution which causes at least a 
50% reduction in SEAP expression compared to the maximum (corrected) SEAP 
expression possible.  
 
The scale used to measure titres employing a well-plate with the configuration in 
figure 17.3.1 is an ordinal categorical scale with seven categories, one for each 
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dilution including a “negative” category. With the dilutions ultimately used, these 
categories were: negative, 1-in-40, 1-in-120, 1-in-360, 1-in-1080, 1-in-3240, and 1-
in-9720. In theory, linear interpolation could also be used to obtain an “exact”  
measurement of the titre measured on a “continuous scale. 
 
The result is calculated as follows: 
 
1) The mean signal from all of the well-plate “background wells” is calculated. 
 
2) The signal from each of the remaining non-empty wells on the well-plate is 
“corrected for background”, by subtracting the mean signal calculated from the 
background wells in step 1. In practice, the magnitude of the signals from these wells 
was small compared to those from the rest of the wells on the well-plate, and so this 
step was found to make little difference in practice. 
 
3) The maximum possible signal is determined by calculating the mean corrected 
signal from all of the “maximum signal wells”. 
 
4) The corrected signal from each sample-well is divided by the maximum possible 
signal. The “50% neutralization titre” is then the value of the highest dilution at which 
a 50% reduction in signal is first achieved.  
 
5) For the positive- and negative-controls, calculate the 50% neutralization titre as in 
step 4. The results of the assay, for all samples tested on the same well-plate, will be 
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rejected if the well-plate is judged to have “failed” according to the known results for 
the positive- and negative-controls. A certain amount of fluctuation was apparent 
with this assay in practice. Therefore, two negative-control wells were included on 
each well-plate, with the well-plate being accepted if at most one negative-control 
was erroneously positive. 
 
6) Compare the observed 50% neutralization titre against HPV16 or HPV18, with the 
observed 50% neutralization titre against BPV1. 
 
BPV1 pseudovirus was included as a specificity control. Human exposure to BPV1 is 
assumed to be rare, certainly within the context of the study described in this thesis 
i.e. young women attending an urban family planning clinic are considered unlikely to 
have been exposed to a virus carried by cattle. Therefore, sera samples from 
humans are not expected to display substantial anti-BPV1 neutralizing activity. 
Consequently, any observed inhibition of the activity of BPV1 PsV will not result from 
cross-neutralizing antibodies against HPV16 or HPV18, but rather from non-specific 
factors present in sera. Pastrana et al. (Pastrana 2004) found that all but one of the 
60 unvaccinated human subjects they tested had a titre against BPV1 of at most 1-
in-40; the exception being a subject with a titre of 1-in-160. They therefore 
recommend that a serum sample should only be considered positive for HPV type-
specific neutralizing antibodies if its HPV type-specific neutralization titre is greater 
than 1-in-40 and also at least one titre category greater than that found in the BPV1 
assay. 
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Therefore, although one 96-well well-plate can be used to test a maximum of eight 
study samples for neutralizing antibodies to a given HPV type (with the configuration 
given in figure 17.3.1), this well-plate must be “supported” by an additional well-plate 
testing the samples for neutralizing antibodies to BPV1. Provided samples are tested 
contemporaneously for neutralizing antibodies to both HPV16 and HPV18 (on 
separate well-plates), a single BPV1 assay can be used to support both type-specific 
assays. Hence, testing N well-plates containing study samples implies running 3N 
well-plates in total i.e. no matter how many HPV types a sample is tested for, only 
one test for the non-specific neutralizing response needs to be undertaken. 
  
An illustrative example of the calculation of the 50% neutralizing antibody titre is 
shown in figure 17.3.2. In this case, the well at a dilution of 1-in-360 yields a signal 
which is 44% of the maximum signal possible i.e. a decrease of 56%; the well at a 
dilution of 1-in-1080 yields a signal which is 62% of the maximum i.e. a decrease of 
only 38%. The 50% neutralization titre, the point at which 50% inhibition of the 
expression of SEAP was achieved, is therefore 1-in-360. Note that this implies that 
the “true” titre could be as low as 1-in-121 or as high as 1-in-1079, i.e. just above the 
next lowest titre, or just below the next highest titre; interpolation to identify the “true” 
titre (a value measured on a continuous scale) could be performed if required.  
 
Provided the 50% neutralization titre against BPV1 is either negative, 1-in-40, or 1-
in-120, then the sample illustrated in figure 17.3.2a is seropositive for neutralizing 
antibodies against the specific HPV type, and we conclude that the sample has a 
titre of 1-in-360 for reducing the expression of SEAP by 50%. If, however, the 50% 
neutralization titre against BPV1 had been 1-in-360 or greater, then the conclusion 
would be that this sample is seronegative for neutralizing antibodies against the 
specific HPV type. 
 
 
Figure 17.3.2a. Calculation of the 50% neutralizing antibody titre. Three-fold 
dilutions used. 
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A numerical example of this assay is shown in figure 17.3.2b. This figure presents 
the observed signals from all of the wells on the 96-well well-plate for a HPV16 
assay (plate 2 of the 25.08.2006 assay).  
 
In this example, the signals from the perimeter wells (the grey wells) are the lowest 
signals on the well-plate, but vary a great deal. These signals are not interpreted 
further. 
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The mean background signal for this well-plate is 1,745 (the mean of 1,600 and 
1,890, the yellow wells). The magnitude of this signal is thus smaller than the signal 
from all other non-empty wells on the well-plate and, except when compared to 
some wells in the first two “rows”, is essentially negligible. 
 
The mean signal from the six maximum signals wells is 134,793, or 133,048 when 
corrected for plate background. Hence for 50% neutralization, the “target” for study 
samples is to reduce this signal by at least half i.e. to a corrected signal of 66,524. 
 
Figure 17.3.2b. Numerical example of the calculation of the 50% neutralizing 
titre: observed signals. Three-fold dilutions used. Grey cells correspond to empty wells on 
the well-plate; blue to maximum signal wells; yellow to well-plate background wells; green and red to 
positive- and negative-control wells, respectively; white cells correspond to study samples, with all 
wells in the same column being used to test the same sample at different dilutions, starting at 1-in-40 
in row 2 and proceeding in multiples of three until 1-in-9720 is reached in row 7. 
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The ratio of the background-corrected signal to the mean corrected maximum signal 
for each of the wells used to test the study samples is shown in figure 17.3.2c, 
expressed as a percentage.  
 
The relative signals from the negative-control wells were 57% and 63%. Therefore, 
in neither well was SEAP expression reduced by at least 50%, and so both are 
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seronegative, and the well-plate is not rejected on the basis of this criterion, and the 
results from this well-plate are accepted. 
 
The positive-control wells were at a dilution of 1-in-360 and 1-in-1080. The relative 
signals from these wells were 10% and 42%, respectively. Therefore, SEAP 
expression was reduced by greater than 50% in both of these wells, and so the titre 
for the positive-control is at least 1-in-1080 i.e. the positive-control is positive, and 
the well-plate is not rejected on the basis of this criterion. 
 
This well-plate was not rejected according to failure to pass either the positive- or 
negative-control criteria: therefore, the results (titres) of all samples tested on this 
well-plate were accepted as valid. 
 
Sample 8 appears to contain no neutralizing antibodies. Even at the most 
concentrated dilution of 1-in-40, the signal is 92% of the maximum signal i.e. SEAP 
expression is essentially at a maximum. The expression at the other dilutions shows 
some fluctuation, but is close to 100%: the greatest signal reduction is 19% at a 
dilution of 1-in-9720. 
 
Samples 1 to 7 are apparently seropositive for neutralizing antibodies. For each of 
these samples, the relative signal increases as the dilution increases. Although 
increases are not monotonic, wells at lower dilutions tend to produce greater relative 
signal reductions than those at higher dilutions. In each case, at least one well 
corresponds to a reduction in relative signal of 50% or more. Although the observed 
348 
 
50% neutralizing antibody titres for samples 3 and 7 are both 1-in-360, sample 3 
produced a 73% relative reduction in signal at this dilution, compared to only a 52% 
reduction for sample 7. This suggests that the titre of sample 3 is in fact higher than 
that of sample 7. Similarly for samples 2 and 6. 
 
Now, the 50% neutralizing antibody titres against BPV1 for the samples ranges from 
negative to 1-in-360. However, for most samples the BPV1 titre is less than the 
observed HPV16 titre. The exception is sample 1, for which there is an observed titre 
of 1-in-40 against HPV16, but 1-in-360 against BPV1, i.e. the observed titre against 
HPV16 is not at least three times that against BPV1, and therefore this sample is 
seronegative for neutralizing antibodies against HPV16. 
 
Figure 17.3.2c. Numerical example of the calculation of the 50% neutralizing 
antibody titre: background-corrected signals relative to mean corrected 
maximum signals. Grey cells correspond to the observed 50% neutralization titre. 
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17.4 STATISTICAL METHODS 
 
17.4.1 The measurement of intra- and inter-assay reliability 
 
To measure within-assay (intra-assay) reliability, samples were tested in duplicate 
on the same well-plate; to measure between-assay (inter-assay) reliability, the 
analysis of the samples on these well-plates was repeated, with the well-plate kept in 
the same configuration. Estimates of intra- and inter-assay reliability were then 
obtained using weighted kappa statistics. 
 
To assess the extent to which a given measurement on a subject is reliable, it is 
necessary to make repeated measurements on a number of subjects: the observed 
degree of agreement provides an upper bound on the degree of reliability of the 
measurements (Fleiss 2003). 
 
In any set of repeated observations on the same subject, some observations will be 
in agreement purely by chance. The kappa statistic is a chance-corrected measure 
of interrater agreement, taking the value one for complete agreement, values close 
to zero for no agreement, and values less than zero when observed agreement is 
less than that expected by chance; the minimum value depends on marginal 
proportions, but is not important in this context. 
 
The unweighted kappa statistic depends on exact agreement only: it is the difference 
between the observed agreement (O) and the agreement expected by chance (E), 
350 
 
as a proportion of the maximum possible excess agreement above that expected by 
chance (1-E), i.e. unweighted kappa =  (O – E) / (1 – E). When measurements are 
made on a categorical scale with more than two categories, and the categories are 
ordered, a difference of one category between two measurements is less serious 
than a difference of two or more categories. The weighted kappa statistic is a 
statistic which incorporates this aspect of the measurements, with values interpreted 
in the same way as values for the unweighted kappa statistic.  
 
Landis and Koch (Landis 1977) give ranges for interpreting the strength of 
agreement based on kappa: less than 0.00 is “poor”, 0.00 to 0.20 is “slight”, 0.21 to 
0.40 is “fair”, 0.41 to 0.60 is “moderate”, 0.61 to 0.80 is “substantial”, and 0.81 to 
1.00, is “almost perfect”. Although the authors are clear in their paper that this 
categorization is arbitrary (clearly, it is obtained by dividing the range 0 to 1 into five 
equal parts) and intended for the specific purpose described in their paper, this 
categorization (which I will refer to as the “Landis scale”) is now frequently used to 
report levels of agreement (including for the continuous analogue of the kappa 
statistic, the intracluster correlation coefficient). In essence, values of kappa of 0.75 
or greater may be taken to represent excellent agreement beyond chance; values 
below 0.40 represent poor agreement beyond chance; and values between 0.40 and 
0.75 represent fair to good agreement beyond chance (Fleiss 2003). Kappa does not 
have a probabilistic interpretation: even with a high value of kappa for a particular 
measurement technique, one has no quantifiable guarantee that if any given 
observation were repeated, one would obtain an essentially identical observation. 
However, a large value of kappa implies that an observed difference in 
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measurements made on the same individual, for instance at two different points in 
time, is a true difference rather than an artefact of the measurement technique: the 
higher the value of kappa, the greater is the reassurance that observed differences 
are real. 
 
17.4.2 Further statistical analyses 
 
Given the small sample size ultimately available, and the small number of serum 
samples involved, only a descriptive analysis was appropriate. 
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Chapter 18 
 
THE KINETICS OF THE HUMORAL IMMUNE RESPONSE TO 
INCIDENT CERVICAL HPV16 AND HPV18 INFECTIONS 
 
RESULTS 
 
 
 
 
 
Orientation 
 
In this chapter I: 
  
• describe the laboratory and statistical analyses undertaken to establish a working 
assay for the analysis of the neutralizing antibody response to infection with 
HPV16 and HPV18 
 
• determine the reproducibility of the neutralizing antibody assay 
 
• describe the practical challenges involved with the use of the neutralizing 
antibody assay 
 
• describe changes over time in the neutralizing antibody response against HPV16 
and HPV18 
 
 
 
 
 
18.1 RESTATEMENT OF OBJECTIVES 
 
To investigate how the natural history of cervical HPV infection varies with the 
humoral immune response. Specifically: 
 
o To evaluate the performance of an assay for the measurement of the 
neutralizing antibody response to infection with HPV16 and/or HPV18. 
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o To describe the kinetics of the neutralizing antibody response in a 
cohort of young women who were recruited soon after first sexual 
intercourse, and who first tested positive for HPV16 DNA, or HPV18 
DNA, or both, in cervical samples during follow-up. 
 
 
18.2 DEVELOPMENT AND VALIDATION OF AN ASSAY USED FOR THE 
MEASUREMENT OF THE NEUTRALIZING ANTIBODY RESPONSE TO 
CERVICAL HPV16 AND/OR HPV18 INFECTIONS 
 
In the study described in this thesis, an adaption of a neutralizing antibody assay 
originally developed by Pastrana et al. (Pastrana 2004) was used. The development, 
validation, and implementation of the assay in the laboratory used to undertake the 
assay described in this thesis, occurred in three stages. The first stage was a 
laboratory process to establish the procedures for the production and purification of 
pseudovirions, and for the determination of the amount of pseudovirions to use in the 
assays, for each of the three viruses involved (HPV16, HPV18 and BPV1). This 
stage did not involve the candidate directly. The second stage involved applying, and 
evaluating, the techniques established in the first stage, to samples from women in 
the cohort described in this thesis: the objectives of this stage were to refine the 
procedures for the assay, including the determination of the optimal configuration of 
the well-plates; to determine whether the technique was reproducible; and to identify 
potential controls for use in future assays of samples from the study population 
described in this thesis. The third stage was the testing of study samples from cohort 
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members: this stage could only begin when assay development reached a point at 
which the technique could be applied with confidence to the testing of study 
samples, a limited resource.  
 
18.2.1 Selection of study samples for use in the development and validation of 
the neutralizing antibody assay 
 
The measurement of intra- and inter-assay reliability used 42 sera samples taken 
from 21 women in the full study cohort, and a further seven sera samples which had 
been included in the WHO collaborative study on the standardization of the detection 
of antibodies to human papillomaviruses (Ferguson 2006, hereafter referred to as 
the “WHO collaborative study”) (kindly supplied by Morag Ferguson). The frequency 
distribution of the number of sera samples tested per woman during the 
developmental stages of the neutralizing antibody assay is given in table 18.2.1a. 
 
The samples from the study described in this thesis are a limited resource, and so 
must be used sparingly with future uses kept in mind, both known and as yet 
unperceived. The 42 sera samples from the study cohort women were therefore 
chosen with the larger aims of the longitudinal study described in this thesis, kept  in 
view. Most women in the analysis used to develop and evaluate the neutralizing 
antibody assay contributed only a single sample because they only ever had one 
evaluable serum sample, or because they were from the “prevalent cohorts” i.e. 
women who were HPV DNA-positive, or cytologically abnormal in the cervical 
sample taken at study entry, or both. Such women already have cervical disease, or 
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are already infected with cervical HPV infection, and are therefore less valuable in 
an analysis of incident cervical HPV infection or disease. The women contributing 
more than one serum sample to this analysis tended to be those used in an attempt 
to identify suitable internal positive- and negative-controls (see section 18.2.3). 
 
Table 18.2.1a. Frequency distribution of the number of 
serum samples tested per woman in the development and 
validation of the neutralizing antibody assay. 
 
Number of samples tested per woman Number of 
women 
1 21a 
2 1 
3 1 
4 4 
7 1 
aincluding the samples from the WHO collaborative study. 
 
 
The cytological samples corresponding to the sera samples tested had been found 
to test positive for HPV16 DNA, HPV18 DNA, or both, using the GP5+/GP6+ system, 
either alone or in the presence of other HPV types; or to test negative for HPV (table 
18.2.1b). The seven sera samples from the WHO collaborative study had been taken 
from women who were described as having “good histories of benign natural 
monovalent infections” (three with HPV16, two with HPV18, and one with both), with 
the other described as negative; however, the contemporaneous cervical HPV DNA 
status of these samples was unknown. 
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Table 18.2.1b. Frequency distribution of the cervical HPV infection status of 
the cervical cytological samples taken contemporaneously with the sera 
samples used in the development and validation of the neutralizing antibody 
assay. 
 
HPV DNA status and types detected Number of women 
  
Negative 15 
Positive 26 
Missinga 1 
Unknownb 7 
  
16 9 
18 6 
16;18 4 
6/11;16;18;52 1 
18;33 1 
56c 1 
6/11;16;33 1 
16;58 1 
16;18;52 1 
16;31 1 
aThe cytological sample taken on the date corresponding to the sera sample was missing; bthese 
are the samples from the WHO collaborative study; ctype obtained by sequencing. 
 
 
18.2.2 Development and refinement of the neutralizing antibody assay: sera 
samples used 
 
During the development and refinement of the neutralizing antibody assay, the assay 
was used to test a limited number of samples on several occasions. The frequency 
distribution of the number of occasions on which sera samples were tested is shown 
in table 18.2.2a. 
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Table 18.2.2a. Frequency distribution of the number of times 
sera samples were tested during the development and 
validation of the neutralizing antibody assay. 
 
Number of samples Number of times tested
HPV16a HPV18a 
0 – 12 
2 8 11 
4 27 13 
6 1 1 
8 2 4 
10 3 – 
14 1 1 
aHPV type tested for. 
 
During the developmental stage of the neutralizing antibody assay, samples were 
tested in duplicate on the same well-plate to enable the measurement of intra-plate 
reliability, as described subsequently. The lowest dilution used in all assays was 1-
in-40, as recommended by Pastrana et al. (Pastrana 2004). However, the 
increments in dilution evaluated were two, three and four. This means that, even with 
a perfectly reliable (reproducible) assay, although the results of the repeated tests of 
the same sample can be compared for consistency, the observed titres can not be 
expected to be identical. 
 
For example, possible titres for a sample tested using a dilution of two are negative, 
1-in-40, 1-in-80, 1-in-160, 1-in-320, 1-in-640, and 1-in-1280; possible titres for a 
sample tested using a dilution of three are 0, 1-in-40, 1-in-120, 1-in-360, 1-in-1080, 
1-in-3240, and 1-in-9720. A sample which has a titre of 1-in-360 using a dilution of 
three is consistent with a titre of either 1-in-320 or 1-in-640 using a dilution of two; it 
is not consistent with a titre of 1-in-1280 since then we would have expected a titre 
of 1-in-1080 using a dilution of three. 
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The frequency with which each serum sample was tested for neutralization against 
HPV16 at each dilution increment, is shown in table 18.2.2b; the corresponding 
frequency distribution for HPV18 is shown in table 18.2.2c. 
 
Table 18.2.2b. Frequency distribution of the number of times with 
which each serum sample was tested for neutralization against 
HPV16, and the dilution increment used. For example, three samples were 
tested for HPV16 twice in assays using two-fold dilutions, six times using three-fold 
dilutions, and twice using four-fold dilutions. 
 
Number of times tested and dilution used 
2 3 4 
0 2 0 2 4 6 8 10 0 2 4 
Number of 
samples 
 X  X      X  1 
 X   X     X  1 
 X    X    X  3 
 X      X  X  1 
 X X       X  6 
X    X    X   10 
X    X      X 1 
X  X       X  8 
X  X        X 11 
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Table 18.2.2c. Frequency distribution of the number of times with 
which each serum sample was tested for neutralization against 
HPV18 and the dilution increment used. For example, 10 samples were tested 
for HPV18 four times in assays using three-fold dilutions, but not at all in any of the 
assays which used two- or four-fold dilutions. 
 
Number of times tested and dilution used 
2 3 4 
0 2 0 2 4 6 8 10 0 2 4 
Number of 
samples 
X  X      X   12 
 X X      X   4 
 X  X     X   1 
 X   X     X  1 
 X    X   X   2 
 X    X    X  1 
 X      X  X  1 
 X X       X  2 
X    X    X   10 
X    X     X  1 
X  X       X  7 
 
 
18.2.3. Development and refinement of the neutralizing antibody assay: 
developmental analyses 
 
Twelve analyses were conducted during the developmental stage of the neutralizing 
antibody assay (recall that an “analysis” consisted of a group of well-plates tested at 
the same time). In all analyses, the overriding objective was to determine whether 
the assay was reproducible, but different analyses also had additional practical 
objectives. The analyses and their specific objectives are adumbrated in table 
18.2.3a. Note that, had the technique proved reproducible at the first attempt, it is 
likely that at least four, but less than 12, analyses would have been undertaken prior 
to proceeding to stage three of the analysis. 
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Table 18.2.3a. Analyses undertaken during the developmental stage of the 
neutralizing antibody assay, and their specific objectives. 
 
Analysis Objective(s) and comments 
1 To measure intra-assay reliability; first use of study samples 
2 To measure intra- and inter-assay reliability; repeat of analysis 1 
3 To identify potential internal positive and negative-controls 
4 To identify potential internal positive and negative-controls 
5 To identify potential internal positive and negative-controls 
6 To evaluate the effect of refining the HPV18 assay; first use of 
controls from the WHO collaborative study 
7 Training for a new laboratory technician; repeat of analysis 6 for 
HPV18 only 
8 To evaluate the effect of refining the HPV18 assay 
9 To measure intra- and inter-assay reliability; repeat of analysis 8 
10 To evaluate the effect of refining the HPV18 assay; to measure intra- 
and inter-assay reliability; repeat of analysis 8 
11 To identify potential internal and external positive- and negative-
controls for use during testing of the study samples; to measure intra-
assay reliability 
12 To identify potential internal and external positive- and negative-
controls for use during the testing of study samples; to measure intra- 
and inter-assay reliability; repeat of analysis 11 
 
 
As well as varying in their objectives, these analyses involved different well-plate 
configurations: these are described in table 18.2.3b. In most analyses, the 
neutralizing antibody response to both HPV16 and HPV18 infection was determined, 
but two analyses measured the response to HPV16 only, and one to HPV18 only. 
The number of well plates which could be set-up and read by a single laboratory 
technician in one analysis was limited to three for each of the virus types i.e. a total 
of nine well-plates in any single analysis. Each sample was measured in duplicate 
on each well-plate, therefore a maximum of four samples could be measured on 
each well-plate. In the first two analyses, only 10 samples were analysed on each 
well-plate; thereafter, 12 samples were analysed on each well-plate in all analyses. 
Initially, the increment in dilutions used was four (i.e. dilutions of 0, 1-in-40, 1-in-160 
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etc.). Once experience had been gained with the assay, and the likely range of titres 
for study samples established, the increment was altered, first to two (i.e. dilutions of 
0, 1-in-40, 1-in-80, etc.), and then to three (0, 1-in-40, 1-in-120 etc.); after analysis 5, 
all subsequent analyses used an increment of three. On each well-plate, the aim 
was to measure as many study samples as possible, whilst still allowing some wells 
to be used for measuring well-plate-specific data, i.e. the background for the well-
plate, the maximum signal possible for the well-plate, and the signal for controls (see 
section 17.3.1). In practice, this meant that two “columns” were available for well-
plate-specific data on each well-plate. The number of wells used for each of these 
purposes was varied in the first few analyses. Once it had been observed that the 
background signal was always very low, the number of wells used for measuring the 
background signal was reduced from four to two; the use of only one well in analysis 
4 was not repeated, since it was considered prudent to allow for at least some 
variability in estimating all signals and thereby to enable an aberrant measurement 
to be identified. Given that the (corrected) maximum signal is used as a comparator 
for all other wells, most available wells were used for measuring this parameter to 
enable a more precise, or stable, estimate to be obtained. Ultimately, once the 
testing of study samples began, all usable wells in one column, i.e. six wells, were 
used for measuring the maximum signal. In most laboratory analyses, positive- and 
negative-controls are included to rule out systematic errors: however, as will be 
discussed subsequently, only analyses 3 and 4 included such controls during the 
developmental stage of the assay. 
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Table 18.2.3b. Well-plate configurations used in the twelve analyses 
undertaken during the developmental stage of the neutralizing antibody assay. 
 
Analysis HPVa Sample 
size 
Number of 
well plates
Dilutions Number of 
maximum 
signal wells
Number of 
background 
wells 
Number of 
control 
wellsb 
1 16+18 10 9 4 8 4 0 
2 16+18 10 9 4 8 4 0 
3 16 12 6 4 4 2 4+/2– 
4 16+18 12 6 4 5 1 4+/2– 
5 16+18 12 9 2 10 2 0 
6 16+18 12 9 3 10 2 0 
7 18 12 6 3 10 2 0 
8 16+18 12 9 3 10 2 0 
9 16+18 12 9 3 10 2 0 
10 16+18 12 9 3 10 2 0 
11 16+18 12 9 3 10 2 0 
12 16+18 12 9 3 10 2 0 
aHPV type assayed; bNo. For positive-/negative-controls. 
 
A brief description of some of the issues raised by each of these analyses follows. 
 
18.2.3.1 Developmental analyses 1 and 2 
 
These two analyses were the first attempts to measure intra- and inter-assay 
reliability, and will be described in greater detail than the others to illustrate the data 
produced by the assay and the method of analysis. Summary tables for all of the 
developmental analyses appear at the end of this section, but in this subsection I 
provide a more full description of the type of data produced by the assay, and the 
approach adopted for the analysis of the data collected for the study described in 
this thesis. 
 
In analyses 1 and 2, a total of ten sera samples from women in the full study cohort 
of 2,011 women were analysed for their neutralizing antibody response to both 
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HPV16 and HPV18, with each sample analysed in duplicate on the same well-plate. 
Although not a requirement of the assay, in practice the same sample was analysed 
in contiguous columns of the well-plate. In an attempt to obtain a mixture of 
seropositive and seronegative results for both types in these initial analyses, the 
cytological samples corresponding to the sera samples were deliberately chosen to 
be a mixture of HPV16 DNA- and/or HPV18 DNA-positive, and HPV DNA-negative 
samples. Well-plates for analysis 1 were set-up on Monday 7th November 2005, with 
SEAP-expression signals being measured (“read”) the following Thursday; those for 
analysis 2 were set-up on Tuesday 8th November 2005, and read the following 
Friday, a clear demonstration of how the working week limited the number of assays 
which could be performed by a single laboratory technician. 
 
The sera samples used in analyses 1 and 2, and the HPV DNA status of the 
corresponding cytological samples, are shown in table 18.2.3.1a. 
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Table 18.2.3.1a. Sera samples, and the HPV DNA status of the 
corresponding virological samples, used in analyses 1 and 2 
 
Neutralizing antibody 
assay identifier 
Serum sample 
study number 
HPV DNA status of corresponding 
virological sample 
   
1 1619.1 HPV16 
2 1688.1 HPV18 
3 1675.1 HPV-negative 
4 1766.3 HPV16+HPV31 
5 1239.1 HPV16 
6 1161.2 HPV16+HPV58 
7 965.1 HPV16+HPV6/11+HPV33 
8 974.1 HPV18 
9 126.1 HPV16 
10 1008.1 HPV16 
 
 
The 50% neutralization titres against HPV16 and HPV18 for each replicate of each 
sample from analyses 1 and 2 are shown in table 18.2.3.1b. Note that the lowest 
non-zero dilution used was 1-in-40, with increments in multiples of four.  
 
Titres ranged from zero (sernegative) to 1-in-2560 for HPV16, and from zero to 1-in-
640 for HPV18. Sixteen of the 40 BPV1 results were non-zero (i.e. non-
seronegative), with a maximum titre of 1-in-160; nine non-zero HPV16 titres were 
changed to zero (seronegative) following comparison with the BPV1 titre, as were 
three non-zero HPV18 titres; one replicate from one analysis had a BPV1 titre of 1-
in-40 in the absence of any titre against HPV16 or HPV18; two results indicated a 
titre against BPV1 of 1-in-160 (BPV1 results not illustrated). 
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Table 18.2.3.1b. The 50% neutralization titres against HPV16 and 
HPV18 for each replicate of each sample from analyses 1 and 2. 
AnRm denotes analysis n (n=1,2) replicate m (m=1,2). Numbers in the table are 
inverse titres, except for “0”, which is “seronegative”. 
 
HPV16b HPV18b Samplea 
A1R1 A1R2 A2R1 A2R2 A1R1 A1R2 A2R1 A2R2
1 160 160 160 160 0 0 160 0 
2 0c 0c 0c 0c 0 0 0 0 
3 40 0 40 0 640 640 640 640 
4 40 40 40 40 0 0 0 0 
5 40 0c 40 40 0 0 0 0 
6 0 0c 0c 0c 0 0 0c 0c 
7 640 640 2560 2560 0 0 0 160 
8 0 40 0 0 40 40 0c 0 
9 0c 160 160 160 640 640 640 640 
10 0 0 0 40 0 0 40 40 
aCorresponds to “neutralizing antibody assay identifier” in table 18.2.3.1a; bzero 
means seronegative for neutralizing antibodies; cthese samples are seronegative after 
comparison with the non-specific neutralizing response obtained for BPV1. 
 
In table 18.2.3.1b, there appears to be reasonable agreement between replicates 
and between analyses for each virus type. Agreement is perfect between replicates 
1 and 2 for HPV18 in analysis 1, but for all other comparisons there is some 
discrepancy. The greatest discrepancy between titres for the same sample is a 
difference of two titre categories, but there are also several discrepancies of only 
one titre category. Tables 18.2.3.1c and 18.2.3.1d present estimates of weighted 
kappa statistics measuring agreement between each possible pair of replicates, for 
HPV16 and HPV18, respectively. Agreement ranges from “moderate” to “almost 
perfect” for HPV16, and from “substantial” to perfect for HPV18, using the Landis 
scale (see section 17.4.1). 
 
Comparisons between replicates within the same analysis yield measurements of 
intra-assay (within-assay) reliability. For HPV16, intra-assay reliability is “moderate” 
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in analysis 1, but “almost perfect” in analysis 2. For HPV18, intra-assay reliability is 
perfect in analysis 1, and “substantial” in analysis 2.  
 
Comparisons between replicates in different analyses yield measurements of inter-
assay (between-assay) reliability: there are four ways in which a replicate from the 
first analysis can be paired with a replicate from the second (A1R1-A2R1, A1R1-
A2R2, A1R2-A2R1, and A1R2-A2R2), hence there are four (dependent) estimates of 
inter-assay reliability. For HPV16, values of weighted kappa statistics measuring 
inter-assay reliability indicate reliability which ranges from “moderate” to 
“substantial”. For HPV18, values of weighted kappa statistics measuring inter-assay 
reliability are consistently 0.66 (to two decimal places), corresponding to 
“substantial” agreement. Ignoring the extreme result, intra- and inter-assay reliability 
are identical for HPV18. 
 
Table 18.2.3.1c. Estimates of weighted kappa statistics measuring 
agreement between each possible pair of replicates included in 
analyses 1 and 2: HPV16. Shaded cells indicate inter-assay measurements, 
unshaded cells intra-assay measurements. 
 
 
Analysis 1 
Replicate 2 
Analysis 2 
Replicate 1 
Analysis 2 
Replicate 2 
Analysis 1 Replicate 1 0.53 0.74 0.57 
Analysis 1 Replicate 2 – 0.67 0.67 
Analysis 2 Replicate 1 – – 0.84 
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Table 18.2.3.1d. Estimates of weighted kappa statistics 
measuring agreement between each possible pair of replicates 
included in analyses 1 and 2: HPV18. Shaded cells indicate inter-assay 
measurements, unshaded cells intra-assay measurements. 
 
 
Analysis 1 
Replicate 2 
Analysis 2 
Replicate 1 
Analysis 2 
Replicate 2 
Analysis 1 Replicate 1 1.00 0.66 0.66 
Analysis 1 Replicate 2 – 0.66 0.66 
Analysis 2 Replicate 1 – – 0.67 
 
The comparison with the least agreement is that between replicates 1 and 2 from 
analysis 1 of HPV16 (kappa=0.53). Figure 18.2.3.1 presents a cross-tabulation of the 
results for these two replicates. 
 
Figure 18.2.3.1. Comparison of the 50% neutralization titres against HPV16 
for both replicates in analysis 1. Inverse titres are given in the table for ease of display, 
except for 0 which is “seronegative”. Shaded cells correspond to perfect intra-assay agreement. 
 
    Analysis 1 Replicate 1 
Titre 0 40 160 640 2560 10240 40960
0 3 1a 1b – – – – 
40 2a 1 – – – – – 
160 – – 1 – – – – 
640 – – – 1 – – – 
2560 – – – – – – – 
10240 – – – – – – – 
Analysis 1 
Replicate 2 
40960 – – – – – – – 
aTitre discrepant by one category; btitre discrepant by two categories 
 
 
Ideally, all results would lie on the leading diagonal of table 18.2.3.1e. However, 
three results are discrepant by one titre category, and one is discrepant by two 
categories, yielding a titre of 1-in-160 for replicate 1, but a negative result for 
replicate 2. The weighted kappa statistic measuring agreement in this table is 0.53 
(95% CI 0.05 to 1.00), indicating “moderate” agreement only; kappa is significantly 
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different from zero at the 5% two-sided significance level. The 95% confidence 
interval and test of statistical significance are reliant on large sample approximations, 
which, however, are unlikely to be met with a sample size of 10. Even if the 
approximation is valid, this confidence interval suggests that the data is consistent 
with the full range of agreement which is possible, from none to “almost perfect”. 
 
For HPV16, the results of these first two analyses were certainly encouraging, but 
achieved “almost perfect” agreement for only one comparison. For HPV18, the well-
plate signals were found to be somewhat erratic, not withstanding the reasonable 
values of kappa statistics obtained. It was suggested that the HPV18 pseudovirions 
(PsV) were not maturing sufficiently i.e. PsV were self-constructing correctly, but 
were not maintaining their structural integrity. Although the HPV16 PsV did not, 
apparently, suffer from this problem, further refinement of both assays was felt to be 
required. 
 
18.2.3.2 Developmental analyses 3 and 4 
 
As well as refining the assay, and gaining more experience in its use and 
interpretation, it was necessary to try and identify suitable positive- and negative-
controls for use when testing study samples. The criteria for a suitable positive-
control was that it produce a high-titre, which was towards the middle of the possible 
range of titres i.e. not too extreme. The ideal criteria for a suitable negative control 
was that it was consistently seronegative. 
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To identify potential positive controls, and in the absence of better criteria, all women 
who did not belong to any of the “important” sub-cohorts (women who were free of 
cervical HPV infection and cervical disease at study entry and who had further 
follow-up: for these women, ideally all samples would be used as little as possible) 
were identified. Those women with a lengthy sequence of HPV16 DNA- or HPV18 
DNA-positive virological samples and who had sera samples available, were then 
identified, and three of each selected. All samples for the women identified were 
tested during analyses 3 and 4. The possible flaw with this approach was that 
women who had a long sequence of seropositive results may have had such a 
sequence because they did not, or could not, produce a neutralizing antibody 
response to their infection, thus defeating the purpose of this approach. 
 
For negative-controls, all women who never acquired cervical HPV infection of any 
type, or cervical cytological abnormality, during follow-up, and who had sera samples 
available were identified, and one serum sample selected. Also, one woman who 
had several sera samples available prior to first sexual intercourse was selected. 
Again, all samples for the women identified were tested during analyses 3 and 4. 
 
These analyses included wells for positive- and negative-controls. The positive-
control used was the serum sample with sample ID 965.1, which had given a titre of 
1-in-640 in both analyses 1 and 2. The negative-control used was the serum sample 
with sample ID 1675.1, which had given two titres of 1-in-40, as well as two 
seronegative results, in analyses 1 and 2. Clearly, this was therefore a less-than-
ideal negative-control. 
370 
 
Analysis 3 was restricted to testing for the neutralizing antibody response to HPV16 
only, whilst the production of HPV18 PsV was re-examined; analysis 4 then included 
testing for HPV18 once again. 
 
In analysis 3, all sera samples from the HPV16 DNA-positive women were found to 
be seropositive to HPV16, with the exception of one sample which had a titre of 1-in-
40 for one replicate, but was seronegative for the other; the greatest titre observed 
was 1-in-640. All sera samples from the HPV DNA negative and cytologically normal 
woman were seronegative in all replicates; three replicates had titres of 1-in-40 for 
the woman who was a virgin during the period when the sera samples were taken. 
Three replicates disagreed by one titre category. The weighted kappa statistic 
measuring intra-assay reliability for this analysis was 0.87, indicating “almost perfect” 
agreement. 
 
In analysis 4, the value of the weighted kappa statistic measuring intra-assay 
reliability for HPV16 was 0.85, indicating “almost perfect” agreement. For HPV18, 
the value of the weighted kappa statistic measuring intra-assay reliability was 0.80, 
again indicating “almost perfect” agreement, but it was nevertheless felt that this 
assay remained unstable (this was the first time a discrepancy of two titres had been 
seen). 
 
It became apparent that the use of only one well for measuring the background 
signal from a well-plate was ill-advised. One of the three well-plates used to measure 
BPV1 had a very large background signal which was three to four times higher than 
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had been observed previously. In the absence of another well measuring this signal, 
it was not possible to state that this unusual signal was an extreme value, and 
therefore that it could be disregarded. 
 
18.2.3.3 Developmental analysis 5 
 
Instead of four-fold dilutions (1-in-40, 1-in-160, 1-in-640, 1-in-2560, 1-in-10240, 1-in-
40960), as used in all previous analyses, this analysis used two-fold dilutions (1-in-
40, 1-in-80, 1-in-160, 1-in-320, 1-in-640, 1-in-1280). This was not a direct repeat of 
an earlier analysis, but all samples involved had been tested previously. Seven of 
the samples tested in this analysis were potential HPV16-positive controls, two were 
potential HPV18 positive-controls, and three were potential negative-controls for 
both types. No non-specific assay (BPV1) controls were included. 
 
The HPV16 assay appeared to be very reliable once again. Taken at face value, the 
dilutions chosen for this analysis did not cover the range of interest for HPV18 (all 
observed titres were at 1-in-1280, the maximum possible with this dilution), so the 
results were largely non-informative: all samples were either HPV18-seronegative or 
HPV18-seropositive at the maximum titre. However, the assay was again unstable: 
several sample wells gave signals either less than, or comparable in magnitude to, 
that from the background wells. 
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18.2.3.4 Developmental analyses 6 and 7 
 
Attention was now focussed on producing a working assay for HPV18, and so 
HPV16 was not tested for in analyses 6 and 7. Included in these analyses were five 
samples from the study cohort described in this thesis, together with seven samples 
supplied from the WHO collaborative study for use as potential controls. Analysis 7 
was a direct repeat of analysis 6, with the additional aim of training a laboratory 
technician (K Wen) who was new to this particular assay (he was otherwise very 
experienced), in performing the assay, under the guidance of the previous technician 
(G Ryan). The new technician would undertake all subsequent analyses, including, 
ultimately, those testing study cohort samples. 
 
In both analyses 6 and 7, the laboratory scientists were concerned about observed 
signal variability, and recommended that the results be discarded (nevertheless, 
results for analyses 6 and 7 appear in tables 18.2.3.5a and 18.2.3.5b). 
 
18.2.3.5 Developmental analyses 8 to 12 
 
The laboratory scientists now believed that they had resolved the issue with the 
HPV18 assay, whatever its true nature. Analyses 8 and 9 were therefore the second 
attempt to estimate intra- and inter-assay reliability for both HPV16 and HPV18, and 
analysis 10 combined with analysis 8 was the third attempt. The samples included in 
these analyses, some of which had been analysed previously, were chosen in the 
hope that they would yield a range of titres against HPV18, to avoid the problem 
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found in analysis 5. The belief was that the samples chosen previously may have 
been responsible for the aberrant results observed, to some extent.  
 
Unfortunately, the HPV18 results from analysis 9 again had to be discarded: the 
laboratory scientists stated that they had been “suspicious” of analysis 9 for HPV18 
prior to obtaining any results for HPV18, and were not confident about the HPV16 
results either. The estimate of the weighted kappa statistic measuring intra-assay 
reliability for analysis 8 was also unimpressive. 
 
Based on analysis 10, reliability of the HPV16 assay was “almost perfect”, with only 
one intra-assay discrepancy between replicates, which was of one titre category 
only; also, at least one titre per sample from analysis 8 was consistent with at least 
one titre for that sample from analysis 10. 
 
Results from the HPV18 assay were more variable than those from the HPV16 
assay. Eleven of the twelve samples had discrepancies of one titre category 
between replicates in analysis 10, compared with five of 12 in analysis 8. However, 
at least one titre per sample from analysis 10 was consistent with at least one titre 
for that sample from analysis 8, and there were no discrepancies of two titres 
categories or more.  
 
It was now concluded that the greater variability of the HPV18 assay was an inherent 
feature of the assay. The laboratory scientists were convinced that the HPV18 assay 
had reached the limits of possible refinement. Given the difficulties with analysis 8, 
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and the requirement, which still remained, of identifying potential positive and 
negative controls, two further analyses were undertaken. The developmental phase 
of the assay was then considered complete. 
 
A summary of the results regarding intra-assay reliability of the developmental 
analyses is given in tables 18.2.3.5a and 18.2.3.5b, for HPV16 and HPV18 
respectively. For HPV16, estimates of the weighted kappa statistic ranged from 0.56, 
corresponding to “moderate” agreement, to 0.95, for “almost perfect” agreement on 
the Landis scale; in all analyses, observed agreement was greater than 92%, 
consistent with most discrepancies being of only one titre category. In eight of the 
eleven analyses, estimates of the weighted kappa statistic suggest “almost perfect” 
agreement, according to the Landis scale. The analyses with the worst intra-assay 
reliability for HPV16 (analyses 1 and 8), were the first conducted by each of the two 
laboratory technicians involved in the validation of the assay (although the same 
result was not seen for the HPV18 assay). 
 
Ignoring the extreme result from analysis 1, for HPV18 estimates of the weighted 
kappa statistic ranged from 0.52, corresponding to “moderate” agreement, to 0.90, 
“almost perfect” agreement; in all analyses, observed agreement was at least 85%. 
In four of the eight analyses, kappa values suggest “almost perfect” agreement 
according to the Landis scale. The HPV18 assay is clearly more erratic than the 
HPV16 assay, with a substantial number of discrepancies between titres, including 
several of two titre categories. 
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Table 18.2.3.5a. Estimates of weighted kappa statistics measuring intra-assay 
reliability for the developmental analyses of the neutralizing antibody assay: 
HPV16. 
 
Analysis Sample 
sizea 
Dilution Number of 
discrepanciesb
Observed 
agreement 
(%) 
Expected 
agreement 
(%) 
Weighted 
kappa 
1 10 4 3(1) 93 84 0.57 
2 10 4 2(1) 97 82 0.82 
3 12 4 2(1) 97 78 0.87 
4 12 4 3(1) 96 72 0.85 
5 12 2 3(1) 96 55 0.91 
6 12 3 1(1), 1(2) 96 67 0.87 
7c 12 3 NA NA NA NA 
8 12 3 6(1) 92 81 0.56 
9 12 3 4(1) 94 79 0.73 
10 12 3 1(1) 99 85 0.91 
11 12 3 1(1) 99 71 0.95 
12 12 3 2(1) 97 74 0.89 
aNumber of sera samples tested; bnumber of discrepancies between replicates, with the number of 
titre categories difference in brackets e.g. in analysis 6 there was one difference of one titre, and 
one of two titres; ctested for HPV18 only 
 
 
 
Table 18.2.3.5b. Estimates of weighted kappa statistics measuring intra-assay 
reliability for the developmental analyses of the neutralizing antibody assay: 
HPV18. 
 
Analysis Sample 
size 
Dilution Number of 
discrepanciesa
Observed 
agreement 
(%) 
Expected 
agreement 
(%) 
Weighted 
kappa 
1 10 4 0 100 82 1.00 
2 10 4 1(1), 2(2) 92 79 0.60 
3 12 4 NA NA NA NA 
4 12 4 3(1), 1(2) 93 65 0.80 
5 12 2 NA NA NA NA 
6 12 3 4(1) 94 58 0.87 
7 12 3 NA NA NA NA 
8 12 3 5(1) 93 67 0.79 
9 12 3 5(1), 2(2) 88 65 0.64 
10 12 3 11(1) 85 68 0.52 
11 12 3 3(1), 1(2) 93 62 0.82 
12 12 3 3(1) 96 59 0.90 
aNumber of discrepancies between replicates, with the number of titre categories difference in 
brackets e.g. in analysis 9 there were five differences of one titre, and two of two titres. 
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Summary 
 
An adaption of a neutralizing antibody assay originally developed by Pastrana et al. 
(Pastrana 2004) was adapted for use in the measurement of the humoral immune 
response to HPV16 and HPV18 infections in sera samples. During the development 
and refinement of this assay, it was used to test a limited number of sera samples on 
several occasions: 42 sera samples taken from 21 women, and a further seven sera 
samples from an external source, were tested (often several times) in 12 analyses. 
An optimum well-plate configuration had been determined and the assay was 
considered to have reached the stage where the adaptation was believed to have 
been successful, and the reliability of the assay could be formally evaluated.  
 
 
 
 
18.3 RELIABILITY OF THE NEUTRALIZING ANTIBODY ASSAY 
 
To provide definitive measurements of the intra- and inter-assay reliability (within- 
and between-assay reliability, respectively) of the neutralizing antibody assay, and to 
confirm the viability of potential positive- and negative-controls identified for use 
during the testing of the samples from the study cohort described in this thesis, two 
final analyses were undertaken (analyses D1 and D2). These analyses provided two 
estimates of intra-assay reliability, and four (correlated) estimates of inter-assay 
reliability. 
 
The configuration used for well-plates used is shown in figure 18.3. In analyses D1 
and D2, the same set of 12 sera samples was tested, with four samples tested in 
duplicate in contiguous columns on each of the three well-plates analysed in each 
assay. This example shows samples 1 to 4; the second plate was used to test 
samples 5 to 8, and the third 9 to 12. The lowest dilution of serum was 1-in-40, 
increasing in multiples of three to a maximum of 1-in-9720. Ten wells containing 
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target cells and PsV in identical concentrations were used to measure the maximum 
signal. Two wells, containing target cells alone in identical concentrations, were used 
to measure the well-plate background signal.  
 
Figure 18.3. The well-plate configuration for each of the well-plates used in 
the analyses to demonstrate the intra- and inter-assay reliability of the 
neutralizing antibody assay. Sn is sample number n, n=1 to 4. 1-in-D is the dilution of 
sera samples. Wells labelled “Cells+PsV” are wells used to measure maximum signal; those 
labelled “Cells alone” are wells used to measure the well-plate background signal. 
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The samples tested are presented in table 18.3a. The samples used comprised 
three potential internal HPV16 and/or HPV18 positive-controls, two potential internal 
HPV16 and HPV18 negative-controls, including one from a woman who was a virgin 
when the serum sample was taken, and seven potential positive- or negative-
controls supplied from the WHO collaborative study. All samples had been tested 
previously on at least one occasion. 
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Table 18.3a. Sera samples, and the HPV DNA status of the corresponding 
virological samples, used in the analyses to demonstrate the reliability of 
the neutralizing antibody assay 
 
Assay 
identifier 
Serum sample 
identifier 
HPV DNA status of corresponding 
virological sample 
1 WHO1 Unknown 
2 WHO2 Unknown 
3 WHO3 Unknown 
4 WHO4 Unknown 
5 WHO5 Unknown 
6 WHO6 Unknown 
7 WHO7 Unknown 
8 277.4 HPV-negative 
9 368.7 HPV18 
10 894.1 Result missing 
11 1621.3 HPV16 
12 1621.5 HPV-negative 
 
 
The 50% neutralizing antibody titres against HPV16 and HPV18 for each replicate of 
each sample from analyses D1 and D2, are shown in table 18.3b. Note that the 
lowest dilution used in these analyses was 1-in-40, with increments in multiples of 
three.  
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Table 18.3b. The 50% neutralizing antibody titres (inverse) against 
HPV16 and HPV18 for each replicate of each sample from the final 
developmental analyses for the neutralizing antibody assays. DnRm 
denotes analysis Dn (n=1,2) replicate m (m=1,2). 
 
Sample HPV16a HPV18a 
 D1R1 D1R2 D2R1 D2R2 D1R1 D1R2 D2R1 D2R2
1 1080 1080 360 360 0 0 0 0 
2 0 0 0 0 0 0 0 0 
3 360 360 360 120 40 0 0 0 
4 40 0b 0b 40 360 360 120 120 
5 0 40 0 0 0 0 0 0 
6 0 0 0 0 40 40 40 0 
7 0 0 0 0 1080 3240 1080 3240 
8 0 0 0 0 40 0 0 0 
9 40 0b 0 0 1080 1080 1080 1080 
10 0 0 0 0 0 0 0 0 
11 1080 1080 1080 1080 3240 3240 9720 9720 
12 1080 1080 1080 360 1080 9720 3240 9720 
aZero means seronegative for neutralizing antibodies; bthese samples are seronegative after 
comparison with the non-specific neutralizing antibody response obtained for BPV1. 
 
18.3.1 Intra-assay reliability 
 
18.3.1.1 HPV16 
 
Estimates of weighted kappa statistics measuring intra-assay (within-assay) 
reliability for the neutralizing antibody response to HPV16 from analyses D1 and D2 
are presented in table 18.3.1.1. 
 
In analysis D1 there were three discrepancies between replicates in their measured 
neutralizing antibody response to HPV16, all of one titre category: the estimate of 
the weighted kappa statistic was 0.86 (95% CI 0.70 to 1.00), indicating “almost 
perfect” intra-assay agreement. 
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In analysis D2, there were also three discrepancies of only one titre category, with 
one of these samples also being discrepant in analysis D1: the estimate of the 
weighted kappa statistic was 0.84 (95% CI 0.69 to 0.99), indicating “almost perfect” 
intra-assay agreement. 
 
Note that in analysis D1, before accounting for the non-specific immune response 
(i.e. that to BPV1), there was only one discrepancy between observed titres, 
compared with two in analysis D2 (table 18.3c). As well as HPV16 and HPV18, 
samples were also tested in duplicate for BPV1, the results of which are also subject 
to fluctuation. In analysis D1, all BPV1 results were seronegative, with the exception 
of four which gave titres of 1-in-40: in each of these cases, the seropositive results 
were from one replicate only. In analysis D2, only one sample was seropositive for 
neutralizing antibodies against BPV1, at a titre of 1-in-40. Ignoring the impact of 
accounting for the non-specific immune response, estimates of the weighted kappa 
statistic were 0.95 and 0.89 from analyses D1 and D2, respectively. 
 
Table 18.3.1.1. Estimates of weighted kappa 
statistics measuring intra-assay reliability for the 
neutralizing antibody response to HPV16 from 
analyses D1 and D2. 
 
Analysis Discrepanciesa Weighted 
kappa 
D1 3(1) 0.86 
D2 3(1) 0.84 
aNumber of discrepancies between replicates, with the difference 
in terms of the number of titre categories, in brackets. 
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18.3.1.2 HPV18 
 
Estimates of weighted kappa statistics measuring intra-assay (within-assay) 
reliability for the neutralizing antibody response to HPV18 from analyses D1 and D2 
are presented in table 18.3.1.2. 
 
In analysis D1 there were four discrepancies between replicates in their measured 
neutralizing response to HPV18, three of only one titre category, and one of two: the 
estimate of the weighted kappa statistic was 0.82 (95% CI 0.68 to 0.96), indicating 
“almost perfect” intra-assay agreement. 
 
In analysis D2, there were three discrepancies, all of only one titre category, with two 
of these samples also being discrepant in analysis D1: the estimate of the weighted 
kappa statistic was 0.90 (95% CI 0.80 to 0.99), indicating “almost perfect” intra-
assay agreement. 
 
Accounting for the non-specific immune response to BPV1 did not change the 
measured titres against HPV18 in either of the two analyses. 
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Table 18.3.1.2a. Estimates of weighted kappa 
statistics measuring intra-assay reliability for the 
neutralizing antibody response to HPV18 from 
analyses D1 and D2. 
 
Analysis Discrepanciesa Weighted 
kappa 
D1 3(1), 1(2) 0.82 
D2 3(1) 0.90 
aNumber of discrepancies between replicates, with the difference 
in terms of the number of titre categories, in brackets. 
 
18.3.2 Inter-assay reliability 
 
Measurements of inter-assay reliability were obtained for each of the four ways in 
which a replicate from analysis D1 could be paired with a replicate from analysis D2; 
hence these two analyses yielded four correlated estimates of weighted kappa for 
measuring inter-assay reliability. I have been unable to identify a statistical method 
which will combine these four estimates into a single estimate. 
 
18.3.2.1 HPV16 
 
Estimates of weighted kappa statistics measuring inter-assay (between-assay) 
reliability for the neutralizing antibody response to HPV16 from analyses D1 and D2 
are presented in table 18.3.2.1. 
 
For HPV16, values of weighted kappa statistics measuring inter-assay reliability 
indicate reliability which ranges from “substantial” to “almost perfect”. The 
comparison between replicate 2 from analysis D1 with replicate 2 from analysis D2 
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included five discrepant results, all of one titre category; replicate 2 from analysis D1 
had only two discrepancies of one titre category when compared against replicate 1 
from analysis D2.  
 
Table 18.3.2.1a. Estimates of weighted kappa statistics 
measuring agreement between measurements of the 
neutralizing antibody response to HPV16, for each possible 
pair of replicates included in analyses D1 and D2. 
 
 
Analysis D2 
Replicate 1 
Analysis D2 
Replicate 2 
Analysis D1 Replicate 1 0.85 0.80 
Analysis D1 Replicate 2 0.90 0.75 
 
 
18.3.2.2 HPV18 
 
Estimates of the weighted kappa statistics measuring inter-assay (between-assay) 
reliability for the neutralizing antibody response to HPV18 from analyses D1 and D2 
are presented in table 18.3.2.2. 
 
For HPV18, values of weighted kappa statistics measuring inter-assay reliability 
indicate reliability which ranges from “substantial” to “almost perfect” according to the 
Landis scale. The comparison between replicate 1 from analysis D1 and replicate 2 
from analysis D2 includes seven discrepant results, six of one titre category, and one 
of two; replicate 2 from analysis D1 has only three discrepancies of one titre 
category when compared against replicate 2 from analysis D2.  
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Table 18.3.2.2. Estimates of weighted kappa statistics 
measuring agreement between measurements of the 
neutralizing antibody response to HPV18, for each 
possible pair of replicates included in analyses D1 and 
D2. 
 
 
Analysis D2 
Replicate 1 
Analysis D2 
Replicate 2 
Analysis D1 Replicate 1 0.81 0.72 
Analysis D1 Replicate 2 0.86 0.90 
 
 
 
Summary 
 
The reproducibility of the HPV16 assay was excellent: values of the intra- and inter-
assay weighted kappa statistics were 0.95 and 0.89, respectively. Discrepancies 
between titres from repeated measurements of the same sample were at most one 
titre category. The HPV18 assay was clearly more variable, and therefore less 
reliable, than the HPV16 assay: the estimates of the weighted kappa statistics 
measuring intra- and inter-assay reliability were, however,  both 0.90. 
 
 
 
18.3.2.3 Identification of positive- and negative-controls 
 
All of the sera samples supplied from the WHO collaborative study were tested on 
three occasions, in duplicate. Results from this testing are shown in figure 18.3.2.3. 
This figure sheds further light on the reproducibility of the assay. In this figure, the 
darkest boxes were from analysis R1, which will be discussed in section 18.5.2.  
 
On the basis of these results, sample WHO1 was selected for use as the HPV16 
positive control when testing patient samples from the cohort described in this thesis. 
Sample WHO7 was used as the HPV18 positive-control; and sample WHO5 was 
used as the negative-control for all viral types. 
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Figure 18.3.2.3. Results of the repeated testing of sera samples supplied from the 
WHO collaborative study. Cross-hatched boxes indicate sample results changed to 0 (seronegative) 
after comparison with the BPV1 result. Sample IDs appear in the centre of the figure. Inverse titres are 
shown, except for 0 which is seronegative. 
 
    HPV16         HPV18    
Titre (Inverse)         WHO1           
                     
9720                    9720                   
3240                    3240                   
1080                    1080                   
360                    360                   
120                    120                   
40                    40                   
0                    0                   
                                       
                     
Analysis  6 6 D1 D1 D2 D2 R1 R1    6 6 D1 D1 D2 D2 R1 R1 
Replicate 1 2 1 2 1 2 1 2    1 2 1 2 1 2 1 2 
                     
9720                  WHO2 9720                  
3240                    3240                   
1080                    1080                   
360                    360                   
120                    120                   
40                    40                   
0                    0                   
                                       
                     
  6 6 D1 D1 D2 D2 R1 R1    6 6 D1 D1 D2 D2 R1 R1 
  1 2 1 2 1 2 1 2    1 2 1 2 1 2 1 2 
                     
9720                  WHO3 9720                  
3240                    3240                   
1080                    1080                   
360                    360                   
120                    120                   
40                    40                   
0                    0                   
                                       
                     
  6 6 D1 D1 D2 D2 R1 R1    6 6 D1 D1 D2 D2 R1 R1 
  1 2 1 2 1 2 1 2    1 2 1 2 1 2 1 2 
                     
9720                  WHO4 9720                  
3240                    3240                   
1080                    1080                   
360                    360                   
120                    120                   
40                    40                   
0                    0                   
                                       
                     
  6 6 D1 D1 D2 D2 R1 R1    6 6 D1 D1 D2 D2 R1 R1 
  1 2 1 2 1 2 1 2    1 2 1 2 1 2 1 2 
                     
9720                  WHO5 9720                  
3240                    3240                   
1080                    1080                   
360                    360                   
120                    120                   
40                    40                   
0                    0                   
                                       
                     
  6 6 D1 D1 D2 D2 R1 R1    6 6 D1 D1 D2 D2 R1 R1 
  1 2 1 2 1 2 1 2    1 2 1 2 1 2 1 2 
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Figure 18.3.2.3 (continued). Results of the repeated testing of sera samples 
supplied from the WHO collaborative study. Cross-hatched boxes indicate sample results 
changed to 0 (seronegative) after comparison with the BPV1 result. Sample IDs appear in the centre of the 
figure. Inverse titres are shown, except for 0 which is seronegative. 
 
    HPV16         HPV18    
Titre (Inverse)                    
                     
                     
9720                  WHO6 9720                  
3240                    3240                   
1080                    1080                   
360                    360                   
120                    120                   
40                    40                   
0                    0                   
                                       
                     
Analysis  6 6 D1 D1 D2 D2 R1 R1    6 6 D1 D1 D2 D2 R1 R1 
Replicate 1 2 1 2 1 2 1 2    1 2 1 2 1 2 1 2 
                     
9720                  WHO7 9720                  
3240                    3240                   
1080                    1080                   
360                    360                   
120                    120                   
40                    40                   
0                    0                   
                                       
                     
  6 6 D1 D1 D2 D2 R1 R1    6 6 D1 D1 D2 D2 R1 R1 
  1 2 1 2 1 2 1 2    1 2 1 2 1 2 1 2 
 
 
 
 
 
 
 
Summary 
 
Following twelve developmental and confirmatory analyses, carried out over a period 
of five months, substantial experience had been gained in the use of the neutralizing 
antibody assay, an optimum well-plate configuration had been determined, suitable 
positive- and negative-controls had been identified, and, most importantly, adequate 
reliability of the assay had been demonstrated. The analysis of samples from the 
cohort described in this thesis could now proceed with confidence. 
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18.4 INTENDED STUDY POPULATION FOR THE ANALYSIS OF THE KINETICS 
OF THE NEUTRALIZING ANTIBODY RESPONSE TO INCIDENT CERVICAL 
HPV16 AND HPV18 INFECTIONS 
 
The neutralizing antibody assay was next used to describe the kinetics of the 
neutralizing antibody response to incident cervical HPV16 and HPV18 infections in a 
cohort of young women who were recruited soon after first sexual intercourse. 
 
All women within the full study cohort (n=2,011) who were HPV DNA-negative and 
cytologically normal at study entry, who had further follow-up after this time, and who 
first tested positive in cervical cytological samples for HPV16 DNA, or HPV18 DNA, 
or both, during follow-up, were identified. For the purposes of identifying the study 
population, the method used for the detection of HPV DNA was general primer 
(GP5+/GP6+)-mediated PCR, as described previously (see section 5.5.4.1). 
 
One hundred and fifty five women fulfilled these criteria: 91 women acquired an 
incident cervical HPV16 infection, 45 acquired an incident cervical HPV18 infection, 
and 19 acquired both, at some point prior to the end of follow-up, either 
contemporaneously or otherwise. When appropriate, these three cohorts will be 
referred to as the “HPV16-only”, “HPV18-only” and “HPV16-and-HPV18” cohorts, 
respectively. When combined by type, the 110 women who acquired an incident 
cervical HPV16 infection during follow-up will be referred to as the “HPV16 cohort”; 
similarly, the 64 women who acquired an incident cervical HPV18 infection during 
follow-up will be referred to as the “HPV18 cohort”.  
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18.4.1 Characteristics of the intended study population 
 
Baseline characteristics. The mean age (standard deviation) at study entry of women 
with an incident cervical HPV16, or HPV18, infection was 17.4 (1.2) and 17.5 (1.2) 
years, respectively. The median age at first sexual intercourse of the women in these 
two groups was 16 years, and the median duration of sexual activity before study 
entry was 19.6 months, and the median number of sexual partners before study 
entry was two. 
 
Time on study. Time on study (follow-up) was measured from the date of the first 
evaluable virological sample, with censoring on the earliest of date of: diagnosis of 
high-grade CIN; treatment; or last smear. The median time on study for women with 
an incident HPV16 or HPV18 infection was 47 months (range 6 to 105) and 50 
months (6 to 107), respectively. The median time interval between study visits was 
6.4 months. 
 
Availability of virological samples. The median numbers of virological samples 
available for HPV DNA testing were 7 (range 2 to 14) and 8 (2 to 14) for women with 
cervical HPV16 and HPV18 infections, respectively. 
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18.4.2 The number of sera samples available for testing for each woman 
according to cohort 
 
The frequency distribution of the number of sera samples available for each woman, 
according to (GP5+/GP6+) cohort, is presented in table 18.4.2; this table includes 
multiple sera samples from the same visit. 
 
There were 19 women in the HPV16+HPV18 cohort. The median number of sera 
samples available for each woman was 4 (range 0 to 11); three women had no sera 
samples. The total number of sera samples available was 75; one woman had 
duplicate samples from the same visit, so 74 sera samples were available from 
distinct occasions. 
 
There were 91 women in the HPV16-only cohort. The median number of sera 
samples available for each woman was 3 (range 0 to 15); 25 women had no sera 
samples. The total number of sera samples available was 317; five women had a 
duplicate sample from the same visit, so 312 sera samples were available from 
distinct occasions. 
 
There were 45 women in the HPV18-only cohort. The median number of sera 
samples available for each woman was 3 (range 0 to 14); 13 women had no sera 
samples. The total number of sera samples available was 172; six women had a 
duplicate sample from the same visit, so 166 sera samples were available from 
distinct occasions. 
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Table 18.4.2. Frequency distribution of the number of sera 
samples available for each woman in the HPV16-and-HPV18, 
HPV16-only, and HPV18-only, cohorta. 
 
Cohort: Number of women Number 
of sera 
samples 
HPV16+HPV18 
(n=19) 
HPV16-only
(n=91) 
HPV18-only 
(n=45) 
Total
0 3 25 13 41 
1 3 10 6 19 
2 1 9 2 12 
3 1 11 3 15 
4 3 7 4 14 
5 2 4 4 10 
6 2 5 3 10 
7 2 7 2 11 
8 1 5 2 8 
9 0 1 1 2 
10 0 2 2 4 
11 1 3 0 4 
13 0 1 2 3 
14 0 1 1 2 
ae.g. three women in the HPV16+HPV18 cohort had four sera samples, compared 
with seven and four in the HPV16-only and HPV18-only cohorts, respectively. 
 
 
 
 
 
Summary 
 
All women who were HPV DNA-negative in cervical cytological samples and 
cytologically normal in cervical smears at study entry, who had further follow-up after 
this time, and who first tested positive for HPV16 DNA, or HPV18 DNA, or both 
(using GP5+/GP6+ mediated PCR), during follow-up, were identified: 155 women 
were identified, 91 of whom acquired an incident cervical HPV16 infection, 45 
acquired HPV18 infection, and 19 acquired both. Mean age (standard deviation) at 
study entry of women with HPV16, or HPV18, infections was 17.4 (1.2) and 17.5 
(1.2) years, respectively; median age at first sexual intercourse in both groups was 
16 years; the median duration of sexual activity before study entry was 19.6 months; 
and the median number of sexual partners before study entry was two. The median 
time on study for women with HPV16 or HPV18 infection was 47 months (range 6 to 
105) and 50 months (6 to 107), respectively. The median interval between study 
visits was 6.4 months. The median numbers of virological samples available for HPV 
DNA testing were 7 (range 2 to 14) and 8 (2 to 14) for women with cervical HPV16 
and HPV18 infections, respectively. 
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18.5 TESTING OF SERA SAMPLES 
 
18.5.1 Configuration of well-plates when conducting the neutralizing antibody 
assay 
 
The configuration of the well-plates used to test study samples is shown in figure 
18.5.1. The configuration of the well-plates was identical for each of the virus types 
tested for, except with respect to the positive control wells. 
 
Twenty four samples were analysed in each assay, with one assay consisting of a 
total of nine well-plates, i.e. three well-plates used to test samples for their 
neutralizing antibody response against each of HPV16, HPV18, and BPV1. Each 
well-plate was used to test eight study samples. For example, figure 18.5.1 shows 
the configuration of the well-plate used to test samples 1 to 8.  
 
Two wells containing identical concentrations of target cells and PsV were used for 
testing a positive-control: on the HPV16 and HPV18 well-plates, one of these two 
wells had a serum dilution of 1-in-360, and the other 1-in-1080. These dilutions were 
used since both positive-controls, i.e. the HPV16 and the HPV18 positive-controls, 
were found to have 50% neutralizing antibody titres of at least 1-in-360, and so 
should always have given a seropositive result when the assay was working 
correctly. Clearly, the positive control used on the HPV16 well-plate was different 
from that used on the HPV18 well-plate. The BPV1 well-plate also had two “positive-
control” wells, but both at a dilution of 1-in-360: one used to test the HPV16 positive-
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control, the other the HPV18 positive-control. Two wells were used for testing a 
negative-control, both at a serum dilution of 1-in-40. 
 
Note: The controls used on the BPV1 well-plates were effectively redundant, since 
no controls for BPV1 were available, and since the number of wells available on a 
well-plate for measuring the signals from controls was severely limited. This meant 
that, in practice, the results from the controls on the BPV1 well-plate were 
disregarded; and, in contrast to “samples wells”, where a result was only positive if it 
had a non-zero titre at least three times greater than the BPV1 titre (see section 
17.3.2), the results from the “control wells” on the HPV16 and HPV18 well-plates 
were interpreted at face value, without a supporting BPV1 result. 
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Figure 18.5.1. The well-plate configuration for each of the well-plates used 
in the analysis to determine the reliability of the neutralizing antibody 
assay. Sn is sample number n, n=1 to 8. White cells correspond to empty wells on the well-
plate. Blue cells are wells used to measure the maximum signal. Yellow cells are used to 
measure well-plate background. Green and red cells measure positive- and negative-control 
signals, respectively. Interior cells correspond to wells used to test study samples, with all wells 
in the same column being used to test the same sample at different dilutions: dilutions start at 1-
in-40 in row 2, and proceed in multiples of three until 1-in-9720 is reached in row 7. 
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18.5.2 Difficulties encountered using the neutralizing antibody assay 
 
Each well-plate in the configuration shown in figure 18.5.1 could be used to test a 
total of eight study sera samples. In filling the available spaces on the well-plates, 
each of the three subcohorts (i.e. the HPV16+HPV18, HPV16-only, and HPV18-only, 
cohorts) was treated separately. Table 18.5.2 describes the number of analyses 
which would have been required to analyse all available sera samples in the relevant 
study cohorts. A total of 216 well-plates in 72 analyses would have been required. At 
a rate of two analyses a week, with no unforeseen problems, this would have taken 
eight or nine months.  
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Table 18.5.2. The number of neutralizing antibody analyses required to 
analyse all available sera samples in the HPV16-only and HPV18-only 
subcohorts. Each potential analysis consists of nine sets of well-plates. 
 
Subcohort Number of sera 
samples 
Number of analyses 
required 
Number of well-
plates required 
HPV16-only 317 40 120 
HPV18-only 172 22 66 
HPV16+HPV18 75 10 30 
Total 564 72 216 
 
 
Women were prioritised according to the order in which they would have their sera 
samples tested. These priorities changed during the course of testing due to various 
external influences (the availability of HPV viral load measurements, conference 
deadlines,  etc.). Initially, the intention was to test every serum sample from every 
woman within the three relevant subcohorts; therefore, the changing priorities were 
not perceived as presenting any threat to the study. However, ultimately, testing was 
discontinued before all women had been tested. 
 
Difficulties arose with the assay during the testing of sera samples from the cohort 
described in this thesis; and conducting two analyses per week proved 
unsustainable, due to the strain it placed on the (single) laboratory scientist 
conducting the assay. Ultimately, this led to the decision to cease testing any further 
study samples using this assay. 
 
According to the original developers of this neutralizing antibody assay, PsV, once 
manufactured, could be snap-frozen at -80oC and stored for a period of two years: 
this was not confirmed in our laboratory. Within a year of manufacture, the “activity” 
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of the BPV1 PsV was found to have deteriorated to a point at which they could no 
longer be relied upon to work correctly in the assay. The records of the refrigerator 
used to store the stock of BPV1 PsV did not reveal any concerns: it was speculated 
that the BPV1 PsV had become denatured to some extent, at least within 
subpopulations of the PsV. 
 
It was predicted that the BPV1 PsV could still be used, but at a higher dilution than 
had been used previously. Initially, the dilution used had been 1-in-800; now, 
however, it was proposed to use a dilution of 1-in-25,600. The use of BPV1 PsV at 
higher dilutions was validated by testing previously tested samples, measuring intra- 
and inter-assay reliability, and confirming that results were consistent with those 
obtained previously. The opportunity was also taken to identify a new negative-
control, since the existing negative-control (sample WHO2) was nearing exhaustion. 
This approach failed. It was therefore necessary to manufacture new BPV1 PsV, 
determine the amount to use in each assay, confirm the reproducibility of the assays 
using these new BPV1 PsV, and confirm that results were consistent with those 
obtained previously (analysis R1). Subsequently, at different stages during the 
period when study samples were being tested, the HPV16 and HPV18 PsV were 
also found to have deteriorated to a point where they could no longer be relied upon 
to work correctly in the assay, and so the same time-consuming procedures were 
required to re-manufacture and re-evaluate the new HPV16 and HPV18 PsV. 
 
The original laboratory kits used in these assays, which cost £700 each, were 
manufactured by BD Biosciences: one kit contained enough reagent to analyse 
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eighteen 96-well well-plates, with no leeway for error. One kit could therefore be 
used to test 48 study samples, assuming that eight study samples were tested on 
each well-plate. This meant that one kit was exhausted every week initially, and 
every two weeks subsequently. During the period when samples from the cohort 
described in this thesis were being tested, BD Biosciences was bought by Clontech, 
and the original kits were no longer available. The “new” kit offered by Clontech, 
which cost £470, was sufficient for conducting 300 reactions (one reaction=one well). 
That being said, the catalogue number for ordering these kits was the same as it 
was previously, and the catalogue description for the old kit also seemed to suggest 
that it was only sufficient for conducting 300 reactions. So, on the face of it, it 
appeared that the new and original kits were equivalent, if now more expensive. 
However, it was necessary to confirm this. The new kit was evaluated in the same 
way as the original kit: intra- and inter-assay reliability were measured by repeating 
analyses D1 and D2 from the developmental stage with the assay, and comparing 
the new results with those taken previously. 
 
18.5.3 Study population tested 
 
Due to competing priorities within the study, the decision was made to stop testing 
samples when equal numbers of women from each of the three relevant study 
subcohorts (the HPV16-only, the HPV18-only and the HPV16+HPV18 cohorts) had 
been tested: the intention was that testing would resume at some point in the future. 
Since all women with sera samples available in the HPV16-and-HPV18 cohort had 
been tested when this decision was taken, this determined the total number of 
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women from each of the remaining two subcohorts which would be tested. 
Subsequently, it was decided that sufficient data was available to draw conclusions 
about the utility of the neutralizing antibody assay, and to provide a description of the 
kinetics of the immune response following acquisition of the relevant type-specific 
cervical HPV infections. However, as a result of the cumulative difficulties 
encountered with this expensive, and difficult to perform assay, no further testing 
was undertaken, and none is planned. 
 
The final population tested for their neutralizing antibody response to cervical HPV16 
and HPV18 infections comprised 48 women. Table 18.5.3 describes the relationship 
between the study population it was the intention to test and the population actually 
tested. Forty eight (42%) women with sera samples available were tested for their 
neutralizing antibody response: all women in the HPV16+HPV18 cohort who could 
have been tested were tested, compared with just over half of the women in the 
HPV18-only cohort, and slightly more than a fifth of women in the HPV16-only 
cohort. 
 
Table 18.5.3. Relationship between the study population it was the 
intention to test and the population actually tested for their neutralizing 
antibody response to incident cervical HPV16 or HPV18 infections, or 
both. Frequencies are numbers of women. 
 
Subcohort Population 
HPV16-only HPV18-only HPV16-and-HPV18 
Total 
Intended study 
population 91 45 19 155 
Number with 
serum samples 
available 
66 32 16 114 
Population 
actually tested 15 17 16 48 
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18.5.3.1 Sera samples available 
 
The availability of sera samples from each study visit for each woman in the study 
population are illustrated in table 18.5.3.1. As an example, the woman with study 
number (ID) 350 belongs to the HPV16+HPV18 cohort, and HPV18 was first 
detected at an earlier visit than HPV16 (hence 18-16). She made 14 visits to the 
study: the maximum number of visits made by any woman was 16, hence this 
woman has her last two (16-14) cells “blacked-out”. For five of her 14 visits, at least 
one serum sample was available for testing; for the remaining nine visits, no sera 
samples were available. For her fourth visit, there were two sera samples available. 
For her tenth visit, there was one serum sample available, but this was tested twice 
for the neutralizing antibody response to HPV16. 
 
The median number of study visits was 9 (range 2 to 16). The median number of 
study visits for which a serum sample was available was 5 (range 1 to 14), with nine 
women providing a serum sample on only a single occasion. The median number of 
study visits for which no serum sample was available was 3 (range 0 to 11), with 
only five women having a “complete” set of sera samples, i.e. a serum sample taken 
at every possible study visit. However, this latter result should be interpreted as 
missed opportunities at measurement, rather than as missing samples per se.  
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Table 18.5.3.1. The availability of sera samples from each study visit for each woman in the 
population tested for their neutralizing antibody response to HPV16 and HPV18. ID=study 
number; C=Cohort (the order in which HPV16 and HPV18 were detected e.g. 16-18 means 16 followed by 18, whereas 
16+18 means both types were first detected at the same time); V=Number of study visits; S=Number of visits for which a 
serum sample is available; M=number of visits with no serum sample. A white cell indicates a visit for which at least one 
serum sample was available; a grey cell indicates a visit for which no serum sample was available; a black cell indicates that 
the woman had reached the end of follow-up; 2S=Two sera samples available for this visit; T2=one serum sample available 
which was tested twice. 
Visit number ID C V S M 
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16
2 16-18 10 5 5
27 18 14 9 5 2S    
29 18 12 10 2    
43 18 10 7 3      
69 16 16 7 9      
92 16-18 5 5 0      
94 18 2 1 1      
118 16-18 9 3 6      
128 18-16 16 11 5      
147 16-18 11 1 10      
150 16-18 12 9 3     
189 16 9 8 1      
240 16-18 7 7 0    
244 16 9 7 2      
247 16+18 9 7 2      
292 18 16 14 2   T2 T2    
330 16 5 3 2      
350 18-16 15 5 10   2S T2    
360 16 4 1 3      
379 16-18 13 5 8      
381 18 11 5 6    
393 16+18 7 4 3      
446 18 8 7 1      
490 18 9 8 1      
515 16 6 6 0   2S    
524 18 8 1 7      
561 18 3 3 0      
590 16 8 7 1      
692 18 8 3 5    
744 18 8 6 2    
761 16 2 2 0    
938 18 13 12 1   2S    
941 16 8 6 2      
997 18-16 9 4 5      
1011 16 11 7 4 2S    
1016 18 8 2 6      
1268 16-18 9 1 8      
1278 18 6 5 1 2S     
1347 16 2 1 1    
1365 16 4 1 3      
1367 16 12 8 4      
1413 16 7 1 6      
1430 18 9 8 1      
1540 18-16 9 4 5      
1551 16+18 12 8 4      
1604 16 12 1 11    
1803 16+18 5 2 3      
1814 18 12 6 6      
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18.5.3.2 Practical issues arising during the testing of the final study population 
 
The analysis of all sera samples from the women comprising the final population 
tested required 11 analyses, excluding those discarded due to problems with the 
assay, as described previously (section 18.5.2.1). Each well-plate could be used to 
test a total of eight samples from the relevant study subcohorts. In allocating 
samples to the available spaces on the well-plates, each of the three relevant 
subcohorts (the HPV16-only, HPV18-only and the HPV16-and-HPV18 cohorts) were 
treated separately, as far as possible. Despite the relatively large value of the 
weighted-kappa statistic measuring inter-assay reliability, the first criteria for 
allocating samples to well-plates was to test all samples from the same woman on 
the same well-plate, where possible. However, five women had samples tested on 
two different well-plates.  
 
A total of 264 sera samples from 254 study visits made by 48 women were tested; 
six women had two sera samples from the same visit for one of their visits; and for 
three samples, the opportunity was taken to repeat the testing of the same sample. 
For one sample (ID 92.8), there was no corresponding visit: this sample was 
mislabelled, and was excluded from all analyses. 
 
The status of the controls on the well plates, the requirement for a BPV1 titre against 
which to judge a type-specific titre, and the fact that testing was discontinued before 
all women had been tested, all had an impact on the size of the final study 
population tested. 
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All well-plates were read automatically, with numerical signal measurements for 
each well-plate being output to a computer file. Unfortunately, for one analysis, the 
same output file was inadvertently saved twice under different file names. This 
meant that the BPV1 titre for the samples tested on those well-plates were unknown; 
given that titres against BPV1 of 1-in-120 and 1-in-360 had been observed in women 
from the cohort described in this thesis, there was no choice but to exclude the two 
women involved (study IDs 69 and 150), from all analyses. 
 
For all well-plates, testing for either HPV16 or HPV18, the positive-controls were 
always seropositive at a titre of at least 1-in-360, as required. All well-plates were 
therefore acceptable on the basis of the positive-control result. 
 
The negative-controls were interpreted together: a well-plate was considered to have 
a seronegative result for the negative-control if at least one of the negative-control 
wells indicated a seronegative result. For well-plate 7-2-190606, both negative 
control wells in the HPV16 analysis indicated a seropositive result; for well-plates 7-
1-190606 and 10-1-040806, both negative-control wells in the HPV18 analysis 
indicated a seropositive result. These well-plates were considered to have “failed”, 
and the results for the study samples on these well-plates were therefore rejected. 
The intention was to complete testing of all eligible study samples once, before 
repeating the testing of samples whose first result had been rejected due to failure of 
the well-plates on which they were tested. However, as stated previously, no further 
testing was undertaken. Therefore, one woman (ID 490) was excluded from all 
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analyses of HPV16, but not of HPV18; and three women (ID’s 29, 244, and 360) 
were excluded from all analyses of HPV18, but not of HPV16. 
 
 
Summary 
 
Difficulties arose with the assay, so testing stopped before all eligible women had 
been tested. However, sufficient data was available to draw conclusions about the 
utility of the assay, and to describe the kinetics of the immune response following the 
acquisition of the relevant type-specific cervical HPV infections. The final population 
tested comprised 48 women out of a possible 114 who had sera samples available. 
The median number of study visits was 9 (range 2 to 16); the median number of 
visits for which a serum sample was available was 5 (range 1 to 14). The analysis of 
all sera samples from the women comprising the final population tested required 11 
analyses in which 264 samples from 254 visits were tested.  
 
 
 
18.6 FINAL STUDY POPULATION FOR THE ANALYSIS OF THE KINETICS OF 
THE NEUTRALIZING ANTIBODY RESPONSE TO INCIDENT CERVICAL HPV16 
AND HPV18 INFECTIONS 
 
The final study population for the analysis of the kinetics of the neutralizing antibody 
response to incident cervical HPV16 and HPV18 infections comprised 45 women for 
the analysis of HPV16, and 43 for the analysis of HPV18 (42 women were common 
to both groups). The derivation of the final study population from the full cohort of 
2,011 women is shown in figure 18.6. For ease of reference, in this subsection, the 
45 (42+3) women will be referred to as the “HPV16 study population”, and the 43 
(42+1) women as the “HPV18 study population”. 
 
Figure 18.6. Derivation of the final study population from the cohort of all 
women recruited to the study. 
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42
3
1
1,075 
HPV-negative with a cytologically normal cervical 
smear at study entry and have further follow-up 
155 
Acquire incident cervical HPV16 (n=91) infection, 
HPV18 (n=45), or both (n=19), during follow-up 
48 Tested for their neutralizing antibody response to both HPV16 and HPV18 
46 Evaluable BPV1 results available 
Total number of women recruited into the study 2,011 
Eligible for both the HPV16 and the 
HPV18 analyses
Eligible for the HPV16 analysis only 
Eligible for the HPV18 analysis only 
 
 
 
18.6.1 Characteristics of the final study population 
 
All women included in the final study populations for the analysis of the kinetics of 
the neutralizing antibody response to incident cervical HPV16 and HPV18 infections 
were sexually experienced to some extent. The median interval between the date of 
first sexual intercourse and the date the first serum sample was taken was 542 days 
for women in the HPV16 study population, and 503 days for women in the HPV18 
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study population; the median number of sexual partners prior to the date of the first 
available serum sample was 2 (range 1 to 9) for both study populations. 
 
For both the HPV16 and HPV18 study populations: the median number of study 
visits was 9 (range 2 to 16); the median number of study visits for which at least one 
serum sample was available was 5 (range 1 to 14); the median number of study 
visits for which no serum sample was available was 3 (range 0 to 11), with only five 
women having a “complete” set of sera samples, i.e. a serum sample for every 
possible study visit. However, this latter result should be interpreted as missed 
opportunities at measurement, rather than as missing samples per se. 
 
In the HPV16 population, 36 women provided at least two sera samples: the median 
time interval between the date of the first and last sera samples was 1,341 days. In 
the HPV18 population, 35 women provided at least two sera samples: the median 
time interval between the dates of the first and last sera samples was 1,329 days. In 
both study populations, for all women the first serum sample available was that 
taken at study entry; for 14 women, the last serum sample available was that taken 
at the last visit. 
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Summary 
 
The final study population for the analysis of the kinetics of the neutralizing antibody 
response to incident cervical HPV16 and HPV18 infections comprised 45 women for 
the analysis of HPV16, and 43 for the analysis of HPV18 (with 42 common to both 
groups). The median interval between first sexual intercourse and the first serum 
sample was taken was 542 days for women in the HPV16 study population, and 503 
days for women in the HPV18 study population; the median number of sexual 
partners prior to the date of the first available serum sample was 2 (range 1 to 9) for 
both study populations. For both study populations: the median number of study 
visits was 9 (2 to 16); the median number of study visits for which at least one serum 
sample was available was 5 (1 to 14). In the HPV16 population, 36 women provided 
at least two sera samples: the median interval between the dates of the first and last 
sera samples was 1,341 days. In the HPV18 population, 35 women provided at least 
two sera samples: the median interval between the dates of the first and last sera 
samples was 1,329 days. 
 
 
18.7 TYPE-SPECIFIC DISTRIBUTION OF NEUTRALIZING ANTIBODY TITRES 
 
The result of this assay is the 50% neutralization titre, the lowest dilution which 
causes at least a 50% reduction in SEAP expression (see section 17.3.2).  
 
18.7.1 Cross-sectional analysis of the neutralizing antibody response to HPV16 
 
Forty-five women were tested for their neutralizing antibody response to HPV16. The 
observed 50% neutralization titre against HPV16 for all sera samples from every 
woman in the HPV16 study population are shown in table 18.7.1a. The frequency 
distribution across all visits of the observed 50% neutralization titres is shown in 
table 18.7.1b. In these women with natural infections (as opposed to infections seen 
in vaccinated women), all possible titres were observed at least once. Three women 
had a maximum titre of 1-in-9720, including one woman (ID 938) who appears to 
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have maintained this titre for at least three visits, corresponding to a period of 371 
days. 
 
Table 18.7.1a. The frequency distribution of the 
observed 50% neutralizing antibody titre against 
HPV16 across all visits for all women. Where multiple 
sera samples were available, or the same serum sample was 
tested more than once, the greatest titre observed was taken as 
the result of testing that sample. 
 
Titre Number of visits 
  
Seronegative 156 
  
1-in-40 12 
1-in-120 17 
1-in-360 15 
1-in-1080 12 
1-in-3240 14 
1-in-9720 4 
  
Total 230 
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Table 18.7.1b. The observed 50% neutralizing antibody titre (inverse) against 
HPV16 of sera samples from each study visit for each woman in the study 
population. ID=study number; C=Cohort (the order in which HPV16 and HPV18 were detected 
e.g. 16-18 means 16 followed by 18, whereas 16+18 means both types were first detected at the 
same time). A white cell indicates a visit for which a serum sample was available; a grey cell 
indicates a visit for which no serum sample was available; a black cell indicates that the woman had 
reached the end of follow-up. A cell which is split indicates where two sera samples were available 
for that visit, or where one serum sample was available which was tested twice. A black outline to a 
cell indicates that the cytological sample taken at that visit was positive for HPV16 DNA according to 
the GP5+/GP6+ system. A titre of zero indicates a seronegative result. 
 
ID C Visit
  1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16
2 16-18 0   0     0 0 40     
27 18 0 0 0 0 0   0 0 0 0 0
29 18 120 0 0 0 0 0 40 0 0 0   
43 18 0 0 0   120 0 0 0     
92 16-18 3240 3240 3240 1080 3240     
94 18 0             
118 16-18 0   0     0     
128 18-16 0 0 0 0 0 0 0 0 0   0 0
147 16-18   0           
189 16 0 0 0 0 0 0 0 0     
240 16-18 0 0 3240 3240 1080 3240 9720     
244 16 0 0 0 0 0 0 0     
247 16+18 40 0 0   0 120 0 120     
292 18 0 0 0 0 0 0 0 0 0 0 0 0 0   0 0 0
330 16 0 120 360         
350 18-16 0   0 120 360   120 40 120     
360 16     0         
379 16-18 0 0 360   360 360     
381 18 40 0 0   40 0     
393 16+18 0 0 0 40       
446 18 0 0 40 0 0 0 120     
515 16 360 360 0 360 120 120 120     
524 18           0     
561 18 0 9720 1080         
590 16 0 1080 360 1080 360 1080 360     
692 18 0 0     0     
744 18 0     0 0 0 0 0     
761 16 0 0           
938 18 0 0 360 1080 3240 3240 9720 9720 3240 3240 3240 3240 3240
941 16 0   0 0 0 0 0     
997 18-16 0       0 0 0     
1011 16 0 360 1080 3240 1080 1080 1080 1080     
1016 18 0       0     
1268 16-18 40             
1278 18 0 0 0 0 0 0     
1347 16 0             
1365 16 0             
1367 16 0 0 0   40 0 0 0 0   
1413 16 0             
1430 18 0 120   0 0 0 0 40 0     
1540 18-16 0 0     360 1080     
1551 16+18 0 0       120 120 120 40 40   120
1604 16           360     
1803 16+18 0       0     
1814 18 0 0       0 0 0 0     
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The frequency distribution of the number of visits for which the cytological sample 
taken at that visit was positive for HPV16 DNA, and the number of HPV16 DNA-
positive samples for which there was a corresponding serum sample is shown in 
table 18.7.1c (note also that such visits are distinguished by a black outline to the 
cell in table 18.7.1b). Twenty nine women had one or more HPV16 DNA-positive 
samples during follow-up; just over half had only one such sample, but one woman 
had six. Twenty five of these women had 37 sera samples taken at the same time as 
a HPV16 DNA-positive sample; 25 visits for which the cervical cytological sample 
was HPV16 DNA-positive had no corresponding serum sample. 
 
Table 18.7.1c. Frequency distribution of the number of visits for which the 
cervical cytological sample taken at that visit was positive for HPV16 DNA, 
and the number of HPV16-positive samples for which there was a 
corresponding serum sample. Example: five women had a total of three HPV16 DNA-
positive samples during follow-up; however, for one woman there were no corresponding sera 
samples from two of those visits, one woman had serum samples corresponding to two of those 
positive samples but not the third, and the remaining three women had sera samples for all three 
visits. 
 
Number of HPV16 DNA-positive cervical 
cytological samples for which there was 
a corresponding serum sample 
Number of 
cervical 
cytological 
samples 
positive for 
HPV16 DNA 
Number of 
women (n=45) 
0 1 2 3 4 5 6 
0 16 16 – – – – – – 
1 15 6 9 – – – – – 
2 3 1 0 2 – – – – 
3 5 0 1 1 3 – – – 
4 4 2 1 0 1 0 – – 
5 1 0 0 0 0 1 0 – 
6 1 0 0 0 0 1 0 0 
 
The frequency distribution of the 50% neutralization titres of the sera samples taken 
at visits for which the corresponding cervical cytological sample was positive for 
HPV16 DNA is shown in table 18.7.1d. Most sera samples were seronegative for 
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neutralizing antibodies. The frequency distribution of the 50% neutralization titres of 
the sera samples taken at every visit, stratified by the HPV16 DNA status, and the 
study cohort to which the woman belonged, is shown in table 18.7.1e. 
 
Table 18.7.1d. Frequency distribution of the 50% 
neutralization titres of the sera samples taken at 
visits for which the corresponding cervical 
cytological sample was positive for HPV16 DNA. 
Where multiple sera samples were available, or the same 
serum sample was tested more than once, the greatest titre 
observed was taken as the result of testing that sample. 
 
Titre 
Number of sera 
samples 
  
Seronegative 21 
  
1-in-40 1 
1-in-120 3 
1-in-360 6 
1-in-1080 2 
1-in-3240 4 
1-in-9720 0 
  
Total 37 
 
 
18.7.2 Cross-sectional analysis of the neutralizing antibody response to HPV18 
 
The observed 50% neutralization titre against HPV18 of all sera samples from every 
woman in the study population are shown in table 18.7.2a. The frequency 
distribution across all visits of the observed titres is shown in table 18.7.2b. In these 
women with natural infections, all possible titres were observed at least once. Two 
women had the maximum possible titre of 1-in-9720, on one occasion. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 18.7.1e. Frequency distribution of the 50% neutralizing antibody titres of the sera samples taken at 
every visit, stratified by the HPV16 DNA status of the cervical cytological sample and the study cohort to 
which the woman belongs. 
 
HPV16 DNA-positive samples HPV16 DNA-negative samples Titre 
HPV16-only 
cohort 
HPV16+
HPV18 
Total HPV16-only 
cohort 
HPV18-only 
cohort 
HPV16+
HPV18 
Total 
All samples 
         
Seronegative 12 (67%) 9 (47%) 21 (57%) 24 (62%) 78 (79%) 33 (60%) 135 (70%) 156 (68%) 
         
1-in-40 0 (0%) 1 (5%) 1 (3%) 1 (3%) 5 (5%) 5 (9%) 11 (6%) 12 (5%) 
1-in-120 2 (11%) 1 (5%) 3 (8%) 2 (5%) 4 (4%) 8 (15%) 14 (7%) 17 (7%) 
1-in-360 2 (11%) 4 (21%) 6 (16%) 6 (15%) 1 (1%) 2 (4%) 9 (5%) 15 (7%) 
1-in-1080 1 (6%) 1 (5%) 2 (5%) 6 (15%) 2 (2%) 2 (4%) 10 (5%) 12 (5%) 
1-in-3240 1 (6%) 3 (16%) 4 (11%) 0 (0%) 6 (6%) 4 (7%) 10 (5%) 14 (6%) 
1-in-9720 0 (0%) 0 (0%) 0 (0%) 0 (0%) 3 (3%) 1 (2%) 4 (2%) 4 (2%) 
         
Total 18 19 37 
 
 39 99 55 193 
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Table 18.7.2a. Frequency distribution of the 
observed 50% neutralizing antibody titres 
against HPV18 across all visits for all women. 
Where multiple sera samples were available, or the same 
serum sample was tested more than once, the greatest titre 
observed was taken as the result of testing that sample. 
 
Titre Number of visits 
Seronegative 170 
  
1-in-40 9 
1-in-120 6 
1-in-360 6 
1-in-1080 12 
1-in-3240 15 
1-in-9720 2 
  
Total 220 
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Table 18.7.2b. The observed 50% neutralizing antibody titre (inverse) against 
HPV18 of sera samples from each study visit for each woman in the study 
population. ID=study number; C=Cohort (the order in which HPV16 and HPV18 were detected 
e.g. 16-18 means 16 followed by 18, whereas 16+18 means both types were first detected at the 
same time). A white cell indicates a visit for which a serum sample was available; a grey cell 
indicates a visit for which no serum sample was available; a black cell indicates that the woman had 
reached the end of follow-up. A cell which is split indicates where two sera samples were available 
for that visit, or where one serum sample was available which was tested twice. A black outline to a 
cell indicates that the cytological sample taken at that visit was positive for HPV18 DNA according to 
the GP5+/GP6+ system. A titre of zero indicates a seronegative result. 
 
ID C Visit  
  1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16
2 16-18 0   0   0 0 0       
27 18 0 0 0 0 0 0 0  0 0 0
43 18 1080 360 40   120 120 120 360      
92 16-18 0 0 0 0 0       
94 18 0            
118 16-18 0   0   0       
128 18-16 0 0 0 120 0 0 0 0 0   0 40
147 16-18   0          
189 16 0 0 0 0 0 0 0 0       
240 16-18 40 0 9720 1080 1080 1080 360       
247 16+18 0 0 0   0 0 0 0       
292 18 0 0 3240 1080 3240 3240 3240 1080 3240 3240 3240 1080 3240   1080 3240 3240
330 16 0 0 0         
350 18-16 0   0 0 0 0 0 0      
379 16-18 0 0 0   0 360       
381 18 0 0 0   0 40       
393 16+18 0 0 0 0       
446 18 0 0 40 3240 1080 1080 360       
490 18 0 0 0 0 0 0 0 1080       
515 16 0 0 1080 0 0 0 0       
524 18        0       
561 18 0 0 0         
590 16 0 0 0 0 0 0 0       
692 18 0 0    0       
744 18 0    3240 9720 3240 3240 3240       
761 16 0 0          
938 18 0 0 0 0 0 0 0 0 0 120 0 0 0
941 16 0   0 0 0 0 0       
997 18-16 40      0 0 0       
1011 16 0 0 0 0 0 0 0 0       
1016 18 0      0       
1268 16-18 0            
1278 18 40 0 0 0 0 1080       
1347 16 0            
1365 16 0            
1367 16 40 0 0   0 0 0 0 0     
1413 16 120            
1430 18 0 0  0 0 0 0 40 0       
1540 18-16 0 0    3240 360       
1551 16+18 0 0    0 0 0 0 0   0  
1604 16        0       
1803 16+18 0      0       
1814 18 0 0    0 0 0 0      
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The frequency distribution of the number of visits for which the cervical cytological 
sample taken at that visit was positive for HPV18 DNA, and the number of HPV18 
DNA-positive samples for which there was a corresponding serum sample, is shown 
in table 18.7.2c (note also that such visits are distinguished by a black outline to the 
cell in table 18.7.2b). Thirty-one women had one or more HPV18 DNA-positive 
samples during follow-up; the vast majority had only one such sample, but one 
woman had five. Twenty three of these women had 33 sera samples taken at the 
same time as a HPV18 DNA-positive sample; 20 visits for which the cervical 
cytological sample was HPV18 DNA-positive had no corresponding serum sample. 
 
Table 18.7.2c. Frequency distribution of the number of visits for which 
the cervical cytological sample taken at that visit was positive for HPV18 
DNA, and the number of HPV18-positive samples for which there was a 
corresponding serum sample. Example: 26 women had only one HPV18 DNA-
positive sample during follow-up; however, for eight women there were no corresponding sera 
samples from that visit, but the remaining 18 did have a serum sample from that visit. 
 
Number of HPV18-positive samples for which 
there was a corresponding serum sample 
Number of samples 
positive for HPV18 
Number 
of women 
(n=43) 0 1 2 3 4 5 
0 12 12 – – – – – 
1 26 8 18 – – – – 
2 1 0 0 1 – – – 
3 2 0 0 0 2 – – 
4 1 0 0 1 0 0 – 
5 1 0 0 0 0 0 1 
 
 
The frequency distribution of the 50% neutralizing antibody titres of the sera samples 
taken at visits for which the corresponding cervical cytological sample was positive 
for HPV18 DNA, is shown in table 18.7.2d. Most sera samples were seronegative for 
neutralizing antibodies. The frequency distribution of the 50% neutralizing antibody 
412 
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titres of the sera samples taken at every visit, stratified by the HPV18 DNA status 
and the study cohort to which the woman belonged, is shown in table 18.7.2e. 
 
Table 18.7.2d. The frequency distribution of the 
50% neutralization titres of the serum samples 
taken at visits for which the corresponding 
cervical cytological sample was positive for 
HPV18 DNA. Where multiple sera samples were available, 
or the same serum sample was tested more than once, the 
greatest titre observed was used as the result of testing that 
sample. 
. 
 
Titre Number of samples 
  
Seronegative 22 
  
1-in-40 1 
1-in-120 1 
1-in-360 1 
1-in-1080 0 
1-in-3240 6 
1-in-9720 2 
  
Total 33 
 
 
Summary 
 
In the 45 and 43 women who were tested for their neutralizing antibody response to 
HPV16, and HPV18, respectively, all possible titres were observed at least once. 
Twenty nine women had one or more HPV16 DNA-positive samples during follow-
up; 25 of these had 37 sera samples taken at the same time as a HPV16 DNA-
positive sample. Thirty-one women had one or more HPV18 DNA-positive samples 
during follow-up; 23 of these had 33 sera samples taken at the same time as a 
HPV18 DNA-positive sample. For both HPV types, most sera samples were 
seronegative for neutralizing antibodies. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 18.7.2e. Frequency distribution of the 50% neutralizing antibody titres of the sera samples taken at 
every visit, stratified by the HPV18 DNA status of the cervical cytological sample and the study cohort to 
which the woman belongs. 
 
HPV18 DNA-positive samples HPV18 DNA-negative samples Titre 
 HPV18-only 
cohort 
HPV16+
HPV18 
Total HPV16-
only cohort 
HPV18-
only cohort 
HPV16+
HPV18 
Total 
All samples 
         
Seronegative 13 (59%) 9 (82%) 22 (67%) 48 (94%) 49 (65%) 51 (84%) 148 (79%) 170 (77%) 
         
1-in-40 1 (5%) 0 (0%) 1 (3%) 1 (2%) 4 (5%) 3 (5%) 8 (4%) 9 (4%) 
1-in-120 1 (5%) 0 (0%) 1 (3%) 1 (2%) 3 (4%) 1 (2%) 5 (3%) 6 (3%) 
1-in-360 0 (0%) 1 (9%) 1 (3%) 0 (0%) 3 (4%) 2 (3%) 5 (3%) 6 (3%) 
1-in-1080 0 (0%) 0 (0%) 0 (0%) 1 (2%) 8 (11%) 3 (5%) 12 (6%) 12 (5%) 
1-in-3240 6 (27%) 0 (0%) 6 (18%) 0 (0%) 8 (11%) 1 (2%) 9 (5%) 15 (7%) 
1-in-9720 1 (5%) 1 (9%) 2 (6%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 2 (1%) 
         
Total 22 11 33 
 
 51 75 61 187 
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18.8 TIME TO SEROCONVERSION TO HPV16 AND HPV18 
 
Changes in the neutralizing antibody response to HPV16 and HPV18 over time are 
presented in figure 18.8 for all women tested for their neutralizing antibody response 
to HPV16 and/or HPV18. For ease of comparison, all figures are plotted on the same 
horizontal (time) and vertical scales (inverse of the 50% neutralizing antibody titre). 
In each case, time is measured from the date of the first evaluable smear. For 
aesthetic reasons, if a sample from a visit was not available, not tested, or not 
evaluable, the previously measured value of neutralizing antibody response was 
plotted (observed values are plotted with a closed plotting symbol, backwards-
interpolated values are plotted with an open symbol) to form a left-continuous curve. 
Unique identifiers for women (study numbers) and the HPV type being analysed in 
the figure appear in the top right-hand corner of each of the charts. Just above the 
time axis, acquisition of a GP5+/GP6+ positive sample of the relevant HPV type is 
indicated by a red triangle (note that all women who were tested for their neutralizing 
antibody response to cervical HPV infection, were tested for both HPV16 and 
HPV18; some women were positive for only HPV16 DNA, or for only HPV18 DNA, 
hence some of these charts have no red triangle). 
 
414 
 
Figure 18.8. Changes in HPV16 (—) and HPV18 (—) 50% neutralizing antibody titre over time. The woman’s study number and the 
HPV type being analysed appear in the top right-hand corner. All graphs are plotted on the same time scale (months) and vertical scale (inverse of the 50% neutralizing antibody titre). A 
closed (open) plotting symbol indicates that a sample was taken (was not taken, or was unavailable): the 50% neutralizing antibody titre retains it’s last known value until updated. Red 
triangles indicate a GP5+/GP6+ positive sample of the relevant type. 
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Figure 18.8 (continued). Changes in HPV16 (—) and HPV18 (—) 50% neutralizing antibody titre over time. The woman’s study 
number and the HPV type being analysed appear in the top right-hand corner. All graphs are plotted on the same time scale (months) and vertical scale (inverse of the 50% neutralizing 
antibody titre). A closed (open) plotting symbol indicates that a sample was taken (was not taken, or was unavailable): the 50% neutralizing antibody titre retains it’s last known value until 
updated. Red triangles indicate a GP5+/GP6+ positive sample of the relevant type.  
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Figure 18.8 (continued). Changes in HPV16 (—) and HPV18 (—) 50% neutralizing antibody titre over time. The woman’s study 
number and the HPV type being analysed appear in the top right-hand corner. All graphs are plotted on the same time scale (months) and vertical scale (inverse of the 50% neutralizing 
antibody titre). A closed (open) plotting symbol indicates that a sample was taken (was not taken, or was unavailable): the 50% neutralizing antibody titre retains it’s last known value until 
updated. Red triangles indicate a GP5+/GP6+ positive sample of the relevant type. 
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Figure 18.8 (continued). Changes in HPV16 (—) and HPV18 (—) 50% neutralizing antibody titre over time. The woman’s study 
number and the HPV type being analysed appear in the top right-hand corner. All graphs are plotted on the same time scale (months) and vertical scale (inverse of the 50% neutralizing 
antibody titre). A closed (open) plotting symbol indicates that a sample was taken (was not taken, or was unavailable): the 50% neutralizing antibody titre retains it’s last known value until 
updated. Red triangles indicate a GP5+/GP6+ positive sample of the relevant type. 
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Figure 18.8 (continued). Changes in HPV16 (—) and HPV18 (—) 50% neutralizing antibody titre over time. The woman’s study 
number and the HPV type being analysed appear in the top right-hand corner. All graphs are plotted on the same time scale (months) and vertical scale (inverse of the 50% neutralizing 
antibody titre). A closed (open) plotting symbol indicates that a sample was taken (was not taken, or was unavailable): the 50% neutralizing antibody titre retains it’s last known value until 
updated. Red triangles indicate a GP5+/GP6+ positive sample of the relevant type. 
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Figure 18.8 (continued). Changes in HPV16 (—) and HPV18 (—) 50% neutralizing antibody titre over time. The woman’s study 
number and the HPV type being analysed appear in the top right-hand corner. All graphs are plotted on the same time scale (months) and vertical scale (inverse of the 50% neutralizing 
antibody titre). A closed (open) plotting symbol indicates that a sample was taken (was not taken, or was unavailable): the 50% neutralizing antibody titre retains it’s last known value until 
updated. Red triangles indicate a GP5+/GP6+ positive sample of the relevant type. 
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Figure 18.8 (continued). Changes in HPV16 (—) and HPV18 (—) 50% neutralizing antibody titre over time. The woman’s study 
number and the HPV type being analysed appear in the top right-hand corner. All graphs are plotted on the same time scale (months) and vertical scale (inverse of the 50% neutralizing 
antibody titre). A closed (open) plotting symbol indicates that a sample was taken (was not taken, or was unavailable): the 50% neutralizing antibody titre retains it’s last known value until 
updated. Red triangles indicate a GP5+/GP6+ positive sample of the relevant type. 
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Figure 18.8 (continued). Changes in HPV16 (—) and HPV18 (—) 50% neutralizing antibody titre over time. The 
woman’s study number and the HPV type being analysed appear in the top right-hand corner. All graphs are plotted on the same time scale (months) and vertical scale (inverse of 
the 50% neutralizing antibody titre). A closed (open) plotting symbol indicates that a sample was taken (was not taken, or was unavailable): the 50% neutralizing antibody titre retains 
it’s last known value until updated. Red triangles indicate a GP5+/GP6+ positive sample of the relevant type. 
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Figure 18.8 (continued). Changes in HPV16 (—) and HPV18 (—) 50% neutralizing antibody titre over time. The 
woman’s study number and the HPV type being analysed appear in the top right-hand corner. All graphs are plotted on the same time scale (months) and vertical scale (inverse of 
the 50% neutralizing antibody titre). A closed (open) plotting symbol indicates that a sample was taken (was not taken, or was unavailable): the 50% neutralizing antibody titre retains 
it’s last known value until updated. Red triangles indicate a GP5+/GP6+ positive sample of the relevant type. 
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Figure 18.8 (continued). Changes in HPV16 (—) and HPV18 (—) 50% neutralizing antibody titre over time. The 
woman’s study number and the HPV type being analysed appear in the top right-hand corner. All graphs are plotted on the same time scale (months) and vertical scale (inverse of 
the 50% neutralizing antibody titre). A closed (open) plotting symbol indicates that a sample was taken (was not taken, or was unavailable): the 50% neutralizing antibody titre retains 
it’s last known value until updated. Red triangles indicate a GP5+/GP6+ positive sample of the relevant type. 
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Figure 18.8 (continued). Changes in HPV16 (—) and HPV18 (—) 50% neutralizing antibody titre over time. The 
woman’s study number and the HPV type being analysed appear in the top right-hand corner. All graphs are plotted on the same time scale (months) and vertical scale (inverse of 
the 50% neutralizing antibody titre). A closed (open) plotting symbol indicates that a sample was taken (was not taken, or was unavailable): the 50% neutralizing antibody titre retains 
it’s last known value until updated. Red triangles indicate a GP5+/GP6+ positive sample of the relevant type. 
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Figure 18.8 (continued). Changes in HPV16 (—) and HPV18 (—) 50% neutralizing antibody titre over time. The 
woman’s study number and the HPV type being analysed appear in the top right-hand corner. All graphs are plotted on the same time scale (months) and vertical scale (inverse of 
the 50% neutralizing antibody titre). A closed (open) plotting symbol indicates that a sample was taken (was not taken, or was unavailable): the 50% neutralizing antibody titre retains 
it’s last known value until updated. Red triangles indicate a GP5+/GP6+ positive sample of the relevant type. 
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When estimating the time between the date of the first acquisition of cervical 
infection with HPV16 or HPV18 DNA and seroconversion to that type, the Kaplan-
Meier method and the approach adopted by Carter et al. (Carter 2000) was used. 
This was to enable a direct comparison to be made between the results from the 
cohort study described in this thesis those of the “Carter cohort”. With this approach, 
time to seroconversion was measured from the date of the visit corresponding to the 
sample in which HPV16 or HPV18 DNA was first detected, until the date of the visit 
corresponding to the sample in which women first seroconverted to that type, with 
censoring on the date of the last available serum sample. Both analyses were limited 
to women who acquired HPV16 or HPV18 DNA during follow-up, who were 
seronegative at all visits prior to the detection of HPV DNA, who had serology results 
available after the visit at which they were first HPV DNA-positive, and who were not 
missing a serology sample from the visit which corresponded to the first visit at 
which HPV DNA was detected, unless the woman was seronegative at the 
subsequent visit. Clearly, this approach is less than ideal, but is a pragmatic 
approach to dealing with the substantial amount of missing data. 
 
18.8.1 The time to seroconversion to HPV16 in women who tested positive for 
HPV16 DNA using GP5+/GP6+ 
 
Thirty eight women were seronegative, and seven were seropositive, to HPV16 in 
their first evaluable serum sample. Twenty two of the women who were HPV16-
seronegative in their first evaluable sample first tested positive for HPV16 DNA at a 
follow-up visit, as determined using GP5+/GP6+ general-primer-mediated PCR. Of 
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these, 17 had one or more evaluable sera samples at or subsequent to this visit, and 
10 seroconverted to HPV16: two were first found to be seropositive to HPV16 at the 
same visit HPV16 DNA was first detected; four at a subsequent visit; and four before 
HPV16 DNA was first detected. Of those who first tested positive for HPV16 DNA 
and who subsequently seroconverted to HPV16 during follow-up, one each had a 
greatest titre of 1-in-40, 1-in-120, 1-in-360, and 1-in-9720. One woman (study 
number 1604) was seropositive at a visit subsequent to the first detection of HPV16 
DNA, but had only a single serum sample. 
 
In women with an incident cervical HPV16 infection, the median time from the first 
detection of HPV16 DNA in a cervical sample to seroconversion to HPV16 was 10.6 
months. 
 
18.8.2 The time to seroconversion to HPV18 in women who tested positive for 
HPV18 DNA using GP5+/GP6+ 
 
Thirty seven women were seronegative, and six were seropositive, to HPV18 in their 
first evaluable serum sample. Twenty three of the women who were HPV18-
seronegative in their first evaluable sample first tested positive for HPV18 DNA at a 
follow-up visit, as determined using GP5+/GP6+ general-primer-mediated PCR. Of 
these, 21 had one or more evaluable sera samples at or subsequent to this visit, and 
10 seroconverted to HPV18: two were first found to be seropositive to HPV18 at the 
same visit as HPV18 DNA was first detected; seven at a subsequent visit; and one 
before HPV18 DNA was first detected. Of those who first tested positive for HPV18 
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DNA and who subsequently seroconverted to HPV18 during follow-up, two each had 
a greatest titre of 1-in-40, 1-in-120, and 1-in-3240, and one had a greatest titre of 1-
in-1080.  
 
In women with an incident cervical HPV18 infection, the median time from the first 
detection of HPV18 DNA to seroconversion to HPV18 was 31.3 months. 
 
18.8.3 The time to seroconversion to HPV16 and/or HPV18 in women who 
tested positive for HPV16 DNA and HPV18 DNA using GP5+/GP6+ 
 
The study population for the analysis of the time to seroconversion to HPV16 and/or 
HPV18 in women who tested positive for HPV16 DNA and HPV18 DNA using 
GP5+/GP6+ is restricted to the 42 women who were eligible for inclusion in both the 
HPV16 and HPV18 analyses. No woman was seropositive for both HPV16 and 
HPV18 in her first evaluable serum sample. Nine women who were seronegative for 
both HPV16 and HPV18 in their first evaluable serum sample, first tested positive for 
both of these HPV types during follow-up; four seroconverted to HPV16 alone, and 
two seroconverted to both HPV16 and HPV18. 
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Summary 
 
Twenty two of the 38 women who were HPV16-seronegative in their first evaluable 
sample first tested positive for HPV16 DNA at a follow-up visit. Of these, 17 had one 
or more evaluable sera samples at or subsequent to this visit, and 10 seroconverted 
to HPV16. In women with an incident cervical HPV16 infection, the median time from 
the first detection of HPV16 DNA in a cervical sample to seroconversion to HPV16 
was 10.6 months. Twenty three of the 37 women who were HPV18-seronegative in 
their first evaluable sample first tested positive for HPV18 DNA at a follow-up visit. 
Of these, 21 had one or more evaluable sera samples at or subsequent to this visit, 
and 10 seroconverted to HPV18. In women with an incident cervical HPV18 
infection, the median time from the first detection of HPV18 DNA to seroconversion 
to HPV18 was 31.3 months. Nine women who were seronegative for both HPV16 
and HPV18 in their first evaluable serum sample, first tested positive for both of 
these HPV types during follow-up; four seroconverted to HPV16 alone, and two 
seroconverted to both HPV16 and HPV18. 
 
 
 
18.9 SEROCONVERSION TO HPV16 AND/OR HPV18 IN WOMEN WHO DID NOT 
TEST POSITIVE FOR HPV16 OR HPV18 DNA 
 
18.9.1 Prior to Seroconversion 
 
Four women who were HPV16-seronegative in their first evaluable serum sample, 
who first tested positive for HPV16 DNA at a follow-up visit, as determined using 
GP5+/GP6+ general-primer-mediated PCR, and who had one or more evaluable 
sera samples at, or subsequent to, this visit, seroconverted to HPV16 before HPV16 
DNA was first detected; one had a greatest neutralizing antibody titre prior to the first 
detection of HPV16 DNA in a cervical sample of 1-in-40, two 1-in-360, and one a 
greatest titre of 1-in-1080. Four women were HPV16-seropositive in their first 
evaluable sample and first tested positive for HPV16 DNA at a follow-up visit; two 
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had a greatest neutralizing antibody titre prior to the first detection of HPV16 DNA in 
a cervical sample of 1-in-40, one 1-in-360, and one a greatest titre of 1-in-3240. 
 
One woman who was HPV18-seronegative in her first evaluable serum sample, who 
first tested positive for HPV18 DNA at a follow-up visit, as determined using 
GP5+/GP6+ general-primer-mediated PCR, and who had one or more evaluable 
sera samples at, or subsequent to, this visit, seroconverted to HPV18 before HPV18 
DNA was first detected: her greatest neutralizing antibody titre prior to the first 
detection of HPV18 DNA in a cervical sample was 1-in-3240. Five women were 
HPV18-seropositive in their first evaluable sample and first tested positive for HPV18 
DNA at a follow-up visit; four had a greatest neutralizing antibody titre prior to the 
first detection of HPV18 DNA in a cervical sample of 1-in-40, and one a greatest titre 
of 1-in-1080. 
 
18.9.2 At any time during follow-up 
 
When HPV status was determined using GP5+/GP6+ general-primer-mediated PCR, 
seven women were found to have seroconverted to HPV16 without ever having 
tested positive for HPV16 DNA during the study period; two of these women were 
seropositive to HPV16 at study entry. The greatest titre observed in these seven 
women was 1-in-40 for one woman, 1-in-120 for four women, and the maximum 
possible titre of 1-in-9720 for two women. 
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Similarly, three women were found to have seroconverted to HPV18 without ever 
testing positive for HPV18 DNA, including one woman who was seropositive to 
HPV18 at study entry and who had no further serological samples. The greatest titre 
found during follow-up was 1-in-40, 1-in-120 and 1-in-1080 for one each of these 
three women. 
 
 
 
Summary 
 
 
Four women who were HPV16-seronegative in their first evaluable serum sample, 
who first tested positive for HPV16 DNA at a follow-up visit, and who had one or 
more evaluable sera samples at, or subsequent to, this visit, seroconverted to 
HPV16 before HPV16 DNA was first detected; for HPV18, the corresponding 
number was one woman. Seven women seroconverted to HPV16 without ever 
having tested positive for HPV16 DNA during the study period, including two who 
were seropositive to HPV16 at study entry; for HPV18, the corresponding numbers 
were three and one. 
 
 
 
18.10 DURATION OF THE NEUTRALIZING ANTIBODY RESPONSE 
 
18.10.1 HPV16 
 
Of the 22 women who were seropositive to HPV16 at some time during follow-up, 15 
remained seropositive to HPV16 until the end of follow-up. The median time interval 
between the dates of the first and last HPV16-seropositive samples was 859.5 days 
(range 102 to 2,058); the median number of consecutive HPV16-seropositive 
samples was 5.5 (range 2 to 10), excluding two women who were HPV16-
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seropositive on only one occasion. Seven of the 22 women became seronegative to 
HPV16, of whom five had a subsequent sample which was seropositive to HPV16.  
 
18.10.2 HPV18 
 
Of the 17 women who were seropositive to HPV18 sometime during follow-up, nine 
remained seropositive to HPV18 until the end of follow-up. The median time interval 
between the dates of the first and last HPV18-seropositive samples was 1,106 days 
(range 203 to 2,836); the median number of consecutive HPV18-seropositive 
samples was 6 (range 2 to 12), excluding three women who were HPV18-
seropositive on only one occasion. Eight of the 17 women became seronegative to 
HPV18, of whom five had a subsequent sample which was seropositive to HPV18.  
 
 
 
 
 
 
Summary 
 
 
Of the 22 women who were seropositive to HPV16 at some time during follow-up, 15 
remained seropositive to HPV16 until the end of follow-up; for HPV18, the 
corresponding numbers were 17 and nine. The median time between the dates of 
the first and last seropositive samples was 859.5 days (range 102 to 2,058) for 
HPV16 and 1,106 days (203 to 2,836) for HPV18; the median number of consecutive 
seropositive samples was 5.5 (2 to 10) for HPV16, and 6 (2 to 12) for HPV18. Seven 
(8) of the 22 (17) women became seronegative to HPV16 (HPV18), of whom five 
had a subsequent sample which was seropositive to HPV16 (HPV18).  
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Chapter 19 
 
THE KINETICS OF THE HUMORAL IMMUNE RESPONSE TO 
INCIDENT CERVICAL HPV16 AND HPV18 INFECTIONS 
 
DISCUSSION 
 
 
 
 
We set out to adapt the neutralization assay first developed by Pastrana et al., 2004 
(Pastrana 2004) for the purposes of testing sera samples from the cohort study 
described in this thesis. This assay uses HPV16 and HPV18 pseudovirions (PsV) 
carrying a secretory embryonic alkaline phosphatase (SEAP) reporter gene, and 
measures functionally-relevant HPV type-specific neutralizing antibodies. 
 
19.1 RELIABILITY OF THE NEUTRALIZING ANTIBODY ASSAY 
 
My first objective was to determine the reliability of the neutralizing antibody assay. 
This was an interactive, and iterative, process involving the candidate and the 
laboratory scientists collaborating on the study described in this section of the thesis. 
A laboratory analysis would be followed by a statistical analysis undertaken to 
measure the reliability of the assay. The results of this analysis would then be 
interpreted by, and a consensus reached between, the candidate and the laboratory 
scientists regarding the reliability of the assay, following which further assays either 
would, or would not, be undertaken. Results of statistical analyses were not the only 
criteria for judging success: however, some laboratory analyses undertaken early in 
the developmental stage of the assay appeared to produce statistically reliable 
results, but nevertheless this was insufficient to convince the laboratory scientists 
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that the results of the assay were in fact reliable. Similarly, only the results of a 
statistical analysis could undermine the confidence of the laboratory scientists in the 
results of some laboratory analyses of which they were otherwise uncritical. 
 
The laboratory scientists were ultimately successful in adapting the assay to the 
purpose for which it was needed. The reproducibility of the HPV16 assay was 
excellent: the values of the weighted-kappa statistics measuring intra- and inter-
assay reliability were 0.95 and 0.89, respectively, compared to a maximum possible 
value of 1.00. Discrepancies between titres from repeated measurements were at 
most one titre category for the final laboratory analyses undertaken during the 
developmental phase of the assay. The HPV18 assay was clearly more variable, 
and therefore less reliable, than the HPV16 assay: however, the values of the 
weighted-kappa statistics measuring intra- and inter-assay reliability were still 
impressive, both being 0.90. Although most discrepancies between replicates were 
of only one titre category, there were many such discrepancies, and two analyses 
each included one set of replicates for which there was a discrepancy of two titre 
categories between replicates. The greater variability of this assay almost certainly 
reflects the greater instability of the HPV18 PsV. HPV18 VLP are also more unstable 
than HPV16 VLP, which may have a biological basis, i.e. this may also be true of 
“real” viruses. A HPV18 VLP ELISA is therefore more likely than a HPV16 VLP-
based ELISA to detect both cross-reactive and non-neutralizing antibodies. 
However, unlike for VLP-based assays, the impact of PsV degradation on the assay 
is at least immediately apparent: only an intact PsV will be able to “infect” a target 
virus and generate a detectable signal. 
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Titres against HPV were analysed on a categorical scale in analyses of reliability, 
although clearly the 50% neutralizing antibody titre is, strictly speaking, a continuous 
quantity. When the “exact” 50% neutralizing antibody titre was obtained by 
interpolation from the categorical titres, and an intra-cluster correlation coefficient 
used to estimate reliability, results were, in my opinion, deceptively impressive. This 
was true even for some of the early developmental assays, which were clearly sub-
optimal. I believe the weighted-kappa statistic derived using categorical titres 
provides a more accurate summary of the performance of this assay: ultimately, 
impressive estimates of this statistic were obtained. Given the limited scope of the 
analyses subsequently performed, and the invariance of the results to the chosen 
scale of measurement, interpolated “exact” titres were not considered further. 
 
Neutralization assays, such as have been described in this thesis, are reported to 
have a higher specificity than VLP-based ELISA (Buck 2005, Fleury 2008). Direct 
comparisons between the two suggest that the HPV16 neutralizing antibody assay is 
possibly more sensitive than the HPV16 VLP-based ELISA, whereas sensitivity is 
similar for the HPV18 version of this assay (Pastrana 2004). Therefore, although the 
HPV16 neutralizing antibody assay is superior to a VLP-based ELISA because it 
detects functionally relevant antibodies, i.e. those antibodies which prevent infection 
of a host cell by virus, the HPV16 VLP-based ELISA may have comparable 
performance. The HPV18 neutralizing antibody assay is superior to a HPV18 VLP-
based ELISA on two counts, since not only is it more sensitive, it is also highly 
specific. 
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19.2 THE KINETICS OF THE NEUTRALIZING ANTIBODY RESPONSE 
 
My second objective was to describe the kinetics of the neutralizing antibody 
response to incident cervical HPV16 and HPV18 infections in a cohort of young 
women who were recruited soon after first sexual intercourse, and who first tested 
positive for HPV16 DNA, or HPV18 DNA, or both, in cervical cytological samples 
during follow-up. Only limited inferences can be drawn from this small series. 
However, the findings reported in this thesis are broadly consistent with those of two 
other cohort studies which have measured the humoral immune response following 
an incident HPV infection using the technically simpler VLP-based ELISA. 
 
In women with an incident cervical HPV16 infection in the cohort described in this 
thesis, the median time from the date of the first detection of HPV16 DNA in a 
cervical sample to the date of seroconversion to HPV16 was 10.6 months, greater 
than the 8.3 months reported by Ho et al. (Ho 2004), but similar to the 11.8 months 
reported by Carter et al. (Carter 2000). Carter et al. also report that 18 months after 
the first detection of HPV16 DNA, 59.1% of women with an incident HPV16 infection 
had seroconverted; the corresponding seroconversion rate for women in the cohort 
described in this thesis was 61.1%. Ho et al. report a 12 month cumulative 
seroconversion rate following an incident HPV16 infection of 56.7%; the 
corresponding rate for women in the cohort described in this thesis was 51.4%. In all 
three studies, most women who seroconverted remained seropositive until the end 
of follow-up. 
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In women with an incident cervical HPV18 infection in the cohort described in this 
thesis, the median time from the date of the first detection of HPV18 DNA in a 
cervical sample to the date of seroconversion to HPV18 was 31.3 months, 
substantially in excess of the 12.8 months reported by Carter et al., although the 
numbers in both series are small. Carter et al. also report that 18 months after the 
first detection of HPV DNA, 54.8% of women with an incident HPV18 infection had 
seroconverted; the corresponding seroconversion rate for women in the cohort 
described in this thesis was 36.2%. Ho et al do not report seroconversion rates 
following an incident HPV18 infection. 
 
Although in this thesis a potentially more sensitive and more type-specific 
neutralizing antibody assay than VLP-based ELISA was used, it was found, as 
others who have used a VLP-based ELISA have found, that some women failed to 
seroconvert. For example, among those women who failed to seroconvert to HPV16, 
one had five opportunities, i.e. measurements, to do so, and the other six; during 
which time these women tested positive for HPV16 using GP5+/GP6+ general-
primer-mediated PCR on three and four occasions, respectively. We also found that 
seroconversion could be transient, and seropositivity intermittent, although this may 
merely reflect antibody levels which fluctuate around the threshold of detection. 
Although we recruited women soon after first sexual intercourse, some already 
appeared to have cleared a primary infection at study entry. For example, of 12 
women who were seropositive for either HPV16 or HPV18 at study entry, and who 
tested negative for HPV DNA at this time, four had been sexually active for less than 
a year. Of course, it is also possible that vulval, or vaginal, infections, which are not 
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detected in cervical samples, may also generate an immune response (in particular, 
a neutralizing antibody response) against HPV (Winer 2003). The observations in 
this thesis, although not novel, again illustrate how DNA testing, or serology, may fail 
to identify those sexually active women who have previously been exposed to HPV. 
This would be an important consideration were the admission of such women to a 
prophylactic immunization program dependent upon adducing evidence of no 
previous exposure to vaccine types. 
 
19.3 CONCLUSION 
 
The final study population for this analysis differed from the intended study 
population. This was unintentional, as has been described earlier. The neutralization 
assay of Pastrana et al. proved to be complex to conduct in practice, and, although 
use of the assay was ultimately successful, as with all cell-based assays, 
reproducibility (intra- and inter-assay reliability) was not easily achieved or 
maintained. Given the expense of the assay, in terms of both monetary costs and 
laboratory staff time, the decision was made no to carry out any further testing, but 
instead to preserve the study sera samples for future analyses. In light of the 
experience gained with the use of the neutralizing antibody assay in a non-
automated setting, the work described in this thesis cannot be used in support of the 
claim that this neutralizing antibody assay is a high-throughput assay suitable for use 
in large-scale epidemiological enquiries. 
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19.4 PUBLICATION 
 
A paper based on the work described in chapters 16, 17, 18 and 19 of this thesis 
was published in 2008 (Steele 2008: see appendix 6). The definitive results of HPV 
viral load testing became available only after the completion of the analyses 
presented in the part of the thesis relating to the neutralizing antibody response to 
cervical HPV infections. An analysis of the association between HPV viral load and 
the humoral immune response may be the subject of a future report (see chapter 
24). 
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Chapter 20 
 
THE NATURAL HISTORY OF CERVICAL HPV16 AND HPV18 
INFECTIONS – VIRAL LOAD 
 
INTRODUCTION 
 
 
 
 
 
Orientation 
 
In this chapter I: 
 
• define HPV viral load 
 
• provide an overview of the evidence regarding the determinants of HPV viral 
load, its role in the kinetics of cervical HPV infection and its’ association with the 
acquisition of cervical disease 
 
• describe the measurement of HPV viral load 
 
 
 
 
 
20.1 DEFINITION OF HPV VIRAL LOAD 
 
The HPV viral load (or HPV copy number) of a given sample is the number of HPV 
virions, or the number of copies of the HPV genome, present in that sample. 
 
20.2 BACKGROUND 
 
The identification of high-risk HPV types as a necessary cause of cervical cancer 
offers not only the prospect of effective primary-prevention, but also the possibility of 
improving the efficiency of cervical screening programmes. Among women who test 
429 
 
positive for high-risk HPV types, cytological abnormality has been reported to be 
more common in those with a high- than in those with a low-viral load (Hall 1996, 
Nindl 1997, Ho 1998, Swan 1999, Heard 2000, Lillo 2005). The apparent 
consistency of this finding has persuaded many that the inclusion of a measurement 
of HPV viral load could improve the effectiveness of HPV-based cervical screening 
and triage strategies (Joseffson 2000). However, for this opportunity to be realised, a 
more complete understanding than we currently possess of the natural history of 
HPV infection, and its relationship to the acquisition of epithelial abnormalities of the 
cervix, is required. 
 
20.3 LITERATURE OVERVIEW  
 
In this section, I provide an overview of the evidence of how cervical HPV viral load 
varies according to virus- and disease-related factors, study design, and the method 
used to measure cervical HPV viral load. First, I describe studies which have 
investigated factors related to changes in HPV viral load itself. 
 
20.3.1 The determinants of HPV viral load 
 
20.3.1.1 Life cycle 
 
Two studies investigating the association between HPV viral load and the risk of 
transmission of HPV in sexual couples  have reported that high viral load is 
associated with an increased risk of transmission (Wickenden 1988, Bleeker 2005). 
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Cellular differentiation is vital to the life-cycle of HPV, and the physical state of the 
virus is a potentially important factor contributing to malignant transformation and 
disease progression (see section 3.1.5). Four studies have investigated the 
association between HPV viral load and cellular differentiation (Schneider 1987, 
Bedell 1991, Spink 2005, Wilson 2005): three were in vitro studies of HPV31, and 
one was a cross-sectional analysis in human subjects. The three in vitro studies 
demonstrated that viral load increased with increasing cellular differentiation, 
consistent with the postulated model for the life-cycle of cervical HPV infections (see 
section 3.1.2.3). Two studies, both performing cross-sectional analyses, found that 
viral load was lower in tumours containing integrated forms than in those which did 
not (Berumen 1995, Jeon 1995, Spartz 2005, Cricca 2006).  
 
20.3.1.2 HPV type 
 
Ten studies have investigated the association between HPV viral load and HPV 
type, including one study which has reported this association in two separate reports 
(Swan 1999, Zerbini 2001, Weissenborn 2003, Moberg 2004, Ho 2005, Moberg 
2005, Carcopino 2006, Flores 2006, Lai 2006, Snijders 2006). Two of these studies 
were longitudinal, one of which nevertheless conducted a cross-sectional analysis, 
and the remainder were cross-sectional. All found that HPV viral load varied by HPV 
type, and that this was true in different grades (severities) of cytological abnormality, 
but the pattern was not consistent, either within or between HPV types. 
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20.3.1.3 Infections with more than one HPV type 
 
Five cross-sectional studies have investigated the association between HPV viral 
load and the presence of multiple HPV types (Sherman 2003a, Weissenborn 2003, 
Giuliano 2004, Levi 2004, Flores 2006). Results were not consistent, either between 
studies, or within the same population. One report states that "as expected, the HPV 
viral load increases when more types are present", which, while accurately reflecting 
naïve a priori expectation, is too simplistic (Levi 2004). This expectation is by no 
means met in all of the remaining studies. 
 
20.3.1.4 Duration of HPV infection 
 
Eight studies have investigated the association between HPV viral load and the 
duration, or “persistence”, of HPV infection: all were necessarily longitudinal 
epidemiological studies (Clavel 2000, De Marco 2001, Van Duin 2002, Dalstein 
2003, Molano 2003, Syrjanen 2005a, Cricca 2006, Song 2006).  Results were 
inconsistent. Four studies found that HPV viral load was not associated with duration 
of infection, whereas the other four found that a higher viral load was associated with 
an increased duration of, or risk of persistent, HPV infection. 
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20.3.2 Association of HPV viral load with disease endpoints 
 
Many studies have examined the association between HPV viral load and various 
aspects of the natural history of cervical disease (Woodman 2007). The conclusions 
of these studies are summarised in table 20.3.2. 
 
Table 20.3.2. Association between high HPV viral load and the natural 
history of cervical neoplasia: number of studies reporting a positive-
association. 
 
Positive-association Study design 
  
Outcome variable 
  Yes No 
Cross-sectional Presence of disease 29 1 
Cross-sectional Severity of disease 17 25 
                        HSIL>LSILbc 14a - 
                        LSIL>HSILbc 6a - 
    
Longitudinal Acquisition of disease 8 4 
Longitudinal Duration of disease 3 2 
Longitudinal Progression of disease 3 2 
ain two studies, exposure-disease relationship varied with HPV type; bdirection of 
association; cH(L)SIL=high(low)-grade squamous intraepithelial lesion. 
 
 
Cross-sectional studies investigating the association between increasing HPV viral 
load and the presence of cervical disease of any severity have been mainly 
consistent in reporting a positive association. Cross-sectional studies have been less 
consistent in their reports of the association between HPV viral load and severity of 
disease: some have found an association, others none; and those which have found 
an association are in disagreement as to the direction of that association, i.e. 
whether increasing viral load is associated with increasing severity of disease, or 
vice versa. 
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Fewer longitudinal than cross-sectional studies have investigated the association 
between HPV viral load and the acquisition of cervical disease, or its impact on the 
duration or progression of disease. The majority have reported a positive-
association, but findings from these more appropriate study designs have been less 
consistent than those from cross-sectional studies. 
 
Factors relating to HPV viral load and characteristics of disease have also been 
investigated. Two cross-sectional studies have determined the association between 
HPV viral load and lesion size (Sun 2001, Sherman 2003b). Results were not 
consistent, with one reporting an increase in viral load with increasing lesion size 
(Sun 2001) and the other (Sherman 2003b) that viral load was associated with lesion 
size for CIN1 but not for CIN3. Of course, lesions are not necessarily homogeneous 
entities. The latter study also reported that cases of CIN3, or worse, for which the 
primary lesion was also surrounded by extensive CIN1, had the highest HPV viral 
loads, irrespective of the number of HPV types detected.  
 
It should be noted that many of the results in table 20.3.2 are based on multiple 
reports from the same study. For example, the 12 reports investigating the 
association between HPV viral load and the risk of acquisition of cervical cytological 
disease are from six studies, including one study which has addressed this issue in 
four separate reports, one in three, and one in two: all were necessarily longitudinal 
(Clavel 2000, Josefsson 2000, Ylitalo 2000, Bory 2002, Castle 2002a, Lorincz 2002, 
Van Duin 2002, Schlecht 2003a, Moberg 2004, Castle 2005, Moberg 2005, Monnier-
Benoit 2005). Multiple reports from the same study population were internally 
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consistent, except for those from one study population. One report found that HPV 
viral load in the baseline sample was not associated with the risk of acquiring CIN3, 
or worse (Lorincz 2002), in women who were positive for any oncogenic HPV type at 
baseline; the other found that viral load of HPV16 in the baseline sample was 
associated with the risk of acquiring CIN3, or worse (Castle 2005). 
 
20.3.3 Critique of high-profile cohort studies describing an association 
between HPV viral load and the risk of the acquisition of cervical disease 
 
In this section I critique reports from two particular longitudinal studies which have 
been extensively cited in support of an association between HPV viral load and the 
risk of acquiring high-grade CIN, and illustrate methodological shortcomings in two 
others. The names given to these studies are for convenience of reference only, and 
are not necessarily those with which the principal investigators endowed them. 
 
20.3.3.1 The Uppsala cohort study 
 
The Uppsala cohort study was a retrospective cohort study of women attending 
routine cervical cytological screening in Uppsala County, Sweden. The study 
population comprised women aged 25 to 49 years who were cytologically normal in 
their baseline smear and who were followed-up at intervals of three to four years (the 
routine screening interval). The HPV viral load of all smears taken from cases and 
controls prior to diagnosis of the case was measured using a modified quantitative 
PCR technique. Analyses were conducted using a nested case-control design. 
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Results from this cohort study have now been described in several publications 
(Joseffsson 1999, Ylitalo 1999, Josefsson 2000, Ylitalo 2000a, Ylitalo 2000b, 
Moberg 2003, Moberg 2004, Moberg 2005). The study design and the assumptions 
underpinning the analyses of HPV viral load are now discussed. 
 
20.3.3.1.2 The Uppsala cohort study: Ascertainment of outcomes in cases and 
controls 
 
In this study, cases and controls were matched only on age and the result of the 
baseline smear (Ylitalo 1999a, Josefsson 2000, Ylitalo 2000a, Ylitalo 2000b). The 
decision not to match on total number of smears was justified on the basis that “this 
variable is likely to be associated with sexual practices (e.g. the need for 
contraceptives, or treatment for sexually transmitted diseases) and hence with the 
probability of HPV infection”. This argument is not persuasive. The validity of 
inferences made from a cross-sectional case-control study depends on the 
assumption that controls selected for inclusion in the study were eligible to have 
become cases if they had developed disease. Similarly, in a nested case-control 
study, controls must remain eligible to become cases during follow-up. Cervical 
carcinoma in situ is an asymptomatic condition, the presence of which can only be 
suspected following an abnormal cervical smear test (see section 2.2.1.1). Therefore 
a control who has had only a baseline smear can never become a case during 
follow-up; over a quarter of the 608 controls included in one analysis fall into this 
category (Ylitalo 2000a).  
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Another requirement for the validity of statistical inferences with the case-control 
design is that the control is in fact free of disease i.e. that cases are not, in fact, 
being compared with cases at the point in time at which the control is matched to the 
case. In the absence of a smear reported as “normal” taken close to the date of 
diagnosis of the corresponding case, there is no certainty that a “control” is free of 
disease at the time the case was diagnosed. The median number of smears 
provided by cases was 4 (range 1 to 17), and by controls 2 (range 1 to 14). The 
authors attribute this mismatch in large part to an excess of “confirmatory” smears 
taken from cases in the year before diagnosis, and smears taken during this time 
were excluded from some analyses. However, although the excess is greatest 
during this interval, a substantial excess is also seen in the preceding years (Ylitalo 
2000b): nearly half of the controls either had only one smear, or did not have a 
smear in the year preceding the date of diagnosis of the corresponding case, or both 
(Ylitalo 2000b).  
 
In this instance, this study clearly violates two of the basic requirements of the case-
control design. 
 
20.3.3.1.3 The Uppsala cohort study: Estimation of HPV viral load 
 
In the first paper from this cohort study describing the methods used to estimate 
HPV viral load, it is stated that, “after normalizing the samples for genomic DNA 
content, the mean number of copies per cell could be calculated”. However, when 
reporting the results of the cohort study, threshold cycle numbers (Ct values - see 
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section 21.1.2) and not the mean number of copies per cell are reported. Although in 
the final model, comparisons are adjusted for “small” and “large” quantities of DNA, 
such a crude comparison is in itself surprising, given the comment in their earlier 
methods paper that “Ct values for β-actin can vary with more than six cycles 
between individual samples” (Joseffsson 1999). In fairness, in two later reports are 
copy numbers normalized for cellular DNA content. In the study described in this 
thesis, all measurements of HPV viral load were normalized for cellular content. 
 
20.3.3.2 The Amsterdam cohort study 
 
The Amsterdam cohort study was a prospective cohort study describing the 
development, persistence, and progression, of CIN lesions in relation to the natural 
history of HPV infection, including the humoral immune response. The cohort 
consisted of 353 women aged 18 to 55 years who were routinely referred to a single 
colposcopy clinic in Amsterdam, The Netherlands. All women had mild to moderate 
or severe dyskaryosis at study entry, and were followed at intervals of three to four 
months until they clinically progressed to CIN3; a secondary endpoint was 
histologically-verified CIN3 at the end of follow-up. Biopsies were not taken during 
follow-up, but all women were biopsied at their last visit, including women with a 
normal colposcopy, for whom random biopsies were taken. PCR was used to test for 
14 high-risk HPV types. 
 
Results from this cohort study have now appeared in several publications (Remmink 
1995, De Gruijl 1996a, Rozendaal 1996, De Gruiijl 1996b, De Gruijl 1997, Bontkes 
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1998a, Bontkes 1998b, Nobbenhuis 1999, Bontkes 1999a, Bontkes 1999b, De Gruijl 
1999, Bontkes 2000, Rozendaal 2000, VanDuin 2002). The study design, and the 
assumptions underpinning the analyses of viral load, are now discussed. 
 
20.3.3.2.1 The Amsterdam cohort study: Primary outcome 
 
In a cohort study, subjects are followed-up until the outcome of interest occurs, 
thereby revealing the temporal aspects of any associations observed. A critical 
assumption in a cohort study, especially one in which the main interest is in the 
natural history of the exposure-disease relationship, is therefore that subjects are 
free of the outcome of interest at study entry. 
 
Given that the primary outcome in this study was determined clinically, it should 
have been possible to confidently classify women as being free of the primary 
outcome at baseline. However, either two or four women apparently had CIN3 at 
baseline (Nobbenhuis 1999). And despite the use of a panel of experts to determine 
the primary outcome there was non-classification of colposcopic impression for 17 
women; women for whom there was discordance between the “cytomorphological”, 
i.e. cytological, result and the colposcopic impression, were also considered to have 
failed to complete follow-up (Nobbenhuis 1999). 
 
One report states that “women with normal Pap smears containing high-risk HPV 
genotypes were 116 times more at risk of developing CIN3, in contrast to women 
without high-risk HPV” (Rozendaal 1996). The characterisation of these women as 
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“cytologically normal” is questionable, since at baseline 21% of the study population 
had a smear reported as containing “very mild squamous dyskaryosis, including 
atypical squamous cells of unknown significance [ASCUS]”.  Furthermore, 
cytological review revealed that, in fact, two of the seven women subsequently found 
to have CIN3 had moderate dyskaryosis in their baseline smear, and in two more a 
baseline smear which was initially graded as normal was subsequently re-graded as 
mildly abnormal. The end-point used also presents a difficulty, since women were 
not histologically sampled at baseline. Of the 353 women in the cohort, 133 were 
colposcopically adjudged to have at least CIN2 at study entry, i.e. these women 
were not free of disease at study entry. The study described in this thesis used a 
study population which comprised women who were negative for HPV DNA of any 
type, according to the GP5+/GP6+ system, and free of cervical cytological 
abnormalities, and undoubtedly free of high-grade CIN, at study entry.  
 
20.3.3.2.2 The Amsterdam cohort study: Viral load 
 
One report includes observations on members of two cohorts, one of which was the 
Amsterdam cohort described in the previous subsection (Van Duin 2002); the other 
study also recruited a cohort of women from the Amsterdam area of The 
Netherlands. Women with normal cytology were followed-up, 125 with a single 
HPV16 infection at baseline were identified, and a nested, matched, case-control 
study was undertaken. Cases comprised twelve women who progressed to high-
grade CIN; each case was matched with four controls who had CIN1, or less, at the 
end of follow-up. However, the matching criteria are not stated in this report (the 
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other reports on this study describe cohort analyses); no reassurance is provided, for 
example, that cases and matched-controls were followed-up for the same period of 
time. It is also unclear from the description of the statistical methods whether the 
analysis was appropriate to the matched design. 
 
In one report, mean copy numbers per sample are reported for HPV and β-globin, 
but no adjustment is made for cellular content (Van Duin 2002) (see section 
20.4.1.1). It is stated that “a logistic regression analysis with adjustment for β-globin 
levels was used to study viral load in relation to the development of CIN”, but no 
further details of this sub-optimal analysis are provided. In the study described in this 
thesis, all measurements of HPV viral load were normalized for cellular content. 
 
20.3.3.2.3 The Amsterdam cohort study: Statistical considerations 
 
When estimating the risk of developing high-grade CIN associated with HPV viral 
load, the investigators dichotomized viral load into high- and low-viral load, around 
the median value of the observed distribution of copy numbers (Van Duin 2002). 
This is poor practice from a statistical standpoint since it is “well recognized in the 
methodological literature that dichotomization of continuous variables introduces 
major problems in the analysis and interpretation of models derived in a data-
dependent fashion” (Altman 2006, Royston 2006). And not only does high-viral load 
defined in this way have no external validity, in this case it has no internal validity 
either. For example, in this paper (Van Duin 2002), high-viral load is defined as 
240,000 copies or more per smear when estimating the risk of disease acquisition, 
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whereas later in the paper the authors choose greater than 4,300,000 copies as 
being a high-viral load (neither normalized for cellular DNA content). 
 
Median HPV viral loads in baseline smears were found to be significantly lower in 
women who cleared their infection and in those with spontaneous regression of 
cytological abnormality. However: methods appropriate to the analysis of time-to-
event data were not used; viral loads were not normalized for cellular content; the 
distribution of β-globin values was not reported, so even the suboptimal analysis 
performed for the previous study could not be reproduced; and, again, measures of 
association were based on a dichotomization of viral load around the median value. 
 
20.3.3.3 The Ludwig-McGill cohort study 
 
The Ludwig-McGill cohort study was a prospective cohort study of “persistent” HPV 
infection, and its role in the natural history of cervical disease. A systematic sample 
of 2,746 women aged 18 to 60 years was recruited from the family medicine, 
gynaecology, and family planning clinics at a single municipal hospital in Sao Paolo, 
Brazil, a high-risk area for cervical cancer. Follow-up was every four months during 
the first year, and every six months thereafter. PCR was used to test for HPV DNA. 
 
Results from this cohort study have now appeared in several reports (Franco 1999a, 
Franco 1999b, Rousseau 2000, Villa 2000, Rousseau 2001, Schlecht 2001, Maciag 
2002, Giuliano 2003, Rousseau 2003a, Rousseau 2003b, Schlecht 2003a, Schlecht 
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2003b, Schlecht 2003c). There are various unusual methodological approaches 
used in the analysis of certain of these reports. 
 
In one report, the authors state that "we calculated average [sic] viral loads for each 
HPV-positive subject, using results from the first two follow-up visits to reduce the 
level of misclassification." This approach assumes that HPV viral load is a static 
quantity, rather than a dynamic quantity which is capable of changing rapidly over 
relatively short periods, which surely prejudges the natural history of HPV infections. 
 
In at least two reports (Schlecht 2001, Schlecht 2003c), the investigators adopted an 
unusual approach to dealing with “missing” values. They state that “delays in 
returning for a given appointment were allowed, with information and specimens 
collected during any post-due visit being assigned to the delayed follow-up return, 
which precluded the occurrence of missing interval tests”. This statement is 
disingenuous: this merely describes the procedure selected by the investigators for 
dealing with missing values, the existence of missing values was still an issue which 
had to be dealt with. It is only made clear in one paper that time-to-event analyses 
were based on the date of the visit. 
 
In one report, when estimating measures of association between outcomes and 
HPV, the investigators allocated to the “exposed” category any woman who tested 
positive for HPV at either of her first two study visits. However, time to occurrence of 
an event was measured from enrolment. Thus a woman who was found to have a 
squamous intraepithelial lesion (SIL) at her second visit, and who first tested positive 
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for HPV at this time, would be considered to have had an incident SIL following HPV 
exposure, although both events occurred at the same visit; one report suggests that 
a number of incident SIL were diagnosed at the second visit. In a later report 
(Schlecht 2003b), only events which occurred after exposure had been defined were 
included in time-to-event analyses. Similarly, “all incident cases of SIL were 
compared with subjects who had no detected lesions or ASCUS [atypical squamous 
cells of undetermined significance] during the entire period of follow-up”. Compared 
with women with normal smears, those with ASCUS had an increased risk of SIL. 
The number of women with ASCUS is not stated, and it is not clear why such a 
heterogeneous, and therefore suboptimal, reference category was chosen. 
 
20.3.3.4 The Kaiser Permanente cohort study 
 
The Kaiser Permanente cohort study was a prospective cohort study investigating 
the natural history of HPV infection. In total, 23,702 women from the Kaiser-
Permanente prepaid health plan in Oregon, USA, were followed, passively, at 
approximately yearly intervals as part of standard cytological screening. Hybrid 
capture II (probe B) was used to test for HPV, and as a semiquantitative 
measurement of viral load. 
 
Results from this cohort study have now appeared in several publications 
(Hildesheim 1998, Liaw 2001, Castle 2002a, Castle 2002b, Lorincz 2002, Castle 
2003, Sherman 2003c, Khan 2005, Castle 2005). The only real criticism of this study 
is the use of the hybrid capture II assay, a semiquantitative assay, to measure viral 
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load: for reasons described below, use of this assay meant an opportunity to make a 
substantial contribution to clarifying issues surrounding HPV viral load was missed. 
The study described in this thesis used a quantitative assay to measure HPV viral 
load and so was able to make a substantial contribution to the understanding of HPV 
viral load. 
 
20.4 THE MEASUREMENT OF HPV VIRAL LOAD 
 
There are several possible explanations for inconsistent findings between studies, 
including differences in study design, investigation of different disease or infection 
outcomes, and methodological flaws. However, one of the greatest potential sources 
of inconsistent findings is the assay used to measure HPV viral load. Comparisons 
between results based on laboratory analyses from different studies must account 
for differences in the performance of the assays used. 
 
20.4.1 Criteria for an adequate assay of viral load 
 
Since testing for HPV DNA began, several methods have been used for measuring 
HPV viral load, most of which were used in at least one of the reports described in 
the previous sections. Table 20.4.1 presents the characteristics of an ideal assay of 
viral load, many of which are interdependent. 
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Table 20.4.1. Criteria for an adequate assay of HPV viral load. 
 
Criteria 
1 Uses stable reagents  
2 Uses appropriate controls 
3 High-throughput 
4 Inexpensive 
5 Uses minimal sample material 
6 High sensitivity 
7 High specificity 
8 High reproducibility 
9 Adequate linear dynamic range 
10 Quantitative 
11 Type-specific 
12 Enables normalisation for sample cellular content 
 
 
The first two criteria are requirements of any laboratory assay. High-throughput, 
inexpensive, and use of minimal sample material are important considerations in any 
study which calls for the analysis of large numbers of samples, and for which 
samples may be tested on several occasions. High sensitivity, specificity and 
reliability are requirements for many methods of measurement. 
 
The linear dynamic range is the working range of the assay, the range of true viral 
loads for which the assay is capable of producing accurate measurements. It is the 
range of viral loads over which a calibration curve remains linear: for example the 
range within which a doubling of viral load in a target sample yields a doubling in 
measured viral load (see section 21.2.7 for an example from this study). Again, this 
requirement is common to many measurement techniques which rely upon 
calibration. If this range is too narrow, either it will not be possible to measure all 
samples, or the quantity of DNA required for the assay may be prohibitive. 
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Methods for measuring viral load can be quantitative, yielding an “exact” count of the 
number of copies of a virus present in a sample, or semiquantitative, yielding 
measurements on a relative scale, such as high- or low-viral load. Categorisation of 
a continuous quantity should be avoided until it can be demonstrated that such a 
transformation does not lead to an important loss of information: a quantitative 
method is therefore preferred initially. 
 
Measurements of HPV viral load which combine all HPV types present in a sample 
into a single measurement are of limited use in natural history studies, since there 
are now known to be critical differences between the behaviour and pathogenic 
potential of the individual HPV types. If cervical cancer is a clonal disease, and 90% 
of cancers are associated with the detection of a single virus type (Bosch 1995), 
then a measure of viral load accumulated across a number of HPV types may 
distort, or conceal, underlying type-specific associations. A type-specific assay is 
therefore a requirement for all but low-resolution analyses. 
 
20.4.1.1 Criteria for an adequate assay of viral load: Normalisation for cellular 
content 
 
To compare two measurements, it must be possible to express them using the same 
units of measurement. In the context of measuring viral load, this means that the 
measurement must account for the amount of cellular DNA present in a sample (a 
process often referred to as “normalisation for cellular content”). Unless an assay 
allows measurements of viral load to be normalised for cellular content, 
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interpretation of these measurements will be impossible. For example, if one sample 
has a viral load which is three times that of another, we cannot interpret this 
difference at face value, unless we know that the same number of cells are present 
in both samples. 
 
Figure 20.4.1.1 illustrates the concept of normalisation of HPV viral load for cellular 
content. In this crude example, both sample A and sample B contain the same 
proportion of HPV-infected and uninfected cells, and each HPV-infected cell in each 
sample contains exactly the same number of copies of the HPV virus. However, 
since sample B contains three times as many cells as sample A, the HPV crude viral 
load for sample B is three times the crude viral load of sample A. Sample B would 
therefore be reported as containing a higher HPV viral load than sample A, simply 
because of a difference in cellular content. If crude viral loads are adjusted for 
cellular content, by dividing the crude viral load by the number of cells in each 
sample, the samples have identical normalised viral loads. Note that normalisation 
as described here implies that a reliable technique for counting the number of cells 
present in the sample is a prerequisite. Although cervical smears and cervical 
biopsies are taken using standardised instruments according to standard protocols, 
the cellular content of these samples will nevertheless vary greatly. Therefore, if it is 
the intention to make comparisons between viral load measurements in these 
samples, measurements must be normalised for cellular content.  
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Figure 20.4.1.1. Normalisation of viral load for cellular content. 
Sample A Sample B
Uninfected cell
Cell infected by 
10 virions
Crude viral load
Viral load after 
normalisation
80 240
5 copies per cell 5 copies per cell
No. of cells 16 48
 
 
20.4.2 Assays available for the measurement of HPV viral load 
 
Early methods for measuring viral load, which now appear to have been superseded, 
at least in studies of HPV, include end-product PCR, PCR enzyme immunoassay, 
dot-blot and in situ hybridisation. All but in situ hybridisation are semiquantitative 
methods, and all fail to meet several of the criteria in table 20.4.1, in particular high-
reproducibility (see section 21.1.2 for further discussion of the limitations of end-
product PCR). In situ hybridisation in its most basic form involves denaturing sample 
DNA (i.e. separating the DNA strands so that they become “accessible”) so that the 
HPV DNA can be directly labelled with a probe and the labelled virus can then be 
counted directly. Whilst it is a quantitative method, this is a low-throughput, 
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insensitive, technique, with poor discrimination between samples with high-viral 
loads, and it requires large quantities of purified DNA (Hubbard 2003).  
 
Methods for measuring HPV viral load which are still currently in use include hybrid 
capture, or rather it’s successor hybrid capture II (HC2), low-stringency PCR, and 
real-time PCR. HC2 is a high-throughput semiquantitative method. However, 
although there are type-specific versions (Castle 2005), in general it is not type-
specific, has a poor dynamic range, has low sensitivity, and does not enable 
normalisation for cellular content (Fontaine 2005). Low-stringency PCR, on the other 
hand, is a quantitative method, which is reproducible and has an adequate dynamic 
linear range. However, this method is labour-intensive, and although it allows for 
normalisation for cellular content without requiring an accurate quantification of the 
amount of DNA present in the initial sample, it does so by relying on measuring the 
ratio between the area and net intensity of a band on a gel and an arbitrary 
reference human band (Caballero 1995). 
 
Real-time PCR is a quantitative method for measuring viral load, that meets all of the 
criteria adumbrated in table 20.4.1. Quantitative PCR (qPCR), as it is also known, 
and as it will be referred to throughout the remainder of this thesis, enables 
monitoring of the PCR, as it occurs rather than on completion of the assay as with 
conventional (end-point) PCR; it also allows for normalisation for cellular content. 
This assay is currently considered the “gold standard” for determining viral load, and 
was used to measure HPV viral load in the cohort study described in this thesis (see 
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section 21.2 for a full description of the qPCR technique used in testing study 
samples). 
 
20.5 COMMENT 
 
It is now clear that the relationship between HPV viral load and cervical disease is 
more complex than was previously thought. Whereas many cross-sectional studies 
have reported an increase in HPV viral load in cervical samples with increasing 
severity of cervical disease, others have found either no association, or a higher viral 
load in women with low-grade cervical lesions than in those with high-grade lesions. 
Longitudinal studies have also failed to find a consistent association between a 
baseline measurement of HPV viral load and: the duration of infection; the risk of 
clearance of disease; and the subsequent risk of acquisition of, or progression of, 
cervical disease. Many studies have had flaws in their design or in the way in which 
they were analysed, or have used a sub-optimal technique for measuring viral load. 
 
Only well-designed, well-conducted, and correctly analysed longitudinal studies 
which use an appropriate quantitative assay to measure HPV viral load, are capable 
of providing reliable evidence regarding how cervical HPV viral load changes over 
time, and the role of HPV viral load in the natural history of cervical disease. I 
describe the analysis of measurements of the viral load of HPV16 and HPV18 in 
serial cervical samples taken during the follow-up of a cohort of young women 
recruited soon after they first had sexual intercourse and who first tested positive for 
HPV16 DNA, or HPV18 DNA, or both, in cervical samples, during follow-up. 
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Chapter 21 
 
THE NATURAL HISTORY OF CERVICAL HPV16 AND HPV18 
INFECTIONS – VIRAL LOAD 
 
METHODS 
 
 
 
 
 
Orientation 
 
In this chapter I: 
 
• describe the laboratory methods and procedures used to establish and conduct 
the assay used to measure HPV16 and HPV18 viral load in this thesis; 
 
• describe the way in which the assay used to measure HPV16 and HPV18 viral 
load was carried out in practice; 
 
• provide a numerical example to illustrate the data produced by the viral load 
assay and the method used to calculate HPV viral load; 
 
• describe the statistical methods used in the assessment of the reliability and 
reproducibility of the viral load assay, and for the analysis of HPV16 and HPV18 
viral load. 
 
 
 
 
 
21.1 THE MEASUREMENT OF HPV VIRAL LOAD 
 
21.1.1 The polymerase chain reaction 
 
The polymerase chain reaction (PCR) is an in vitro method for primer-directed 
enzymatic amplification of specific target DNA sequences (Young 1996). An initial 
small quantity of target DNA sequence present in a biological specimen is selectively 
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amplified in a series of identical biochemical reactions to produce a final product 
containing an exponentially-increased number of copies of the target DNA sequence 
(Iftner 2003). 
 
Reagents required for a PCR include: the sample potentially containing the target 
DNA to be amplified; a thermostable polymerase, an enzyme which mediates the 
synthesis of DNA; molecules corresponding to the four nucleotides of which DNA is 
composed; and primers (see below). The last two components are present in large 
quantities since they are the building-blocks for synthesising copies of the target 
DNA sequence: a PCR will continue to synthesise copies of the target sequence at a 
varying rate until these components have been exhausted (Rapley 2004). 
 
The PCR technique requires some knowledge of the DNA sequence which flanks 
the fragment of DNA to be amplified. Two oligonucleotide primers must be designed, 
one for each of the two strands of DNA, which are complementary to a sequence of 
DNA downstream of the target DNA. Primers are typically around 20 nucleotides in 
length (hence “oligonucleotide”). The most widely used PCR protocols, i.e. the set of 
instructions for conducting the PCR, employ consensus primers which are targeted 
at a highly-conserved region of the HPV L1 gene, and are therefore potentially 
capable of detecting all mucosal HPV types; among these are the consensus 
primers GP5+/GP6+ which, with further distinction of individual HPV types obtained 
using type-specific primers in an additional PCR, were used to test study samples 
from the cohort described in this thesis (see section 5.5.4.1). 
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A conventional (non-quantitative) PCR proceeds in a series of cycles, typically 
between 30 and 60 in number, each consisting of three steps carried out in order: 
denaturation, annealing and extension (figure 21.1.1 panel a). In the first step, the 
components of the reaction are heated to above 90oC to denature, or separate, the 
DNA strands and make them accessible to the primers. In the second step, the 
temperature of the reaction is cooled to the annealing temperature of the primers, 
typically between 40oC and 60oC, to allow the primers to bind to their complementary 
sites. In the third step, new DNA is synthesised: both primers are extended by 
polymerisation until the new strands extend beyond the target DNA to be amplified; 
these new strands will now therefore contain a region which is complementary to the 
other primer, i.e. the primer which did not bind to this particular DNA strand (figure 
21.1.1 panel b). This means that during the next cycle (cycle n, say), both the 
original and the new strands (strands synthesised during cycle n-1) will be available 
as templates for DNA-synthesis. As the reaction proceeds through successive 
cycles, all the strands present in the reaction will act as templates, and there will be 
an exponential increase in the amount of DNA produced (figure 21.1.1 panel c). After 
each cycle, there will be two new copies of the target sequence for every copy 
present in the previous cycle (a “single” copy comprises the pair of complementary 
sequences present in double-stranded DNA). Therefore after n cycles of a PCR, 2n 
copies of the target sequence will have been synthesised i.e. 20 cycles is sufficient 
to amplify by a million (220=1,048,576) a single target sequence present in the 
starting sample. The vast majority of the copies present in the amplified product will 
have a precise length delimited exactly by the two regions complementary to the 
primers (the first double stranded molecules of exactly the right length appear in the 
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third cycle). On completion of the PCR, it can therefore be verified that the correct 
target sequence has been amplified, by detecting the product after electrophoresis 
on an agarose gel: a “band” will be produced on the gel which can be compared 
against controls of known sizes to ensure that the product of the PCR is of the 
correct size (Rapley 2004). 
 
The sensitivity and specificity of PCR varies according to: the primers used; the size 
of the amplified product; reaction conditions; and the performance of the DNA 
polymerase. Particular care must be taken to avoid false-positive results derived 
from cross-contaminated specimens, or reagents. 
 
Figure 21.1.1. The polymerase chain reaction. 
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21.1.2 Quantitative PCR 
 
It may be thought reasonable to assume that the amount of target DNA present in 
the final product of a conventional PCR, as described in the previous section, has a 
deterministic relationship with the amount of target DNA present in the starting 
sample. For example, it might be anticipated that the brightness, or vertical extent, of 
a band on an agarose gel following electrophoresis would be directly-proportional to 
the amount of target DNA initially present in the target sample, thus providing at 
least a semiquantitative measurement of the viral load of that sample. However, over 
a large range of starting quantity of target DNA, whatever the starting quantity, the 
final quantity of target DNA amplified by the PCR will be the same (this is determined 
largely by the amount of primers added to the reaction). Conventional PCR, which is 
an endpoint assay only, i.e. the result is only obtained after the assay has been 
completed, is thus unable to distinguish even large differences in viral load. The 
result of a conventional PCR test is thus essentially only interpretable as “positive” or 
“negative”. 
 
However, the addition of a fluorescent probe to a PCR enables the detection of the 
accumulation of copies of the target DNA sequence in a PCR in real time i.e. whilst 
the assay is underway, and thereby enables the quantification of the amount of 
target DNA present in the initial sample. A PCR undertaken in this way is known as a 
quantitative PCR (qPCR) (it is also known as “real-time” PCR), and provides both a 
positive or negative status, and an estimate of the number of copies of target DNA 
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present in a sample. If the target DNA sequence is a unique sequence within a HPV 
virus genome, qPCR can thus be used to determine HPV viral load. 
 
The principle behind the use of a fluorescent probe, as used in the study described 
in this thesis, is illustrated in figure 21.1.2. A DNA-probe is designed which is 
complementary to a sequence within the region amplified by the primers. The probe 
has a fluorescent "reporter" at one end, and a "quencher" at the other. When the 
reporter and the quencher are in close proximity, as they are initially before the 
reaction begins (at which point the probe is intact), the quencher prevents detection 
of the fluorescence produced by the reporter. If the reporter is moved away from the 
quencher, the influence of the quencher is attenuated, and the reporters' 
fluorescence becomes detectable. 
 
A qPCR assay is conducted in essentially the same way as a conventional PCR, 
with the probe as an additional component of the reaction. As a new DNA strand is 
synthesised from the primers by polymerisation during the PCR, the new strand 
increases in length until eventually it reaches the position of the probe. The 
polymerase used in the PCR has two actions: as exploited in a conventional PCR, it 
adds additional nucleotides to an existing primer (hence “polymerase”); and it also 
removes any nucleotides in the region of the site of activity (called its “exonuclease 
activity”). Hence, once the newly produced DNA strand reaches the probe, the 
polymerase starts to excise (remove) the nucleotides forming the probe so that they 
can be replaced by new nucleotides. Since the fluorescent reporter is attached to the 
first part of the probe reached by the polymerase, it is excised first. Thereafter, it 
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moves away from the quencher, and begins to fluoresce unhindered by the 
quencher. In this way, an increase in the number of copies of target DNA during 
each PCR cycle causes a proportional increase in fluorescence, which can be 
detected and quantified. The number of cycles at which fluorescence can first be 
detected, the cycle threshold, or “Ct”, value, is proportional to the initial target DNA 
concentration. If a “standard” sample, i.e. one with known amounts of target DNA, is 
included in the reaction together with a sample containing an unknown amount, it is 
then possible to quantify the number of copies of target DNA present in that 
unknown sample. 
 
Note that the use of the fluorescent DNA probe not only enables quantification of the 
target DNA sequence, it also increases the specificity of the qPCR assay compared 
to conventional PCR. No assay is perfect, and one of the main threats to a PCR is 
non-specific binding, i.e. one or more of the primers bind to the wrong part of the 
DNA template, and hence amplify the incorrect DNA sequence. However, the 
probability of non-specific binding by both the primers and the probe in a qPCR is 
extremely low, and certainly less than the probability of non-specific binding by the 
primers alone in a conventional PCR. 
 
It is possible to quantify several target DNA sequences simultaneously in the same 
PCR: such an assay is known as a multiplex assay. However, in the study described 
in this thesis, only one HPV type at a time was assayed in each qPCR i.e. a 
singleplex assay. However, the number of copies of two target DNA sequences 
present in the same patient sample were quantified in separate qPCR conducted on 
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the same well-plate, as will be described below. This was to enable measurements 
of HPV viral load to be adjusted (normalised) for the number of cells present in the 
sample, and thus to be expressed as copy number per 1,000 cells. 
 
Figure 21.1.2. The principle behind the use of a fluorescent probe in a 
quantitative PCR assay. 
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21.2 THE MEASUREMENT OF HPV16 AND HPV18 VIRAL LOAD IN STUDY 
SAMPLES 
 
Having described the principle behind the qPCR assay, I will now describe how it 
was conducted in practice for the analysis of patient samples from the cohort study 
described in this thesis; a formal technical description appears in appendix 7. 
 
21.2.1 Sample Preparation 
 
DNA extraction 
 
A PCR assay cannot be performed on a cell which is structurally intact: the DNA 
content must first be separated from the remainder of the cell. This was done using a 
standard procedure, although in this instance the laboratory scientist refined the 
technique to ensure the maximum yield of DNA from the samples. Prior to testing 
study samples for HPV viral load, all of the DNA in that sample was extracted and 
stored under appropriate conditions. 
  
Quality of the samples: DNA yield 
 
Ideally, when a sample of cells is taken for subsequent DNA analysis, the cells 
should be stored immediately at -80°C, or ideally in liquid nitrogen, until the DNA can 
be extracted. Unfortunately, this was not the case for the cervical cytological 
samples taken in this study. All samples were initially stored as intact cellular 
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material at -20°C. Although storage at this temperature retards the activity of 
enzymes present in the sample (e.g. DNAses, RNAses, proteases, etc.), and 
therefore slows down the degradation of the samples, storage at -20°C does not 
arrest degradation completely. In addition, every time a sample is thawed (a 
necessary step prior to taking a subsample for a specific laboratory test), the activity 
of these enzymes increases. And samples sometimes arrived in the laboratory in 
poor condition, a result of being stored in apparently suboptimal conditions prior to 
being sent to the laboratory for final storage. Therefore, over time the integrity of the 
samples was deteriorating even when apparently lying dormant, and this is likely to 
have had an impact on the DNA yield from these samples. 
 
21.2.2 Primer design 
 
Initially, the primers and probes used for measuring HPV16 viral load were those 
designed by Gravitt et al. (Gravitt 2003). However, it was found that these primers 
were not specific, and also amplified a product [including the target DNA sequence] 
exceeding the length recommended by the manufacturers of the qPCR-kit. 
Therefore, for the analysis of samples from the cohort described in this thesis, new 
(optimised) primers and probes were designed for both HPV16 and HPV18. As well 
as being designed to amplify only the target DNA sequence of interest, primers for 
use in a PCR, quantitative or otherwise, must be designed within certain technical 
constraints; similarly for the fluorescent probe, which is specific to qPCR. In this 
study, primers and probes were designed with the constraints specified by the 
manufacturer as a guide only: primer parameters are presented in table A4a of 
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appendix 4. The HPV16 primers were designed to amplify the HPV16 E6 gene; the 
HPV18 primers were designed to amplify the HPV18 E7 gene. 
 
21.2.3 Generation of standard curves 
 
Plasmids were used to generate standard curves for HPV16, HPV18, and the 
GAPDH housekeeping gene (the use of which is described subsequently). A plasmid 
is a small extra-chromosomal DNA molecule which is capable of independent 
replication. In brief, the gene of interest is incorporated into the plasmid, which is 
then inserted into bacterial “vectors”. Bacteria multiply at an extremely high rate, i.e. 
they undergo rapid cell-division, during which all DNA in the “parent” cell is copied 
and carried into “daughter” cells. Therefore, very large numbers of copies of a gene 
can be produced relatively easily. Commercially-available vectors were used for 
producing plasmids containing the HPV16 and HPV18 genomes. However, the 
production of the GAPDH plasmid was undertaken in-house, using a cell-free 
method (see table A4b of appendix 4 for PCR primer parameters). 
 
21.2.4 Well-plate configuration 
 
In this study only one HPV type at a time was assayed in each qPCR. However, 
each sample standard and control was tested three times in the same qPCR assay, 
with the result from each test subsequently being combined. Each patient sample 
was thus tested six times in the same qPCR assay. The procedure for testing a 
patient sample, for example, is illustrated in figure 21.2.4a.  
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Figure 21.2.4a. Description of the method for obtaining triplicate patient 
samples for GAPDH and HPV in the qPCR assay. 
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The qPCR assay was conducted using a 96-well well-plate, called a TaqMan® plate. 
Each well-plate can be considered to comprise a grid of eight rows and 12 columns 
of wells. A typical well-plate configuration for conducting the HPV16 assay is shown 
in table 21.2.4; the well-plate configuration for the HPV18 assay was similar. The 
wells can be divided into seven groups, each with a distinct purpose. 
 
1) HPV type-specific plasmids 
 
These wells are used for generating a standard curve for estimating the number of 
copies of HPV which were present. They hold serial ten-fold dilutions of plasmids 
containing a genome which incorporates the relevant portion of the HPV16, or 
HPV18, genome, as appropriate: therefore, within limits, these wells contain known 
numbers of copies of the HPV genome of the relevant type.  
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2) GAPDH plasmids 
 
These wells are used for generating a standard curve for estimating the number of 
cells which are present in a sample. They hold serial ten-fold dilutions of plasmids 
containing a genome which incorporates the GAPDH housekeeping gene: therefore, 
within limits, these wells contain known numbers of copies of the GAPDH gene. 
 
3) Patient samples: HPV 
 
These wells are used for estimating the number of copies of  HPV which are present 
in patient samples; they hold genomic DNA from patient samples. The genomic DNA 
will be a mixture of DNA from normal cells, DNA from cells with hyperploidy (i.e. an 
abnormal increase in the number of chromosomes usually found in a cell), and HPV 
DNA (if the sample was taken from an HPV-infected woman). 
 
4) Patient samples: GAPDH 
 
These wells are used for estimating the number of copies of the GAPDH 
housekeeping gene which are present in patient samples; they hold genomic DNA 
from patient samples. 
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5) Positive-control: HPV 
 
These wells are used for estimating the number of copies of  HPV which are present 
in the positive-control, with the objective of determining whether the assay has 
worked correctly, and therefore whether the results of the assay can be accepted. 
They contain DNA from a cervical carcinoma cell line with a known range of copy 
numbers per cell of the HPV type of interest. In assays used to measure HPV16 viral 
load, DNA from the HPV16-positive cervical cancer cell line SiHa was used as a 
positive internal control; for HPV18, the HPV18-positive cervical cancer cell line 
HeLa was used. SiHa has been reported to contain between one and 10 copies of 
the HPV16 genome per cell; HeLa between one and 50 copies of the HPV18 
genome per cell. If the measured viral load per cell for a positive-control was not 
consistent with the previously reported range, the results of the assay were rejected. 
 
6) Positive-control: GAPDH 
 
These wells are used for estimating the number of copies of the GAPDH 
housekeeping gene which are present in patient samples; they hold DNA from a cell 
line containing known copy numbers of the HPV type of interest. Note that, although 
the number of copies of the virus per cell present in the sample is assumed known 
(i.e. within a known range), the number of cells in the sample used to measure that 
number is still unknown. 
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7) Negative-control: water 
 
These wells are used to determine whether the assay has worked correctly, and 
therefore whether the results of the assay can be accepted. When preparing all wells 
on the well-plate, the same supply of DNase/RNase-free water was used to dilute 
samples to the necessary concentration. Therefore, any contamination of this water 
source, or of the equipment used to dilute the samples, would affect all samples. 
These wells are used to detect any such contamination. There are six of these wells 
in table 21.2.4, labelled in two groups: however, these wells essentially provide six 
identical negative control measurements. 
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Table 21.2.4. Well-plate configuration for conducting the HPV16 qPCR assay 
using a 96-well well-plate. Scientific notation is used, i.e. 10eN is equivalent to 
10N. 
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21.2.5 qPCR conditions 
 
Optimal qPCR conditions were determined and pre-programmed into a machine 
called a thermal cycler. The thermal cycler conducts the qPCR automatically, 
monitors accumulating fluorescence, and outputs the data to a computer in a format 
suitable for analysis by specialised software. 
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During the initial cycles in a qPCR, there is no detectable increase in fluorescence: 
the cycle number at which fluorescence can first be detected (the cycle threshold, or 
Ct, value) is determined automatically. 
 
21.2.5.1 The Ct value and a qPCR-negative result 
  
The number of cycles in the qPCR assay used in this thesis was arbitrarily chosen to 
be 50 (typically, qPCRs use between 30 and 70 cycles). This means that any sample 
whose Ct value wass 50 would be measured as having a viral load of zero. This may 
have been because the sample was in fact HPV-negative for the specific type 
assayed; or because the number of copies of HPV present in the sample was very 
low, and the number of cycles undertaken was insufficient to produce detectable 
fluorescence. Thus “qPCR-negative” (or, equivalently, a viral load of zero) refers to 
an arbitrary cut-off value. However, this is no different from a “negative” in a 
conventional PCR which also uses an arbitrary, and finite, number of cycles. 
 
21.2.6 Determination of virus copy numbers and cell copy numbers 
 
Inverse regression was used to obtain estimates of the number of copies of HPV 
(the HPV viral load) which were present in cervical samples taken from patients in 
the study samples. A standard curve for the specific virus type assayed was 
obtained by plotting the logarithm of the observed Ct values from the triplicate 
measurements made on the standard virus plasmid controls, against the “known” 
input concentration (serial ten-fold dilutions containing “known” copy numbers of the 
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relevant HPV-type were used). A line of best-fit was then estimated using ordinary 
least-squares regression. To quantify viral load in a target sample, the mean of the 
Ct values from each of the accepted triplicate wells was referred to the fitted 
regression line, and the corresponding concentration for that Ct value was 
determined. The measurement so obtained was then used as an estimate of the 
total number of copies of the virus genome present in the target sample. 
 
To “normalise” virus copy number for specimen cellular content, the number of 
copies of the GAPDH gene present in the target sample was estimated in the same 
way, but using the standard GAPDH plasmid controls. GAPDH is a so-called 
“housekeeping” gene which is assumed to be present in the genome of all human 
cells, with one copy of this gene per DNA strand: each host-cell of the target sample 
was therefore assumed to contain two copies of the GAPDH gene. Therefore, since 
each normal cell contains two strands of DNA, and each strand of DNA contains a 
single copy of the GAPDH gene, the number of cells present in the target sample 
was estimated by dividing the estimate of the number of copies of the GAPDH gene 
which were present by two. The viral load of the target sample, normalised or 
“corrected” for cellular content, was then obtained by dividing the estimate of the 
number of copies of the virus which were present in the target sample, by the 
estimate of the number of cells which were present in the target sample. 
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21.2.6.1 GAPDH failures 
 
The GAPDH gene sometimes failed to amplify for a particular sample: this could 
indicate that the sample contained no DNA, or that a problem had occurred with the 
PCR-amplification of that sample. On repeating the assay, sometimes the problem 
could be resolved, but not always. If GAPDH failed to amplify for a sample, the 
sample could not be evaluated for viral load since it could not be normalised for 
cellular DNA content, unless the result for the virus indicated that it was negative.  
 
21.2.7 Numerical example 
 
A numerical example is the best way to demonstrate the procedure for obtaining 
estimates of HPV viral load. 
 
In this example, numbers are approximate: more accurate values were used in the 
actual calculations for study samples. Examples of the two results tables from the 
qPCR assay, as supplied to the candidate by the laboratory scientist following 
preliminary analysis, are presented in tables 21.2.7a and 21.2.7b. Five patient 
samples were tested in this assay (study ID’s 247.5, 247.6, 247.7, 247.8 and 247.9). 
 
1) The first thing to notice is that all three of the negative-control wells for GAPDH 
are negative, as are all three of the negative-control wells for HPV16 (the row 
labelled “water”: Ct value=50, in all cases). Thus the results of this assay are not 
rejected on the grounds of contamination. 
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2) Each well-plate yields three Ct values for each of the samples on that well-plate. 
Ultimately, a mean Ct value across the replicates for each sample was used as the 
observation for that sample. However, only Ct values which did not display 
excessive variability amongst replicates were retained in the analysis. “Excessive 
variability” was defined as follows. If the standard deviation among the three Ct 
values was 1.5 or more, the most extreme Ct value would be excluded; the 
remaining two Ct values would then be used to form the mean Ct value for that 
sample. Apparently, this is a common practice in other laboratory assays where 
triplicates are used. However, the use of a standard deviation of 1.5 is clearly 
arbitrary, although more stringent than others would normally use within the 
laboratory where the qPCR assay described in this thesis was undertaken. That 
being said, this procedure typically led to the exclusion of a clear outlier. The same 
rule was then applied to the remaining two Ct values: if the standard deviation 
among the remaining two Ct values was 1.5 or more, the results for this sample were 
excluded, and the sample was tested again. Where the standard deviation among 
the three Ct values exceeded 1.5, and there was more than one choice of pairs of Ct 
values for which the standard deviation among the remaining pair of Ct values did 
not exceed 1.5 (i.e. where it is was not clear-cut which Ct value should be excluded), 
the pair of Ct values yielding the smallest standard deviation was used. If the Ct 
values measuring the GAPDH copy number suggested the result should be 
excluded, but the Ct values measuring the virus copy number indicated a zero viral 
load (i.e. that a sample which was negative for the specific HPV type), the zero viral 
load result was accepted. In addition, Ct values of 50 required special handling. A Ct 
value of 50 was not included in calculations of standard deviations since these 
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represented either a specific value of viral load (zero), or a censored value i.e. a viral 
load below the limits of detection. If two of the triplicates had Ct values of 50, the 
third (non-50) Ct value was excluded. If two triplicates had non-50 Ct values, the Ct 
value of 50 was excluded. These rules were applied for all types of sample on the 
well-plate, but excluding Ct values from samples used to fit the standard curves had 
a greater impact on estimates of viral load than did excluding Ct values which only 
affected the results of an individual patient or control sample. 
 
In this example, none of the values from the GAPDH analysis require further 
manipulation. In the HPV16 analysis (table 21.2.7b), Ct value 2 for patient sample 
247.6 was excluded, making this sample HPV16-qPCR-negative; and Ct value 1 for 
patient sample 247.9, indicating a HPV-negative result, was also excluded. 
 
Table 21.2.7a. Example of the Ct values output from the qPCR assay for plate 
VL061: GAPDH. Scientific notation is used, i.e. 10eN is equivalent to 10N. 
 
Sample Ct Value 
1 
Ct Value 
2 
Ct Value 
3 
Mean Ct 
value 
Ct value SDa 
Plasmid: 10e8 copiesb 14.96 14.94 14.80 14.90 0.09 
Plasmid: 10e7 copies 17.09 16.74 17.06 16.96 0.19 
Plasmid: 10e6 copies 19.92 20.36 20.52 20.27 0.31 
Plasmid: 10e5 copies 23.18 23.11 23.26 23.18 0.08 
Plasmid: 10e4 copies 25.47 26.22 25.95 25.88 0.38 
Plasmid: 10e3 copies 28.30 28.51 28.41 28.41 0.11 
Plasmid: 10e2 copies 33.39 33.77 33.91 33.69 0.27 
Water 50.00 50.00 50.00 50.00 NA 
SiHa  23.71 23.72 23.75 23.73 0.02 
Patient sample 247.5 31.09 29.78 29.62 30.16 0.81 
Patient sample 247.6 42.45 40.10 40.91 41.15 1.19 
Patient sample 247.7 29.11 29.24 29.06 29.14 0.09 
Patient sample 247.8 25.74 25.46 25.37 25.52 0.19 
Patient sample 247.9 24.71 24.71 24.47 24.63 0.14 
aStandard deviation; bScientic notation used: 10e8 = 10 x 108 
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Table 21.2.7b. Example of the Ct values output from the qPCR assay for 
plate VL061: HPV16. Scientific notation is used, i.e. 10eN is equivalent to 10N. 
 
aStandard deviation; bScientic notation used: 10e8 = 10 x 108; cExcluding the outlier Ct value. 
Sample Ct Value 
1 
Ct Value 
2 
Ct Value 
3 
Mean CT 
value 
Ct value SDa 
Plasmid: 10e8 copiesb 14.28 14.19 14.23 14.23 0.05 
Plasmid: 10e7 copies 18.30 18.28 18.20 18.26 0.05 
Plasmid: 10e6 copies 21.76 21.69 21.67 21.71 0.05 
Plasmid: 10e5 copies 27.20 26.56 27.23 27.00 0.38 
Plasmid: 10e4 copies 29.86 29.49 29.62 29.66 0.19 
Plasmid: 10e3 copies 32.77 33.24 33.20 33.07 0.26 
Plasmid: 10e2 copies 36.25 36.11 36.87 36.00 0.40 
Water 50.00 50.00 50.00 50.00 NA 
SiHa  23.76 23.68 23.76 23.73 0.05 
Patient sample 247.5 21.80 21.58 21.33 21.57 0.24 
Patient sample 247.6 50.00 46.71 50.00 50.00 NAc 
Patient sample 247.7 31.07 31.23 31.11 31.14 0.08 
Patient sample 247.8 33.02 33.22 32.20 32.81 0.54 
Patient sample 247.9 50.00 39.56 39.11 39.34 0.32c 
 
 
3) Next two standard curves were generated based on the observed Ct values from 
the wells containing known copy numbers of plasmids, one for GAPDH (figure 
21.2.7a) and one for the virus (figure 21.2.7b). Each (accepted) Ct value was plotted 
against the natural logarithm of the known copy number, and a straight line was then 
fitted using ordinary least squares regression. 
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Figure 21.2.7a. Example standard curve from the qPCR assay for plate VL061: 
GAPDH. 
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Figure 21.2.7b. Example standard curve from the qPCR assay for plate VL061: 
HPV16. 
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Slopes and intercepts of the regression curves were estimated using the internal 
functions in Microsoft Excel. These were subsequently verified using the R statistical 
package, with no differences being found. The slope and intercept were taken from 
the equation displayed on an Excel chart, which are reported to four decimal places, 
and were used in calculations. 
 
In this case the equation of the GAPDH standard curve is 
 
Ct ValueGAPDH=38.4250 – (1.3164 x ln (Copy NumberGAPDH)) 
 
Hence: 
 
Copy NumberGAPDH = exp((38.4250 – Ct ValueGAPDH)/1.3164)  (1) 
 
Similarly, for HPV16: 
 
Copy NumberHPV16 = exp((44.3512 – Ct ValueHPV16)/1.6146)  (2) 
  
Given a Ct value from a sample containing an unknown number of copies of HPV16, 
or of GAPDH, we are now in a position to estimate this unknown quantity. 
 
4) The first unknown copy number which must be calculated is that for the positive-
control. If the measured viral load per cell for the positive-control is not consistent 
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with the acceptable range for the cell line, the results of the assay must be rejected 
and further calculations are unnecessary. 
 
The mean Ct value for HPV16 for the positive-control is 23.73. Hence the number of 
copies of virus present in this sample is 352,113.26 (from equation 2 above). By 
itself, this value is of little use: we need to know the number of cells present in that 
sample. The mean Ct value for GAPDH for the positive-control is also 23.73 
(unusual, but by no means a unique phenomenon). Hence the number of copies of 
GAPDH present in this sample is 70,475.50 (from equation 1 above). If it is assumed 
that each cell has two copies of the GAPDH gene (one copy per DNA strand), then 
there are 35,248 cells (70,475.50/2) present in this sample. Hence, this sample of 
the SiHa cell line contains 10 copies (352,113.26/35,248) of HPV16 per cell, 
consistent with the previously reported range of one to 10. Hence the results of this 
assay are not rejected due to failure of the positive-control, and the results of the 
assay can be accepted. 
 
5) The number of copies of HPV16 present in the sample can now be estimated, and 
further expressed as copy number per cell. Figure 21.2.7c illustrates this process for 
GAPDH, and figure 21.2.7d for HPV16 for the patient samples tested in this qPCR 
assay. Clearly, for sample 247.6 and GAPDH, it was necessary to extrapolate 
beyond the range of copy numbers used to generate the standard curve; similarly for 
sample 247.9 and HPV16, but the extrapolation is not as extreme in this case. 
 
 
 
Figure 21.2.7c. Illustration of the calculation of the GAPDH copy number from the standard curve for patient 
samples on qPCR well-plate VL061. The horizontal numbers in green are patient sample IDs; the vertical numbers in 
green are estimated ln(copy number) for those samples. 
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Figure 21.2.7d. Illustration of the calculation of the HPV16 copy number from the standard curve for patient 
samples on qPCR well-plate VL061. The horizontal numbers in green are patient sample IDs; the vertical numbers in 
green are estimated ln(copy number) for those samples. 
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Although the estimation of copy numbers (viral load) using the method described 
above is clearly an exercise in regression, specifically inverse regression, it is not 
treated as a statistical procedure in standard laboratory practice (in the laboratory 
testing the samples used in this thesis, or any other apparently). Since statistical 
techniques are used to estimate the standard curve, there is uncertainty in the 
estimates produced using that curve. Figures 21.2.7e and 21.2.7f also include a 95% 
confidence interval, and a 95% prediction interval, for the standard curve. Clearly, in 
this particular assay, measured copy numbers have a substantial range of values 
which are consistent with the point estimate of the observed copy number (tables 
21.2.7c and 21.2.7d illustrate this for GAPDH and HPV16, respectively). 
 
Table 21.2.7c. Point estimates of GAPDH copy numbers and 95% confidence 
limits for patient samples assayed on qPCR plate VL061. 
 
Sample 
ID 
Mean Ct 
Value 
GAPDH Copy 
Number 
Lower 95% 
Confidence Limit 
Upper 95% 
Confidence Limit 
247.5 30.16 555.43 367.57 811.45 
247.6 41.15 0.13 0.06 0.28 
247.7 29.14 1,211.56 830.07 1,718.39 
247.8 25.52 18,855.62 14,184.90 24,794.10 
247.9 24.63 37,167.74 28,325.02 48,458.45 
 
 
Table 21.2.7d. Point estimates of HPV16 copy numbers and 95% confidence 
limits for patient samples assayed on qPCR plate VL061. 
 
Sample 
ID 
Mean Ct 
Value 
HPV16 Copy 
Number 
Lower 95% 
Confidence Limit 
Upper 95% 
Confidence Limit 
247.5 21.57 1,341,237.24 1,103,697.01 1,641,883.58 
247.6 50.00 0.00 0.00 0.00 
247.7 31.14 3,583.76 2,881.32 4,415.79 
247.8 32.81 1,268.71 993.41 1,600.46 
247.9 39.34 22.35 15.40 31.66 
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 The uncertainty in these estimates could easily be reduced. It should be noted that 
standard “curve” is a misnomer since whatever Ct values are observed following the 
assay, a straight line will always be fitted to the data rather than any other function, 
e.g. a quadratic curve. There are theoretical reasons to justify why a straight-line 
relationship on a logarithmic scale is expected rather than any other, but 
conventionally no diagnostics are performed in the modelling of the standard curve. 
Given that this is the case, it would be better to fit the line using only two points with 
known copy numbers, with a greater number of observations concentrated at the 
extremes of the range of interest, rather than spreading them over the entire range 
(Draper 1998). This would increase precision within the range of copy numbers 
covered by the standard curve and reduce uncertainty in estimates. 
 
In standard laboratory practice, the uncertainty in estimates is ignored: estimated 
values are treated as being known precisely. In particular, when calculating viral load 
normalised for cellular content, a ratio of two correlated values estimated with 
uncertainty from two regression curves is formed and used thereafter without regard 
for any uncertainty in the estimates. A crude estimate of the range of values 
potentially consistent with the observed normalised copy numbers for the patient 
samples in this assay is presented in table 21.2.7e. The lower limit was calculated by 
dividing the lower 95% confidence limit for the HPV16 copy number by the upper 
95% confidence limit for the GAPDH copy number; the upper limit by dividing the 
upper 95% confidence limit for the HPV16, copy number by the lower 95% 
confidence limit for the GAPDH copy number. 
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Table 21.2.7e. Observed and corrected HPV16 copy numbers and range of 
plausible values for normalised copy number for patient samples assayed on 
qPCR plate VL061. 
 
Sample 
ID 
HPV16 Copy 
Number 
HPV16 
Normalised 
Copy Number
Lower Limit Of 
Plausible 
Values 
Upper Limit Of 
Plausible 
Values 
Ratio Of Upper 
To Lower Limit
247.5 1,341,237.241 4,829.549 2,720.299 8,933.672 3.3 
247.6 0.000 0.000 0.000 0.000 - 
247.7 3,583.759 5.916 3.354 10.640 3.2 
247.8 1,268.709 0.135 0.080 0.226 2.8 
247.9 22.347 0.001 0.001 0.002 3.5 
 
 
21.3 qPCR ASSAY PERFORMANCE 
 
Dynamic range 
When a standard curve is generated, a straight line is fitted to the observed Ct 
values by ordinary least squares regression. This curve will only be valid if it is 
reasonable to assume that a straight line is the appropriate model. To determine the 
linear dynamic range of the assay i.e. the range of copy numbers over which a 
straight line is a valid model for the data, serial ten-fold dilutions of plasmids were 
assayed for viral load. For this assay, the dynamic range exceeded 109 to one 
copies. 
 
Type specificity 
Primer cross-reactivity was assessed by testing DNA from the HPV18-positive 
cervical cancer cell line HeLa using the HPV16 primers; and DNA from the HPV16-
positive cervical cancer cell line CaSki using the HPV18 primers. No cross-reactivity 
was found i.e. the HPV16 primers did not amplify HPV18, and vice versa. As 
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desired, both sets of primers also failed to amplify when the HPV-negative cervical 
cancer cell line C33a was tested. 
 
Inhibition and PCR artefacts 
Samples containing varying concentrations of DNA from the HPV16-positive cell 
lines SiHa and CaSki, or the HPV18-positive cell line HeLa (1000 ng; 500 ng; 100 
ng; 50 ng; 10 ng and 5 ng) were used to identify the presence of inhibitors of PCR or 
concentration-dependent PCR artefacts. Results were as expected for all 
concentrations, with no evidence of interference from inhibitors, or of PCR artefacts: 
the estimated number of copies of the virus genome per cell were approximately the 
same in each assay. Competitive inhibition of the qPCR assay for measuring HPV16 
and HPV18 viral load was assessed by mixing SiHa and HeLa DNA together in 
varying concentrations, and no competitive inhibition was found, i.e. the presence of 
HPV16 did not have an effect on the performance of the HPV18 qPCR, and vice 
versa. 
 
21.4 STATISTICAL METHODS 
 
21.4.1 Measuring assay reliability 
 
The data structure for the experiments used to measure intra- and inter-assay 
reliability is shown in figure 21.4.1. Each sample was measured in three wells on 
each of two well-plates. 
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Figure 21.4.1. Data structure for experiments used to measure intra- and 
inter-assay reliability. 
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21.4.1.1 Intra-assay reliability 
 
An intra-cluster correlation coefficient (ICC) was used to measure intra-assay and 
inter-assay reliability. The ICC takes values of one for perfect reliability (perfect 
agreement), and values close to zero for little reliability. 
 
Both a random effects model and a closed formula were used to estimate the ICC, 
with no material differences between the results of the two methods: only the results 
derived from the random effects model are presented (Pinheiro 2002, Rousson 
2002). 
 
In this context, intra-assay reliability refers to within-plate agreement between the 
three Ct values whose mean value was ultimately used to determine viral load for a 
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single sample: the same sample was not tested more than once on the same plate. 
Further, given the procedure used for selecting valid Ct values (see section 21.2.7 
point 2), intra-assay reliability was effectively constrained to be almost perfect: only 
samples with Ct values within strict limits were retained in the analysis. ICC were 
calculated for the observed Ct values used for measuring both viral DNA copy 
number and GAPDH gene copy number.  
  
The calculation of the ICC assumes that the data arise from a normal, or at least a 
continuous, distribution. In this case, observed Ct values range from 1 to 50, with a 
value of 50 being “HPV-negative” for the type tested for. Therefore, a priori, these 
data cannot be considered to be a sample from a normal distribution. Any 
transformation to a different scale, e.g. using a complementary log-log 
transformation, would still present problems in dealing with numerical zeroes, as well 
as with assay-specific “zeroes”, i.e. Ct=50. When appropriate, analyses were carried 
out both including and excluding these values. Given that in each case where a Ct 
value of 50 was observed for any replicate, all other replicate Ct values were also 
50, excluding such perfectly replicated results is likely to have yielded a more 
conservative estimate of reliability. 
 
If the mean Ct value from the replicated GAPDH wells was used to estimate the 
copy number of the GAPDH gene in cytological samples, then each experiment 
could also be considered as yielding three estimates of viral copy number. ICC were 
therefore also calculated for observed virus copy numbers per cell. 
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21.4.1.2 Inter-assay reliability 
 
An intra-cluster correlation coefficient (ICC) was used to estimate inter-assay 
reliability, calculated using a random effects model. 
 
In this context, inter-assay reliability refers to the agreement between the virus copy 
number per cell of a sample measured on each of two separate plates. A single 
measurement of virus copy number per cell was obtained for each sample from each 
well-plate. These well-plates were then repeated, yielding two measurements of 
virus copy number per cell for each sample. Inter-assay reliability, unlike intra-assay 
reliability, was not artificially constrained within tight limits. In this test-retest reliability 
situation, there was no “learning” effect: therefore the ICC is the usual product-
moment correlation coefficient. 
 
21.4.2 The analysis of HPV viral load 
 
21.4.2.1 Measurement of HPV viral load as a time-varying covariate 
 
When repeated measurements over time are made on both exposure and outcome, 
determining how exposure influences the risk of that outcome presents a complex 
challenge (see section 6.6). Analysing HPV viral load as a time-fixed covariate, by 
including in the analysis only HPV status at baseline for example, is one possibility. 
However, estimates of association may be unreliable if changes in HPV viral load 
are also important. In an analysis incorporating a time-varying measurement of HPV 
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viral load, several possibilities exist for how to measure viral load. For example, at a 
given point in time the most recent measurement of viral load can be used; or the 
measurement of viral load taken at an earlier time, such as at the previous visit, or 
the measurement from two visits earlier. Alternatively, it may be preferable to use a 
variable which summarises how viral load has changed over time, or one which 
captures important features of that change ,e.g. mean viral load, area under curve, 
maximum viral load attained, etc. But again, if this approach is adopted, the variable 
can take its current value, or its value from an earlier point in time. 
 
For example, figure 21.4.2.1 illustrates how HPV viral load changes with time for one 
hypothetical woman. The true form of the viral load curve is unknown; instead we 
observe the discrete set of viral load measurements VN to VN+6 taken at 
measurement times TN to TN+6, respectively. For each of the measurement times, the 
viral load observed at the previous time is shown in green: this is undefined at time 
TN. Similarly, the viral load observed two measurement occasions in the past is 
shown in yellow: this is undefined at times TN and TN+1. The maximum viral load 
attained at each of the measurement times is shown in blue: this can only increase 
as time increases, i.e. as more measurements are made. 
 
In the cohort study described in this thesis measurements of viral load and outcome, 
for example cervical cytological status, were made at the same time (see figures 
5.2.3b and 6.1). Therefore outcome status and the potential risk factor for that 
outcome are measured contemporaneously. Using measurements of risk factor 
variables taken contemporaneously with measurements on outcome status 
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introduces difficulties of interpretation (see section 6.6.3). For example, the presence 
of cervical cytological abnormality may lead to an increase in viral production and 
therefore viral load: in this case current viral load status would not be a “cause” but 
rather a “consequence” of the presence of cytological abnormality. If the analysis is 
to be able to establish temporality, it is preferable to relate current outcomes to 
previous values of risk factor variables (note that it still cannot be ruled out that a 
cervical abnormality at a stage at which it cannot be detected by cytology still leads 
to an increase in HPV viral load which can be detected). 
 
Figure 21.4.2.1. Measurement of HPV viral load as a time-varying covariate 
 
 
True viral load (Unobserved)
 
21.4.2.2 Time to the acquisition of incident cervical cytological abnormality 
 
Analyses of the time to the acquisition of incident cervical cytological abnormality 
were undertaken using methods appropriate to interval-censored time-to-event data. 
Time
TN TN+1 TN+2 TN+3 TN+4 TN+5 TN+6
VN
VN+1
VN+2
VN+3
VN+4
VN+5
VN+6
Observed viral load
Maximum viral load attained
Viral load observed at previous visit
Viral load lagged by two visits
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Time to the acquisition of cervical cytological abnormality was measured from the 
date of the first qPCR-evaluable sample until the interval between the date of the 
first detection of cervical cytological abnormality and the date of the immediately 
preceding cytologically normal smear; censoring occurred on the earliest of the date 
of the diagnosis of high-grade CIN, the date of the last qPCR-evaluable sample, and 
the date of the last smear. 
 
Estimates of hazards ratios were obtained using a semi-parametric method for 
modelling interval-censored time-to-event data as a generalized linear model (see 
section 6.5.2), with various estimates of viral load treated as time-varying covariates. 
The optimal analysis of the association between viral load and the incidence of 
cervical cytological abnormality is not immediately apparent.  Consequently, five 
exposure variables were investigated in analyses: 
 
• a time-fixed binary variable indicating HPV viral load status at baseline 
(positive or negative); 
• a time-fixed continuous variable measuring HPV viral load at baseline; 
• a time-varying binary variable indicating “ever HPV viral load positive” up-to 
and including the previous visit (yes or no); 
• a time-varying continuous variable measuring HPV viral load at previous visit; 
• a time-varying continuous variable measuring the maximum HPV viral load 
attained up-to and including the previous visit. 
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For example, for the woman illustrated in figure 21.4.2.1, at time TN+4 these variables 
have the values “positive”, VN, “yes”, VN+3, and VN+2, respectively. 
 
95% confidence intervals were constructed from parameter estimates and their 
standard errors; and statistical tests of hypotheses were undertaken using likelihood 
ratio tests. 
  
21.4.2.3 Time to clearance of an incident cervical HPV infection 
 
Analyses of the duration of incident cervical HPV infections were undertaken using 
methods appropriate to interval-censored time-to-event data. 
 
An incident qPCR HPV infection was defined as an infection in a woman who was 
qPCR-negative for that type in her first qPCR-evaluable sample, but who 
subsequently became qPCR-positive during follow-up. An episode of qPCR infection 
was then defined as being the interval between this first qPCR-positive sample and 
the last subsequent qPCR positive sample, during which interval of time the woman 
was continuously qPCR-positive. Duration of an incident cervical HPV16 or HPV18 
qPCR infection was measured from the date of the first qPCR-positive sample until 
the interval between the date of the first subsequent qPCR-negative sample and the 
date of the immediately preceding qPCR-evaluable sample; censoring occurred on 
the earliest of: the date of the diagnosis of high-grade CIN; and the date of the last 
qPCR-evaluable sample. 
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Estimates of the cumulative risk of the clearance of a qPCR infection were obtained 
using a non-parametric maximum likelihood estimator (Turnbull 1976) (see section 
6.4.1). Estimates of hazards ratios were obtained using a semi-parametric method 
for modelling interval-censored time-to-event data as a generalized linear model 
(Smith 1997), with various estimates of HPV viral load treated as time-varying 
covariates. Three exposure variables were investigated in analyses: 
 
• a time-fixed continuous variable measuring HPV viral load at the start of the 
episode; 
• a time-varying continuous variable measuring HPV viral load at the previous 
visit; 
• and a time-varying continuous variable measuring maximum HPV viral load 
attained by the previous visit 
 
21.4.2.4 The risk of being free of cervical HPV infection in the last qPCR-
evaluable sample 
 
An additional exploratory analysis, which was related to the time to clearance of a 
cervical HPV qPCR-infection, was used to determine the association between the 
maximum HPV16 and HPV18 viral load observed during follow-up and the 
probability of being clear of HPV16 or HPV18 infection in the last evaluable sample, 
after controlling for the length of follow-up. Estimates of odds ratios measuring the 
risk of being free of cervical HPV infection in the last qPCR-evaluable sample were 
obtained using binary logistic regression. 
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21.4.3 Estimation and hypothesis testing 
 
All tests of statistical significance were conducted at the 5% two-sided significance 
level. 
 
In multivariate analyses, all numerical values of HPV viral load were log-transformed; 
95% confidence intervals were constructed from parameter estimates and their 
standard errors; and tests of hypotheses were undertaken using likelihood ratio 
tests.  
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Chapter 22 
 
THE NATURAL HISTORY OF CERVICAL HPV16 AND HPV18 
INFECTIONS – VIRAL LOAD 
 
RESULTS 
 
 
 
 
 
Orientation 
 
In this chapter I: 
 
• determine the reliability of an assay used for the measurement of the viral load of 
HPV16 and HPV18 in cervical samples 
 
• describe how the distribution of HPV viral load varies with infecting HPV type, for 
HPV16 and HPV18 
 
• describe how HPV viral load changes over time in women with incident cervical 
HPV16 and/or HPV18 infections 
 
• describe the relationship between HPV16 and HPV18 viral load in cervical 
samples and the detection of epithelial abnormalities of the cervix 
 
 
 
 
 
22.1 RESTATEMENT OF OBJECTIVES 
 
To investigate how the natural history of cervical HPV infection varies with viral load. 
 
o To evaluate the performance of an assay for the measurement of the 
viral load of cervical infections with HPV16 and HPV18. 
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o To describe changes in HPV16 and HPV18 viral load in cervical 
samples taken from a cohort of young women who were recruited soon 
after first sexual intercourse, and who first tested positive for HPV16 
DNA, or HPV18 DNA, or both, during follow-up. 
 
o To describe the association between the acquisition of epithelial 
abnormalities of the cervix and changes in HPV16 and HPV18 viral 
load in cervical samples taken from a cohort of young women who 
were recruited soon after first sexual intercourse, and who first tested 
positive for HPV16 DNA, or HPV18 DNA, or both, during follow-up. 
 
22.2 ASSESSMENT OF TEST PERFORMANCE FOR THE MEASUREMENT OF 
VIRAL LOAD BY QPCR 
 
The development and implementation of the qPCR assay used for measuring HPV 
viral load occurred in three stages, with some overlap in practice. In the first stage, 
the experienced laboratory scientist who would be carrying out the analysis of study 
samples: designed HPV type-specific primers for use in the assay; and established 
the procedures for conducting the assay (section 21.2). The second stage was to 
determine whether the assay was valid, i.e. yielded accurate measurements of HPV 
viral load, and reliable, i.e. gave the “same” result in repeated measurements of the 
same sample. The third stage was the testing of study samples: this stage could only 
begin when development reached a point at which the technique could be used with 
confidence. 
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22.2.1 Selection of study samples for use in validation of the qPCR assay 
 
The samples from the study described in this thesis are a limited resource, and so 
must be used sparingly with future uses kept in mind. The samples from the study 
cohort were therefore chosen with the larger aims of the study in view. Most women 
in the analyses used to develop this assay contributed only a single sample because 
they only ever had one evaluable cervical cytological sample, or because they were 
from the “prevalent cohorts” i.e. women who were HPV DNA-positive, or had a 
cytologically abnormal cervical smear, at study entry, or both. Such women are 
already diseased, or infected with HPV, at study entry, and are therefore less 
valuable in an analysis of incident cervical HPV infections or cervical disease. 
 
Samples were selected from those provided by women who were either cytologically 
abnormal in their cervical smear, or HPV-positive at study entry, or both, and tended 
to be from women with limited, or no, further follow-up. Initially, samples were 
selected neither at random nor in a systematic way, but rather to give a mixture of 
samples which were cytologically normal and cytologically abnormal in the 
corresponding cervical smear, and which were positive for the HPV type of interest 
according to the GP5+/GP6+ system (see section 5.5.4.1). 
 
No formal sample size calculation was performed. It was decided that, initially, three 
qPCR experiments including a minimum of 15 samples should be performed. It was 
hoped that this would be sufficient to establish that the qPCR assay was reliable, 
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and therefore that only one qPCR per sample would be needed when analysing 
patient samples from the study population of interest. 
 
22.2.1.1 Study samples and analyses undertaken for the validation of the 
HPV16 qPCR assay 
 
To determine whether the qPCR assay for measuring HPV16 viral load was reliable, 
10 analyses were undertaken (table 22.2.1.1).  
 
Table 22.2.1.1. Analyses undertaken for determining the reliability of the 
qPCR assay measuring HPV16 viral load. 
 
Well-plate ID Analysis Primers Comments 
 Date Time   
VL005 12/10/05 12pm Gravitt  
VL006 12/10/05 5pm Gravitt Repeat of VL005 
VL007 13/10/05 12pm Gravitt  
VL008 13/10/05 230pm Gravitt Repeat of VL007 
VL021 20/01/06 12pm Optimized Repeat of VL007 
VL022 20/01/06 230pm Optimized Repeat of VL021 
VL023 20/01/06 5pm Optimized  
VL024 20/01/06 7pm Optimized Repeat of VL023 
VL025 23/01/06 230pm Optimized  
VL026 23/01/06 5pm Optimized Repeat of VL025 
Note: apparently missing plate ID’s relate to interim analyses undertaken for assay-
refinement purposes. 
 
Strictly speaking, only four analyses were required to estimate intra-plate and inter-
plate reliability. However, following the first set of experiments, the primers were 
redesigned (optimized): this decision was based on technical reasons and was not 
influenced by the results of the reliability analyses using the original primers (see 
section 21.2.2); the results of these first four analyses are not considered further. 
Further opportunistic analyses were also undertaken. 
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The study population for assessing the reliability of the HPV16 qPCR assay 
comprised 21 samples from 19 women. Well-plates VL021 to VL024 inclusive were 
the primary analyses undertaken to establish reliability. These analyses tested 16 
samples, with 12 women each providing one sample, and two providing two samples 
(one sample from each of two separate visits: one woman had one sample tested on 
well-plates VL021 and VL022, and another on well-plates VL023 and VL024, and 
one had both samples tested on well-plates VL023 and VL024). Well-plates VL025 
and VL026 were additional opportunistic analyses which also contributed to 
establishing the reliability of the qPCR assay. These analyses tested seven samples, 
with seven women each providing one sample. None of these samples had been 
tested before, and none of the women included had previously had other samples 
tested. 
 
22.2.1.2 Study samples and analyses undertaken for the validation of the 
HPV18 qPCR assay 
 
To determine whether the qPCR assay for measuring HPV18 viral load was reliable, 
four analyses were undertaken (table 22.2.1.2).  
 
Table 22.2.1.2. Analyses undertaken for determining the reliability of the 
qPCR assay used for measuring HPV18 viral load. 
 
Well-plate ID Analysis Primers Comments 
 Date Time   
VL012 13/12/05 12pm Optimized  
VL013 13/12/05 230pm Optimized Repeat of VL012 
VL014 14/12/05 12pm Optimized  
VL015 14/12/05 5pm Optimized Repeat of VL014 
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Well-plates VL012 to VL015 inclusive, used nine samples; on each well-plate, nine 
women each provided one sample, but one woman contributed two samples to the 
analysis. In all of these analyses, redesigned (optimized) primers were used. The 
study population for assessing the reliability of the HPV18 qPCR assay thus 
comprised 18 samples from 17 women. 
 
22.2.2 Intra-assay reliability 
 
22.2.2.1 Intra-assay reliability of the qPCR assay measuring HPV16 viral load 
 
Estimates of intraclass correlation coefficients used to measure intra-assay (within-
assay) reliability are presented in table 22.2.2.1. Using either observed Ct values, or 
observed virus copy numbers, estimates of intraclass correlation coefficients used to 
measure intra-assay reliability exceeded 0.99: this was the case whether the 
analysis included all six well-plates used in the reliability analyses, or was restricted 
to the four “definitive” well-plates; and whether assay “zeroes” were included or 
excluded. Similar results were obtained when GAPDH Ct values were analyzed. 
Most of the variability was clearly due to different samples being tested, rather than 
different wells being used to test those samples. As discussed earlier (see section 
21.4.1.1), this is not a particularly informative finding but rather a consequence of the 
approach adopted to accepting Ct values as valid. 
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Table 22.2.2.1. Estimates of the intraclass correlation coefficient used to 
measure intra-assay reliability of the qPCR assay measuring the viral load of 
HPV16.  
 
Proportion of 
Variability 
Analyses Samples Negative 
Values 
Quantity Number 
of Well-
plates 
Number of 
Measurements
Plate Sample Well
ICCa
All Viral DNA Included Ct Value 6 41 5.1% 94.6% 0.3% 0.997
All Viral DNA Excluded Ct Value 6 38 12.5% 87.0% 0.5% 0.994
Definitive Viral DNA Included Ct Value 4 27 9.8% 90.0% 0.2% 0.998
Definitive Viral DNA Excluded Ct Value 4 24 23.9% 75.6% 0.4% 0.994
Opportunistic Viral DNA Included Ct Value 2 14 0.0% 99.3% 0.7% 0.993
Opportunistic Viral DNA Excluded Ct Value 2 14 0.0% 99.3% 0.7% 0.993
         
All GAPDH Included Ct Value 6 42 8.5% 91.1% 0.4% 0.995
Definitive GAPDH Included Ct Value 4 28 0.0% 99.8% 0.2% 0.998
Opportunistic GAPDH Included Ct Value 2 14 0.0% 99.3% 0.7% 0.993
         
All Viral DNA Included Copy Number 6 41 1.3% 97.9% 0.8% 0.992
All Viral DNA Excluded Copy Number 6 38 0.0% 99.2% 0.8% 0.992
Definitive Viral DNA Included Copy Number 4 27 7.4% 91.9% 0.7% 0.993
Definitive Viral DNA Excluded Copy Number 4 24 6.8% 92.6% 0.7% 0.993
Opportunistic Viral DNA Included Copy Number 2 14 0.0% 99.1% 0.9% 0.991
Opportunistic Viral DNA Excluded Copy Number 2 14 0.0% 99.1% 0.9% 0.991
aintraclass correlation coefficient, calculated essentially as Sample/(Sample+Well) 
 
22.2.2.2 Intra-assay reliability of the qPCR assay measuring HPV18 viral load 
 
Estimates of intraclass correlation coefficients used to measure intra-assay reliability 
of the HPV18 qPCR assay are presented in table 22.2.2.2. In these analyses, all 
samples tested were qPCR-positive for HPV18. Using either observed Ct values or 
observed virus copy numbers, estimates of intraclass correlation coefficients used to 
measure intra-assay reliability exceeded 0.97: this was the case whether the 
analysis included all four well-plates used in the reliability analyses, or was restricted 
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to subsets of these well-plates; similar results were obtained when GAPDH Ct 
values were analyzed. This is not a particularly informative finding, but rather a 
consequence of the approach adopted to accepting Ct values as valid. 
 
Table 22.2.2.2. Estimates of the intraclass correlation coefficient used to 
measure the intra-assay reliability of the qPCR assay for measuring HPV18 
viral load. 
 
Proportion of 
Variability 
Analyses Samples Quantity Number 
of Plates
Number of 
Measurements
Plate Sample Well 
ICCa
All Viral DNA Ct Value 4 36 0.0% 99.6% 0.4% 0.996
VL012 and VL013 Viral DNA Ct Value 2 18 0.0% 99.5% 0.5% 0.995
VL014 and VL015 Viral DNA Ct Value 2 18 0.0% 99.6% 0.4% 0.996
         
All GAPDH Ct Value 4 36 0.0% 99.3% 0.7% 0.993
VL012 and VL013 GAPDH Ct Value 2 18 0.0% 99.5% 0.5% 0.995
VL014 and VL015 GAPDH Ct Value 2 18 0.0% 99.1% 0.9% 0.991
         
All Viral DNA 
Copy 
Number 4 36 1.1% 96.8% 2.2% 0.978
VL012 and VL013 Viral DNA 
Copy 
Number 2 18 0.0% 98.4% 1.6% 0.984
VL014 and VL015 Viral DNA 
Copy 
Number 2 18 0.0% 97.7% 2.3% 0.977
aintraclass correlation coefficient, calculated essentially as Sample/(Sample+Well) 
 
 
22.2.3 Inter-assay reliability 
 
22.2.3.1 Inter-assay reliability of the qPCR assay measuring HPV16 viral load 
 
The HPV16 viral load for each sample, measured on each of two occasions, is 
presented in table 22.2.3.1a. The median viral load in the first measurement was 
2,198 copies per 1,000 cells (range 0 to 249,628), compared with 1,849 copies per 
1,000 cells (range 0 to 172,481) in the second measurement, a decrease of 16%. 
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Sample 553.10 was excluded from analyses of inter-assay reliability since only one 
observation was available. For all but one sample (ID 138.3), there were notable 
differences between the first and second measurement of viral load. However, the 
relative differences tended to be small. The exception was the sample with ID 
1191.3, which was HPV16-qPCR-negative in the first measurement, but had a viral 
load of 935 copies per 1,000 cells in the second. Recall that a Ct value of 50 means 
“negative” for the qPCR assay for the specific type as it was used in these analyses 
(see section 21.2.5.1).  The three virus Ct values for this sample were 50, 38.11, and 
50 i.e. two qPCR-negative values and one qPCR-positive value. Given the system 
adopted for accepting Ct values as valid, for this sample the qPCR-positive value 
was excluded, meaning that it was classified as HPV16-qPCR-negative. On more 
than one occasion, the Ct value which was excluded was a value of 50 in the 
presence of two non-50 values, i.e. something appeared to have gone awry with a 
sample which was in fact qPCR-positive. Of course, if it is possible for one Ct value 
to be aberrant, it is also possible for two. If the qPCR-positive value had been 
accepted for sample 1191.3, and the qPCR-negative values excluded, this sample 
would have been scored as having 804 copies per 1,000 cells, a ratio of 0.86 relative 
to the first measurement. Nevertheless, the discrepancy in values for this sample 
have to be accepted in this analysis. 
 
Excluding the samples with IDs 1191.3 and 553.10, two samples had a different rank 
order for measurement two compared to measurement one, and vice versa; in each 
case, there was a difference of only one rank (see section 23.2 for a discussion of 
the disparity between the GP5+/GP6+ result and the qPCR result). 
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Table 22.2.3.1a. Raw data for the measurement of inter-assay reliability of the 
viral load assay for HPV16.  
 
Test 1 Test 2 IDa Visit HPV status 
(GP5+/GP6+)b
Cytologyc
Analysis Viral Load d Analysis Viral Load d
Ratio 
T2:T1e
83 3 Negative Normal VL023 16.86 VL024 10.41 0.62 
138 3 16;31 Moderate VL021 49,407.41 VL022 49,518.06 1.00 
168 4 Negative US VL023 47.31 VL024 60.28 1.27 
553 10 Negative Normal VL023 Virus Ctf VL024 0.28 - 
702 2 16 Moderate VL021 2,408.02 VL022 1,988.66 0.83 
878 1 16 US VL021 30,470.92 VL022 28,438.01 0.93 
937 3 16;18 Moderate VL021 713.70 VL022 679.63 0.95 
1191 3 Type X Normal VL021 0 VL022 934.61 - 
1191 7 Negative Moderate VL023 0 VL024 0 - 
1466 2 16 Mild VL021 75.40 VL022 60.59 0.80 
1621 3 16 Mild VL023 2,459.88 VL024 2,710.01 1.10 
1621 4 Negative Normal VL023 0.50 VL024 0.30 0.59 
1784 4 6/11;16 Normal VL021 2,447.32 VL022 2,855.84 1.17 
1832 5 Negative Normal VL023 130.65 VL024 109.78 0.84 
126 2 Negative Normal VL025 1.15 VL026 0.63 0.55 
294 2 16 Normal VL025 3,125.84 VL026 4,912.92 1.57 
426 1 16 Mild VL025 249,627.98 VL026 172,481.45 0.69 
869 2 16 Moderate VL025 6,743.14 VL026 5,067.09 0.75 
1400 1 16;33 Mild VL025 64,752.71 VL026 59,610.61 0.92 
1463 1 16 Mild VL025 2,093.30 VL026 1,848.79 0.88 
2091 1 16 Normal VL025 2,303.03 VL026 2,662.67 1.16 
aUnique identifier for a woman; bHPV DNA status according to the GP5+/GP6+ system; cSeverity of 
dyskaryosis; dCopy number per 1,000 cells; eRatio of the viral load from the second test compared 
to that from the first test; fResult excluded due to excessive variability in observed Ct values for 
HPV16. 
 
 
Estimates of intraclass correlation coefficients (ICC) used to measure inter-assay 
test-retest reliability are presented in table 22.2.3.1b. In the definitive analysis of 
inter-assay reliability, the estimate of ICC exceeded 0.99; combining results from all 
analyses yielded an ICC in excess of 0.93. In either case, inter-assay reliability is 
excellent.  
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Table 22.2.3.1b. Estimates of the intraclass correlation coefficient 
(ICC) used to measure inter-assay test-retest reliability of the 
qPCR assay measuring viral load for HPV16.  
 
Analyses Number of 
Well-plates 
Number of 
Samples 
ICC 
All 6 20 0.939 
Definitive 4 13 0.999 
Opportunistic 2 7 0.934 
 
 
22.2.3.2 Inter-assay reliability of the qPCR assay measuring HPV18 viral load 
 
The HPV18 viral load for each sample, measured on each of the two occasions, is 
presented in table 22.2.3.2a. In these analyses, all samples tested were HPV18 
qPCR-positive. The median viral load in the first measurement was 4,079 copies per 
1,000 cells (range 0.23 to 886,139), compared to 4,809 copies per 1,000 cells (range 
0.39 to 336,070) in the second measurement, an increase of 18%. For all but one 
sample (sample ID 138.3), there were notable differences between the first and 
second measurements of viral load. However, the relative differences tended to be 
small. 
 
The exception was the sample with ID 1708.2, which had a viral load of 886,139 
copies per 1,000 cells in the first measurement compared with 336,070 in the 
second; although both measurements clearly indicate a high-viral load, the second 
measurement indicates a viral load which is 62% less than that indicated by the first. 
There is no indication from the assay results as to why this discrepancy may have 
occurred. 
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Compared with their rank order in measurement two, three samples had a different 
rank order in measurement one; there was a difference of one rank for two of these 
samples, and two ranks for the other. Compared with their rank order in 
measurement one, four samples had a different rank order in measurement two; in 
each case, there was a difference of only one rank. 
 
Table 22.2.3.2a. Raw data for the measurement of inter-assay reliability of 
the qPCR assay for measuring HPV18 viral load.  
 
 Test 1 Test 2 IDa Visit HPV status 
(GP5+/GP6+)b 
Cytologyc
Analysis Viral Loadd Analysis Viral Loadd
Ratio 
T2:T1e
107 1 18 Normal VL014 350.25 VL015 304.34 0.87 
178 1 18 Mild VL012 8.74 VL013 9.74 1.11 
459 2 18 Normal VL012 9,249.61 VL013 13,635.06 1.47 
582 2 18 Moderate VL014 68,541.00 VL015 97,660.62 1.42 
652 2 18 US VL014 0.23 VL015 0.39 1.75 
698 1 18 Normal VL012 138.18 VL013 125.98 0.91 
968 1 18 Normal VL012 73.07 VL013 78.70 1.08 
974 1 18 No result VL014 5,022.00 VL015 6,304.19 1.26 
1008 2 16;18 Normal VL014 74,237.68 VL015 62,381.39 0.84 
1171 3 18 Normal VL014 27,739.75 VL015 25,840.30 0.93 
1625 1 18 Normal VL012 90.54 VL013 130.33 1.44 
1625 3 Negative Normal VL014 4,999.32 VL015 7,641.18 1.53 
1688 1 18 Normal VL012 2,370.26 VL013 2,760.10 1.16 
1695 2 18 Moderate VL012 33,528.59 VL013 36,444.69 1.09 
1708 2 16;18 Moderate VL014 886,138.92 VL015 336,069.68 0.38 
1739 2 18 Normal VL012 3,158.04 VL013 3,314.30 1.05 
1864 1 18 Normal VL012 8,128.04 VL013 7,487.90 0.92 
2000 1 18;52 Normal VL014 214.27 VL015 203.22 0.95 
aUnique identifier for a woman; bHPV DNA status according to the GP5+/GP6+ system; cSeverity 
of dyskaryosis; dCopy number per 1,000 cells; eRatio of the viral load from the second test 
compared to that from the first test. 
 
Estimates of ICC used to estimate test-retest reliability for the HPV18 qPCR assay 
are presented in table 18.4.2b. In the definitive analysis of inter-assay reliability, the 
estimate of ICC was only 0.66. This poor reliability was due to the effect of the 
sample with ID 1708.2; when this sample is excluded, all estimates of ICC exceed 
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0.94, indicating excellent inter-assay reliability. However, the result for sample 
1708.2 clearly remains a concern. 
 
Table 22.2.3.2b. Estimates of the intraclass correlation coefficient (ICC) 
used to measure inter-assay test-retest reliability of the qPCR assay for 
measuring the viral load of HPV18.  
 
Analyses Number of 
Well-plates 
Number of 
Samples 
ICC 
All 4 18 0.655 
VL012 vs VL013 2 9 0.989 
VL014 vs VL015 2 9 0.644 
    
All excluding 1708.2 4 17 0.952 
VL014 vs VL015 excluding 1708.2 2 8 0.941 
 
 
22.2.4 Viral load in replicate samples and samples tested more than once 
 
Although this section is an aside to some extent, and relies on analyses described in 
subsequent sections, it is related to the issue of repeated testing; it is also important 
in that it establishes which measurement of viral load is reported and analysed for 
the remainder of the chapter. 
 
Some women in the study population had more than one sample taken at the same 
study visit, which I refer to as replicates; and some had samples from the same 
study visit which were tested more than once. In the analysis of both HPV16 and 
HPV18, the majority of tests on replicates were concordant with respect to HPV 
status, with HPV16 results being slightly more concordant than those for HPV18. In 
the concordant positive pairs of replicates, the ratio of the largest copy number to the 
smallest ranged from 1 to 9,388 for HPV16, and 2 to 14,058 for HPV18. For both 
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types, in the replicates with discrepant results, copy number in the positive sample 
was numerically low in the majority of cases. 
 
One woman had three of her samples tested for HPV16 viral load on two occasions: 
all samples were found to have zero HPV16 viral load in all tests. Three women had 
a total of four samples which were tested for HPV18 viral load on two occasions. 
Results were in close agreement, with no discrepant results in terms of positive or 
negative status. 
 
For the remainder of this chapter, where a woman had several replicates available 
for a given visit and/or more than one test result for the same sample, the qPCR 
status and viral load at that visit was determined by the mean viral load across all 
replicates and all tests. 
 
 
 
 
Summary 
 
The primers used in the qPCR assays for measuring both HPV16 and HPV18 viral 
load were shown to be sensitive, with a linear dynamic range exceeding 109 to one 
copies; and specific, with no cross-reactivity when tested in cell lines. Using either 
observed Ct values, or observed virus copy numbers, estimates of intraclass 
correlation coefficients (ICC) used to measure intra-assay reliability of the qPCR 
assay exceeded 0.99 and 0.97 for the HPV16 and HPV18 assay, respectively; 
similar results were obtained when GAPDH Ct values were analyzed: the intra-assay 
reliability of both assays was therefore excellent. For both assays, the ICC 
measuring inter-assay reliability exceeded 0.94: the inter-assay reliability of both 
assays was therefore also excellent. The assay was now considered to be suitable 
for use in testing samples from the study population. 
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22.3 SELECTION AND IDENTIFICATION OF STUDY POPULATIONS 
 
In this section I, describe the identification of the study population for use in 
subsequent analyses. 
 
22.3.1 Intended study population for the analysis of HPV16 and HPV18 viral 
load 
 
The study population for the analysis of incident cervical HPV16 infection comprises 
all women who were HPV DNA-negative and cytologically normal in their first 
evaluable sample, and who were subsequently found to be HPV16 DNA-positive 
prior to the end of follow-up; HPV status was determined using the GP5+/GP6+ 
system, with type-specific primers for HPV16. 
 
The study population for the analysis of incident cervical HPV18 infection comprises 
all women who were HPV DNA-negative and cytologically normal in their first 
evaluable sample, and who were subsequently found to be HPV18 DNA-positive 
prior to the end of follow-up; HPV status was determined using the GP5+/GP6+ 
system, with type-specific primers for HPV18. 
 
One hundred and fifty five women fulfilled these criteria: 91 women acquired an 
incident cervical HPV16 infection, 45 acquired an incident cervical HPV18 infection, 
and 19 acquired both, at some point prior to the end of follow-up, either 
contemporaneously or otherwise. When appropriate, these three cohorts will be 
referred to as the “HPV16-only”, “HPV18-only” and “HPV16+HPV18” cohorts, 
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respectively. When combined by type, the 110 women who acquired incident 
cervical HPV16 infection during follow-up will be referred to as the “incident HPV16 
cohort”; similarly, the 64 women who acquired incident cervical HPV18 infection 
during follow-up will be referred to as the “incident HPV18 cohort”.  
 
22.3.2 Study population tested 
 
It was the intention to test all women in the incident HPV16 cohort for HPV16 viral 
load, and all women in the incident HPV18 cohort for HPV18 viral load. To 
accomplish this, for practical reasons rather than any other, women in the study 
population were divided into subsets for testing.  
 
1) First, women with a “complete” set of cervical cytological samples available would 
be tested for HPV16 and/or HPV18 viral load. These were women for whom samples 
from consecutive visits 1 to n (n>1) were available, with no missing samples within 
the sequence. 
  
2) Second, women with an “incomplete” set of cervical cytological samples available 
would be tested for HPV viral load.  
 
Given that all women would eventually be tested, this artificial division should have 
been of little consequence. As described in the methods section, prior to testing a 
study sample for viral load, all DNA in that sample was extracted and stored in 
appropriate conditions (see section 21.2.1). In the first instance, DNA was extracted 
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from samples from women in subset 1, which were then tested for viral load; and 
then DNA was extracted from women in subset 2, and these were then tested for 
viral load 
 
The finding that some samples which were negative for HPV DNA of a specific type 
(or even of any type) using the GP5+/GP6+ system were nevertheless positive for 
that type according to the qPCR assay, was unexpected (see section 23.2). This 
implied that the study cohorts were potentially not as well-defined as anticipated; and 
that samples from women in the HPV16 cohort would also have to be tested for 
HPV18 viral load, and vice versa. At a stroke, this doubled the amount of work which 
it had been anticipated would be required for this assay. Although the qPCR assay 
was not difficult to perform per se, and comparatively inexpensive, the unanticipated 
requirement to test all samples for both HPV types was not budgeted for. The assay 
was also time consuming, and so had substantial opportunity costs associated with 
it. Due to competing priorities within the study, the decision was therefore made to 
stop the testing of samples when women from the “complete samples” group had 
been tested. At that point, sufficient data was available to draw conclusions about 
the utility of a measurement of HPV viral load. 
 
Table 22.3.2 describes the relationship between the intended study population and 
the population actually tested. All but one of the women in the HPV16+HPV18 cohort 
who could have been tested, were tested, compared with 86% of the women in the 
HPV18-only cohort, and 43% of women in the HPV16-only cohort. 
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Table 22.3.2. Relationship between the study population it was intended to test 
and the population actually tested for HPV16 and/or HPV18 viral load in the 
incident HPV16 or HPV18 cohorts. Numbers in the table are numbers of women. 
 
Cohort Population 
HPV16-only HPV18-only HPV16+HPV18 
Total 
Intended study 
population 91 45 19 155 
Number with cytological 
samples available 90 36 16 142 
Population actually 
tested 39 31 15 85 
 
 
The derivation of the final study population from the full cohort of 2,011 women 
recruited is shown in figure 22.3.2. The final study population for the analysis of 
HPV16 and HPV18 viral load comprised 85 women: 67 could contribute to the 
analysis of HPV16 viral load; (a different) 67 could contribute to the analysis of 
HPV18; and the 51 women common to both groups could contribute to the analysis 
of both types. For ease of reference, in this subsection, the 67 women will be 
referred to as the HPV16 cohort, the other 67 women the HPV18 cohort, and the 51 
women as the HPV16+HPV18 cohort. 
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Figure 22.3.2. Derivation of the final study population tested for 
HPV16 and/or HPV18 viral load from the cohort of all 2,011 
women recruited to the study. Numbers in the figure are numbers of 
women. 
 
 
aSamples tested for HPV16 were not necessarily tested for HPV18, and vice versa. 
1,075 
HPV negative and cytologically normal at study entry 
and have further follow-up 
155 
Acquire incident GP5+/GP6+ cervical HPV16 (n=91) 
infection, HPV18 (n=45), or both (n=19) during follow-up 
142 Women with cytological samples available 
49
18
18
85 
Samples tested for HPV16 and HPV18 
viral loada 
Samples tested for HPV16 viral load only 
Samples tested for HPV18 viral load only 
At least one cytological sample tested for HPV16 or HPV18 
viral load, or both 
Women with a “complete” set of cytological samples ? 
Total number of women recruited into the study 2,011 
 
 
 
22.3.2.1 Follow-up of the study population tested 
 
The availability and qPCR testing history of cervical cytological samples from each 
study visit for each woman in the study population are illustrated in table 22.3.2.1a. 
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For convenience of presentation, this table has been separated according to cohort. 
Some examples to illustrate interpretation may be helpful. 
 
Note the deliberate choice of colours to aid interpretation: HPV16 testing is indicated 
by a blue cell, HPV18 testing by a yellow cell. When blue and yellow are mixed the 
result is green: hence a sample tested for both HPV16 and HPV18 is indicated by a 
green cell. 
 
Example 1. The woman with study number (ID) 511 belongs to the HPV16-only 
cohort, and so appears in part one of the table. She made nine visits to the study: 
the maximum number of visits made by any woman was 16, hence this woman has 
her last seven cells “blacked out” (16-9=7). For eight of her visits, at least one 
cytological sample was available for testing; for the remaining visit (her last), no 
sample was ever taken, to the best of our knowledge. For her third visit, there were 
two samples available. This woman was unusual in that samples from visits 1, 2, 3, 5 
and 6 were all tested for both HPV16 and HPV18 viral load; however, the sample 
from visit 5 was tested for HPV16 only, whereas the samples from visits 7 and 8 
were tested for HPV18 viral load only. 
 
Example 2. The woman with study number (ID) 1413 belongs to the HPV16+HPV18 
cohort, and so appears in part three of the table. She made seven visits to the study 
and had a single cytological sample available for testing at all of her visits. All of her 
samples were tested for both HPV16 and HPV18 viral load. However, her samples 
from visits 2, 3 and 4, were each tested for HPV16 twice, but only once for HPV18. 
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Example 3. The woman with study number (ID) 253 belongs to the HPV16-only 
cohort and made 11 visits to the study. She had a single cytological sample available 
for testing from nine of her visits, but two samples were available for visit 8; the 
sample from visit 7 was missing. The samples from visits 1 to 6 inclusive were tested 
for HPV16 viral load only; all of her remaining samples were tested for both HPV16 
and HPV18 viral load. Although she had two samples available at visit 8, testing was 
“discrepant” for the two types: one sample was tested for both types, but the other 
was tested for HPV16 only. The same occurred for study number (ID) 1011 at visit 7. 
In contrast, for study number (ID) 1814 at visit 10, both samples were tested for both 
HPV types, but one was tested twice for HPV18 but only once for HPV16; the single 
sample at visit 8 for this woman was also tested twice for HPV18, but only once for 
HPV16. 
 
Example 4. The woman with study number (ID) 27 belongs to the HPV18-only cohort 
and made 14 visits to the study. She had a single cytological sample available for 
testing from 13 of her visits, but no sample was taken at visit 2. The samples from 
visits 6 to 14 inclusive were tested for HPV18 viral load only. However, although 
samples from visits 1, 3, 4 and 5 were available, they were not tested since there 
was insufficient DNA remaining in these samples. 
  
Note: It is not always possible to distinguish a visit for which the cytological sample 
was missing, i.e. had been lost, from a visit at which no sample was ever taken. If a 
GP5+/GP6+ result was available, but the sample could not be found when an 
attempt was made to test it for viral load, then this sample was unequivocally 
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missing. However, at some visits no attempt was made to collect a cytological 
sample for HPV DNA testing. Typically, these were visits at the end of follow-up, 
after the diagnosis of high-grade CIN for example, or during the final follow-up phase 
of women with cytological abnormalities who were in the process of being 
“discharged” from the study. But this practice may also have occurred at interim 
visits. In a few instances, a sample for which no GP5+/GP6+ result was available 
was, however, located and tested for viral load (e.g. 69.14, 69.16, 128.1, 1011.5). 
 
The median number of study visits was 8 (range 2 to 16). The median number of 
study visits for which at least one cytological sample was available was 7 (range 2 to 
16), with four women providing only two samples and 17 providing at least 10. The 
median number of study visits for which no sample was available was 0 (range 0 to 
6): 47 women had a “complete” set of samples available for testing. Fifty four women 
had a single sample tested from each of their visits, whereas 26 women had two 
samples tested from one of their visits, and five had two samples tested from  two 
visits. 
 
Table 22.3.2.1b summarises the viral load testing status for all women in the study 
population. Forty-nine women had at least one sample tested for both HPV16 and 
HPV18 viral load, compared with 18 whose samples were only tested for HPV16, 
and 18 whose samples were only tested for HPV18. 
  
 
 
 
Figure 22.3.2.1a (Part 1-The HPV16-only cohort). Availability and qPCR testing 
status of cervical cytological samples from each study visit for each woman in the 
study population. ID=study number; C=Cohort; V=Number of study visits; N=number of visits with no sample; S=Number of 
visits for which at least one cytological sample is available; R=Number of visits for which two cytological samples are available; 
T=Total number of times the sample was tested; X=Number of samples tested twice for 16 and 18, separated by a dash; Blue=Tested 
for HPV16 viral load only; Yellow=Tested for HPV18 viral load only; Green=Tested for HPV16 and HPV18 viral load; Red=Not tested; 
Grey=Sample missing; Diagonal lines on white background=No sample taken; Black=End of full follow-up (a diagonal line in a 
coloured cell indicates a sample taken after first diagnosis of high-grade CIN and therefore after the formal end of follow-up); 2S=Two 
samples available for this visit; Tn/m=sample tested for HPV16[HPV18] n[m] times; E=Excised i.e. treated for high-grade CIN. 
Visit Number ID C V N S R T X 
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16
13 0                           18 16 13 0 13 0       
69 16 16 0 16 0 16 0                                 
73 16 0 3 0 3 0                           3       
150 16 12 2 10 0 10 0                               E 
244 16 9 1 8 0 8 0                                 
11 0             2S/TD             253 16 11 1 10 1       
287 16 4 0 4 0 4 0                                 
305 16 0 2 0 2 0                           2       
320 16 4 0 4 0 4 0                                 
0       E                 16 5 1 4 0 4     330     
345 16 7 7 0 7 0                             0     
355 16 4 0 4 1 5 0     2S                           
408 16 10 9 1 10 0                             1 2S   
433 16 6 0 6 0 6 0                                 
508 16 5 5 0 5 0                             0     
511 16 9 1 8 1 9 0   2S                             
515 16 6 0 6 0 6 0                                 
519 16 16 2 14 1 15 0                               2S
545 16 4 0 4 0 4 0                                 
556 16 5 0 5 0 5 0                                 
590 16 8 0 8 0 8 0                                 
622 16 5 0 5 1 6 0       2S                         
761 16 2 0 2 0 2 0                                 
820 16 9 4 5 0 5 0                                 
910 16 4 0 4 0 4 0                                 
914 16 2 0 2 0 2 0                                 
928 16 12 0 12 0 12 0                                 
932 16 7 0 7 0 7 0                                 
941 16 8 1 7 1 8 0     2S                           
981 16 2 0 2 0 2 0                                 
1005 16 7 3 4 0 4 0         E                       
1011 16 11 2 9 1 10 0             2S/TD                   
1066 16 4 0 4 0 4 0                                 
1115 16 4 0 4 0 4 0                                 
1181 16 14 2 12 1 13 0                     2S           
1205 16 5 0 5 0 5 0                                 
1231 16 8 0 8 0 8 0                                 
1365 16 4 1 3 0 3 0                                 
1367 16 12 1 11 2 13 0                   2S 2S           
 
 
Figure 22.3.2.1a (Part 2-The HPV18-only cohort). Availability and qPCR testing 
status of cervical cytological samples from each study visit for each woman in the 
study population. ID=study number; C=Cohort; V=Number of study visits; N=number of visits with no sample; S=Number of 
visits for which at least one cytological sample is available; R=Number of visits for which two cytological samples are available; T=Total 
number of times the sample was tested; X=Number of samples tested twice for 16 and 18, separated by a dash; Blue=Tested for 
HPV16 viral load only; Yellow=Tested for HPV18 viral load only; Green=Tested for HPV16 and HPV18 viral load; Red=Not tested; 
Grey=Sample missing; Diagonal lines on white background=No sample taken; Black=End of full follow-up (a diagonal line in a coloured 
cell indicates a sample taken after first diagnosis of high-grade CIN and therefore after the formal end of follow-up); 2S=Two samples 
available for this visit; Tn/m=sample tested for HPV16[HPV18] n[m] times; E=Excised i.e. treated for high-grade CIN. 
 
Visit Number ID C V N S R T X 
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16
27 18 14 5 9 0 9 0                                 
29 18 12 1 11 0 11 0                                 
43 18 10 0 10 0 10 0                                 
49 18 8 2 6 1 7 0     2S                           
292 18 16 2 14 1 15 0                               2S
381 18 12 1 11 1 12 0     2S                           
406 18 6 0 6 0 6 0                                 
446 18 8 1 7 1 8 0             2S                   
490 18 9 1 8 2 10 0     2S       2S                   
524 18 8 0 8 1 9 0       2S                         
561 18 3 0 3 1 4 0   2S                             
577 18 4 0 4 0 4 0                                 
692 18 8 0 8 0 8 0                                 
739 18 5 0 5 0 5 0                                 
744 18 8 1 7 1 8 0     2S                           
825 18 4 0 4 1 5 0   2S                             
905 18 8 1 7 0 7 0                                 
938 18 13 6 7 1 8 0     2S                           
1016 18 8 0 8 0 8 0                                 
1067 18 7 1 6 1 7 0     2S                           
1086 18 7 1 6 0 6 0                                 
1276 18 4 0 4 0 4 0                                 
1278 18 6 0 6 0 6 0                                 
1296 18 9 0 9 0 9 0                                 
1430 18 9 1 8 1 9 0     2S                           
1559 18 5 0 5 0 5 0                                 
1613 18 5 0 5 0 5 0                                 
1629 18 9 1 8 1 9 0               2S                 
1665 18 6 0 6 0 6 0                                 
1732 18 3 0 3 0 3 0                                 
1814 18 12 3 9 1 10 0-2               T1/2   2S/TD E            
 
 
 
 
 
Figure 22.3.2.1a (Part 3-The HPV16+HPV18 cohort). Availability and qPCR testing 
status of cervical cytological samples from each study visit for each woman in the 
study population. ID=study number; C=Cohort; V=Number of study visits; N=number of visits with no sample; S=Number of 
visits for which at least one cytological sample is available; R=Number of visits for which two cytological samples are available; T=Total 
number of times the sample was tested; X=Number of samples tested twice for 16 and 18, separated by a dash; Blue=Tested for HPV16 
viral load only; Yellow=Tested for HPV18 viral load only; Green=Tested for HPV16 and HPV18 viral load; Red=Not tested; Grey=Sample 
missing; Diagonal lines on white background=No sample taken; Black=End of full follow-up (a diagonal line in a coloured cell indicates a 
sample taken after first diagnosis of high-grade CIN and therefore after the formal end of follow-up); 2S=Two samples available for this 
visit; Tn/m=sample tested for HPV16[HPV18] n[m] times; E=Excised i.e. treated for high-grade CIN. 
 
Visit Number ID C V N S R T X 
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16
2 16+18 10 2 8 0 8 0                                 
92 16+18 5 1 4 0 4 0                                 
118 16+18 9 1 8 1 9 0 2S                               
128 16+18 16 3 13 0 13 0                                 
147 16+18 11 0 11 1 12 0-1     2S         T1/2                 
240 16+18 7 1 6 2 8 0   2S     2S                       
247 16+18 9 0 9 0 9 0                                 
350 16+18 15 4 11 1 12 0                       2S         
393 16+18 7 2 5 0 5 0         E                       
1268 16+18 9 0 9 1 10 0 2S                               
1413 16+18 7 0 7 0 7 3-0   T2/1 T2/1 T2/1                         
1512 16+18 12 2 10 2 12 0                 2S     2S         
1551 16+18 12 1 11 2 13 0                   2S   2S         
1803 16+18 5 0 5 0 5 0                                 
1913 16+18 5 0 5 0 5 0                                 
 
Table 22.3.2.1b. Summary of the qPCR testing status for all women in 
the study population according to GP5+/GP6+ cohort. 
 
 HPV16-
only 
HPV18-
only 
HPV16+ 
HPV18 
Total
Number tested 39 31 15 85 
     
Number of women with all samples tested for: 
HPV16 and HPV18 15 10 15 40 
HPV16 only 17 0 0 17 
HPV18 only 1 17a 0 18 
     
Number of women with some samples tested for both HPV16 and 
HPV18, with others tested for: 
HPV16 only 4 2 0 6 
HPV18 only 0 2 0 2 
HPV16 and HPV18 but not 
both 
2 0 0 2 
aIncludes woman with ID 27 for whom not all available samples were tested 
 
 
Table 22.3.2.1c summarises the qPCR testing history of women with respect to 
cytological samples taken at each visit. During the course of making a total of 664 
visits, the 85 women in the study population provided at least one sample for viral 
load testing on 600 of these visits, with samples from four of these visits (all from the 
woman with ID 27) not being tested for viral load. 
 
Table 22.3.2.1c. Summary of the qPCR testing history of cytological samples 
taken at each visit according to GP5+/GP6+ cohort. 
 
Cohort Total 
number 
of visits 
Number of visits with at least one 
sample tested for viral load:  
Number of visits with:  
  HPV16 and 
HPV18 
HPV16 
only 
HPV18 
only 
Total Samples 
not tested 
All samples 
missing 
No sample 
taken 
HPV16-only 279 136 114 6 256 0 3 20 
HPV18-only 246 98 12 108 218 4 12 12 
HPV16+HPV18 139 122 0 0 122 0 5 12 
Total 664 356 126 114 596 4 20 44 
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Summary 
 
Eighty-five women who first tested positive for HPV16, or HPV18, or both, using 
GP5+/GP6+ primers contributed samples to this analysis. Of these 39 women had 
tested positive during follow-up for HPV16 but not HPV18, 31 for HPV18 but not for 
HPV16, and 15 for both HPV16 and HPV18, either in the same sample or at different 
follow-up visits. Sixty-seven and 67 women had at least one sample tested for 
HPV16 or HPV18 viral load, respectively, with 51 women common to both groups. 
During the course of making a total of 664 visits, the 85 women in the study 
population provided at least one sample for viral load testing on 600 of these visits.  
 
 
 
22.4 HPV TYPE AND THE DISTRIBUTION OF HPV VIRAL LOAD 
 
22.4.1 HPV type and the distribution of HPV viral load in cervical samples 
which tested positive for HPV16 by qPCR 
 
Sixty seven women had at least one cervical sample tested for HPV16 viral load; 
these samples were obtained during the course of making a total of 482 study visits. 
The median number of visits for which a woman had at least one sample tested for 
HPV16 viral load was 7 (range 2 to 16). 
 
It is possible for a sample to be positive by qPCR, but for the viral load in that 
sample to be unevaluable i.e. it is not possible to obtain a numerical measurement of 
copy number. Results from six and two visits were non-evaluable for HPV16 viral 
load due to excessive variability in virus and GAPDH Ct values, respectively; and 
results from 16 visits were non-evaluable due to GAPDH failures (see section 
21.2.6.1 and section 21.2.7 point 2). Among the results for the remaining 458 study 
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visits, 251 (52%) from 64 women had a non-zero HPV16 viral load; and 207 (48%) 
from 54 women had a HPV16 viral load of zero. 
 
The median number of visits per woman for which an evaluable measurement of 
HPV16 viral load was available was 7 (range 2 to 15). The median number of visits 
per woman for which a non-zero measurement of HPV16 viral load was obtained 
was 3 (range 0 to 10). The distribution of HPV16 viral load in study samples which 
tested qPCR-positive for HPV16, and which had evaluable results, is shown in tables 
22.4.1a and 22.4.1b. 
 
In samples which were found to test qPCR-positive for HPV16, the median HPV16 
viral load was 41 copies per 1,000 cells. Eight (3%) of the qPCR HPV16-positive 
samples were found to have a HPV16 viral load in excess of 1 million copies per 
1,000 cells; four women had one such sample, and one woman had three taken at 
consecutive visits with intervals of 10 and three months between visits. Forty seven 
(19%) of the HPV16-qPCR-positive samples were found to have a HPV16 viral load 
of less than 1 copy per 1,000 cells, with the smallest viral load observed being 7 
copies per million cells. Twenty eight women had at least one such “weak-positive” 
result: 15 had one, seven had two, and six had three; for four women, all of their 
positive results were weak-positives. 
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Table 22.4.1a. The distribution of HPV16 viral load 
(expressed as copy number per 1,000 cells) in all cervical 
cytological samples with evaluable HPV16 viral loads and 
which were HPV16-qPCR-positive. 
 
HPV16 Viral Loada Number of samples 
  n % 
(0,1) 47 18.7 
[1,100) 92 36.7 
[100,1000) 34 13.5 
[1000,1000000) 71 28.3 
1,000,000+ 7 2.8 
Total 251 100.0 
a[x, y) is a mathematical convention indicating that viral load is greater than 
or equal to x, but less than y 
 
 
Table 22.4.1b. The distribution of HPV16 viral load (expressed as copy 
number per 1,000 cells) in cervical cytological samples with evaluable 
HPV16 viral loads according to the qPCR system. N is the number of evaluable 
samples; W is the number of “weak positive” samples, defined as samples with a non-zero 
viral load of less than 1 copy per 1,000 cells. 
 
HPV16 Viral Load Group Number of 
Women N W Median Min Max 
HPV16-
qPCR-positive 64 251 47 41 0.01 420,953,588 
 
 
22.4.2 HPV type and the distribution of HPV viral load in cervical samples 
which tested positive for HPV18 by qPCR 
 
Sixty-seven women had at least one sample tested for HPV18 viral load; these 
samples were obtained during the course of making a total of 470 study visits. The 
median number of visits for which a woman had at least one sample tested for 
HPV18 viral load was 7 (range 2 to 14). 
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Results from nine and one visits were non-evaluable for HPV18 viral load due to 
excessive variability in virus and GAPDH Ct values, respectively; and results from 16 
visits were non-evaluable due to GAPDH failures. Among the results for the 
remaining 444 study visits, 235 (53%) from 60 women had a non-zero HPV18 viral 
load; and 209 (47%) from 55 women tested qPCR-negative for HPV18. 
 
The median number of visits per woman for which an evaluable measurement of 
HPV18 viral load was available was 6 (range 2 to 14). The median number of visits 
per woman at which a non-zero measurement of HPV18 viral load was obtained was 
1 (range 0 to 14). The distribution of HPV18 viral load in study samples which tested 
qPCR-positive for HPV18 and which had evaluable results, is shown in tables 
22.4.2a and 22.4.2b. 
 
In samples which were found to test qPCR-positive for HPV18, the median HPV18 
viral load was 4 copies per 1,000 cells. Two (0.9%) of the HPV18-qPCR-positive 
samples were found to have a HPV18 viral load in excess of 1 million copies per 
1,000 cells; two women had one such sample each. Seventy-three (31%) of the 
qPCR HPV18-positive samples were found to have a HPV18 viral load of less than 1 
copy per 1,000 cells, with the smallest viral load observed being 0.1 copies per 
million cells. Forty women had at least one such “weak-positive” result: 20 had one, 
eight had two, 11 had three, and one had four; for 14 women, all of their positive 
results were weak-positives. 
 
516 
 
Table 22.4.2a. The distribution of HPV18 viral load 
(expressed as copy number per 1,000 cells) in all cervical 
cytological samples with evaluable HPV18 viral loads and 
which were HPV18-qPCR-positive. 
 
HPV18 Viral Loada Number of samples 
  n % 
(0,1) 73 31.1 
[1,100) 97 41.3 
[100,1000) 29 12.3 
[1000,1000000) 34 14.5 
1,000,000+ 2 0.9 
Total 235 100.0 
a[x, y) is a mathematical convention indicating that viral load is 
greater than or equal to x, but less than y 
 
 
Table 22.4.2b. The distribution of HPV18 viral load (expressed as copy 
number per 1,000 cells) in all cervical cytological samples with evaluable 
HPV18 viral loads according to the qPCR system. N is the number of evaluable 
samples; W is the number of “weak positive” samples, defined as samples with a non-zero 
viral load of less than 1 copy per 1,000 cells. 
 
HPV18 Viral Load Group Number 
of 
Women
N W Median Min Max 
HPV18-qPCR-
positive 60 235 73 4 0.0001 25,564,280 
 
 
22.4.3 HPV type and the distribution of HPV viral load in cervical samples 
according to both HPV16 and HPV18 status 
 
The study population for this analysis is restricted to samples which were qPCR-
evaluable for both HPV16 and HPV18. This is to ensure that all results relate to the 
same study population, allowing direct comparisons to be made.  
 
Forty-nine women had at least one sample tested for both HPV16 and HPV18 viral 
load; these samples were obtained from a total of 356 study visits. The median 
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number of visits per woman for which an evaluable qPCR result was available for 
both HPV16 and HPV18 was 7 (range 2 to 14). Results from five and one visits were 
non-evaluable for HPV16 viral load only due to excessive variability in virus and 
GAPDH Ct values, respectively; the corresponding numbers for the HPV18 analysis 
are six and zero. The median number of visits per woman for which an evaluable 
measurement of both HPV16 and HPV18 viral load was available was 7 (range 2 to 
14). Forty-nine women had 328 study visits for which an evaluable measurement of 
both HPV16 and HPV18 viral load was available. 
 
The distribution of HPV16 and HPV18 viral load in all cervical cytological samples for 
which both an evaluable HPV16 and HPV18 viral load was available is shown in 
table 22.4.3. HPV16 viral load in HPV16-qPCR-positive samples which were also 
HPV18-qPCR-positive was slightly lower than in HPV16-qPCR-positive samples 
which were HPV18-qPCR-negative (45 compared to 69 copies per 1,000), but the 
difference was slight. Differences in HPV18 viral load according to HPV16 qPCR 
status were trivial, but the median viral loads were also very small. 
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Table 22.4.3. The distribution of HPV16 and HPV18 viral load (expressed as copies 
per 1,000 cells) in all cervical cytological samples for which both evaluable HPV16 
and HPV18 viral loads were available. Rows in the table are not mutually exclusive. For example, 
the 166 samples which were HPV16 qPCR-positive (labelled “HPV16+ve”) combines two groups of 
samples: the 60 which were also HPV18 qPCR-positive, and the 106 which were HPV18 qPCR-negative. 
Viral Load (Copies per 1,000 cells) 
HPV16 HPV18 Sample Classificationa 
Number 
of 
women
Number 
of 
samples Median Min Max Median Min Max 
HPV16+ve; HPV18-ve 32 106 69 0.01 4,803,266 0 0 0
HPV16-ve; HPV18+ve 22 77 0 0 0 3 0.0001 25,564,280
HPV16+ve; HPV18+ve 34 60 45 0.02 420,953,588 2 0.0001 236,315
HPV16+ve 45 166 52 <1 420,953,588 0 0 236,315
HPV18+ve 39 137 0 0 420,953,588 3 <1 25,564,280
HPV16-ve 40 162 0 0 0 0 0 25,564,280
HPV18-ve 49 191 0.27 0 4,803,266 0 0 0
Total 49 328 0.03 0 420,953,588 0 0 25,564,280
aAccording to qPCR 
 
 
 
 
Summary 
 
In qPCR-positive samples, the median HPV16 and HPV18 viral loads were 
numerically low, but were greater for HPV16 than for HPV18. In samples for which 
both an evaluable HPV16 and HPV18 viral load was available, viral load for one type 
did not differ greatly according to the presence or absence of the other type. 
 
 
 
22.5 CERVICAL CYTOLOGICAL STATUS AND THE DISTRIBUTION OF HPV 
VIRAL LOAD 
 
The study population for this analysis comprises all visits with evaluable viral load 
results for both HPV16 and HPV18, and for which an evaluable cytological smear 
result was available. 
 
Forty-nine women had at least one sample tested for both HPV16 and HPV18 viral 
load, obtained from a total of 356 study visits. Results from 45 visits were excluded: 
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27 due to GAPDH failures, or excessive variability in the Ct values for either GAPDH 
or HPV, in the HPV16 and/or the HPV18 qPCR assays; 17 due to the cytological 
smear result being missing, or the smear being unreadable; and one due to both 
reasons. The final study population for this analysis thus comprises evaluable viral 
load and cytological results from 311 study visits made by 49 women. 
 
22.5.1 Cytologically normal cervical smears 
 
Forty-eight women had a total of 224 cytologically normal cervical smears with 
evaluable qPCR results for both HPV16 and HPV18 in the corresponding virological 
sample. The median number of normal cervical smears per woman was 5 (range 0 
to 10). One woman contributed no cytologically normal cervical smears to the 
analysis since qPCR results were not evaluable in the corresponding virological 
sample.  
 
The distribution of HPV16 and HPV18 viral load in all cytologically normal cervical 
smears for which both evaluable HPV16 and HPV18 viral loads were available, is 
shown in table 22.5.1. The median viral load in cytologically normal cervical smears 
was zero, for both HPV16 and HPV18. However, clearly some women had 
substantial HPV16 or HPV18 viral loads at the same time as they had no detectable 
cervical cytological abnormality. Viral load for one of the HPV types did not vary 
according to the presence or absence of the other type. 
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Table 22.5.1. The distribution of HPV16 and HPV18 viral load (expressed as 
copies per 1,000 cells) in all cytologically normal cervical smears for which both 
evaluable HPV16 and HPV18 viral loads were available. Rows in the table are not 
mutually exclusive. For example, the 89 samples which were HPV18 qPCR-positive comprise two 
groups of samples: the 35 which were also HPV16 qPCR-positive, and the 54 which were HPV16 qPCR-
negative. 
Viral Load (Copies per 1,000 cells) 
HPV16 HPV18 Sample Classificationa Women Samples Median Min Max Median Min Max 
HPV16+ve; HPV18-ve 27 66 5 0.01 1,341,411 0 0 0
HPV16-ve; HPV18+ve 19 54 0 0 0 1 0.0001 25,564,280
HPV16+ve; HPV18+ve 26 35 4 0.02 5,482 1 0.0006 85,024
HPV16+ve 41 101 5 0.01 1,341,411 0 0 85,024
HPV18+ve 34 89 0 0 5,482 1 0.0001 25,564,280
HPV16-ve 38 123 0 0 0 0 0 25,564,280
HPV18-ve 40 135 0 0 1,341,411 0 0 0
Total 48 224 0 0 1,341,411 0 0 25,564,280
aAccording to qPCR 
 
 
22.5.2 Cytologically abnormal cervical smears 
 
Thirty women had a total of 87 cytologically abnormal cervical smears with evaluable 
qPCR results for both HPV16 and HPV18 in the corresponding virological sample. 
The median number of abnormal cervical smears per woman was 3 (range 1 to 7). 
The number of cervical smears reported as containing borderline nuclear 
abnormalities (BNA) only, mild dyskaryosis, moderate dyskaryosis, or severe 
dyskaryosis, were 36 (41%), 47 (54%), 3 (3%) and 1 (1%), respectively. 
 
The distribution of HPV16 and HPV18 viral load in all cytologically abnormal cervical 
smears for which both evaluable HPV16 and HPV18 viral loads were available, by 
severity of abnormality, is shown in table 22.5.2. 
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The median HPV16 viral load in all cytologically abnormal cervical smears was 74 
copies per 1,000 cells, compared to 0 for cytologically normal cervical smears. In 
smears with a non-zero HPV16 viral load, the median HPV16 viral load was 
substantially higher when cytological abnormalities were present (2,134 copies per 
1,000 cells) than when they were not (5 copies per 1,000 cells). HPV16 viral load 
increased with increasing severity of cervical cytological abnormality, within the 
limited range available in this analysis. In all abnormal cervical smears combined, 
HPV16 viral load did not vary according to the presence or absence of HPV18 in 
these smears; however, in cervical smears containing at worst BNA, HPV16 viral 
load was higher in the absence of HPV18 than when it was present; the reverse was 
true in cervical smears containing at worst mild dyskaryosis. In both cases, the 
number of samples in the analysis was small. 
 
The median HPV18 viral load in all cytologically abnormal cervical smears was zero, 
as it was in cytologically normal smears. However, the greatest HPV18 viral load 
observed in cytologically abnormal smears was considerably less than that seen in 
cytologically normal smears. In smears with a non-zero HPV18 viral load, the 
median HPV18 viral load was substantially higher when cytological abnormalities 
were present (376 copies per 1,000 cells) than when they were not (1 copy per 
1,000 cells), a much smaller difference than for HPV16. In contrast to HPV16, 
HPV18 viral load decreased with increasing severity of cervical cytological 
abnormality, although the numbers of samples available in these analyses were 
clearly small. In all abnormal cervical smears combined, and in smears containing at 
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worst BNA, HPV18 viral load was greater in the absence of HPV16 than in its 
presence; the reverse was true in smears containing at worst mild dyskaryosis. 
 
Table 22.5.2. The distribution of HPV16 and HPV18 viral load in all cytologically 
abnormal cervical smears for which both evaluable HPV16 and HPV18 viral 
loads were available, by severity of abnormality. Note that in this table, for example, the 
42 cytologically abnormal cervical smears which were HPV18 qPCR-positive combine two groups of 
smears: the 22 which were also HPV16 qPCR-positive, and the 20 which were HPV16 qPCR-
negative. 
Viral Load (Copies per 1,000 cells) 
HPV16 HPV18 Sample Classificationa 
Number 
of 
women 
Number 
of 
samples Median Min Max Median Min Max 
Cytology abnormal                 
HPV16+ve; HPV18-ve 18 38 2,134 0.6 4,803,266 0 0 0
HPV16-ve; HPV18+ve 9 20 0 0 0 599 0.9 332,323
HPV16+ve; HPV18+ve 19 22 1,533 0.2 420,953,588 39 0.02 236,315
HPV16-ve; HPV18-ve 5 7 0 0 0 0 0 0
HPV16+ve 27 60 2,134 0.2 420,953,588 0 0 236,315
HPV18+ve 20 42 2 0 420,953,588 376 0.02 332,323
HPV16-ve 13 27 0 0 0 17 0 332,323
HPV18-ve 20 45 748 0 4,803,266 0 0 0
Total 30 87 74 0 420,953,588 0 0 332,323
                  
Cytology BNA                 
HPV16+ve; HPV18-ve 10 12 304 0.6 78,795 0 0 0
HPV16-ve; HPV18+ve 7 12 0 0 0 837 0.9 144,188
HPV16+ve; HPV18+ve 8 9 47 5 48,806 11 0.03 236,315
HPV16+ve 15 21 123 0.6 78,795 0 0 236,315
HPV18+ve 13 21 0 0 48,806 693 0.03 236,315
HPV16-ve 10 15 0 0 0 505 0 144,188
HPV18-ve 11 15 166 0 78,795 0 0 0
Total 20 36 8 0 78,795 0.7 0 236,315
                  
Cytology Mild 
Dyskaryosis                 
HPV16+ve; HPV18-ve 13 22 7,142 1 4,803,266 0 0 0
HPV16-ve; HPV18+ve 4 8 0 0 0 12 2 332,323
HPV16+ve; HPV18+ve 11 13 9,530 0.2 420,953,588 42 0.02 31,265
HPV16+ve 21 35 9,530 0.2 420,953,588 0 0 31,265
HPV18+ve 12 21 391 0 420,953,588 37 0.02 332,323
HPV16-ve 6 12 0 0 0 5 0 332,323
HPV18-ve 14 26 1,668 0 4,803,266 0 0 0
Total 23 47 748 0 420,953,588 0 0 332,323
aAccording to qPCR 
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Summary 
 
The median viral load in cytologically normal cervical smears was zero, for both 
HPV16 and HPV18, but with some substantial viral loads measured for both types. 
In abnormal cervical smears, the median HPV16 viral load was 74 copies per 1,000 
cells, compared to zero for HPV18. For both HPV types, cervical smears with non-
zero viral loads had substantially higher viral loads when cytological abnormalities 
were present than when they were not. HPV16, but not HPV18, viral load increased 
with increasing severity of cervical cytological abnormality. In normal cervical 
smears, viral load for one HPV type (HPV16 or HPV18) did not vary according to the 
presence or absence of the other type. In cervical smears containing at worst BNA, 
viral load of either HPV type was higher in the absence of the other type than when it 
was present; the reverse was true in smears containing at worst mild dyskaryosis. 
 
 
 
22.6 CHANGES IN HPV VIRAL LOAD OVER TIME 
 
Data is available from 85 women with incident cervical (GP5+/GP6+) HPV16 or 
HPV18 cervical infections with which to describe how viral load changes over time. 
Typically, the first stage in a longitudinal analysis is to model and summarise these 
changes. The aim of statistical modelling in this situation, as in others, is to capture 
the important features of the underlying process, without being unduly influenced by 
irrelevant fluctuations in measurements. If this can be done, the data will be reduced 
from a large number of individual viral load profiles, to a manageable set of 
parameters describing key aspects of how viral load changes over time. 
 
I present changes over time in HPV16 and HPV18 viral load for all women tested for 
HPV16 or HPV18 viral load, or both in figure 22.6. For ease of comparison, all 
figures are plotted on the same time scale (x-axis) and viral load (y-axis) scales. In 
each case, time is measured from the date of the first evaluable smear. For aesthetic 
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reasons, and to avoid giving prominence to very small viral loads, all samples with a 
viral load of 0.1 copies per 1,000 cells (i.e. 1 copy per 10,000 cells) or less, including 
samples with a zero viral load, were given a viral load value of 0.1; when plotting this 
figure, the label for 10-1 was changed to “0”. Again for aesthetic reasons, if a sample 
from a visit was not available, not tested, or not evaluable, the previously measured 
value of viral load was plotted (observed values are plotted with a closed plotting 
symbol, backwards-interpolated values with an open symbol) to form a left-
continuous curve. This is a pragmatic approach, and matches how missing viral load 
would presumably be handled in practice, in a screening programme for example: a 
woman’s viral load status will be assumed to be that of her last measurement, until 
updated with a new measurement. Unique identifiers for women (study numbers) 
appear in bold in the top right-hand corner of each of the graphs which appear on a 
page. A vertical coloured line indicates the date of the first detection of cervical 
cytological abnormality: a blue line represents a smear containing at worst borderline 
nuclear abnormalities; a green line, mild dyskaryosis (other severities of abnormality 
were not detected). 
 
I have been unable to find a suitable statistical method for modelling changes in viral 
load over time. Any model must be able to simultaneously account for large numbers 
of zero viral loads, small viral loads, and extreme viral loads. Within the range of 
statistical methods available, in particular for repeated measurements, I have been 
unable to find a model which meets these criteria. In addition, it seems unlikely that a 
single statistical model will be able to adequately describe the changes in HPV18 
viral load seen for study numbers 292, 1367, 1512 and 1814 (figure 22.6). It appears  
Figure 22.6. Changes in HPV16 (—) and HPV18 (—) viral load over time. All graphs are plotted on the same time scale (months) and 
vertical scale (HPV copy number per 1,000 cells). A closed (open) plotting symbol indicates that a sample was taken (was not taken, or was unavailable): viral load retains its 
last known value until updated. A coloured vertical line indicates date of first detection of cytological abnormality (blue=borderline nuclear abnormalities; green=mild 
dyskaryosis). The woman’s study number appears in the top right-hand corner.  
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Figure 22.6 (continued). Changes in HPV16 (—) and HPV18 (—) viral load over time. All graphs are plotted on the same time 
scale (months) and vertical scale (HPV copy number per 1,000 cells). A closed (open) plotting symbol indicates that a sample was taken (was not taken, or was unavailable): 
viral load retains its last known value until updated. A coloured vertical line indicates date of first detection of cytological abnormality (blue=borderline nuclear abnormalities; 
green=mild dyskaryosis). The woman’s study number appears in the top right-hand corner.  
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Figure 22.6 (continued). Changes in HPV16 (—) and HPV18 (—) viral load over time. All graphs are plotted on the same time 
scale (months) and vertical scale (HPV copy number per 1,000 cells). A closed (open) plotting symbol indicates that a sample was taken (was not taken, or was unavailable): 
viral load retains its last known value until updated. A coloured vertical line indicates date of first detection of cytological abnormality (blue=borderline nuclear abnormalities; 
green=mild dyskaryosis). The woman’s study number appears in the top right-hand corner. 
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Figure 22.6 (continued). Changes in HPV16 (—) and HPV18 (—) viral load over time. All graphs are plotted on the same time scale 
(months) and vertical scale (HPV copy number per 1,000 cells). A closed (open) plotting symbol indicates that a sample was taken (was not taken, or was unavailable): viral load retains 
its last known value until updated. A coloured vertical line indicates date of first detection of cytological abnormality (blue=borderline nuclear abnormalities; green=mild dyskaryosis). The 
woman’s study number appears in the top right-hand corner. 
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Figure 22.6 (continued). Changes in HPV16 (—) and HPV18 (—) viral load over time. All graphs are plotted on the same time scale (months) 
and vertical scale (HPV copy number per 1,000 cells). A closed (open) plotting symbol indicates that a sample was taken (was not taken, or was unavailable): viral load retains its last known 
value until updated. A coloured vertical line indicates date of first detection of cytological abnormality (blue=borderline nuclear abnormalities; green=mild dyskaryosis). The woman’s study 
number appears in the top right-hand corner.  
 
 
 
that each woman requires a specific model tailored to her own profile, which defeats 
the aim of modelling as set out at the start of this subsection. Although these profiles 
may fall into a smaller set of apparently common groups, these would be artificial 
and for convenience only, and would not necessarily shed any light on the evolution 
of HPV viral load over time in these women.  
 
22.7 HPV VIRAL LOAD AND THE DURATION OF INCIDENT CERVICAL HPV 
INFECTIONS 
 
The association between viral load and the duration of an incident cervical qPCR 
HPV infection was investigated in a time-to-event analysis. Recall that in a time-to-
event analysis of duration, the event is “clearing” the infection (see section 21.4.2.3); 
and therefore, a hazards ratio less than one indicates a decreased risk of clearing an 
infection compared to the reference group, or alternatively an infection of longer 
duration. 
 
Three variables measuring HPV viral load were considered for analysis: a time-fixed 
variable measuring viral load at the start of the episode; a time-varying covariate 
measuring viral load at the previous visit; and a time-varying covariate measuring 
maximum viral load attained by the previous visit. All numerical values of viral load 
were log-transformed. 
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22.7.1 HPV16 
 
The study population for this analysis comprised 27 women who had incident 
cervical HPV16 qPCR infections, and who had further follow-up after their first 
HPV16 qPCR-positive sample.  
 
Twenty women cleared their incident cervical HPV16 infections; the median duration 
of an incident cervical HPV16 infection was 11.0 months (inter-quartile range (IQR) 
6.3 to 28.8). 
 
22.7.1.1 HPV16 viral load in the first qPCR-positive sample and the duration of 
incident cervical HPV16 qPCR infections 
 
A multivariate analysis for interval censored time-to-event data was used to 
determine the association between the HPV16 viral load observed at the start of an 
episode of infection, and the probability of clearing that infection. The results are 
shown in table 22.7.1.1. 
 
For women who cleared their incident cervical HPV16 qPCR infections, median 
(IQR) [range] HPV16 viral load in the first sample of the episode was 29 copies per 
1,000 cells (3 to 81) [0.03 to 676]; in women who did not clear their HPV16 
infections, the median (IQR) [range] viral load was 3,270 copies per 1,000 cells (381 
to 8,170) [0.01 to 397,966]. The duration of an incident cervical HPV16 qPCR 
infection increased as the viral load in the first qPCR-positive sample increased; 
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however, the association was not statistically significant. The risk of clearing an 
infection decreased by 9% (1.00-0.91) for every ten-fold increase in viral load in the 
first sample of an episode of infection, i.e. the hazards ratio was 0.91 (1-0.91=9%) 
for every increase of one in log10 of viral load, which on this scale corresponds to a 
ten-fold increase in viral load. 
 
Table 22.7.1.1. The association between HPV16 viral load in the first sample of 
an incident episode of infection and the duration of incident cervical qPCR 
HPV16 infections. 
 
Variable Frequency Events Hazards 
ratio 
95% CI LR testa 
Log10 of the 
HPV16 viral 
load in the first 
sample 
27 20 0.91 0.70 to 1.18 0.58;1;0.45 
aLikelihood-ratio test: Chi-squared statistic; degrees of freedom; p-value. 
 
 
22.7.1.2 Viral load in the sample taken at the previous visit and the duration of 
incident cervical qPCR HPV16 infections 
 
A multivariate analysis for interval censored time-to-event data was used to 
determine the association between the HPV16 viral load in the sample taken at the 
previous visit as a time-varying covariate, and the probability of clearing that 
infection. The results are shown in table 22.7.1.2. 
 
The duration of an incident cervical qPCR HPV16 infection increased as the viral 
load in the sample taken at the previous visit increased; however, the association 
was not statistically significant. The risk of clearing an infection decreased by 19% 
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(1.00-0.81) for every ten-fold increase in viral load in the sample taken at the 
previous visit. 
  
Table 22.7.1.2. The association between HPV16 viral load in the sample taken 
at the previous visit and the duration of an incident cervical qPCR HPV16 
infection. 
 
Variable Frequency Events Hazards 
ratio 
95% CI LR testa 
Log10 of the 
HPV16 viral load 
at the previous 
visit 
27 20 0.81 0.63 to 1.05 3.23;1;0.07
aLikelihood-ratio test: Chi-squared statistic; degrees of freedom; p-value. 
 
 
22.7.1.3 Greatest viral load observed and the duration of incident cervical 
qPCR HPV16 infections 
 
A multivariate analysis for interval censored time-to-event data was used to 
determine the association between the greatest HPV16 viral load observed during 
the episode of infection, measured as a time-varying covariate updated at each visit, 
and the probability of clearing that infection. The results are shown in table 22.7.1.3. 
 
Each woman had a maximum viral load observed during her episode of infection: 
when the median of these viral loads is taken we obtain the “median maximum” viral 
load. For women who cleared their HPV16 infections, the median (IQR) [range] 
maximum HPV16 viral load observed during their infections was 106 copies per 
1,000 cells (6 to 694) [0.03 to 45,774]; in women who did not clear their HPV16 
infections, the median (IQR) [range] maximum HPV16 viral load was 282,186 copies 
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per 1,000 cells (4,713 to 631,595) [884 to 420,953,588]. The duration of an incident 
HPV16 infection increased as the maximum viral load attained during the episode 
increased; the association was of borderline statistical significance (I dislike this 
phrase, but use it because of the disagreement between the 95% confidence interval 
and the p-value from the likelihood ratio test). The risk of clearing an infection 
decreased by 25% (1-0.75) for every ten-fold increase in the maximum viral load 
observed during the episode of infection. 
 
 
Table 22.7.1.3. The association between the maximum HPV16 viral load 
observed during an episode of infection and the duration of an incident 
cervical qPCR HPV16 infection. 
 
Variable Frequency Events Hazards 
ratio 
95% CI LR testa 
Log10 of the 
greatest HPV16 
viral load 
observed to date 
27 20 0.75 0.55 to 1.02 4.24;1;0.04
aLikelihood-ratio test: Chi-squared statistic; degrees of freedom; p-value. 
 
 
 
 
 
Summary 
 
An increase in viral load was associated with a reduced probability of clearing an 
incident HPV16-qPCR infection, but the association was not statistically significant. 
This was the case whether the analysis included a variable measuring viral load in 
the first positive sample of the episode, a variable measuring viral load in the 
previous evaluable sample, or a variable measuring the greatest viral load attained 
during the episode. There was very little difference between the estimates of 
association. The magnitude of the association was least for the variable measuring 
viral load in the first positive sample, and greatest for that measuring greatest viral 
load attained to date, which was of borderline significance. Numbers are small in 
these analyses, so results must be treated with caution. 
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22.7.2 HPV18 
 
The study population for this analysis comprises 21 women who had incident 
cervical qPCR HPV18 infections, and who had further follow-up after their first 
HPV18 qPCR-positive sample.  
 
Sixteen women cleared their incident cervical HPV18 infections; the median duration 
of an incident cervical HPV18 infection was 6.0 months (IQR 0.7 to 21.6). 
 
22.7.2.1 HPV18 viral load in the first qPCR-positive sample and the duration of 
incident cervical qPCR HPV18 infections 
 
A multivariate analysis for interval censored time-to-event data was used to 
determine the association between the HPV18 viral load observed at the start of an 
episode of infection, and the probability of clearing that infection. The results are 
shown in table 22.7.2.1. 
 
For women who cleared their incident cervical HPV18 infections, the median (IQR) 
[range] HPV18 viral load in the first sample of the episode was 2 copies per 1,000 
cells (0.4 to 190) [0.001 to 413,356]; in women who did not clear their HPV18 
infections, the median (IQR) [range] viral load was 35 copies per 1,000 cells (0.004 
to 26,054) [0.004 to 28,588]. The duration of an incident HPV18 infection increased 
as the viral load in the first qPCR-positive sample increased; however, the 
association was not statistically significant. The risk of clearing an infection 
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decreased by 15% (1-0.85) for every ten-fold increase in viral load in the first sample 
of an episode of infection. 
 
 
Table 22.7.2.1. The association between HPV18 viral load in the first 
sample of an incident episode of infection and the duration of an incident 
cervical qPCR HPV18 infection. 
 
Variable Frequency Events Hazards 
ratio 
95% CI LR testa 
Log10 of the 
HPV18 viral 
load in first 
sample 
21 16 0.85 0.68 to 1.07 2.08;1;0.15
aLikelihood-ratio test: Chi-squared statistic; degrees of freedom; p-value. 
 
 
22.7.2.2 Viral load in the sample taken at the previous visit and the duration of 
incident cervical qPCR HPV18 infections 
 
A multivariate analysis for interval censored time-to-event data was used to 
determine the association between the HPV18 viral load in the sample taken at the 
previous visit, measured as a time-varying covariate, and the probability of clearing 
that infection. The results are shown in table 22.7.2.2. 
 
The duration of an incident cervical HPV18 qPCR infection increased as the viral 
load increased in the sample taken at the previous visit increased; however, the 
association was not statistically significant. The risk of clearing an infection 
decreased by 20% (1.00-0.80) for every ten-fold increase in viral load in the sample 
taken at the previous visit. 
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Table 22.7.2.2. The association between HPV18 viral load in the sample taken 
at the previous visit and the duration of an incident qPCR HPV18 infection. 
 
Variable Frequency Events Hazards 
ratio 
95% CI LR testa 
Log10 of the 
HPV18 viral 
load at the 
previous visit 
21 16 0.80 0.63 to 1.03 3.58;1;0.06 
aLikelihood-ratio test: Chi-squared statistic; degrees of freedom; p-value. 
 
 
22.7.2.3 Greatest viral load observed and the duration of incident qPCR HPV18 
infections 
 
A multivariate analysis for interval censored time-to-event data was used to 
determine the association between the maximum HPV18 viral load observed during 
the episode of infection, measured as a time-varying covariate, and the probability of 
clearing that infection. The results are shown in table 22.7.2.3. 
 
For women who cleared their HPV18 infections, the median (IQR) [range] maximum 
HPV18 viral load observed during their infection was 8 copies per 1,000 cells (0.4 to 
4,313) [0.002 to 2,325,781]; in women who did not clear their HPV18 infections, the 
median (IQR) [range] maximum HPV18 viral load was 106 copies per 1,000 cells 
(0.03 to 26,054) [0.01 to 28,588]. The duration of an incident cervical HPV18 qPCR 
infection increased as the maximum viral load attained during the episode increased; 
the association was not statistically significant. The risk of clearing an infection 
decreased by 12% (1-0.88) for every ten-fold increase in maximum observed viral 
load during the episode of infection. 
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Table 22.7.2.3. The association between greatest HPV18 viral load observed 
and the duration of an incident qPCR HPV18 infection. 
 
Variable Frequency Events Hazards 
ratio 
95% CI LR testa 
Log10 of 
greatest HPV18 
viral load to 
date 
21 16 0.88 0.71 to 1.09 1.57;1;0.21 
aLikelihood-ratio test: Chi-squared statistic; degrees of freedom; p-value. 
 
 
 
Summary 
 
An increase in viral load was associated with a reduced probability of clearing an 
incident HPV18-qPCR positive episode, but the association was not statistically 
significant. This was the case whether the analysis included a variable measuring 
viral load in the first positive sample of the episode, a variable measuring viral load in 
the previous evaluable sample, or a variable measuring the greatest viral load 
attained during the episode. There was very little difference between the estimates 
of association. The magnitude of the association was least for the variable 
measuring greatest viral load attained, and greatest for that measuring viral load at 
the previous visit. Numbers were small in these analyses, so results must be treated 
with caution. 
 
 
 
22.8 HPV VIRAL LOAD AND HPV STATUS AT THE END OF FOLLOW-UP 
 
The association between the maximum viral load observed during follow-up and the 
probability of being clear of infection in the last evaluable qPCR sample was also 
investigated. This was a cross-sectional analysis based on the qPCR status of the 
last sample only. Nevertheless, there are elements of a longitudinal study since the 
viral load exposure variable was updated during a known period of follow-up, and 
length of follow-up was controlled for in the analysis. 
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22.8.1 HPV16 
 
The study population for this analysis comprised 64 women who had two or more 
samples with evaluable HPV16 viral load during follow-up, and who were HPV16-
qPCR-positive on at least one occasion.  
 
Logistic regression analysis was used to determine the association between the 
maximum HPV16 viral load observed during follow-up and the probability of being 
clear of HPV16 infection in the last evaluable sample, after controlling for length of 
follow-up. The outcome in this analysis was being positive in the last sample. The 
results of this analysis are shown in table 22.8.1. 
 
Thirty-seven women were HPV16-qPCR-positive in their last qPCR-evaluable 
sample. For women who were free of HPV16 infection in their last evaluable sample, 
the median (IQR) [range] maximum HPV16 viral load observed during follow-up was 
209 copies per 1,000 cells (18 to 3,295) [0.03 to 393,824]; in women who were 
HPV16-positive in their last evaluable sample, the median (IQR) [range] maximum 
HPV16 viral load was 8,076 copies per 1,000 cells (742 to 282,186) [0.3 to 
420,953,588]. Women were significantly less likely to be free of HPV16 infection in 
their last evaluable sample as the maximum observed viral load during follow-up 
increased, after controlling for the length of follow-up. The odds of being HPV16-
positive in the last evaluable sample increased by 63% (1.63-1) for every ten-fold 
increase in the maximum observed HPV16 viral load during follow-up. There was no 
evidence of an interaction between time and HPV16 viral load. 
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Table 22.8.1. Logistic regression analysis of the association between the 
maximum HPV16 viral load observed during follow-up and the probability of 
being clear of HPV16 infection in the last evaluable sample. 
 
Variable Frequency Eventsc Odds 
ratio 
95% CI LR testab 
Log10 of the 
maximum 
HPV16 viral 
load 
64 37 1.63 1.19 to 2.23 12.09;1;<0.001 
aLikelihood ratio test: chi-squared statistic; degrees of freedom; p-value; bcontrolling for length of 
follow-up; cthe event modelled was: being positive in the last evaluable sample. 
 
 
22.8.2 HPV18 
 
The study population for this analysis comprised 59 women who had two or more 
samples with evaluable HPV18 viral load during follow-up, and who were HPV18-
qPCR-positive on at least one occasion.  
 
Logistic regression analysis was used to determine the association between the 
maximum HPV18 viral load observed during follow-up and the probability of being 
clear of HPV18 infection in the last evaluable sample, after controlling for length of 
follow-up. The results of this analysis are shown in table 22.8.2. 
 
Thirty-seven women were HPV18-qPCR-positive in their last qPCR-evaluable 
sample (this number is a coincidence with the HPV16 analysis). For women who 
were free of HPV18 infection in their last evaluable sample, median (IQR) [range] 
maximum HPV18 viral load observed during follow-up was 3 copies per 1,000 cells 
(0.3 to 1,237) [0.0006 to 25,564,280]; in women who were HPV18-positive in their 
last evaluable sample, the median (IQR) [range] maximum HPV18 viral load was 
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312 copies per 1,000 cells (5 to 15,681) [0.002 to 413,356]. Women were less likely 
to be free of HPV18 infection in their last evaluable sample as the maximum 
observed viral load during follow-up increased, after controlling for the length of 
follow-up, but the association was not statistically significant. The odds of being 
HPV18-positive in the last evaluable sample increased by 22% (1.22-1) for every 
ten-fold increase in the maximum observed HPV18 viral load during follow-up. There 
was no evidence of an interaction between time and HPV18 viral load. 
 
Table 22.8.2. Logistic regression analysis of the association between the 
maximum HPV18 viral load observed during follow-up and the probability of 
being clear of HPV18 infection in the last evaluable sample. 
 
Variable Frequency Eventsc Odds 
ratio 
95% CI LR testab 
Log10 of 
the 
maximum 
HPV18 
viral load 
59 37 1.22 0.97 to 1.53 3.05;1;0.08 
aLikelihood ratio test: chi-squared statistic; degrees of freedom; p-value; bcontrolling for length of 
follow-up; cthe event modelled was: being positive in the last evaluable sample. 
 
 
 
Summary 
 
There was a statistically significant association between the maximum viral load 
observed during follow-up and the probability of being free of infection in the last 
evaluable sample for HPV16, but not for HPV18. The odds of being positive in the 
last evaluable sample increased by 63% for every ten-fold increase in the maximum 
viral load observed during follow-up for HPV16, but by only 22% for HPV18. 
 
 
 
 
537 
 
22.9 HPV VIRAL LOAD AND THE ACQUISITION OF CERVICAL CYTOLOGICAL 
ABNORMALITY 
 
The association between the HPV viral load of cervical HPV infections and the risk of 
acquiring an incident cervical cytological abnormality was investigated in a time-to-
event analysis. 
 
Five viral load exposure variables were considered for analysis: a time-fixed binary 
variable indicating viral load status at baseline (positive or negative); a time-fixed 
continuous variable measuring viral load at baseline; a time-varying binary variable 
indicating “ever viral load positive” status at the previous visit (yes or no); a time-
varying continuous covariate measuring viral load at the previous visit; and a time-
varying continuous covariate measuring maximum viral load attained by the previous 
visit. 
 
22.9.1 HPV16 
 
The study population for this analysis was confined to 62 women who had an 
evaluable HPV16 viral load at study entry, and who had further follow-up after this 
time.  
 
The median HPV16 viral load in the cervical sample taken at study entry was 0.3 
copies per 1,000 cells (IQR 0 to 4.1; range 0 to 11,930.7); excluding the 28 women 
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who had a HPV16 viral load of zero at study entry, the median HPV16 viral load was 
2.9 copies per 1,000 cells (IQR 0.5 to 25.2; range 0.2 to 11,930.7). 
 
Thirty-seven women acquired an incident cervical cytological abnormality during 
follow-up: 19 had smears reported as containing at worst borderline nuclear 
abnormalities at first detection; and 18 had mild dyskaryosis. 
 
22.9.1.1 The association between HPV16 viral load at study entry and the 
acquisition of cervical cytological abnormality 
 
The results of a univariate analysis of the association between HPV16 viral load at 
baseline and the risk of acquiring an incident cervical cytological abnormality, are 
shown in table 22.9.1.1. The association between HPV16 qPCR status at study entry 
and the risk of a subsequent cervical cytological abnormality was not statistically 
significant, when this variable was analysed as a binary variable. However, when 
this variable was included in the model as a (transformed) continuous covariate 
quantifying viral load, the association became highly significant, with an increase in 
risk of acquiring cervical cytological abnormality of 75% (1.75-1.00) for every ten-fold 
increase in HPV16 viral load. 
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Table 22.9.1.1. Univariate analysis of the association between HPV16 viral load 
at baseline and the risk of acquiring an incident cervical cytological 
abnormality. 
 
Variable Frequency Events Hazards 
ratio 
95% CI LR testa 
HPV16-qPCR-
positive at baseline 
     
No 28 17 1.00 Reference 0.01;1;0.93 
Yes 34 20 1.03 0.53 to 1.98  
      
Log10 of HPV16 viral 
load at baselineb 62 37 1.75 1.28 to 2.41 10.82;1;0.001 
aLikelihood-ratio test: Chi-squared statistic; degrees of freedom; p-value; bModel includes a binary 
variable indicating HPV16-qPCR positivity status at baseline. 
 
 
22.9.1.2 The association between HPV16 viral load in the sample taken at the 
previous visit and the risk of acquiring an incident cervical cytological 
abnormality 
 
The results of a univariate analysis of the association between HPV16 viral load in 
the sample taken at the previous visit and the risk of acquiring an incident cervical 
cytological abnormality are shown in table 22.9.1.2. The association between HPV16 
qPCR status in the sample taken at the previous visit and the risk of a subsequent 
cervical cytological abnormality was not statistically significant, when this variable 
was analysed as a binary variable. However, when this variable was included in the 
model as a (transformed) continuous covariate quantifying viral load, the association 
became highly significant, with an increase in risk of 54% (1.54-1.00) for every ten-
fold increase in HPV16 viral load. 
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Table 22.9.1.2. Univariate analysis of the association between HPV16 viral load 
in the sample taken at the previous visit and the risk of acquiring an incident 
cervical cytological abnormality. 
 
Variable Frequency Events Hazards 
ratio 
95% CI LR testa 
Ever HPV16-qPCR-
positive 
     
No 14 10 1.00 Reference 0.64;1;0.42 
Yes 48 27 1.35 0.63 to 2.86  
      
Log10 of HPV16 viral 
load in sample taken 
at previous visitb 
62 37 1.54 1.22 to 1.93 13.33;1;<0.001 
aLikelihood-ratio test: Chi-squared statistic; degrees of freedom; p-value; bModel including a binary 
variable indicating HPV16-qPCR positivity status in previous sample. 
 
 
22.9.1.3 The association between the greatest HPV16 viral load during follow-
up and the risk of acquiring cervical cytological abnormality 
 
For the 37 women who acquired a cervical cytological abnormality, the median of the 
maximum HPV16 viral loads observed during follow-up was 30.7 copies per 1,000 
cells (IQR 0 to 1,050.4; range 0 to 1,341,410.6); in the 25 women who did not 
acquire a cervical cytological abnormality, the median maximum HPV16 viral load 
was 15.8 copies per 1,000 cells (IQR 0.3 to 414.9; range 0 to 45,774.2) ) [Wilcoxon 
rank-sum test with continuity correction: W=460; p=0.60]. In the sample taken 
immediately prior to the date of the first detection of cervical cytological abnormality, 
HPV16 viral load: was unevaluable for one woman; was zero for 10 women, nine of 
whom had zero viral loads in all evaluable samples taken prior to and including this 
sample, with the remaining woman having at least one viral-load positive sample; 
was less than the maximum observed viral load in all samples taken prior to 
detection for six women; attained its greatest observed value for 20 women. 
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The results of a univariate analysis of the association between the greatest HPV16 
viral load observed prior to and including the sample taken at the previous visit and 
the risk of acquiring an incident cervical cytological abnormality are shown in table 
22.9.1.3. The association between a log-transformed continuous covariate 
measuring a woman’s greatest observed HPV16 viral load to date and the risk of 
acquiring an incident cervical cytological abnormality was highly statistically 
significant, with an increase in risk of 76% (1.76-1.00) for every ten-fold increase in 
HPV16 viral load. 
 
Table 22.9.1.3. Univariate analysis of the association between the greatest 
HPV16 viral load and the risk of acquiring an incident cervical cytological 
abnormality. 
 
Variable Frequency Events Hazards 
ratio 
95% CI LR testa 
Log10 of 
greatest 
HPV16 
viral loadb 
62 37 1.76 1.38 to 2.25 21.77;1;<0.001
aLikelihood-ratio test: Chi-squared statistic; degrees of freedom; p-value; bmodel includes a binary 
variable indicating “ever HPV16-qPCR-positive”. 
 
 
 
 
 
 
 
Summary 
 
Each of the analyses in this subsection suggests that it is not the fact of being 
HPV16-qPCR-positive which is important, but the observed magnitude of viral load. 
All three continuous covariates measuring HPV16 viral load: viral load at baseline; 
viral load in the previous sample; and the greatest viral load at the time of the 
previous sample, were significantly associated with the risk of acquiring cervical 
cytological abnormality. The magnitude of the increase in risk associated with a ten-
fold increase in viral load was virtually identical for all three variables. 
 
542 
 
22.9.2 HPV18 
 
The study population for this analysis was confined to 56 women who had an 
evaluable HPV18 viral load at study entry, and who had further follow-up after this 
time.  
 
The median HPV18 viral load in samples taken at study entry was 0.0004 copies per 
1,000 cells (IQR 0 to 1.5; range 0 to 83,292.6); excluding the 27 women who had 
zero HPV18 viral load at study entry, the median HPV18 viral load was 1.3 copies 
per 1,000 cells (IQR 0.5 to 5.0; range 0.0001 to 83,292.6). 
 
Thirty-two women acquired an incident cervical cytological abnormality during follow-
up: 19 had smears reported as containing at worst borderline nuclear abnormalities 
at first detection; and 13 had mild dyskaryosis. 
 
22.9.2.1 The association between HPV18 viral load at study entry and the risk 
of acquiring cervical cytological abnormality 
 
The results of a univariate analysis of the association between HPV18 viral load at 
baseline and the risk of acquiring an incident cervical cytological abnormality are 
shown in table 22.9.2.1. The association between HPV18-qPCR positivity status at 
study entry and the risk of a subsequent cervical cytological abnormality was not 
statistically significant, when this variable was analysed as a binary variable. 
However, when this variable was included in a model as a (transformed) continuous 
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covariate quantifying viral load, the association became highly statistically significant, 
with an increase in risk of 67% (1.67-1.00) for every ten-fold increase in HPV18 viral 
load. 
 
Table 22.9.2.1. Univariate analysis of the association between HPV18 viral load 
at baseline and the acquisition of an incident cervical cytological abnormality. 
 
 Frequency Events Hazards 
ratio 
95% CI LR testa 
HPV18-qPCR-
positive at 
baseline 
     
No 27 16 1.00 Reference 0.06;1;0.81
Yes 29 16 0.92 0.46 to 1.84  
      
Log10 of HPV18 
viral load at 
baselineb 
56 32 1.67 1.15 to 2.43 6.26;1;0.01
aLikelihood-ratio test: Chi-squared statistic; degrees of freedom; p-value; bmodel includes a binary 
variable indicating HPV18-qPCR positivity status at baseline. 
 
 
22.9.2.2 The association between HPV18 viral load in the sample taken at the 
previous visit and the risk of acquiring cervical cytological abnormality 
 
The results of a univariate analysis of the association between HPV18 viral load in 
the sample taken at the previous visit and the risk of acquiring an incident cervical 
cytological abnormality, are shown in table 22.9.2.2. The association between 
HPV18 qPCR status in the sample taken at the previous visit and the risk of a 
subsequent cervical cytological abnormality was not statistically significant, when 
this variable was analysed as a binary variable. However, when this variable was 
included in a model as a (transformed) continuous covariate quantifying viral load, 
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the association became highly statistically significant, with an increase in risk of 77% 
(1.77-1.00) for every ten-fold increase in HPV18 viral load. 
 
Table 22.9.2.2. Univariate analysis of the association between HPV18 viral load 
in the sample taken at the previous visit and the risk of acquiring an incident 
cervical cytological abnormality. 
 
Variable Frequency Events Hazards 
ratio 
95% CI LR testa 
Ever HPV18-
qPCR-
positive 
     
No 14 10 1.00 Reference 0.001;1;0.98 
Yes 42 22 1.01 0.48 to 2.14  
      
Log10 of 
HPV18 viral 
load in 
sample taken 
at previous 
visitb 
56 32 1.77 1.29 to 2.43 12.20;1;<0.001 
aLikelihood-ratio test: Chi-squared statistic; degrees of freedom; p-value; bmodel includes a binary 
variable indicating HPV18-qPCR positivity status in the previous sample was eliminated. 
 
 
22.9.2.3 The association between the greatest HPV18 viral load and the risk of 
acquiring an incident cervical cytological abnormality 
 
For the 32 women who acquired cervical cytological abnormality, the median of the 
maximum HPV18 viral loads observed during follow-up was 1.2 copies per 1,000 
cells (IQR 0 to 21.6; range 0 to 25,564,280); in the 24 women who did not acquire 
cervical cytological abnormality, the median maximum HPV18 viral load was 1.4 
copies per 1,000 cells (IQR 0.002 to 54.7; range 0 to 15,680.6) ) [Wilcoxon rank-sum 
test with continuity correction: W=432; p=0.42]. In the sample taken immediately 
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prior to the date of the first detection of cervical cytological abnormality, HPV18 viral 
load: was unevaluable for one woman; was zero for 18 women, 13 of whom had 
zero viral loads in all evaluable samples taken prior to and including this sample, 
with the remaining five women having at least one HPV18-qPCR-positive sample; 
was less than the maximum observed viral load in all samples taken prior to 
detection for two women; and attained its greatest observed value for 11 women. 
 
The results of a univariate analysis of the association between greatest HPV18 viral 
load observed prior to and including the sample taken at the previous visit and the 
risk of acquiring an incident cervical cytological abnormality are shown in table 
22.9.2.3. The association between a log-transformed continuous covariate 
measuring a woman’s greatest observed HPV18 viral load and the risk of acquiring 
an incident cervical cytological abnormality was highly significant, with an increase in 
risk of 59% (1.59-1.00) for every ten-fold increase in HPV18 viral load. 
 
Table 22.9.2.3. Association between the greatest HPV18 viral load and the risk 
of acquiring an incident cervical cytological abnormality. 
 
 Frequency Events Hazards 
ratio 
95% CI LR testa 
Log10 of 
greatest HPV18 
viral load to 
dateb 
56 32 1.59 1.25 to 2.03 12.14;1;<0.001
aLikelihood-ratio test: Chi-squared statistic; degrees of freedom; p-value; bModel includes a binary 
variable indicating “ever HPV18-qPCR-positive” at baseline. 
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Summary 
 
Each of the analyses in this subsection suggests that it is not the fact of being 
HPV18-qPCR-positive which is important, but the observed magnitude of viral load. 
All three continuous time-varying covariates measuring HPV18 viral load: viral load 
at baseline; viral load in the previous sample; and the greatest viral load at the time 
of the previous sample, were significantly associated with the risk of acquiring 
cervical cytological abnormality. An increase in viral load was associated with an 
increased risk for all three variables: the magnitude of the association was least for 
the variable measuring greatest viral load attained, and greatest for that measuring 
viral load in the first evaluable sample, but the differences were not great. 
 
 
 
22.10 HPV VIRAL LOAD AND THE ACQUISITION OF HIGH-GRADE CIN 
 
The previous section examined the association between HPV viral load and the risk 
of acquiring cervical cytological abnormality. A more appropriate outcome would be 
the incidence of high-grade CIN, the precursor of cervical cancer. The data to 
address this question within the cohort described in this thesis is severely limited by 
number of events, and the age of the women. Nevertheless, given its performance, 
some descriptive results will be presented. 
 
Within the cohort of 1,075 women, the number who were diagnosed with high-grade 
CIN during follow-up was 28, 17 of whom were in the intended study population for 
viral load testing of 155 women: 10, two and five in the HPV16-only, HPV18-only and 
HPV16+HPV18 cohorts, respectively. Of these, only eight were tested for HPV viral 
load: four, one, and three in each of the respective cohorts, with two of the women in 
the HPV16-only cohort being tested for HPV16 viral load only, but with all other 
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women tested for both HPV16 and HPV18 viral load. The results of cytological, 
histological, virological, and serological testing of all women in the study population 
who were diagnosed with high-grade CIN and who were tested for viral load prior to 
diagnosis, is shown in table 22.10. 
 
All of these women had HPV16-associated high-grade CIN when HPV status was 
determined using qPCR, including the woman from the HPV18-only cohort who was 
positive on only one occasion with a viral load of 5 copies per 1,000 cells. Three 
women were infected with HPV16 at study entry, with the remaining four having 
incident HPV16 qPCR infections. Seven women who subsequently acquired HPV16-
associated high-grade CIN had numerically low viral loads in their first evaluable 
sample, including the four women who were qPCR HPV16-negative. One woman 
was qPCR HPV16-negative on five separate occasions over the course of three 
years, before subsequently having a sample containing over 400 million copies per 
1,000 cells. Four women had monotonically-increasing HPV16 viral loads prior to the 
diagnosis of high-grade CIN, i.e. the HPV16 viral load started low and increased in 
all subsequent samples, one had an increase in viral load which was maintained 
until diagnosis, one had a viral load which fluctuated, and two had increases 
followed by a decrease. 
 
Five women had HPV18-associated high-grade CIN when HPV status was 
determined using qPCR, one did not, and two women were not tested for HPV18 
viral load. One woman was infected with HPV18 at study entry, one was non-
evaluable, and the remaining three had incident HPV18 qPCR infections. Four 
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women who subsequently acquired HPV18-associated high-grade CIN had 
numerically low viral loads in their first evaluable sample, including the three women 
who were qPCR HPV18-negative. One woman was qPCR HPV18-negative on six 
separate occasions over the course of nearly seven years, including the date of 
diagnosis of high-grade CIN, but also had a sample containing over 2 million copies 
per 1,000 cells. Two women were only found to be HPV18-qPCR-positive at the date 
of diagnosis of high-grade CIN, and three women had viral loads that increased from 
numerically low values to a peak high-value, before returning to a numerically-low 
value. 
 
 
 
Summary 
 
The number of women with incident high-grade CIN in this analysis was small, so 
observations are suggestive rather than conclusive. All women with incident high-
grade CIN who were tested for viral load in this cohort were qPCR-positive for 
HPV16 at some point during follow-up; many women only ever had numerically-low 
viral loads, and others had zero viral loads for extended periods. Similar results were 
seen for HPV18. 
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Table 22.10 (Part 1). The results of cytological, histological, and virological, 
testing of all women in the study population who were diagnosed with high-
grade CIN and who had cytological samples tested for viral load prior to 
diagnosis. Data presented is restricted to visits prior to and including the date of diagnosis of 
high-grade CIN. Where multiple samples were available, or the same sample was tested more than 
once, the mean viral load across all samples and tests is presented. 
 
ID Visit Time since 
study entry 
(days) 
Cytologya Histologyb HPV DNA 
(GP5+/6+)c 
HPV16 VLd HPV18 VLd 
150 1 0 Normal — Negative 2,904 0
 2 140 Normal — Negative 583,227 0
 3 511 Mild dyskaryosis — 16 Missing Missing
 4 601 Mild dyskaryosis CIN2 6/11; 16 547,175 0
330 1 0 Normal — Negative 0 0
 2 268 Mild dyskaryosis — 16 397,966 0
 3 370 Mild dyskaryosis CIN3 16 583,861 18
350 1 0 Result missing — Negative 0 0
 2 98 Normal  No sample NA NA
 3 259 Normal — X 72 0
 4 575 Normal — Negative 3 0
 5 941 Normal — 18 9,530 31,265
 6 1035 Mild dyskaryosis — X Ct-Ge 2,325,781
 7 1360 Mild dyskaryosis — Negative 21,579 Ct-Vf
 8 1462 Mild dyskaryosis CIN1 X 391 1
 9 1707 Mild dyskaryosis HPV 16 269 0
 10 2043 Mild dyskaryosis — Negative 1,153 0
 11 2414 Mild dyskaryosis CIN2 X 679,329 0
393 1 0 Normal — Negative 34 0
 2 181 Normal — 6/11 373 0
 3 360 Mild dyskaryosis — 6/11 4,402 0
 4 493 BNA CIN3 16;18 9,579 2,419
820 1 0 Normal — Negative <1 Not Tested
 2 455 Normal — 16 100 Not Tested
 3 664 Mild dyskaryosis — 16 25,559 Not Tested
 4 789 Mild dyskaryosis — 16 13,733 Not Tested
 5 1027 Mild dyskaryosis CIN2 16 1,100 Not Tested
1005 1 0 Normal — Negative 0 Not Tested
 2 184 Result missing — No sample NA Not Tested
 3 329 Mild dyskaryosis — 16 8,265 Not Tested
 4 625 Mild dyskaryosis CIN3 16 282,186 Not Tested
aBNA=borderline nuclear abnormality (the least severe grade of cervical cytological abnormality), 
US=unreadable smear; ba dash means NA, not missing; cX means HPV-positive with an unknown 
type which however was known not to be 6/11, 16, 18, 31, 33, 52 or 58; dViral load expressed as 
copy number per 1,000 cells; esample had excess variability in GAPDH Ct values, but is 
nevertheless known to be positive; fsample had excess variability in virus Ct values, but is 
nevertheless known to be positive; gFailure in GAPDH assay. 
550 
 
Table 22.10 (Part 2). The results of cytological, histological, and virological, 
testing of all women in the study population who were diagnosed with high-
grade CIN and who had cytological samples tested for viral load prior to 
diagnosis. Data presented is restricted to visits prior to and including the date of diagnosis of high-
grade CIN. Where multiple samples were available, or the same sample was tested more than once, 
the mean viral load across all samples and tests is presented. 
 
ID Visit Time since 
study entry 
(days) 
Cytologya Histologyb HPV DNA 
(GP5+/6+)c 
HPV16 VLd HPV18 VLd 
1512 1 0 Normal — Negative 0 GFg
 2 180 Normal — X 0 0
 3 405 Normal — 18 0 413,356
 4 546 BNA — 18 0 144,188
 5 739 BNA HPV Negative GFg GFg
 6 1005 BNA HPV X 0 505
 7 1355 Mild dyskaryosis — 33 GFg GFg
 8 1551 Normal — Negative 3,270 0
 9 1733 Mild dyskaryosis CIN1 6/11;16 420,953,588 <1
 10 1995 Mild dyskaryosis — No sample NA NA
 11 2170 BNA CIN2 No sample NA NA
1814 1 0 Normal — Negative 0 4,849
 2 171 BNA — Negative 0 <1
 3 244 BNA HPV Negative 0 1,464
 4 412 BNA — X 0 982
 5 776 Normal CIN1 Negative 0 1
 6 958 Normal — Negative 0 <1
 7 1161 BNA HPV 18 5 30,417
 8 1469 Normal — Positive 0 <1
 9 1864 Normal CIN3 No sample NA NA
aBNA=borderline nuclear abnormality (the least severe grade of cervical cytological abnormality), 
US=unreadable smear; ba dash means NA not missing; cX means HPV-positive of unknown type 
which however was known not to be 6/11, 16, 18, 31, 33, 52 or 58; dViral load expressed as copy 
number per 1,000 cells; esample had excess variability in GAPDH Ct values, but is nevertheless 
known to be positive; fsample had excess variability in virus Ct values, but is nevertheless known to be 
positive; gFailure in GAPDH assay. 
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Chapter 23 
 
THE NATURAL HISTORY OF CERVICAL HPV16 AND HPV18 
INFECTIONS – VIRAL LOAD 
 
DISCUSSION 
 
 
 
 
I have assessed the test performance of an assay measuring HPV16 and HPV18 
viral load with respect to reliability, sensitivity, specificity, and type-specificity, 
described how the distribution of HPV viral load varies with infecting HPV type for 
types 16 and 18, and described the relationship between HPV16 and HPV18 viral 
load and the detection of epithelial abnormalities of the cervix. 
 
23.1 ASSAY PERFORMANCE AND INTERPRETATION 
 
The assay used had an excellent performance: the linear dynamic range exceeded 
109 to one copies, and the primers used were shown to be sensitive and specific, 
with no cross-reactivity when tested in cervical cancer cell lines known to contain 
specific high-risk HPV types. The assay was found to be highly reproducible for 
measuring both HPV16 and HPV18 viral load. Estimates of intraclass correlation 
coefficients used to estimate within-assay reliability, using either observed CT values 
or observed virus copy numbers, corresponded to “almost-perfect” reliability on the 
Landis scale for both the HPV16 and HPV18 assays. Although this was, in part, a 
consequence of the approach adopted to accepting measurements as valid, this is 
primarily a reflection of the excellent reproducibility of these assays. Similarly, 
estimates of intraclass correlation coefficients used to measure inter-assay test-
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retest reliability, while smaller in magnitude than those measuring intra-assay 
reliability, still corresponded to “almost-perfect” reliability for both the HPV16 and the 
HPV18 assay. There is a concern that the HPV18 assay produced an aberrant result 
for one sample, but this can never be ruled out entirely with any assay 
 
Another concern is that some of the viral load results were obtained by extrapolation 
from the standard curves, although the number of results involved was very small. 
To reduce the number of wells used to generate the standard curves, the range of 
these curves was restricted to 102 to 108 copies for HPV16, and 103 to 107 for 
HPV18. However, the dynamic range exceeded 109 to 1 copies, and the vast 
majority of extrapolation occurred towards the lower end of this range, i.e. within the 
known dynamic range. 
 
It is not clear how to interpret some of the numerically very-low viral loads observed 
in the cohort described in this thesis, such as 1 copy per 100,000 cells, or the very-
high viral loads, such as 100,000 copies per cell. There is no benchmark against 
which to compare the observed values of viral load, and no means by which to 
determine whether a viral load is “low” or “high” in some sense. One study using 
qPCR, with GAPDH to normalise for cellular content, reported that the 25th 
percentile of HPV18 viral loads in cytologically normal smears was 2 copies per 
10,000 cells, indicating that even lower viral loads were also found (Gravitt 2003b). 
One study using qPCR to estimate HPV viral load in cervico-vaginal cytological 
specimens, with albumin to normalise for cellular content, suggests that 110,000 
copies per 1,000 cells is a high-viral load for HPV16, or 760,000 copies per 1,000 
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cells for HPV18 (Carcopino 2006). Another study in HIV-infected and uninfected 
women, using qPCR, with β-globin to normalise for cellular content, reports viral 
loads for various HPV types which range from less than 100 copies per 1,000 cells 
to greater than 4.7 million copies per 1,000 cells (Weissenborn 2003); another study 
using the same technique reported a viral load of 5.8 million copies per 1,000 cells 
(Snijders 2006). Clearly, very-high HPV viral loads are possible, and given that the 
qPCR assay is, in theory, capable of detecting a single copy of the virus, very-low 
viral loads are also plausible. 
 
23.2 IDENTIFICATION OF THE STUDY POPULATION 
 
Prior to undertaking this analysis, the intention was to measure HPV viral load in all 
women in the study cohort who had incident HPV16 and/or HPV18 infections. 
Women with incident cervical HPV infections were defined on the basis of the results 
of the first HPV testing system we had used, the GP5+/GP6+ system. It was 
believed that this would yield a well-defined study population for use in the analysis 
of both HPV viral load and the humoral immune response to incident cervical HPV 
infection, since it was anticipated that only samples which were HPV DNA positive 
according to the original nominal system would be positive using the quantitative 
system. 
 
In practice, agreement between the two systems was substantial, although not 
perfect. Not all samples which tested positive for HPV16 or HPV18 using 
GP5+/GP6+ also tested positive for the corresponding type using qPCR; and many 
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which tested negative using GP5+/GP6+, tested positive using qPCR. In retrospect, 
this could perhaps have been anticipated: others have also found a discrepancy 
between the GP5+/GP6+ system and the more sensitive qPCR system (Van Duin 
2002, Gravitt 2003b). It is clear that within the study population of the cohort study 
described in this thesis, more women are likely to be HPV16 and/or HPV18 DNA-
positive than were identified on the basis of the GP5+/GP6+ system. Ideally 
analyses previously undertaken using measurements of HPV exposure defined on 
the basis of the GP5+/GP6+ system would be repeated using qPCR measurements, 
to see if previous conclusions still hold: of course, this is true for all studies which 
have used techniques less sensitive than qPCR to detect HPV. However, given that 
only a very limited subset of the cohort described in this thesis was tested using 
qPCR, this is not possible in this study population. Funding for such a study is now 
unlikely ever to be obtained. 
 
23.3 DISTRIBUTION OF VIRAL LOAD ACCORDING TO HPV TYPE AND 
PRESENCE OF DISEASE 
 
HPV viral load varied according to HPV type and cervical cytological abnormality 
status. For both HPV types which were the focus of analyses in this thesis, smears 
with non-zero viral loads had substantially higher viral loads when cytological 
abnormalities were present than when they were not, and HPV16 but not HPV18 
viral load increased with increasing severity of cytological abnormality. In normal 
smears, HPV viral load for one type did not vary according to the presence or 
absence of the other type. However, in smears containing at worst BNA, viral load of 
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either type was higher in the absence of the other than when it was present; the 
reverse was true in smears containing at worst mild dyskaryosis. 
 
Note that these results relate to all samples taken from all women. Most other 
studies which have investigated the association between HPV viral load and HPV 
type have included only one sample from each woman, typically that taken at 
diagnosis (Swan 1999, Zerbini 2001, Sherman 2003a, Weissenborn 2003, Giuliano 
2004, Levi 2004, Moberg 2004, Ho 2005, Moberg 2005, Carcopino 2006, Flores 
2006, Lai 2006, Snijders 2006). Most have also found that HPV viral load varies by 
HPV type, with several reporting an increase in HPV16 viral load with increasing 
disease severity (Swan 1999, Zerbini 2001, Gravitt 2003b, Weissenborn 2003, 
Carcopino 2006, Lai 2006). One report from a study which found no significant 
difference between the viral load of single and multiple infections (Giuliano 2004) 
was later contradicted by a report on the same population, which found that viral 
load was higher in samples containing any single HPV type compared to samples 
with multiple infections (Flores 2005). Another found that HPV16 viral load is higher 
in high-grade squamous intraepithelial lesions when another type is also present 
(Weissenborn 2003). 
 
23.4 DURATION OF EPISODE OF HPV INFECTION IN RELATION TO VIRAL 
LOAD 
 
An increase in viral load was associated with an increase in the duration of incident 
cervical HPV16 and HPV18 infections, but the association was not statistically 
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significant. This was the case whether the analysis included a variable measuring 
viral load in the first positive sample of the episode, a variable measuring viral load in 
the previous evaluable sample, or a variable measuring the greatest viral load 
attained during the episode. There was very little difference between the magnitudes 
of the estimates of association for either HPV type. For HPV16, the magnitude of the 
association was least for the variable measuring viral load in the first positive 
sample, and greatest for that measuring greatest viral load attained, which was of 
borderline statistical significance. For HPV18, the magnitude of the association was 
least for the variable measuring the greatest viral load attained, and greatest for that 
measuring viral load at the previous visit. Numbers were small in these analyses, so 
results must be treated with caution. Similarly, there was a statistically significant 
association between the maximum viral load observed during follow-up and the 
probability of being free of infection in the last evaluable sample for HPV16, but not 
for HPV18. 
 
Other studies which have investigated the association between HPV viral load and 
the duration, or “persistence” of, infection, disagree in their conclusions (Clavel 2000, 
De Marco 2001, Van Duin 2002, Dalstein 2003, Molano 2003, Syrjanen 2005a, 
Cricca 2006, Song 2006). Four studies found that HPV viral load was not 
significantly associated with duration of infection, although risk estimates suggest a 
positive association, whereas the other four found that a higher viral load was 
associated with an increased duration of, or risk of, persistent infection. 
Unfortunately, both studies which have reported measures of duration or association 
have used the semiquantitative hybrid capture II system to measure viral load and so 
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results are not comparable with the study described in this thesis (Dalstein 2003, 
Syrjanen 2005b). 
 
23.5 VIRAL LOAD AND CYTOLOGICAL ABNORMALITY 
 
An increase in viral load was associated with an increased risk of acquiring an 
incident cervical cytological abnormality. This was the case for both HPV types, and 
for all three continuous variables used to measure viral load. However, for HPV16, 
the magnitude of the increase in risk associated with a ten-fold increase in viral load 
was identical, whether that ten-fold change related to the viral load in the baseline 
sample or in the maximum observed viral load during follow-up, and whether the 
maximum used was based on the current, or the previous, sample (analysis not 
shown). It is not immediately obvious why baseline and greatest viral load are 
essentially interchangeable in a model. Of course on practical, if not purely statistical 
grounds, if a baseline covariate provides as much predictive power as a covariate 
measured at each visit, then the baseline covariate would be preferred. However, 
being HPV-negative in the baseline sample would not then imply that the woman is 
at low-risk of cytological abnormality, since if she subsequently becomes HPV-
positive her risk still increases with increasing viral load, and increases to the same 
extent.  
 
Fewer longitudinal than cross-sectional studies have investigated the association 
between HPV viral load and the risk of  the acquisition of cervical disease. Eight 
reports from these studies have indicated a positive association, including some 
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from studies which have been criticised on methodological grounds earlier (section 
20.3.3). Only one study has used a comparable disease outcome, but also used the 
semiquantitative hybrid capture II technique to measure viral load (Castle 2002a). In 
a cohort of 2,020 women who tested positive for HPV at study entry, the risk of a 
subsequent abnormal smear of any severity was significantly greater when the 
baseline sample contained a high-viral load than when it contained a low-viral load 
(odds ratio 2.7; 95% CI 1.7 to 4.1). 
 
With respect to high-grade CIN, the ideal disease outcome for this cohort study, 
numbers are severely limited, so observations can only be suggestive. All women 
with high-grade CIN who were tested for viral load in this cohort were HPV16-qPCR-
positive at some point during follow-up; many women only ever had numerically-low 
viral loads, and others had zero viral loads for extended periods. Similar results were 
seen for HPV18. 
 
23.6 BIOLOGICAL FACTORS WHICH MAY CONFOUND THE HPV VIRAL LOAD-
CERVICAL DISEASE RELATIONSHIP 
 
Although normalised for cellular DNA content, comparisons made using the qPCR 
assay may still be confounded by differences in the proportion of infected and 
uninfected cells present in a sample. Sampling variation, or heterogeneity within 
cervical lesions, may also distort comparisons: for example, viral load is reported to 
vary with the endocervical cell content of the cytological sample (Depuydt 2006); and 
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to be higher in women with high-grade CIN when low-grade CIN is also present, than 
when it is absent (Sherman 2003a). 
 
Temporal changes in viral load may reflect other aspects of viral infection which are 
in themselves associated with disease progression. For example, whereas the 
prevalence of integrated forms of HPV increases with increasing disease severity, 
integration is followed by a fall in viral load; however, in almost all cross-sectional 
and longitudinal surveys which have measured HPV viral load, HPV integration 
status is undefined and may, of course, change over time (Berumen 1995, Jeon 
1995, Spartz 2005, Cricca 2006). Similarly, the acquisition of new HPV types is 
associated with both changes in viral load and with the development of new cervical 
lesions; therefore, measures of association may be unreliable in longitudinal studies 
which rely on a single measurement of exposure made at baseline (Woodman 2002, 
Crum 2004). 
 
23.7 CLINICAL UTILITY OF A MEASUREMENT OF HPV VIRAL LOAD 
 
Although the observations above are of interest when considering how the exposure-
disease relationship varies with the infecting HPV type, their clinical utility is 
debateable. 
 
At present, cervical screening programmes usually offer screening, by cervical 
cytology, to all women at regular intervals of between three and five years (see 
section 4.2). However, among women who test positive for high-risk HPV types, 
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cytological abnormality is more common in those with a high-viral load, and this has 
been found to be the case irrespective of the method used to measure viral load 
(Hall 1996, Nindl 1997, Ho 1998a, Swan 1999, Heard 2000, Lillo 2005). It has 
therefore been suggested that viral load status can be used to improve the efficiency 
of cervical cytology screening programmes by identifying high-risk (high-viral load) 
women who can then be screened more frequently; whereas low-risk (low-, 
 or zero-viral load) women could be screened less frequently.  
 
The first problem with this suggestion relates to the sampling of cervical HPV 
infection at indeterminate points during it’s natural history. In figure 23.7a, subjects 
A, B and C all have HPV infections starting at different points in calendar time, and 
all are tested for HPV viral load on the same day. In each case, the natural history of 
the infection is identical: after a subject acquires the infection, viral load increases 
steadily to a maximum, and then declines to zero (or to below the threshold of 
detectability). In this scenario, whether subject B is identified as being at high-risk 
depends only on where the threshold is set for viral load to be considered “high”. 
Subjects A and C, with identical (low) measures of viral load, would be categorised 
as low-risk. A single measurement of viral load is unable to determine that these 
three HPV infections are identical and therefore pose identical risks to all three 
subjects. In particular, a single test is unable to determine whether a low-viral load 
measurement is low but increasing towards a (high) maximum, or low following a fall 
from a peak (high) viral load. Additional testing would also not clarify matters. 
Depending on the time scale for these infections, the next test would certainly give a 
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zero-viral load for subject A, a low- or possibly zero-viral load for subject B, and 
either a high- or low-viral load for subject C. 
 
Figure 23.7a. Changes in viral load over time for three hypothetical subjects 
with identical HPV infections tested for HPV viral load at a single point in time. 
 
 
 
Time 
Subject A 
Test 
Viral load of 
HPV infection 
Subject C 
Subject B 
 
Figure 23.7a makes the assumption that the natural history of cervical HPV infection, 
in terms of changes in viral load, is essentially identical in different women, and that 
the manner in which viral load changes over time is smooth and symmetric. Of 
course, if this artificial assumption is confirmed in practice, it would render a 
measurement of viral load unnecessary, since it would then be the mere fact of 
having been infected with HPV which is relevant. However, if a single measurement 
of HPV viral load, or even a small number of measurements, are to tell us anything 
about the risk of disease, the assumption must be made that these measurements 
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are made at comparable points in the natural history, and that they capture an 
important aspect of the infection as a whole, not merely a transient feature.  
 
Figure 23.7b illustrates some other possibilities for how HPV viral load may change 
over time. In example (a), the solid line illustrates a chronic low viral load infection: a 
single test will suggest that this woman has a low-viral load infection, and the second 
test will “confirm” this suggestion; similarly for example (c) and high-viral load. The 
women in examples (a) and (c) will thus be categorised as low- and high-risk, 
respectively. In these cases, although viral load is apparently measuring a consistent 
feature of the infection, it is still not certain, for example, that the risk-levels attributed 
to these women are valid. Why does the woman in example (a) have a long term 
infection? If the virus has become integrated, then viral low will typically be low; but 
an integrated virus may represent more of a risk than a high-viral load infection in 
which the virus remains episomal. Clearly, the two tests conducted on woman (a) 
cannot distinguish an infection which is cleared (example (a) dashed line), or an 
infection in which viral load subsequently increases (example (d)), or an infection in 
which an increase in viral load was shortly followed by a decrease, perhaps as a 
result of viral integration (examples (b) and (e)). If the aspect of an infection which is 
relevant to the risk of disease is ever having had a high-viral load, then of the four 
women in these examples with a high-viral load at some point in time, three will be 
incorrectly categorised as low-risk because testing was not undertaken frequently 
enough. If this is the case,  to correctly categorise women, women will have to be 
tested at every visit until a high-viral load is observed, thus increasing the costs of 
the screening programme and undermining any supposed efficiency gains obtained 
563 
 
by introducing viral load testing. And if all HPV infections have a period during which 
they have a high-viral load, assuming testing occurs frequently enough to detect the 
infection when it is in this period, then there will be no opportunity to reduce the 
frequency of screening. 
 
Figure 23.7b. Changes in HPV viral load over time for five hypothetical 
subjects with HPV infections tested for HPV viral load at two points in time. 
 
 
Note: depending on how much of the curve is observed, and how long the time period, the curves in 
this figure are not mutually exclusive.  
e) 
d) 
c) 
b) 
Viral load 
of HPV 
infection 
TestTest
a) 
Time 
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But in practice, does viral load change in the ways illustrated in figure 23.7b? Within 
limits, yes, certainly for the young women in the cohort described in this thesis. 
 
Figure 22.6 presents changes over time in HPV16 and HPV18 viral load for all 
women tested for HPV16 or HPV18 viral load, or both, in the cohort described in this 
thesis. Examples of women with “type a” profiles are study number 244, who had low 
HPV16 viral load for a period of over five years, and study number 1296, who had a 
low, but non-zero, HPV18 viral load for a period of over two years. Study number 
1367 has a “type b” profile for HPV18 since she can be considered to have two 
consecutive rises in HPV18 viral load, but without becoming HPV18-negative in 
between. Study number 150 has a “type c” profile for HPV16, since HPV16 viral load 
was within the range between 103 and 106 copies for over six years, but seemed to 
fluctuate around a constant value rather than demonstrating a particular pattern. 
From a value of zero at baseline, HPV16 viral load steadily increased over the 
following nine years for study number 350, making her HPV16 profile a “type d”; for 
HPV18 she has a “type e” profile. Study number 1512 has “type e” profiles for both 
HPV16 and HPV18: in both cases viral load rose precipitously from zero to a high-
viral load, before returning equally precipitously to a zero, or at least a low, viral load. 
For other women, study numbers 1551 and 1814, for example, it is difficult to 
conceive of the smooth underlying process which corresponds to the observed 
changes in both HPV16 and HPV18 viral load. 
 
However women are categorised according to their viral load profile, what is 
immediately apparent is that viral load tends not to be a constant, i.e. a 
565 
 
representative, feature of an infection: both HPV16 and HPV18 viral load appear to 
be able to undergo substantial changes over a short period of time (it is difficult to 
say what a “substantial change” is, but with the chosen scale a ten-fold change is, of 
course, easy to distinguish). This may or may not be important: it may be more 
relevant to know how often, or for how long, a high-viral load infection remains a 
high-viral load infection; and similarly for a low-viral load infection. The question may 
then be not whether the viral load of an infection fluctuates, but does it fluctuate 
within a range in which it remains a high-, or low-viral load infection? 
 
As figure 22.6 illustrates, a woman’s viral load status changes over time in terms of 
both whether or not she is positive, and copy number; for the latter, changes can be 
quite dramatic from one sample to the next, i.e. over a period of approximately six 
months. It is therefore doubtful whether a single measurement of HPV viral load can 
ever be used to predict a woman’s risk of cervical disease acquisition, or 
progression. Even if the assumption is made that once a woman is infected with 
HPV16 she remains infected; and that any “negative” viral load measurement is in 
fact a positive measurement which lies below the threshold of detectability for the 
assay; then it is still readily apparent that a single measurement of HPV viral load is 
uninformative with respect to predicting risk status. 
 
A final consideration with respect to the use of viral load as a clinical biomarker is 
that it must be remembered that viral replication is not necessary for maintaining the 
malignant phenotype (see section 3.1.2.1.2). In situ assays on cervical cancer cell 
lines show that not all HPV copies are transcriptionally active; and in pure tumour 
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samples taken from women with invasive disease, E6/E7 messenger RNA levels 
were not correlated with HPV DNA copy number, after normalisation for cellular 
content (Van Tine 2004, De Boer 2007). 
 
Within the restricted resources of a health service, women can only be offered a 
limited number of screening tests. In the UK, cervical screening is currently offered 
to women aged 25 to 64 years at intervals of three to five years, depending on age 
(see section 4.2.3). In the cohort study described in this thesis, which had intervals 
of only six months between study visits, it was possible to describe the kinetics of 
cervical HPV infections at a resolution impossible to obtain when repeated tests are 
separated by such large time intervals. The suggestion that cervical HPV viral load 
can be used to increase the efficiency of cervical cytology screening programmes 
appears to be untenable in young women; whether it is tenable in older women has 
yet to be demonstrated one way or the other, but must be open to doubt.  
 
23.8 PUBLICATION 
 
A paper based on the work described in chapters 20, 21, 22 and 23 of this thesis 
was accepted for publication in August 2009 (Constandinou-Williams 2009). The 
definitive results of HPV viral load testing became available only after the completion 
of the analyses relating to the neutralizing antibody response to cervical HPV 
infections. An analysis of the association between HPV viral load and the humoral 
immune response may be the subject of a future report (see chapter 24). 
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Chapter 24 
 
SUMMARY AND FURTHER ANALYSIS 
 
 
24.1 What has been learned about the natural history of early cervical HPV 
infections? 
 
The candidate is now in a position to construct a tentative biological model of the 
natural history of early cervical HPV infection. This is possible as a result of the work 
undertaken to complete this thesis, and as a result of other work related to the cohort 
study described in this thesis with which the candidate was also intimately involved.  
 
Prior to the time at which the work described in this thesis was undertaken, cervical 
HPV infection was known to be a necessary but not sufficient cause of cervical 
cancer. It had been established that cervical HPV infection was a very common 
sexually transmitted infection, which was acquired soon after the onset of first sexual 
intercourse. 
 
The longitudinal observations generated by the cohort described in this thesis, and 
which were analysed by the candidate, enabled the estimation, for the first time, of 
the incidence of cervical HPV infection, in a cohort of young women who had 
recently experienced penetrative vaginal sexual intercourse for the first time. This 
enabled me to show that cervical HPV infection was acquired soon after first sexual 
intercourse; that the sequential detection of different HPV types was very common; 
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that most incident cervical HPV infections were transient and of short duration; and 
that cervical infection with HPV was frequently associated with cervical cytological 
abnormalities, which were themselves transient.  
 
This cohort also enabled an estimate to be obtained of the incidence of high-grade 
CIN in young women: this estimate underpinned the sample size calculations 
proposed by the federal drug administration in the USA when negotiating the need 
for trials of HPV vaccines with pharmaceutical companies. 
 
The longitudinal observations generated by the cohort described in this thesis, 
enabled me to show that not only is cervical HPV infection very common, but that it 
is acquired as a result of low-risk sexual behaviour, i.e. even during the first sexual 
relationship. It was also possible to confirm the effect of age of sexual partner in the 
risk of the acquisition of cervical HPV infection. 
 
Subsequent work, for which the candidate undertook all statistical analyses, 
demonstrated that: the cervical cytological abnormalities associated with HPV18 
could be understated compared to those associated with HPV16, making the 
detection of HPV18-associated disease by cytological screening more difficult than 
the detection of HPV (this could undermine the effectiveness of such programmes); 
and that HPV16 and HPV18 both appeared to become integrated into the host-cell 
genome within a relatively short period of time following infection, although HPV18 
appeared to become integrated more rapidly than HPV16. I was able to show, using 
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the qPCR assay described in this thesis, that integration appears to be followed by a 
fall in viral load. 
 
Turning now specifically to the areas covered in depth in this thesis. 
 
Aspects of sexual behaviour were known to be the most important risk factors for 
cervical HPV infection. However, as a result of the analyses undertaken to complete 
this thesis, it has proven possible to contradict the popular belief, resulting from the 
use of sub-optimal cross-sectional study designs, that the adolescent cervix is at 
inherently greater risk of infection. As the results presented in this thesis are derived 
from a study using a longitudinal design and a study population recruited during the 
relevant exposure period; I was able to demonstrate that the risk of an incident 
cervical HPV infection of any type increases as the time interval between menarche 
and first sexual intercourse increases: this risk does not appear to decrease. In an 
analysis of this kind is always difficult in distinguishing the effects of possibly 
correlated variables. However, while gynaecological age and calendar age at first 
sexual intercourse are positively-correlated, it has been shown that gynaecological 
age at first sexual intercourse does not appear to be merely a surrogate for calendar 
age at first sexual intercourse. The results from this thesis provide the most 
convincing epidemiological evidence to date that the adolescent cervix is not at 
greater risk of HPV infection: while many results suggest non-significant 
associations, all point estimates of association suggest an increasing risk of cervical 
HPV infection with an increasing gynaecological age at first sexual intercourse. 
Stronger evidence could perhaps be obtained by making more frequent observations 
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in younger women, using a more sensitive HPV detection method; however, it now 
seems unlikely that this will occur, in particular in countries in which vaccination of 
pre-adolescent girls is now planned. 
 
Prior to undertaking this thesis, cervical HPV infection was known to be a necessary 
but not sufficient cause of cervical cancer: therefore it was clear that it was 
necessary to identify other cofactors which modulate the progression of cervical HPV 
infection to cervical cancer. Cigarette smoking was one potential cofactor, which was 
believed to act through any of several biological mechanisms, either alone or in 
combination with other factors, to increase the risk of acquiring cervical HPV 
infection and epithelial abnormalities of the cervix. In this thesis, cigarette smoking, 
typically considered an indicator of high-risk sexual behaviour, was found to be an 
independent (of cervical HPV infection) risk factor for the acquisition of high-grade 
cervical intraepithelial neoplasia; however, it was not found to be an independent risk 
factor for the incidence of cervical HPV infection, once sexual behaviour was taken 
into account. Smoking did not prolong the duration of cervical HPV infections. There 
is now a compelling case for investigating mechanisms which mediate the 
association between smoking and the acquisition of cervical epithelial abnormalities. 
For example, the cohort described in this thesis is being used to explore the extent 
to which smoking-induced promoter methylation of the tumour suppressor gene p16 
(CDKN2A) might explain the association between smoking and the acquisition of 
epithelial abnormalities of the cervix. 
 
The kinetics of the immune response to cervical HPV infections were not well 
characterised prior to undertaking this thesis. The sample size used in analyses was 
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less than planned, which was certainly disappointing, but this thesis did make a 
substantial contribution to our knowledge of the immune response to early cervical 
HPV infections. Many studies have investigated some aspect of the humoral immune 
response to HPV infections. However, the study described in this thesis was able to 
describe the functionally-relevant aspect of the humoral immune response: the 
neutralizing antibody response. It was demonstrated that women do generate an 
often substantial neutralizing antibody response to natural infections, and maintain 
this response for considerable periods of time, although seropositivity may also be 
intermittent. The relationship between the neutralizing antibody response to cervical 
HPV16 and HPV18 infections and the viral load of these infections will be the subject 
of further inquiries based on the cohort described in this thesis (see below). Not all 
women with sera samples which could have been tested were tested. There is no 
intention to complete the testing of these women using the neutralising antibody 
assay. However, it is hoped that in the future, all sera samples available will be 
tested using the technically simpler VLP-based  ELISA: clearly, this will yield a much 
larger sample size. 
 
Prior to the results of this thesis, it was believed that HPV viral load was of potential 
clinical utility, in that it could be used to distinguish between women who were at 
high- and low-risk of epithelial abnormalities of the cervix. This belief was based on 
the results of studies which were often contradictory. This thesis has clearly 
illustrated that the viral load of cervical HPV infections in young women is not a static 
quantity, but varies a great deal throughout the course of an infection. The risk of 
acquiring epithelial abnormalities of the cervix certainly increases with increasing 
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HPV16 and HPV18 viral load. However, the increase in risk is associated with 
increasing viral load in any sample taken from that woman, it is not confined to the 
first sample taken. This renders the clinical utility of a measurement of cervical HPV 
viral load questionable. Nevertheless, a sensitive measure of viral load which is able 
to detect low-copy numbers will be essential for continuing investigations of the 
natural history of cervical HPV infections. For example, although it is now clear that 
HPV can establish a “persistent” infection, it remains to be determined whether 
persistent infections are characterized by the continuing presence of low-copy 
numbers of HPV, or by a state of latency during which the virus remains 
undetectable, only to reappear later. 
 
24.2 Further analyses 
 
Clearly, in the study described in this thesis, it was not possible to exploit the full 
potential of the cohort for defining the kinetics of the humoral immune response to 
cervical HPV infection. It is hoped that it will be possible to do so in future, but this 
will require a suitable high-throughput neutralising antibody assay. 
 
However, with the results currently available, I can now present preliminary results 
describing the association between HPV viral load and the neutralizing antibody 
response to HPV infection, together, for the subset of women who contribute to both 
analyses. Figure 24.2 presents changes over time in the neutralizing antibody titre 
against HPV16 and HPV18, with changes over time in viral load of the relevant HPV 
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type superimposed for all women potentially eligible  for  inclusion  in  this  analysis 
(note  that  figure  24.2  is  essentially  an amalgamation of figures 18.8 and 22.6). 
 
A few preliminary observations can be made regarding this data. One might consider 
that the detection of HPV of a given type, as measured using qPCR, might generate 
an immune response against that type, in particular a neutralizing antibody 
response. Study numbers 43 (for HPV16), 240 (18), 350 (16), 393 (16) and 561 (16) 
might be considered to be examples of this behaviour. Similarly, an immune 
response elicited by an “insult” due to the presence of a HPV infection of a given 
type might persist until that infection is “cleared”. Take study number 292 and 
HPV18, for example: HPV18 becomes detectable in large copy-numbers per 1,000 
cells; this appears to cause a very large neutralizing antibody response, which 
persists for a considerable period of time (a titre of around 1-in-3240 is observed for 
approximately eight years); the presence of this large neutralizing antibody response 
appears to lead to the clearance of HPV18 (the black line measuring HPV18 viral 
load continues to increase initially, but subsequently falls to around zero). Study 
numbers 446 (for HPV18), 590 (16), 744 (18), 938 (16) and 1011 (16) might be 
considered to be further examples of this behaviour. However, sometimes a large 
viral load seems to have failed to elicit a neutralizing antibody response during the 
period when women were under observation in this study, study numbers 147 (for 
HPV16), 350 (18), 1367 (18) and 1814 (18) are good examples of this. There is also 
the question of which viral load “event” causes which neutralizing antibody response 
“event”, and what the time-lag between those events is. For example, for study 
numbers 2 (16), 247 (16) and 393 (16), an increase in viral load seems to be 
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followed shortly after by an increase in the neutralizing antibody response to the 
relevant HPV type; however, for study number 490 (HPV18) there may be a 
threshold effect, with the increase in the neutralizing antibody response being 
caused by the second increase in HPV18 viral load rather than the first, but this is 
likely to prove difficult to determine in practice. This is not the least of the statistical 
challenges posed by the data: these are repeat measurements; there is substantial 
missing data; and HPV viral load may act as both an outcome variable and as an 
explanatory factor. For example, consider study number 292 and HPV18 discussed 
earlier. In this case, HPV18 viral load is both an outcome variable, the values of 
which are of interest in themselves, and also an explanatory variable, since it 
potentially “causes” an immune response which then affects subsequent values of 
HPV18 viral load. 
 
24.3 Conclusion 
 
The natural history of early cervical HPV infections is perhaps more complex than 
was previously thought: until demonstrated otherwise, one can only assume that the 
natural history of cervical HPV infections in older women is similarly complex. It has 
been suggested that the association between cervical HPV infection and cervical 
neoplasia can be exploited to improve the efficiency and effectiveness of primary- 
and secondary-prevention programmes for cervical cancer. The results of this thesis 
suggest that achieving these improvements still requires a greater understanding of 
the natural history of early cervical HPV infection and its role in the acquisition of 
epithelial abnormalities of the cervix, than we currently possess. 
Figure 24.2. Changes in HPV16 (—) and HPV18 (—) 50% neutralizing antibody titre over time with changes over time in 
viral load of the relevant HPV type superimposed (—). The woman’s study number and the HPV type being analysed appear in the top right-hand corner. All 
graphs are plotted on the same time scale (months), left-vertical scale (inverse of the 50% neutralizing antibody titre), and right-vertical scale (HPV copy number per 1,000 cells). The 
measurements of the 50% neutralizing antibody titre and viral load retain their last known value until updated. A coloured vertical line indicates date of first detection of cytological abnormality 
(blue=borderline nuclear abnormalities; green=mild dyskaryosis). Red triangles indicate a GP5+/GP6+ positive sample of the relevant type. 
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Figure 24.2 (continued). Changes in HPV16 (—) and HPV18 (—) 50% neutralizing antibody titre over time with changes 
over time in viral load of the relevant HPV type superimposed (—). The woman’s study number and the HPV type being analysed appear in the top 
right-hand corner. All graphs are plotted on the same time scale (months), left-vertical scale (inverse of the 50% neutralizing antibody titre), and right-vertical scale (HPV copy number per 
1,000 cells). The measurements of the 50% neutralizing antibody titre and viral load retain their last known value until updated. A coloured vertical line indicates date of first detection of 
cytological abnormality (blue=borderline nuclear abnormalities; green=mild dyskaryosis). Red triangles indicate a GP5+/GP6+ positive sample of the relevant type. 
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Figure 24.2 (continued). Changes in HPV16 (—) and HPV18 (—) 50% neutralizing antibody titre over time with changes 
over time in viral load of the relevant HPV type superimposed (—). The woman’s study number and the HPV type being analysed appear in the top 
right-hand corner. All graphs are plotted on the same time scale (months), left-vertical scale (inverse of the 50% neutralizing antibody titre), and right-vertical scale (HPV copy number per 
1,000 cells). The measurements of the 50% neutralizing antibody titre and viral load retain their last known value until updated. A coloured vertical line indicates date of first detection of 
cytological abnormality (blue=borderline nuclear abnormalities; green=mild dyskaryosis). Red triangles indicate a GP5+/GP6+ positive sample of the relevant type. 
 
 0
40
120
360
1080
3240
9720
0 12 24 36 48 60 72 84 96 108 120
0
100
101
102
103
104
105
106
107
108
109244
HPV16
 
 
0
40
120
360
1080
3240
9720
0 12 24 36 48 60 72 84 96 108 120
0
100
101
102
103
104
105
106
107
108
109247
HPV16
 0
40
120
360
1080
3240
9720
0 12 24 36 48 60 72 84 96 108 120
0
100
101
102
103
104
105
106
107
108
109247
HPV18
 
 
0
40
120
360
1080
3240
9720
0 12 24 36 48 60 72 84 96 108 120
0
100
101
102
103
104
105
106
107
108
109292
HPV16
 0
40
120
360
1080
3240
9720
0 12 24 36 48 60 72 84 96 108 120
0
100
101
102
103
104
105
106
107
108
109292
HPV18
 
 
0
40
120
360
1080
3240
9720
0 12 24 36 48 60 72 84 96 108 120
0
100
101
102
103
104
105
106
107
108
109330
HPV16
 0
40
120
360
1080
3240
9720
0 12 24 36 48 60 72 84 96 108 120
0
100
101
102
103
104
105
106
107
108
109330
HPV18
 
 
0
40
120
360
1080
3240
9720
0 12 24 36 48 60 72 84 96 108 120
0
100
101
102
103
104
105
106
107
108
109350
HPV16
 
 
Figure 24.2 (continued). Changes in HPV16 (—) and HPV18 (—) 50% neutralizing antibody titre over time with changes 
over time in viral load of the relevant HPV type superimposed (—). The woman’s study number and the HPV type being analysed appear in the top 
right-hand corner. All graphs are plotted on the same time scale (months), left-vertical scale (inverse of the 50% neutralizing antibody titre), and right-vertical scale (HPV copy number per 
1,000 cells). The measurements of the 50% neutralizing antibody titre and viral load retain their last known value until updated. A coloured vertical line indicates date of first detection of 
cytological abnormality (blue=borderline nuclear abnormalities; green=mild dyskaryosis). Red triangles indicate a GP5+/GP6+ positive sample of the relevant type. 
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Figure 24.2 (continued). Changes in HPV16 (—) and HPV18 (—) 50% neutralizing antibody titre over time with changes 
over time in viral load of the relevant HPV type superimposed (—). The woman’s study number and the HPV type being analysed appear in the top 
right-hand corner. All graphs are plotted on the same time scale (months), left-vertical scale (inverse of the 50% neutralizing antibody titre), and right-vertical scale (HPV copy number per 
1,000 cells). The measurements of the 50% neutralizing antibody titre and viral load retain their last known value until updated. A coloured vertical line indicates date of first detection of 
cytological abnormality (blue=borderline nuclear abnormalities; green=mild dyskaryosis). Red triangles indicate a GP5+/GP6+ positive sample of the relevant type. 
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Figure 24.2 (continued). Changes in HPV16 (—) and HPV18 (—) 50% neutralizing antibody titre over time with changes 
over time in viral load of the relevant HPV type superimposed (—). The woman’s study number and the HPV type being analysed appear in the top 
right-hand corner. All graphs are plotted on the same time scale (months), left-vertical scale (inverse of the 50% neutralizing antibody titre), and right-vertical scale (HPV copy number per 
1,000 cells). The measurements of the 50% neutralizing antibody titre and viral load retain their last known value until updated. A coloured vertical line indicates date of first detection of 
cytological abnormality (blue=borderline nuclear abnormalities; green=mild dyskaryosis). Red triangles indicate a GP5+/GP6+ positive sample of the relevant type. 
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Figure 24.2 (continued). Changes in HPV16 (—) and HPV18 (—) 50% neutralizing antibody titre over time with changes 
over time in viral load of the relevant HPV type superimposed (—). The woman’s study number and the HPV type being analysed appear in the top 
right-hand corner. All graphs are plotted on the same time scale (months), left-vertical scale (inverse of the 50% neutralizing antibody titre), and right-vertical scale (HPV copy number per 
1,000 cells). The measurements of the 50% neutralizing antibody titre and viral load retain their last known value until updated. A coloured vertical line indicates date of first detection of 
cytological abnormality (blue=borderline nuclear abnormalities; green=mild dyskaryosis). Red triangles indicate a GP5+/GP6+ positive sample of the relevant type. 
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Figure 24.2 (continued). Changes in HPV16 (—) and HPV18 (—) 50% neutralizing antibody titre over time with changes 
over time in viral load of the relevant HPV type superimposed (—). The woman’s study number and the HPV type being analysed appear in the top 
right-hand corner. All graphs are plotted on the same time scale (months), left-vertical scale (inverse of the 50% neutralizing antibody titre), and right-vertical scale (HPV copy number per 
1,000 cells). The measurements of the 50% neutralizing antibody titre and viral load retain their last known value until updated. A coloured vertical line indicates date of first detection of 
cytological abnormality (blue=borderline nuclear abnormalities; green=mild dyskaryosis). Red triangles indicate a GP5+/GP6+ positive sample of the relevant type. 
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Figure 24.2 (continued). Changes in HPV16 (—) and HPV18 (—) 50% neutralizing antibody titre over time with changes 
over time in viral load of the relevant HPV type superimposed (—). The woman’s study number and the HPV type being analysed appear in the top 
right-hand corner. All graphs are plotted on the same time scale (months), left-vertical scale (inverse of the 50% neutralizing antibody titre), and right-vertical scale (HPV copy number per 
1,000 cells). The measurements of the 50% neutralizing antibody titre and viral load retain their last known value until updated. A coloured vertical line indicates date of first detection of 
cytological abnormality (blue=borderline nuclear abnormalities; green=mild dyskaryosis). Red triangles indicate a GP5+/GP6+ positive sample of the relevant type. 
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Appendix 5 
 
THE KINETICS OF THE HUMORAL IMMUNE RESPONSE TO 
INCIDENT CERVICAL HPV16 AND HPV18 INFECTIONS 
 
LABORATORY METHODS 
 
 
 
 
The following is a formal and precise description of the laboratory techniques 
used to undertake the neutralization assay used to measure the neutralizing 
antibody response in the cohort described in this thesis, given in sufficient 
detail to enable it to be repeated. Where relevant these laboratory techniques 
have been described in chapter 17 in a more accessible manner. 
 
 
 
 
The preparation of pseudovirions (PsV) for use in the neutralization assays 
was performed essentially as described by Pastrana et al, 2004 (Pastrana 
2004). Briefly, pseudovirus stocks were prepared by transfection of 293TT cells 
with vectors (all kindly provided by Dr John Schiller, Division of Basic 
Sciences, National Cancer Institute, Bethesda, MD 20892-4040, USA) 
expressing HPV16 L1 (p16L1h), HPV16 L2 (p16L2h), HPV18 L1 (peL1fB), 
HPV18 L2 (peL2bhb), BPV1 L1/L2 (pSheLL) together with secreted alkaline 
phosphatase (pYSEAP). For the production of HPV16 and HPV18 
pseudovirions, L1/L2 pairs were co-transfected with the reporter plasmid. 
Three days following transfection, cells were harvested and pseudovirus 
isolated over Optiprep gradients (Accurate Chemical, Westbury, NY). For each 
pseudovirus, fractions were titrated to determine the minimum amount of PsV 
required to give a robust signal in an assay for secreted alkaline phosphatase 
activity following infection of 293TT cells.  This concentration of PsV was then 
used in subsequent neutralization assays. For the titration, 293TT cells (3 x 
104/well) were plated in 96-well plates in neutralization assay medium (NAM; 
100μl/well) comprising DMEM without phenol red (Gibco-Invitrogen), 10% 
heat-inactivated FCS, 1% MEM Non-Essential Amino acids (Gibco-Invitrogen), 
1% Glutamax (Gibco-Invitrogen) and 1% Antibiotic-antimycotic (Gibco-
Invitrogen) and incubated for 2 – 5 hours at 37oC. Serial dilutions of the PsV 
(1:200 - 1:50,000) were prepared using siliconised tips in 96-well polystyrene 
plates (Corning Costar) in triplicate, with and without heparin treatment 
(Sigma; incubation for 1hr at 4oC), added to the preplated cells (final volume 
200μl/well) and incubated at 37oC for 72hours. Cell supernatants were then 
assayed for alkaline phospatase activity by chemiluminescense.  
 
The method for detection of SEAP in 293TT cell supernatants was again 
essentially as described in Pastrana et al, 2004 (Pastrana 2004) using the 
Great Escape SEAP detection kit (BD Bioscience).  Dilution buffer from the kit 
was added directly to the wells of a black optiplate-96 assay plate (Perkin 
Elmer; 45μl/well). The 96-well plates containing 293TT cells and PsV were 
lightly shaken and 50μl of a homogeneous cell suspension from each well was 
 
 
transferred to the corresponding wells of a fresh plate and centrifuged at 800g 
for 5min. Clarified supernatant from each well (15μl) was removed and added 
to wells containing dilution buffer on the optiplate, the plate covered with 
plastic and then incubated for 30min at 65oC. After cooling on ice for 2 - 5min, 
assay buffer was added (60μl/well) and plates incubated at room temperature 
for 5min. Chemiluminescence substrate was added (50μl/well) and following a 
final incubation period of 20min at room temperature, the plates were read on 
a microplate reader set at Glow-Endpoint 0.2sec/wellRAW Data. 
 
Neutralization assays were performed by first diluting various concentrations of 
the test serum in NAM in polystyrene 96-well plates and incubating with 
titrated HPV16, HPV18 and BPV1 pseudovirus stocks (in triplicate) for 1hr on 
ice in a total volume of 100μl. Triplicate wells of titrated pseudovirus alone 
were also set up to determine the maximum signal in the absence of 
neutralizing serum. The contents of each well was transferred to 96-well tissue 
culture plates previously seeded with 293TT cells (3 x 104/well) in 100μl NAM. 
Plates were incubated for 72hr at 37oC and SEAP activity in cell supernatants 
performed using the chemiluminescent assay described above. The 50% 
neutralizing titre was determined for each serum i.e. the highest dilution at 
which the signal was less than 50% of the mean signal seen in the “no sera” 
control wells. A serum was considered to be positive in the HPV16 or HPV18 
assay if it was neutralizing at a dilution at least 4-fold higher than the titre 
observed in the BPV1 assay. 
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Appendix 7 
 
THE NATURAL HISTORY OF HPV16 AND HPV18 INFECTIONS 
– VIRAL LOAD 
 
LABORATORY METHODS 
 
 
 
 
The following is a formal and precise description of the laboratory techniques 
used to undertake the qPCR assay used to measure HPV16 and HPV18 viral 
load in the cohort described in this thesis, given in sufficient detail to enable it 
to be repeated. Where relevant these laboratory techniques have been 
described in chapter 21 in a more accessible manner. 
 
 
 
 
HPV viral load was measured in a modified singleplex quantitative PCR 
(qPCR) assay, with standard curves used to correct measurements of viral 
load for the number of cells present in the sample. 
 
DNA was isolated from study samples using Proteinase K digestion and 
phenol/chloroform extraction. Type-specific primers for the amplification of the 
HPV16 E6 and HPV18 E7 oncogenes, and the GAPDH gene, were designed 
using a web-based computer program called Primer3 
(http://fokker.wi.mit.edu/primer3/input.htm). Standard curves were generated 
using serial 10-fold dilutions of plasmids, which contained known numbers of 
copies of HPV16, HPV18, or GAPDH. A HPV16/Bluescript II KS+ plasmid  
(9,111 bp), which contains HPV16 up to the BAMHI site (6,150 bp), was used 
in assays of HPV16; and a HPV18/pGEM-2 plasmid (10,726 bp), which 
contains the complete HPV18 genome (7,857 bp), was used for HPV18 (both 
plasmids kindly provided by Sally Roberts). The GAPDH plasmid which was 
used was produced by amplification of a 2,039 bp PCR product from DNA 
obtained from the HPV16-positive cervical carcinoma cell line W12. 
 
All assays were performed in singleplex, with target samples, standards and 
controls all tested in triplicate in each assay. Genomic DNA (50 ng), standards, 
positive controls and negative controls were loaded onto TaqMan® plates. 
Each reaction was amplified using 1x TaqMan® Universal PCR Master Mix 
(Applied Biosystems, Foster City, USA) with 0.4 μmol/L primer mix and 0.1 
μmol/L of appropriate fluorogenic probe. TaqMan® plates were centrifuged at 
2,750 RPM for 5 minutes at 4oC and placed into the ABI 7700 SDS thermal 
cycler. Cycle conditions for amplification of GAPDH, HPV16 E6 and HPV18 E7 
were: 50oC for 2 min, 95oC for 12 min, followed by 50 cycles of 95oC for 15 s 
and 55oC for 30 s. Following amplification, the ABI 7700 SDS.1 detection 
software was used to set the cycle threshold (Ct) level within the linear phase 
of the exponential amplification in the growth curves.  
 
 
Table A4a. Primer parameters for the qPCR assay. 
 
Target Accession 
Number 
Nucleotide 
Sequence 
Location 
Nucleotide Sequence Type Length 
(bases)
C G G+C 
Content 
(%) 
Annealing 
Temperature 
(Tm) 
Amplicon 
Length 
(bases) 
3701 5’-GCTCAAGGGAGATAAAATTC-3’ Forward primer 20 3 5 40% 
3858 5’-CGACCAAATCTAAGAGACAA-3’ Reverse primer 20 5 3 40% GAPDH AY340484 
3783 FAM-5'-CCTAGGGCTGCTCACATATT-3'-TAMRA Probe 20 6 4 50% 
55oC 158 
368 5’-GAACAGCAATACAACAAACC -3’ Forward primer 20 6 2 40% 
528 5’-GATCTGCAACAAGACATACA -3’ Reverse primer 20 5 3 40% HPV16 
E6 NC_001526
418 FAM-5'- CTGTCAAAAGCCACTGTGTC-3'-TAMRA Probe 20 6 4 50% 
55oC 161 
76 5’-GTTGACCTTCTATGTCACGA -3’ Forward primer 20 5 4 45% 
226 5’-CAATTCTGGCTTCACACTTA -3’ Reverse primer 20 6 2 40% HPV18 
E7 NC_001357
97 
FAM-5'- 
CAATTAAGCGACTCAGAGGAA-3'-
TAMRA 
Probe 21 4 5 43% 
55oC 151 
 
 
 
 
Table A4b. Primer parameters for manufacturing the GAPDH plasmid. 
 
Target Accession 
Number 
Nucleotide 
Sequence 
Location 
Nucleotide Sequence Type Length 
(bases)
C G G+C 
Content 
(%) 
Annealing 
Temperature 
(Tm) 
Amplicon 
Length 
(bases) 
3233 5’-CCACACACATGCACTTACCT-3’   Forward primer 20 9 1 50% 57.3oC GAPD 
Plasmid AY340484 5271 5’-AAGTCAGAGGAGACCACCTG-3’ Reverse primer 20 5 6 55% 57.3oC 
2039 
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